assay_id,assay_test_type,assay_organism,assay_category,assay_type,relationship_type,curated_by,assay_tissue,assay_tax_id,description,tid,variant_id,src_assay_id,src_id,doc_id,bao_format,assay_strain,assay_cell_type,assay_subcellular_fraction
1,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,,,1,11087,BAO_0000019,,,
2,,,,F,U,Autocuration,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,,,1,684,BAO_0000219,,,
3,,,,B,U,Autocuration,,,,22226,,,1,15453,BAO_0000019,,,
4,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,,,1,17841,BAO_0000249,,,
5,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,1,17430,BAO_0000219,,143B,
6,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,1,17430,BAO_0000219,,143B,
7,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,,,1,13799,BAO_0000219,,143B,
8,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cell cytotoxicity was determined against 143B cell line,80001,,,1,17774,BAO_0000219,,143B,
9,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,,,1,3801,BAO_0000219,,143B,
10,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,1,17430,BAO_0000219,,143B,
11,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,1,17430,BAO_0000219,,143B,
12,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,,,1,17774,BAO_0000219,,143B,
13,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,,,
14,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,,,
15,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,,,
16,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,,,
17,,Rattus norvegicus,,A,D,Expert,,10116.0,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,,,1,11347,BAO_0000357,,,
18,,,,B,H,Autocuration,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,,,
19,,,,B,H,Autocuration,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,,,1,10091,BAO_0000019,,,
20,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,,,
21,,,,B,H,Autocuration,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,,,
22,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,,,
23,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,1,16474,BAO_0000357,,,
24,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,1,16474,BAO_0000357,,,
25,,,,B,U,Autocuration,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,,,1,14352,BAO_0000219,,,
26,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,,,1,5646,BAO_0000357,,,
27,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,,,1,5646,BAO_0000357,,,
28,,,,B,H,Autocuration,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,,,1,10997,BAO_0000219,,,
29,,soya bean,,B,H,Autocuration,,3847.0,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,,,1,6309,BAO_0000357,,,
30,,Glycine max,,B,H,Autocuration,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,,,1,167,BAO_0000357,,,
31,,Glycine max,,B,H,Autocuration,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,,,1,167,BAO_0000357,,,
32,,Glycine max,,B,H,Autocuration,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,,,1,11087,BAO_0000357,,,
33,,Glycine max,,B,H,Autocuration,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,,,1,11087,BAO_0000357,,,
34,,Glycine max,,B,H,Autocuration,,3847.0,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,1,13622,BAO_0000357,,,
35,,Glycine max,,B,H,Autocuration,,3847.0,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,1,13622,BAO_0000357,,,
36,,Rattus norvegicus,,A,U,Autocuration,,10116.0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,,,1,11347,BAO_0000019,,,
37,,Escherichia coli,,B,U,Autocuration,,562.0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,,,1,5926,BAO_0000019,,,
38,,,,B,U,Autocuration,,,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,,,1,4567,BAO_0000019,,,
39,,,,B,M,Intermediate,,,Dissociation constant towards 16S rRNA construct A,22222,,,1,3782,BAO_0000225,,,
40,,,,B,M,Intermediate,,,Dissociation constant towards 16S rRNA construct B,22222,,,1,3782,BAO_0000225,,,
41,,Escherichia coli,,B,M,Expert,,562.0,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,,,1,4466,BAO_0000225,,,
42,,Escherichia coli,,B,M,Expert,,562.0,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,,,1,6592,BAO_0000225,,,
43,,,,B,H,Autocuration,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,,,
44,,,,B,H,Autocuration,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,,,
45,,Homo sapiens,,B,H,Autocuration,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,1,13163,BAO_0000019,,,
46,,Homo sapiens,,B,H,Autocuration,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,1,13163,BAO_0000019,,,
47,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,1,10691,BAO_0000019,,,
48,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,1,10691,BAO_0000019,,,
49,,Rattus norvegicus,,B,D,Expert,,10116.0,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,1,10691,BAO_0000019,,,
50,,Rattus norvegicus,,B,D,Expert,,10116.0,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,1,10691,BAO_0000019,,,
51,,,,B,H,Autocuration,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,,,
52,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,,,1,912,BAO_0000357,,,
53,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,,,1,912,BAO_0000357,,,
54,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,,,1,912,BAO_0000357,,,
55,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,,,1,15103,BAO_0000249,,,Membranes
56,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,,,1,5116,BAO_0000219,,1A9,
57,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,,,1,14578,BAO_0000219,,Oocytes,
58,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,,,1,14578,BAO_0000219,,Oocytes,
59,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,,,1,14578,BAO_0000219,,Oocytes,
60,,Homo sapiens,,F,N,Expert,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,,,1,4787,BAO_0000219,,1A9,
61,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,,,1,4787,BAO_0000219,,1A9,
62,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,,,1,3547,BAO_0000219,,1A9,
63,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,,,1,3547,BAO_0000219,,1A9,
64,,Homo sapiens,,F,N,Intermediate,,9606.0,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,,,1,6726,BAO_0000219,,1A9,
65,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,,,1,3455,BAO_0000219,,1A9,
66,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,,,1,5726,BAO_0000219,,1A9,
67,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,,,1,5726,BAO_0000219,,1A9,
68,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,,,1,5726,BAO_0000219,,1A9,
69,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,,,1,3395,BAO_0000219,,1A9,
70,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,,,1,3415,BAO_0000219,,1A9,
71,,Homo sapiens,,F,N,Expert,,9606.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,,,1,3415,BAO_0000219,,1A9,
72,,Homo sapiens,,F,N,Expert,,9606.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,,,1,17099,BAO_0000219,,1A9,
73,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,,,1,17099,BAO_0000219,,1A9,
74,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,,,1,17099,BAO_0000219,,1A9,
75,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,,,1,17099,BAO_0000219,,1A9,
76,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against Jurkat cells,81072,,,1,17721,BAO_0000219,,Jurkat,
77,,,,F,U,Intermediate,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
78,,Rattus norvegicus,,A,D,Expert,,10116.0,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,,,1,11347,BAO_0000357,,,
79,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,1,17117,BAO_0000357,,,
80,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,1,17117,BAO_0000357,,,
81,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,,,1,17117,BAO_0000357,,,
82,,Candida albicans,,B,H,Autocuration,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,,,1,11375,BAO_0000251,,,Microsomes
83,,Candida albicans,,B,H,Autocuration,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,,,1,11375,BAO_0000251,,,Microsomes
84,,Saccharomyces cerevisiae,,B,H,Autocuration,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,,,1,11375,BAO_0000251,,,Microsomes
85,,Saccharomyces cerevisiae,,B,H,Autocuration,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,,,1,11375,BAO_0000251,,,Microsomes
86,,Sus scrofa,,B,H,Autocuration,Liver,9823.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,,,1,11375,BAO_0000251,,,Microsomes
87,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,,,1,791,BAO_0000019,,,
88,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,,,1,791,BAO_0000019,,,
89,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,,,1,791,BAO_0000019,,,
90,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,,,1,11375,BAO_0000251,,,Microsomes
91,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,,1,11375,BAO_0000251,,,Microsomes
92,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,,1,153,BAO_0000251,,,Microsomes
93,,,,B,H,Expert,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,,,1,8269,BAO_0000357,,,
94,,,,B,H,Expert,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,,,1,8269,BAO_0000357,,,
95,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,,,1,17653,BAO_0000219,,HepG2,
96,,Homo sapiens,,F,N,Intermediate,,9606.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,,,1,14277,BAO_0000219,,HepG2,
97,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,,,1,1717,BAO_0000219,,HepG2,
98,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,,,1,14091,BAO_0000219,,HepG2,
99,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,,,1,14091,BAO_0000219,,HepG2,
100,,Hepatitis B virus,,F,N,Expert,,10407.0,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,,,1,17653,BAO_0000218,,,
101,,Homo sapiens,,F,N,Intermediate,,9606.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,,,1,13105,BAO_0000219,,HepG2,
102,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of 2.2.15 cell line,81020,,,1,1717,BAO_0000219,,HepG2,
103,,Homo sapiens,,A,N,Intermediate,,9606.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,,,1,13105,BAO_0000219,,HepG2,
104,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,,,1,13600,BAO_0000218,,2.2.15,
105,,Homo sapiens,,F,N,Intermediate,,9606.0,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,,2.2.15,
106,,Hepatitis B virus,,F,N,Expert,,10407.0,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,,,1,17477,BAO_0000218,,2.2.15,
107,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti-HBV activity in 2.2.15 cells,50587,,,1,1593,BAO_0000218,,2.2.15,
108,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,,,1,1593,BAO_0000218,,2.2.15,
109,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,,,1,15089,BAO_0000218,,2.2.15,
110,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,,,1,15089,BAO_0000218,,2.2.15,
111,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity in 2.2.15 cells,50587,,,1,1593,BAO_0000218,,2.2.15,
112,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity in 2.2.15 cells; Not determined,50587,,,1,1593,BAO_0000218,,2.2.15,
113,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,,,1,13600,BAO_0000218,,2.2.15,
114,,Homo sapiens,,F,N,Intermediate,,9606.0,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,,2.2.15,
115,,Homo sapiens,,F,N,Intermediate,,9606.0,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,,2.2.15,
116,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiviral activity against HBV was determined in 2.215 cell line,81020,,,1,14764,BAO_0000219,,HepG2,
117,,Homo sapiens,,B,U,Autocuration,,9606.0,Inhibition of 20-HETE synthesis in human renal microsomes,22226,,,1,6531,BAO_0000251,,,Microsomes
118,,,,B,U,Autocuration,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,,,1,17322,BAO_0000019,,,
119,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against 2008 (ovarian) cells,80612,,,1,17072,BAO_0000219,,2008,
120,,Homo sapiens,,F,N,Intermediate,,9606.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,,,1,16936,BAO_0000219,,2008,
121,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,,,1,16936,BAO_0000219,,2008,
122,,Homo sapiens,,F,N,Intermediate,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,,,1,17146,BAO_0000219,,2008,
123,,Homo sapiens,,F,N,Intermediate,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,,,1,17146,BAO_0000219,,2008,
124,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line,80613,,,1,10797,BAO_0000219,,2008/R,
125,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,,,1,10797,BAO_0000219,,2008/R,
126,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line,80614,,,1,10797,BAO_0000219,,2008/S,
127,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,,,1,10797,BAO_0000219,,2008/S,
128,,Homo sapiens,,B,S,Expert,,9606.0,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,,,1,4823,BAO_0000220,,,
129,,Homo sapiens,,B,S,Intermediate,,9606.0,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,,,1,12912,BAO_0000220,,,
130,,,,B,S,Expert,,,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,,,1,2957,BAO_0000220,,,
131,,,,B,S,Expert,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,,,1,2957,BAO_0000220,,,
132,,,,B,S,Intermediate,,,Inhibitory activity against 20S proteosome,100256,,,1,3260,BAO_0000220,,,
133,,Homo sapiens,,B,U,Autocuration,,9606.0,Compound was tested for inhibitory activity against tryptase,22226,,,1,3451,BAO_0000019,,,
134,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,,,1,13885,BAO_0000219,,HepG2,
135,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,,,1,13885,BAO_0000219,,HepG2,
136,,,,B,U,Autocuration,,,Compound was tested for the inhibition of Alpha-glucosidase,22226,,,1,3676,BAO_0000019,,,
137,,,,B,H,Autocuration,,,Inhibitory concentration against human neutrophil elastase (HNE),235,,,1,6043,BAO_0000357,,,
138,,Rattus norvegicus,,F,U,Autocuration,Heart,10116.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,,,1,11140,BAO_0000218,,,
139,,,,F,H,Autocuration,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,,,
140,,,,F,H,Expert,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,,,
141,,,,B,H,Autocuration,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000357,,,
142,,,,F,H,Expert,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,,,
143,,Mus musculus,,F,N,Intermediate,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,,,1,11365,BAO_0000219,,P338,
144,,Mus musculus,,F,N,Intermediate,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,,,1,11365,BAO_0000219,,P338,
145,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,,,1,11803,BAO_0000219,,PBL,
146,,Ovis aries,,F,U,Autocuration,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,,,1,11803,BAO_0000019,,,
147,,Ovis aries,,F,U,Autocuration,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,,,1,11803,BAO_0000019,,,
148,,,,B,H,Autocuration,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,,,1,12278,BAO_0000357,,,
149,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,,,1,8249,BAO_0000019,,,
150,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,,,1,8249,BAO_0000019,,,
151,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,,,1,8249,BAO_0000219,,CCRF-CEM,
152,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,,,1,8249,BAO_0000219,,CCRF-CEM,
153,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,,,1,8249,BAO_0000219,,CCRF-CEM,
154,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,,,1,8249,BAO_0000219,,CCRF-CEM,
155,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,,,1,8249,BAO_0000019,,,
156,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,,,1,8249,BAO_0000019,,,
157,,,,B,H,Autocuration,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,,,1,16992,BAO_0000249,,,
158,,Streptococcus pyogenes,,F,N,Intermediate,,1314.0,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,,,1,10543,BAO_0000218,,,
159,,Human herpesvirus 3,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,,,1,17833,BAO_0000218,,,
160,,vericilla zoster virus,,F,N,Expert,,10335.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,,,1,17290,BAO_0000218,,HEL,
161,,vericilla zoster virus,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,,,1,17290,BAO_0000218,,,
162,,vericilla zoster virus,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,,,1,17290,BAO_0000218,,,
163,,escherichia cloac,,F,N,Intermediate,,561.0,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,,,1,10932,BAO_0000218,,,
164,,,,B,U,Autocuration,,,Ratio of Ki at A2 to Ki at A1 receptors,22226,,,1,9707,BAO_0000019,,,
165,,Candida albicans,,B,H,Expert,,5476.0,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,,,1,2346,BAO_0000249,,,
166,,Candida glabrata CBS 138,,B,H,Expert,,284593.0,"Inhibition of 1,3-beta-glucan synthase",18077,,,1,2205,BAO_0000357,,,
167,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of 1-87 human tumor cell line,80609,,,1,11900,BAO_0000219,,1-87 tumor cell line,
168,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,,,1,14864,BAO_0000219,,,
169,,Glycine max,,B,D,Autocuration,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,,,1,16474,BAO_0000357,,,
170,,Glycine max,,B,D,Autocuration,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,,,1,16474,BAO_0000357,,,
171,,Glycine max,,B,D,Autocuration,,3847.0,% inhibition against soybean 1-lipoxygenase (SLO),100171,,,1,16474,BAO_0000357,,,
172,,Glycine max,,B,D,Autocuration,,3847.0,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,,,1,16474,BAO_0000357,,,
173,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,,,1,3094,BAO_0000357,,,
174,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,,,1,3094,BAO_0000357,,,
175,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,,,1,3094,BAO_0000357,,,
176,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,,,1,3094,BAO_0000357,,,
177,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,,,1,3094,BAO_0000357,,,
178,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,,,1,3094,BAO_0000357,,,
179,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,,,1,3094,BAO_0000357,,,
180,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,,,1,3094,BAO_0000357,,,
181,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,,,1,3094,BAO_0000357,,,
182,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,,,1,3094,BAO_0000357,,,
183,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,,,1,3094,BAO_0000357,,,
184,,Mus musculus,,B,U,Autocuration,,10090.0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,,,1,10413,BAO_0000019,,,
185,,Mus musculus,,F,N,Intermediate,,10090.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,,,1,16929,BAO_0000219,,C3H 10T1/2,
186,,,,F,U,Intermediate,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
187,,,,B,H,Autocuration,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,,,1,16587,BAO_0000357,,,
188,,,,B,H,Autocuration,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,,,1,16587,BAO_0000357,,,
189,,,,B,H,Autocuration,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,,,1,16587,BAO_0000357,,,
190,,,,B,H,Autocuration,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,,,1,16587,BAO_0000357,,,
191,,,,B,H,Autocuration,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,,,1,16587,BAO_0000357,,,
192,,Bos taurus,,F,D,Expert,,9913.0,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,,,1,8058,BAO_0000019,,,
193,,Rattus norvegicus,,B,D,Expert,,10116.0,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,,,1,9065,BAO_0000357,,,
194,,Rattus norvegicus,,B,D,Expert,Adrenal gland,10116.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,,,1,8865,BAO_0000357,,,
195,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,1,9066,BAO_0000357,,,
196,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,1,8394,BAO_0000357,,,
197,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,,,1,8394,BAO_0000357,,,
198,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,,,1,6431,BAO_0000019,,,
199,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,1,6431,BAO_0000357,,,
200,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,1,6431,BAO_0000357,,,
201,,,,F,H,Autocuration,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,,,1,9295,BAO_0000019,,,
202,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,,,
203,,,,B,H,Autocuration,,,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,,,1,13622,BAO_0000019,,,
204,,,,F,H,Autocuration,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,1,12079,BAO_0000019,,,
205,,,,B,H,Autocuration,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,,,1,13622,BAO_0000019,,,
206,,Homo sapiens,,F,D,Autocuration,,9606.0,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,1,12079,BAO_0000019,,,
207,,,,B,H,Expert,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,,,1,13500,BAO_0000019,,,
208,,,,B,H,Expert,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,,,1,13723,BAO_0000357,,,
209,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,,,1,16474,BAO_0000019,,,
210,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase,11134,,,1,1630,BAO_0000019,,,
211,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,,,1,167,BAO_0000019,,,
212,,,,B,H,Autocuration,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,,,1,16474,BAO_0000019,,,
213,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,,,1,167,BAO_0000019,,,
214,,,,B,H,Autocuration,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,,,1,16474,BAO_0000019,,,
215,,,,B,H,Autocuration,,,Inhibitory activity towards porcine 12-lipoxygenase,11601,,,1,10091,BAO_0000357,,,
216,,,,B,H,Autocuration,,,Tested for inhibition against porcine 12-LO,11601,,,1,11966,BAO_0000357,,,
217,,,,B,H,Autocuration,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,,,1,951,BAO_0000019,,,
218,,,,B,H,Autocuration,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,,,1,10997,BAO_0000019,,,
219,,,,B,H,Expert,,,In vitro inhibition of rat platelet 12-lipoxygenase,12052,,,1,10193,BAO_0000019,,,
220,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,,,
221,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,,,1,10193,BAO_0000019,,,
222,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,,,1,10193,BAO_0000019,,,
223,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,,,
224,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,,,1,10193,BAO_0000019,,,
225,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,,,1,11087,BAO_0000019,,,
226,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,,,1,15569,BAO_0000219,,41M,
227,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against 41M cell line.,80007,,,1,12989,BAO_0000219,,41M,
228,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,,,1,16745,BAO_0000219,,41M,
229,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,,,1,15569,BAO_0000219,,41M,
230,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against 41McisR cell line.,80007,,,1,12989,BAO_0000219,,41M,
231,,Homo sapiens,,F,N,Expert,,9606.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,,,1,12989,BAO_0000219,,41M,
232,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,,,1,16745,BAO_0000219,,41M,
233,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,,,1,6210,BAO_0000357,,,
234,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,1,6210,BAO_0000357,,,
235,,,,B,H,Expert,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,1,6226,BAO_0000357,,,
236,,,,B,H,Expert,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,1,17855,BAO_0000357,,,
237,,,,B,H,Expert,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,,,1,17855,BAO_0000357,,,
238,,,,B,H,Expert,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,1,17855,BAO_0000357,,,
239,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,,,
240,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,1,10413,BAO_0000357,,,
241,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,1,10413,BAO_0000357,,,
242,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,,,1,10413,BAO_0000357,,,
243,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,,,
244,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,,,
245,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,,,
246,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,,,1,7587,BAO_0000019,,,
247,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000357,,,
248,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,,,1,7587,BAO_0000357,,,
249,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,,,
250,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000019,,,
251,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,,,1,7587,BAO_0000019,,,
252,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000019,,,
253,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,,,1,7587,BAO_0000019,,,
254,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,,,1,7587,BAO_0000019,,,
255,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,,,
256,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000019,,,
257,,,,B,H,Autocuration,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,,,1,7323,BAO_0000357,,,
258,,Sus scrofa,,B,U,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,,,1,7587,BAO_0000019,,,
259,,Sus scrofa,,B,U,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,,,1,7587,BAO_0000019,,,
260,,Saccharomyces cerevisiae,,B,H,Expert,,4932.0,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,,,1,13750,BAO_0000357,,,
261,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,1,7662,BAO_0000019,,,
262,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,1,7662,BAO_0000019,,,
263,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,,,1,7662,BAO_0000019,,,
264,,,,F,H,Autocuration,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,1,12211,BAO_0000019,,,
265,,,,F,H,Autocuration,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,1,12211,BAO_0000019,,,
266,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,,,1,12211,BAO_0000221,,,
267,,,,F,H,Expert,,,Stimulatory activity of intragastric pressure was tested in the rat,10623,,,1,12211,BAO_0000019,,,
268,,,,B,H,Autocuration,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,,,1,15453,BAO_0000357,,,
269,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,,,1,11884,BAO_0000218,,,
270,,,,F,H,Autocuration,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,,,1,7185,BAO_0000019,,,
271,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,,,1,6876,BAO_0000357,,,
272,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,,,1,6876,BAO_0000357,,,
273,,,,F,H,Autocuration,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,,,1,11863,BAO_0000019,,,
274,,,,B,H,Autocuration,,,Inhibition constant of high-affinity 5-HT uptake,12198,,,1,11863,BAO_0000357,,,
275,,,,F,H,Autocuration,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,,,1,11863,BAO_0000019,,,
276,,,,F,H,Autocuration,,,Maximum rate was determined for high affinity transport of 5-HT,12198,,,1,11863,BAO_0000019,,,
277,,,,F,H,Autocuration,,,Compound was tested for agonistic activity against 5-HT uptake,104714,,,1,4639,BAO_0000019,,,
278,,,,B,H,Expert,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,,,1,15796,BAO_0000019,,,
279,,Bos taurus,,B,H,Expert,,9913.0,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,,,1,15796,BAO_0000357,,,
280,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,,,1,12801,BAO_0000224,,,
281,,,,B,H,Autocuration,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,,,1,12801,BAO_0000224,,,
282,,,,B,H,Autocuration,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,,,1,12120,BAO_0000249,,,Membranes
283,,,,B,H,Autocuration,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,,,1,12120,BAO_0000249,,,Membranes
284,,,,B,H,Autocuration,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,11963,BAO_0000019,,,
285,,,,F,H,Autocuration,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,,,1,11701,BAO_0000019,,,
286,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
287,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
288,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
289,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,,,1,16394,BAO_0000218,,,
290,,Cavia porcellus,,F,D,Intermediate,,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,,,1,11574,BAO_0000019,,,
291,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,1,15779,BAO_0000219,,CHO,
292,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,,,
293,,Rattus norvegicus,,F,D,Expert,,10116.0,Efficacy against 5-hydroxytryptamine 2A receptor,12687,,,1,15363,BAO_0000019,,,
294,,,,F,H,Expert,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,,,1,15329,BAO_0000019,,,
295,,,,F,H,Expert,,,Relative potency towards 5-HT2A receptor of rat tail artery,12687,,,1,15329,BAO_0000019,,,
296,,,,F,H,Expert,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,,,
297,,,,F,H,Expert,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,,,1,15329,BAO_0000019,,,
298,,,,F,H,Autocuration,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,,,1,15329,BAO_0000019,,,
299,,,,F,H,Expert,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,,,
300,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,,,
301,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,,,1,273,BAO_0000221,,,
302,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,,,
303,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,,,1,12092,BAO_0000357,,,
304,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,1,1317,BAO_0000019,,,
305,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,12409,BAO_0000357,,,
306,,Gallus gallus,,B,U,Autocuration,,9031.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,,,1,11126,BAO_0000019,,,
307,,Homo sapiens,,F,U,Autocuration,,9606.0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,,,1,11126,BAO_0000019,,,
308,,Homo sapiens,,F,U,Autocuration,,9606.0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,1,11126,BAO_0000019,,,
309,,Homo sapiens,,B,N,Autocuration,,9606.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,,,1,11126,BAO_0000219,,HL-60,
310,,Homo sapiens,,B,U,Autocuration,,9606.0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,,,1,11126,BAO_0000019,,,
311,,Homo sapiens,,B,U,Autocuration,,9606.0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,1,11126,BAO_0000019,,,
312,,Homo sapiens,,B,D,Autocuration,,9606.0,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,,,1,17807,BAO_0000219,,Oocytes,
313,,,,F,S,Intermediate,,,Chymotryptic inhibitory activity against 26S proteasome,100256,,,1,16575,BAO_0000220,,,
314,,,,B,S,Intermediate,,,Inhibitory activity against 26S proteasome degradation of IkB,100256,,,1,15407,BAO_0000220,,,
315,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,,,1,10797,BAO_0000219,,A2780,
316,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2780/S ovarian cancer cell line,81034,,,1,10797,BAO_0000219,,A2780,
317,,Homo sapiens,,F,U,Autocuration,,9606.0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,,,1,3469,BAO_0000019,,,
318,,,,B,M,Intermediate,,,Association constant for binding to AATT 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,,,
319,,,,B,M,Intermediate,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,,,1,16037,BAO_0000225,,,
320,,,,B,M,Intermediate,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,,,
321,,,,B,M,Intermediate,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,,,
322,,Homo sapiens,,F,U,Autocuration,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,,,1,16524,BAO_0000019,,,
323,,Homo sapiens,,F,U,Autocuration,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,,,1,16524,BAO_0000019,,,
324,,Homo sapiens,,F,U,Autocuration,,9606.0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,,,1,16524,BAO_0000019,,,
325,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,,,1,16758,BAO_0000019,,,
326,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,,,1,16758,BAO_0000019,,,
327,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,,,1,16758,BAO_0000019,,,
328,,,,B,H,Autocuration,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,,,1,14360,BAO_0000357,,,
329,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,,,1,14360,BAO_0000357,,,
330,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Selectivity ratio of ID50 in liver and heart,22226,,,1,9964,BAO_0000019,,,
331,,,,B,H,Autocuration,,,"Selectivity, ratio of relative ID50 in liver and heart",12132,,,1,9964,BAO_0000019,,,
332,,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,,,1,9964,BAO_0000019,,,
333,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,,,
334,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,,,
335,In vivo,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,,,
336,In vivo,,,F,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,,,
337,,,,B,U,Autocuration,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,,,1,9964,BAO_0000019,,,
338,,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,,,1,9964,BAO_0000019,,,
339,,Homo sapiens,,B,U,Autocuration,,9606.0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,,,1,9964,BAO_0000019,,,
340,,,,B,H,Autocuration,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,1,9964,BAO_0000019,,,
341,,,,F,H,Autocuration,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,1,9964,BAO_0000019,,,
342,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,,,
343,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,,,1,9964,BAO_0000218,,,
344,In vivo,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,,,1,9964,BAO_0000218,,,
345,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,,,
346,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,,,1,9964,BAO_0000218,,,
347,,,,B,H,Autocuration,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,,,
348,,,,F,H,Autocuration,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,,,
349,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,,,1,3796,BAO_0000019,,,
350,,Escherichia coli,,B,H,Autocuration,,562.0,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,1,4251,BAO_0000357,,,
351,,Escherichia coli,,B,H,Autocuration,,562.0,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,1,4251,BAO_0000357,,,
352,,Escherichia coli,,B,H,Autocuration,,562.0,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,1,4251,BAO_0000357,,,
353,,Escherichia coli,,B,H,Autocuration,,562.0,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,1,4251,BAO_0000357,,,
354,,,,B,H,Autocuration,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,,,1,166,BAO_0000357,,,
355,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,,,1,17861,BAO_0000357,,,
356,,,,B,H,Autocuration,,,Inhibition constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,,,
357,,,,B,H,Autocuration,,,Association rate constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,,,
358,,,,B,H,Autocuration,,,Rate constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,,,
359,,,,B,U,Autocuration,,,Inhibitory activity against fuc-TVII,22226,,,1,3548,BAO_0000019,,,
360,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
361,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
362,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
363,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
364,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
365,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,,,1,9877,BAO_0000251,,,Microsomes
366,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,,,1,9877,BAO_0000251,,,Microsomes
367,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,,,1,9877,BAO_0000251,,,Microsomes
368,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,,,1,9877,BAO_0000251,,,Microsomes
369,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,,,1,9877,BAO_0000251,,,Microsomes
370,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,,,1,9877,BAO_0000251,,,Microsomes
371,,,,B,H,Autocuration,,,Inhibitory activity against 3-phosphoglycerate kinase.,104832,,,1,3003,BAO_0000224,,,
372,,,,B,H,Autocuration,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,,,1,3003,BAO_0000224,,,
373,,,,B,H,Autocuration,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,,,1,3003,BAO_0000224,,,
374,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,,,1,17185,BAO_0000357,,,
375,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on 3677 melanoma cells,80616,,,1,6072,BAO_0000219,,3677 melanoma cell line,
376,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,,,1,6072,BAO_0000219,,3677 melanoma cell line,
377,,Mus musculus,,F,N,Intermediate,,10090.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,,,1,5018,BAO_0000219,,MC-38,
378,,Homo sapiens,,F,U,Intermediate,,9606.0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,,,1,2852,BAO_0000019,,,
379,,,,F,U,Autocuration,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,,,1,8663,BAO_0000218,,B16,
380,,,,F,U,Autocuration,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,,,1,8663,BAO_0000218,,B16,
381,,Human rhinovirus 14,,F,D,Expert,,12131.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,,,1,3245,BAO_0000019,,,
382,,Human rhinovirus sp.,,F,N,Intermediate,,169066.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,,,1,3245,BAO_0000218,,,
383,,human rhinovirus type 14,,F,N,Intermediate,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,,,1,3877,BAO_0000218,,,
384,,human rhinovirus type 14,,F,N,Intermediate,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,,,1,3877,BAO_0000218,,,
385,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,,,
386,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,,,
387,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,,,
388,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,,,1,5861,BAO_0000019,,,
389,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,,,1,13748,BAO_0000218,,,
390,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,,,1,13748,BAO_0000218,,,
391,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,,,1,13748,BAO_0000218,,,
392,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,,,1,13748,BAO_0000218,,,
393,,Human rhinovirus B,,B,H,Expert,,147712.0,Inhibition of human rhinovirus 3C protease,12464,,,1,13748,BAO_0000357,,,
394,,Homo sapiens,,B,U,Autocuration,,9606.0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,,,1,17699,BAO_0000019,,,
395,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,,,1,7145,BAO_0000218,,3EM 37,
396,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,,,1,7145,BAO_0000218,,3EM 37,
397,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,,,1,7145,BAO_0000218,,3EM 37,
398,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,,,1,7145,BAO_0000218,,3EM 37,
399,,Mus musculus,,F,N,Intermediate,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,,,1,7145,BAO_0000218,,3EM 37,
400,,Mus musculus,,F,N,Intermediate,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,,,1,7145,BAO_0000218,,3EM 37,
401,,Mus musculus,,F,N,Intermediate,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,1,5325,BAO_0000218,,3LL cell line,
402,,Mus musculus,,F,N,Intermediate,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,1,5325,BAO_0000218,,3LL cell line,
403,,Mus musculus,,F,N,Expert,,10090.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,,,1,5325,BAO_0000218,,3LL cell line,
404,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
405,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
406,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
407,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
408,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
409,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
410,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
411,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
412,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
413,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
414,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,,,1,16169,BAO_0000219,,3LL cell line,
415,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,,,1,16169,BAO_0000219,,3LL cell line,
416,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,,,1,16169,BAO_0000219,,3LL cell line,
417,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,,3LL cell line,
418,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
419,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
420,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
421,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
422,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
423,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
424,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
425,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
426,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
427,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
428,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
429,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,,3LL cell line,
430,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,,,1,15547,BAO_0000219,,3LLD122,
431,,,,F,U,Autocuration,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,,,1,8663,BAO_0000218,,,
432,,,,F,U,Autocuration,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,,,1,8663,BAO_0000218,,,
433,,,,F,U,Autocuration,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,,,1,8663,BAO_0000218,,,
434,,,,F,U,Autocuration,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,,,1,8663,BAO_0000218,,,
435,,Mus musculus,,F,N,Intermediate,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,1,4504,BAO_0000219,,NIH3T3,
436,,Mus musculus,,F,N,Intermediate,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,1,4504,BAO_0000219,,NIH3T3,
437,,,,F,H,Expert,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,,,1,12695,BAO_0000219,,NIH3T3,
438,,Mus musculus,,F,N,Intermediate,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,,,1,12695,BAO_0000219,,NIH3T3,
439,,Mus musculus,,F,N,Intermediate,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,,,1,12695,BAO_0000219,,NIH3T3,
440,,Mus musculus,,F,N,Expert,,10090.0,Effective dose against murine 3T3 fibroblasts cells,80951,,,1,17642,BAO_0000219,,NIH3T3,
441,,Mus musculus,,F,N,Expert,,10090.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,,,1,17642,BAO_0000219,,NIH3T3,
442,,Mus musculus,,F,N,Expert,,10090.0,Cytotoxic effect on 3T3 cells,80951,,,1,12340,BAO_0000219,,NIH3T3,
443,,Mus musculus,,F,N,Expert,,10090.0,Cytotoxic effect on 3T3 cells,80951,,,1,12340,BAO_0000219,,NIH3T3,
444,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,,,1,12716,BAO_0000219,,NIH3T3,
445,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,1,6277,BAO_0000219,,NIH3T3,
446,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,,,1,6277,BAO_0000219,,NIH3T3,
447,,Mus musculus,,F,N,Expert,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,,,1,6277,BAO_0000219,,NIH3T3,
448,,Mus musculus,,F,N,Expert,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,,NIH3T3,
449,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,,,1,6277,BAO_0000219,,NIH3T3,
450,,Mus musculus,,F,N,Expert,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,,,1,6277,BAO_0000219,,NIH3T3,
451,,Mus musculus,,F,N,Expert,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,,NIH3T3,
452,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,,,1,6277,BAO_0000219,,NIH3T3,
453,,Mus musculus,,F,N,Expert,,10090.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,,,1,17780,BAO_0000218,,NIH3T3,
454,,Mus musculus,,F,D,Autocuration,,10090.0,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,,,1,12751,BAO_0000219,,,
455,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,,,1,12380,BAO_0000219,,NIH3T3,
456,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory activity against 3T3 cell line,80951,,,1,14892,BAO_0000219,,NIH3T3,
457,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,,,1,12695,BAO_0000219,,NIH3T3,
458,,,,F,H,Expert,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,,,1,12695,BAO_0000019,,,
459,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,,,1,12695,BAO_0000219,,NIH3T3,
460,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,,,1,12695,BAO_0000219,,NIH3T3,
461,,,,F,H,Expert,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,,,1,12695,BAO_0000019,,,
462,,,,F,H,Expert,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,,,1,12695,BAO_0000019,,,
463,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,1,6277,BAO_0000219,,NIH3T3,
464,,Mus musculus,,F,N,Expert,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,,NIH3T3,
465,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,,,1,4959,BAO_0000219,,NIH3T3,
466,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,,,1,4959,BAO_0000219,,NIH3T3,
467,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,,,1,4959,BAO_0000219,,NIH3T3,
468,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,,,1,4959,BAO_0000219,,NIH3T3,
469,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,,,1,12082,BAO_0000219,,NIH3T3,
470,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,,,1,12082,BAO_0000219,,NIH3T3,
471,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,,,1,12082,BAO_0000219,,NIH3T3,
472,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,,,1,12082,BAO_0000219,,NIH3T3,
473,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,,,1,2643,BAO_0000219,,NIH3T3,
474,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,,,1,11926,BAO_0000219,,NIH3T3,
475,,Mus musculus,,A,N,Intermediate,,10090.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,,,1,15204,BAO_0000219,,NIH3T3,
476,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,,,1,15992,BAO_0000219,,NIH3T3,
477,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,,,1,16279,BAO_0000219,,NIH3T3,
478,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,,NIH3T3,
479,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,,NIH3T3,
480,,Mus musculus,,F,N,Intermediate,,10090.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,,NIH3T3,
481,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,,NIH3T3,
482,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,,NIH3T3,
483,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,,,1,12831,BAO_0000219,,NIH3T3,
484,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,,,1,13497,BAO_0000219,,NIH3T3,
485,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
486,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,,,1,13618,BAO_0000219,,3T3-L1,
487,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,,,1,11902,BAO_0000219,,3T3-L1,
488,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,,,1,11902,BAO_0000219,,3T3-L1,
489,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,,,1,11902,BAO_0000219,,3T3-L1,
490,,Mus musculus,,F,N,Intermediate,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,,,1,14840,BAO_0000218,,3T3-L1,
491,,Mus musculus,,F,N,Intermediate,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,,,1,14840,BAO_0000218,,3T3-L1,
492,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,,,1,13715,BAO_0000219,,3T3-L1,
493,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
494,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
495,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
496,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
497,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
498,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
499,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
500,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
501,,,,F,N,Expert,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
502,,,,F,N,Expert,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
503,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
504,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
505,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
506,,,,F,N,Expert,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
507,,,,F,N,Expert,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
508,,,,F,N,Expert,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
509,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
510,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
511,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,1,13715,BAO_0000219,,3T3-L1,
512,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
513,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
514,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
515,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
516,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,1,13715,BAO_0000218,,3T3-L1,
517,,,,F,H,Expert,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,,,1,6411,BAO_0000219,,3T3-L1,
518,,Mus musculus,,F,N,Intermediate,,10090.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,,,1,6411,BAO_0000219,,3T3-L1,
519,,,,F,H,Expert,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,,,1,6411,BAO_0000219,,3T3-L1,
520,,Mus musculus,,F,N,Expert,,10090.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,,,1,3966,BAO_0000219,,3T3-L1,
521,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,,,1,3966,BAO_0000219,,3T3-L1,
522,,Mus musculus,,F,N,Expert,,10090.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,,,1,15556,BAO_0000219,,3T3-L1,
523,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,1,5845,BAO_0000219,,3T3-L1,
524,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,1,14422,BAO_0000219,,3T3-L1,
525,,Mus musculus,,F,N,Expert,,10090.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,,,1,5845,BAO_0000219,,3T3-L1,
526,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,,,1,14508,BAO_0000219,,3T3-L1,
527,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,,,1,14508,BAO_0000219,,3T3-L1,
528,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,,,1,14508,BAO_0000219,,3T3-L1,
529,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,,,1,6349,BAO_0000219,,3Y1 cell line,
530,,Rattus norvegicus,,F,N,Expert,,10116.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,,,1,15899,BAO_0000219,,3Y1 cell line,
531,,Rattus norvegicus,,F,N,Expert,,10116.0,Cytotoxicity in 3Y1 cells.,80622,,,1,15899,BAO_0000219,,3Y1 cell line,
532,,Rattus norvegicus,,F,N,Expert,,10116.0,Cytostatic effect in 3Y1 cells.,80622,,,1,15899,BAO_0000219,,3Y1 cell line,
533,,Rattus norvegicus,,F,N,Intermediate,,10116.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,,,1,15899,BAO_0000219,,3Y1 cell line,
534,,Rattus norvegicus,,F,N,Expert,,10116.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,,,1,17038,BAO_0000219,,3Y1 cell line,
535,,,,B,U,Autocuration,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,,,1,12421,BAO_0000019,,,
536,,,,B,U,Autocuration,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,1,12947,BAO_0000019,,,
537,,,,B,U,Autocuration,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,1,12947,BAO_0000019,,,
538,,Sus scrofa,,B,D,Expert,,9823.0,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,,,1,4896,BAO_0000019,,,
539,,,,B,H,Autocuration,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,,,1,6148,BAO_0000019,,,
540,,,,B,H,Autocuration,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,,,1,16432,BAO_0000019,,,
541,,,,B,H,Expert,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,,,1,4978,BAO_0000019,,,
542,,,,B,H,Expert,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,,,1,4978,BAO_0000019,,,
543,,,,B,H,Autocuration,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,,,1,3723,BAO_0000019,,,
544,,,,B,H,Autocuration,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,,,1,3518,BAO_0000357,,,
545,,,,B,H,Autocuration,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,,,1,4164,BAO_0000019,,,
546,,,,B,H,Autocuration,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,,,1,3518,BAO_0000019,,,
547,,Sus scrofa,,B,D,Expert,,9823.0,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,,,1,4164,BAO_0000019,,,
548,,,,B,H,Autocuration,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,,,1,3518,BAO_0000019,,,
549,,,,B,H,Autocuration,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,,,1,3518,BAO_0000357,,,
550,,,,B,H,Autocuration,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,,,1,4978,BAO_0000019,,,
551,,,,B,H,Autocuration,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,,,1,4978,BAO_0000019,,,
552,,,,B,H,Autocuration,,,Binding affinity against melatonin (MT1) receptor (pC1),104733,,,1,6455,BAO_0000224,,,
553,,,,B,U,Autocuration,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,,,1,2222,BAO_0000019,,,
554,,,,B,U,Autocuration,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,,,1,13020,BAO_0000019,,,
555,,,,B,U,Autocuration,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,,,1,13021,BAO_0000019,,,
556,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,,,1,14532,BAO_0000357,,,
557,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,,,1,14118,BAO_0000357,,,
558,,,,B,H,Autocuration,Hippocampus,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,,,1,11884,BAO_0000221,,,
559,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,,,1,13969,BAO_0000357,,,
560,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor,51,,,1,13392,BAO_0000357,,,
561,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,,,1,14430,BAO_0000019,,,
562,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12248,BAO_0000221,,,
563,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,,,
564,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
565,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
566,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
567,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
568,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
569,,,,B,H,Autocuration,Hippocampus,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,,,
570,,,,B,H,Autocuration,Hippocampus,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,1,11799,BAO_0000221,,,
571,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,,,1,14331,BAO_0000249,,,Membranes
572,,Bos taurus,,B,H,Expert,Hippocampus,9913.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,,,1,11884,BAO_0000221,,,
573,,,,B,H,Autocuration,Hippocampus,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,,,1,14331,BAO_0000221,,,
574,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,,,1,11701,BAO_0000221,,,
575,,,,B,H,Expert,Hippocampus,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,,,1,11701,BAO_0000221,,,
576,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,,,1,12248,BAO_0000221,,,
577,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,,,1,12248,BAO_0000219,,CHO,
578,,,,B,H,Expert,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12248,BAO_0000221,,,
579,,,,B,H,Expert,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,,,
580,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,12248,BAO_0000219,,CHO,
581,,,,B,H,Expert,Hippocampus,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,1,11799,BAO_0000221,,,
582,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,1,634,BAO_0000357,,,
583,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
584,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
585,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
586,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
587,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,,,
588,,,,B,H,Expert,Hippocampus,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,,,1,12210,BAO_0000218,,,
589,,,,B,H,Expert,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,13311,BAO_0000221,,,
590,,Homo sapiens,,B,D,Expert,,9606.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,,,1,2331,BAO_0000219,,CHO,
591,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,,,1,1375,BAO_0000019,,,
592,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,,,1,1375,BAO_0000019,,,
593,,Cavia porcellus,,F,H,Autocuration,Hippocampus,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,,,1,11574,BAO_0000221,,,
594,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,,1,12867,BAO_0000221,,,
595,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,,,
596,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,,1,12867,BAO_0000221,,,
597,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,,,
598,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,,,
599,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,,,
600,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,11574,BAO_0000357,,,
601,,Cavia porcellus,,B,H,Autocuration,,10141.0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,13114,BAO_0000357,,,
602,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,,,1,13181,BAO_0000357,,,
603,,Cavia porcellus,,B,H,Autocuration,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,,1,10639,BAO_0000221,,,
604,,Cavia porcellus,,F,H,Autocuration,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,,1,10639,BAO_0000221,,,
605,,Cricetulus griseus,,B,H,Autocuration,,10029.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,,,1,11883,BAO_0000218,,CHO,
606,,,,B,H,Autocuration,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,,,1,17785,BAO_0000357,,,
607,,,,F,H,Autocuration,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,,,1,1558,BAO_0000219,,HeLa,
608,,,,F,H,Autocuration,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,,,1,1558,BAO_0000219,,HeLa,
609,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000019,,,
610,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,,CHO,
611,,,,F,H,Expert,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,,CHO,
612,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,,,1,17624,BAO_0000219,,CHO,
613,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,,,1,17624,BAO_0000219,,CHO,
614,,,,B,H,Expert,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
615,,,,B,H,Expert,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
616,,,,B,H,Autocuration,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,,,1,17624,BAO_0000219,,CHO,
617,,,,F,H,Autocuration,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,,,1,14256,BAO_0000219,,,
618,,Homo sapiens,,B,D,Expert,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,1,3445,BAO_0000219,,HeLa,
619,,Homo sapiens,,B,D,Expert,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,,,1,3445,BAO_0000219,,HeLa,
620,,Homo sapiens,,B,D,Expert,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000219,,CHO,
621,,Homo sapiens,,B,D,Expert,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,1,17200,BAO_0000219,,CHO,
622,,,,F,H,Autocuration,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000019,,,
623,,,,F,H,Autocuration,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000019,,,
624,,,,F,H,Autocuration,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,,,
625,,,,F,H,Autocuration,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,,CHO,
626,,Homo sapiens,,F,D,Expert,,9606.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,,CHO,
627,,,,F,H,Autocuration,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
628,,Homo sapiens,,F,D,Expert,,9606.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
629,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,,CHO,
630,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,,CHO,
631,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,,CHO,
632,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
633,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
634,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,,,1,3445,BAO_0000019,,,
635,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,,,
636,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,,,
637,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,,,
638,,,,F,H,Autocuration,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
639,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
640,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,1,17624,BAO_0000219,,CHO,
641,,,,F,H,Expert,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
642,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,1,17624,BAO_0000219,,CHO,
643,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,,,1,17624,BAO_0000219,,CHO,
644,,,,F,H,Autocuration,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,,CHO,
645,,,,F,H,Autocuration,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,1,17624,BAO_0000219,,CHO,
646,,,,F,H,Expert,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,,CHO,
647,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,,,1,17624,BAO_0000219,,CHO,
648,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,,CHO,
649,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,1,17624,BAO_0000219,,CHO,
650,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,,,
651,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,,,
652,,,,F,H,Autocuration,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,1,6563,BAO_0000019,,,
653,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,,HEK293,
654,,Homo sapiens,,F,D,Expert,,9606.0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,,,1,6876,BAO_0000019,,,
655,,,,F,H,Expert,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,,,1,6876,BAO_0000019,,,
656,,Homo sapiens,,F,D,Expert,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,,,1,5272,BAO_0000019,,,
657,,Homo sapiens,,F,D,Expert,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,,,1,5272,BAO_0000019,,,
658,,,,F,H,Autocuration,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,,,
659,,,,F,H,Expert,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,,,1,5548,BAO_0000019,,,
660,,,,F,H,Autocuration,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,,,
661,,,,F,H,Autocuration,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,,,
662,,,,F,H,Expert,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,,,1,5929,BAO_0000019,,,
663,,Homo sapiens,,F,D,Expert,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,,,1,5929,BAO_0000019,,,
664,,Homo sapiens,,F,D,Expert,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,,,1,5929,BAO_0000019,,,
665,,,,F,H,Autocuration,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,,,1,16245,BAO_0000019,,,
666,,,,F,H,Expert,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,1,5640,BAO_0000019,,,
667,,,,F,H,Autocuration,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,,,1,5640,BAO_0000019,,,
668,,,,F,H,Autocuration,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,,,1,14509,BAO_0000219,,CHO,
669,,,,F,H,Expert,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,,,1,14509,BAO_0000219,,CHO,
670,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,1,15331,BAO_0000357,,,
671,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,1,15331,BAO_0000357,,,
672,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,,,
673,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,,,1,6563,BAO_0000019,,,
674,,,,F,H,Autocuration,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,1,6563,BAO_0000019,,,
675,,Homo sapiens,,F,D,Expert,,9606.0,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,,,1,6563,BAO_0000019,,,
676,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,,,
677,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,,,1,5272,BAO_0000019,,,
678,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,,,
679,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,,,
680,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,,,1,5272,BAO_0000019,,,
681,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,,,1,5272,BAO_0000019,,,
682,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,,,
683,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,,,
684,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,,,1,5272,BAO_0000019,,,
685,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 1A receptor,51,,,1,16146,BAO_0000357,,,
686,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
687,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,,,1,13706,BAO_0000219,,HEK293,
688,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,,,1,15250,BAO_0000219,,CHO,
689,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,,CHO,
690,,,,B,H,Expert,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,,,1,6861,BAO_0000357,,,
691,,Homo sapiens,,B,D,Expert,,9606.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000357,,,
692,,,,B,H,Autocuration,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
693,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
694,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,,,1,12058,BAO_0000218,,,
695,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,,,1,12058,BAO_0000218,,,
696,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,,,1,12058,BAO_0000218,,,
697,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,,,
698,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,,,
699,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,,,
700,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,,,1,12058,BAO_0000218,,,
701,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,,,1,12058,BAO_0000218,,,
702,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,,,1,12058,BAO_0000218,,,
703,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,,,
704,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,,,
705,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,,,1,12058,BAO_0000218,,,
706,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,,,1,12058,BAO_0000218,,,
707,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,,,
708,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,,,1,12058,BAO_0000218,,,
709,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,,,
710,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,,,
711,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,,,
712,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,,,1,12058,BAO_0000218,,,
713,,,,B,H,Autocuration,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,,,1,11440,BAO_0000019,,,
714,,,,B,H,Autocuration,Hypothalamus,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,,,1,6238,BAO_0000249,,,
715,,,,B,H,Autocuration,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,,,1,10046,BAO_0000019,,,
716,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,,,1,10046,BAO_0000019,,,
717,,,,B,H,Expert,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,1,10046,BAO_0000019,,,
718,,,,B,H,Autocuration,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,,,1,167,BAO_0000357,,,
719,,,,B,H,Autocuration,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,,,1,167,BAO_0000357,,,
720,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,,,1,11520,BAO_0000019,,,
721,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,,,
722,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,,,
723,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,,,
724,,Cavia porcellus,,F,H,Autocuration,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,,,1,135,BAO_0000019,,,
725,,Cavia porcellus,,F,H,Autocuration,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,,,1,135,BAO_0000019,,,
726,,Cavia porcellus,,B,H,Autocuration,,10141.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,,,1,11311,BAO_0000019,,,
727,,Cavia porcellus,,B,H,Autocuration,,10141.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,,,1,10193,BAO_0000357,,,
728,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,,,1,12281,BAO_0000357,,,
729,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,1,11311,BAO_0000219,,,
730,,,,F,H,Autocuration,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,1,12576,BAO_0000218,,,
731,,,,B,H,Autocuration,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,,,1,12281,BAO_0000357,,,
732,,,,F,H,Autocuration,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,1,12576,BAO_0000218,,,
733,,Sus scrofa,,B,H,Expert,,9823.0,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,,,1,11089,BAO_0000019,,,
734,,,,B,H,Expert,,,In vitro inhibition of rat 5-Lipoxygenase,12166,,,1,11006,BAO_0000357,,,
735,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-Lipoxygenase,12166,,,1,11481,BAO_0000357,,,
736,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,,,1,10864,BAO_0000219,,RBL-1,
737,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,,RBL-1,
738,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,,,1,11311,BAO_0000219,,RBL-1,
739,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,,,1,11311,BAO_0000019,,,
740,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,,,1,11311,BAO_0000219,,,
741,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,1,11006,BAO_0000357,,,
742,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,1,3595,BAO_0000219,,RBL-1,
743,,,,B,H,Autocuration,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,,,1,11311,BAO_0000357,,,
744,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ratio of IC50 against 5-LO and COX,22226,,,1,11481,BAO_0000019,,,
745,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,1,11006,BAO_0000357,,,
746,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,,,1,11006,BAO_0000357,,,
747,,,,B,H,Autocuration,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,,,1,11311,BAO_0000219,,,
748,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,,,1,11006,BAO_0000019,,,
749,,,,B,H,Autocuration,Prostate gland,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,,,1,4288,BAO_0000357,,,
750,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,,,1,7587,BAO_0000019,,,
751,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,,,1,7587,BAO_0000019,,,
752,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,,,1,7587,BAO_0000019,,,
753,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,,,1,11249,BAO_0000357,,,
754,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,,,1,8003,BAO_0000019,,,
755,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,1,8003,BAO_0000019,,,
756,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,1,8003,BAO_0000019,,,
757,,,,B,H,Expert,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,1,12416,BAO_0000221,,,
758,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,,,1,16293,BAO_0000357,,,
759,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,,,
760,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,,,
761,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,,,
762,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,,,
763,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,,,
764,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,,,
765,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,,,
766,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,,,1,9841,BAO_0000249,,,Membranes
767,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,,,1,8822,BAO_0000249,,,
768,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,,,1,9806,BAO_0000019,,,
769,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,,,1,9806,BAO_0000019,,,
770,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,,,1,8868,BAO_0000224,,,
771,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,,,1,9036,BAO_0000221,,,
772,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,,,1,11374,BAO_0000221,,,
773,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,,,1,10881,BAO_0000224,,,
774,,,,B,H,Autocuration,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,,,1,8822,BAO_0000019,,,
775,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,,,1,9806,BAO_0000249,,,
776,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,15463,BAO_0000019,,,
777,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,15463,BAO_0000019,,,
778,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,,,
779,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,,,
780,,,,B,H,Autocuration,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,,,1,8569,BAO_0000019,,,
781,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,,,
782,,,,B,H,Autocuration,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,,,1,4771,BAO_0000224,,,
783,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,,,
784,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,,,
785,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,,,
786,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,1,15463,BAO_0000019,,,
787,,,,B,H,Autocuration,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,1,15463,BAO_0000019,,,
788,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,,,1,9098,BAO_0000224,,,
789,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Affinity for 5-hydroxytryptamine 1 receptor,22226,,,1,3070,BAO_0000019,,,
790,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,,,1,14542,BAO_0000221,,,
791,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,,,
792,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,,,1,6398,BAO_0000224,,,
793,,,,B,H,Autocuration,Brain,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,,,1,1344,BAO_0000221,,,
794,,,,B,H,Autocuration,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,11963,BAO_0000019,,,
795,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,,,1,8908,BAO_0000019,,,
796,,,,B,H,Autocuration,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,,,1,9098,BAO_0000019,,,
797,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,,,1,8841,BAO_0000019,,,
798,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,,,1,8814,BAO_0000019,,,
799,,,,B,H,Autocuration,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,,,1,11752,BAO_0000019,,,
800,,,,B,H,Autocuration,Brain,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,,,1,11642,BAO_0000221,,,
801,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,,,1,11642,BAO_0000019,,,
802,,,,B,H,Autocuration,Brain,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,,,1,9231,BAO_0000220,,,
803,,,,B,H,Autocuration,Brain,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,,,1,11351,BAO_0000221,,,
804,,,,B,U,Autocuration,,,Compound was tested for binding affinity against 5-HT1 receptor,22226,,,1,4639,BAO_0000019,,,
805,,,,B,U,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,,,1,1205,BAO_0000019,,,
806,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,1,10025,BAO_0000357,,,
807,,,,F,H,Autocuration,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,1,13241,BAO_0000249,,,
808,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,1,16245,BAO_0000218,,,
809,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,1,16245,BAO_0000218,,,
810,,,,F,H,Autocuration,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,,,1,12438,BAO_0000019,,,
811,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,1,16245,BAO_0000218,,,
812,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,1,16245,BAO_0000218,,,
813,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,,,1,15740,BAO_0000019,,,
814,,,,F,H,Autocuration,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,,,1,15535,BAO_0000219,,,
815,,,,F,H,Expert,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,,,1,15535,BAO_0000219,,,
816,,,,F,H,Autocuration,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,,,1,15535,BAO_0000219,,,
817,,,,B,H,Expert,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,,,1,9888,BAO_0000249,,,
818,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,1,10085,BAO_0000221,,,
819,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,1,10085,BAO_0000221,,,
820,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,,,1,17331,BAO_0000249,,,Membranes
821,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,,,1,10845,BAO_0000221,,,
822,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,,1,10845,BAO_0000221,,,
823,,,,B,H,Expert,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,,,1,10845,BAO_0000221,,,
824,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,,,1,10845,BAO_0000221,,,
825,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,,1,10845,BAO_0000221,,,
826,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,,,1,13730,BAO_0000357,,,
827,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,13508,BAO_0000249,,,
828,,,,B,H,Expert,Hippocampus,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,1,13508,BAO_0000249,,,
829,,,,B,H,Expert,Hippocampus,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,,,
830,,,,B,H,Autocuration,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,,,1,4671,BAO_0000221,,,
831,,,,B,H,Expert,Hippocampus,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,,,1,13631,BAO_0000221,,,
832,,,,B,H,Autocuration,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,,,1,12438,BAO_0000357,,,
833,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,,,1,10483,BAO_0000019,,,
834,,,,B,H,Autocuration,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,,,1,10483,BAO_0000221,,,
835,,,,B,H,Intermediate,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,,,1,12352,BAO_0000249,,,
836,,,,B,H,Autocuration,Hippocampus,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,,,1,14732,BAO_0000249,,,
837,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,,,1,11049,BAO_0000019,,,
838,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,,,1,11049,BAO_0000019,,,
839,,,,B,H,Expert,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,,,1,13657,BAO_0000249,,,
840,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,,,1,11473,BAO_0000019,,,
841,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,1,2014,BAO_0000249,,,
842,,,,B,H,Expert,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,3086,BAO_0000221,,,
843,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,,,1,15854,BAO_0000019,,,
844,,,,B,H,Expert,Hippocampus,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,1,10922,BAO_0000221,,,
845,,,,B,H,Expert,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,,,1,13346,BAO_0000221,,,
846,,,,B,H,Expert,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,,,1,15311,BAO_0000357,,,
847,,,,B,H,Autocuration,Hippocampus,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,1,10922,BAO_0000221,,,
848,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,,,1,10025,BAO_0000357,,,
849,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,1,10025,BAO_0000357,,,
850,,,,B,H,Autocuration,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,,,
851,,,,F,H,Autocuration,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,,,
852,,,,B,H,Expert,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,12304,BAO_0000019,,,
853,,,,B,H,Autocuration,Hippocampus,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,,,1,15789,BAO_0000221,,,
854,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,,,1,9912,BAO_0000019,,,
855,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,,,1,9912,BAO_0000019,,,
856,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,,,1,9912,BAO_0000019,,,
857,,,,B,H,Expert,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,1,16693,BAO_0000019,,,
858,,,,B,H,Expert,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,13276,BAO_0000357,,,
859,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,1,12678,BAO_0000221,,,
860,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,,,1,11825,BAO_0000357,,,
861,,,,B,H,Expert,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,,,1,12443,BAO_0000357,,,
862,,,,B,H,Expert,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,1,13830,BAO_0000357,,,
863,,,,B,H,Expert,Hippocampus,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,,,1,14286,BAO_0000249,,,
864,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,14356,BAO_0000221,,,
865,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,,,1,15306,BAO_0000357,,,
866,,,,B,H,Expert,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,,,1,15306,BAO_0000357,,,
867,,Rattus norvegicus,,F,D,Expert,,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,1,16616,BAO_0000249,,,
868,,,,B,H,Autocuration,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,,,1,3651,BAO_0000221,,,
869,,,,F,H,Autocuration,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14331,BAO_0000221,,,
870,,,,F,H,Autocuration,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14331,BAO_0000221,,,
871,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,,,1,14178,BAO_0000357,,,
872,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,,,1,10639,BAO_0000019,,,
873,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,,,
874,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,,,1,1348,BAO_0000357,,,
875,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,,,1,13605,BAO_0000221,,,
876,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,,CHO,
877,,,,F,H,Autocuration,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,,CHO,
878,,,,F,H,Autocuration,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,,CHO,
879,,,,B,H,Autocuration,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,15267,BAO_0000357,,,
880,,,,B,H,Autocuration,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,,,1,16532,BAO_0000357,,,
881,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,,,
882,,,,B,H,Autocuration,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,,,1,4751,BAO_0000219,,CHO,
883,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,,,1,15463,BAO_0000357,,,
884,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,,,1,3805,BAO_0000357,,,
885,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5640,BAO_0000357,,,
886,,,,B,H,Autocuration,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,,,1,6563,BAO_0000357,,,
887,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,,,1,5548,BAO_0000357,,,
888,,,,B,H,Autocuration,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,6347,BAO_0000357,,,
889,,,,F,H,Autocuration,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,,HEK293,
890,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,,,1,13047,BAO_0000019,,,
891,,,,B,H,Autocuration,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,,,1,15740,BAO_0000357,,,
892,,,,F,H,Expert,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,1,5640,BAO_0000019,,,
893,,,,F,H,Autocuration,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,,,1,5640,BAO_0000019,,,
894,,,,B,H,Expert,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,,,1,17211,BAO_0000219,,HeLa,
895,,,,B,H,Autocuration,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,,,1,4751,BAO_0000219,,CHO,
896,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,,,1,6491,BAO_0000357,,,
897,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,,,1,4707,BAO_0000357,,,
898,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,13910,BAO_0000357,,,
899,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,,,1,16190,BAO_0000219,,HeLa,
900,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16633,BAO_0000357,,,
901,,,,B,H,Autocuration,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,,,1,11898,BAO_0000219,,CHO,
902,,,,B,H,Autocuration,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,11898,BAO_0000219,,CHO,
903,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,1,14331,BAO_0000357,,,
904,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,,,1,17624,BAO_0000219,,CHO,
905,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,,,1,17624,BAO_0000219,,CHO,
906,,,,B,H,Autocuration,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,,,1,3307,BAO_0000357,,,
907,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,6563,BAO_0000219,,CHO,
908,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,,,1,14165,BAO_0000019,,,
909,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,1,5732,BAO_0000357,,,
910,,,,B,H,Expert,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,1,13366,BAO_0000357,,,
911,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,1,17626,BAO_0000357,,,
912,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,,,1,6588,BAO_0000219,,HeLa,
913,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,,,1,16209,BAO_0000357,,,
914,,,,B,H,Autocuration,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,1,15463,BAO_0000357,,,
915,,,,B,H,Autocuration,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,1,15463,BAO_0000357,,,
916,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,,,1,14770,BAO_0000357,,,
917,,,,B,H,Autocuration,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,,,1,16245,BAO_0000219,,Cell line,
918,,,,B,H,Autocuration,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,,,1,16245,BAO_0000019,,,
919,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,,,
920,,,,B,H,Expert,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,,,
921,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,,,
922,,,,B,H,Expert,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,,,1,6876,BAO_0000357,,,
923,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,2598,BAO_0000357,,,
924,,,,B,H,Expert,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,,,1,17785,BAO_0000357,,,
925,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,6013,BAO_0000357,,,
926,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,1,5929,BAO_0000357,,,
927,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16633,BAO_0000357,,,
928,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,1,1558,BAO_0000357,,,
929,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16026,BAO_0000357,,,
930,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,,,1,12469,BAO_0000219,,,
931,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,1,15874,BAO_0000357,,,
932,,,,B,H,Autocuration,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,1,15874,BAO_0000357,,,
933,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,,,1,3935,BAO_0000357,,,
934,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,1,15818,BAO_0000357,,,
935,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,,,1,13706,BAO_0000219,,CHO-K1,
936,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,,,1,13729,BAO_0000219,,CHO-K1,
937,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,,,1,15413,BAO_0000019,,,
938,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,,,1,15413,BAO_0000019,,,
939,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,,,1,15413,BAO_0000019,,,
940,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,,,1,15413,BAO_0000019,,,
941,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,1,3445,BAO_0000219,,HeLa,
942,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000357,,,
943,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,,,1,15740,BAO_0000357,,,
944,,,,B,H,Autocuration,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,,,1,17626,BAO_0000357,,,
945,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,,,1,4234,BAO_0000357,,,
946,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,1,5640,BAO_0000357,,,
947,,Rattus norvegicus,,B,H,Expert,,10116.0,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,,,1,5272,BAO_0000357,,,
948,,,,B,H,Autocuration,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,,,1,4622,BAO_0000219,,CHO,
949,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17085,BAO_0000019,,,
950,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,1,3025,BAO_0000357,,,
951,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15315,BAO_0000357,,,
952,,,,B,H,Autocuration,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,,,1,15267,BAO_0000357,,,
953,,,,B,H,Autocuration,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,,,1,17158,BAO_0000219,,HeLa,
954,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,,,1,14214,BAO_0000219,,HeLa,
955,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,17133,BAO_0000357,,,
956,,,,B,H,Autocuration,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,,,1,16532,BAO_0000357,,,
957,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,,,1,2391,BAO_0000357,,,
958,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,,,1,14447,BAO_0000019,,,
959,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,,,1,14447,BAO_0000019,,,
960,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,,,1,15086,BAO_0000357,,,
961,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,1,13051,BAO_0000357,,,
962,,,,F,H,Autocuration,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,,,1,16026,BAO_0000019,,,
963,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,,,1,17085,BAO_0000019,,,
964,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,17133,BAO_0000357,,,
965,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,,,1,17133,BAO_0000357,,,
966,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,,HeLa,
967,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,,,1,17211,BAO_0000219,,HeLa,
968,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,,HeLa,
969,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,,HeLa,
970,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,,,
971,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,,,
972,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,,,
973,In vivo,,,F,H,Autocuration,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,,,1,16394,BAO_0000218,,,
974,,,,B,H,Autocuration,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,,,1,16394,BAO_0000019,,,
975,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,,,1,15740,BAO_0000019,,,
976,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,,,1,15740,BAO_0000019,,,
977,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000357,,,
978,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,,HEK293,
979,,,,F,H,Expert,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,,,1,5640,BAO_0000019,,,
980,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,,,1,5640,BAO_0000019,,,
981,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,,,1,5640,BAO_0000019,,,
982,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,,,1,5640,BAO_0000019,,,
983,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,,CHO,
984,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,,,1,16394,BAO_0000019,,,
985,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,,,1,16394,BAO_0000019,,,
986,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,,,1,3445,BAO_0000019,,,
987,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,,,1,4316,BAO_0000219,,CHO,
988,,,,B,H,Expert,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,,,1,4316,BAO_0000019,,,
989,,Homo sapiens,,F,D,Expert,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,1,15180,BAO_0000019,,,
990,,Homo sapiens,,F,D,Expert,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,1,15180,BAO_0000019,,,
991,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,,,
992,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,,,
993,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15042,BAO_0000019,,,
994,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,,,
995,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,,,
996,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,,,
997,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15042,BAO_0000019,,,
998,,Homo sapiens,,F,D,Expert,,9606.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,,HeLa,
999,,Homo sapiens,,F,D,Expert,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,,HeLa,
1000,,Homo sapiens,,F,D,Expert,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,,HeLa,
1001,,,,F,H,Autocuration,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,,,1,16245,BAO_0000019,,,
1002,,,,F,H,Autocuration,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,,,
1003,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,,HEK293,
1004,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
1005,,,,F,H,Autocuration,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,2759,BAO_0000219,,CHO,
1006,,Homo sapiens,,F,D,Expert,,9606.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,,,1,2759,BAO_0000219,,CHO,
1007,,,,F,H,Autocuration,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,1,2759,BAO_0000219,,CHO,
1008,,,,F,H,Expert,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,,,1,15419,BAO_0000219,,,
1009,,,,F,H,Autocuration,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,,,1,15419,BAO_0000219,,,
1010,,,,F,H,Autocuration,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,,,
1011,In vitro,,,B,H,Expert,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,,,1,1414,BAO_0000219,,,
1012,In vitro,,,B,H,Expert,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,,,1,1414,BAO_0000219,,,
1013,,,,B,H,Autocuration,,,Binding activity radioligand.,51,,,1,12861,BAO_0000357,,,
1014,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,,,1,12861,BAO_0000019,,,
1015,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,1,5104,BAO_0000357,,,
1016,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,1,5105,BAO_0000357,,,
1017,,,,B,H,Autocuration,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,16312,BAO_0000357,,,
1018,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000357,,,
1019,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,,,1,5033,BAO_0000357,,,
1020,,Homo sapiens,,B,D,Expert,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,1,16909,BAO_0000219,,CHO,
1021,,,,F,H,Autocuration,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,1,2590,BAO_0000019,,,
1022,,,,F,H,Autocuration,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,1,2590,BAO_0000019,,,
1023,,,,B,H,Expert,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,,,1,16394,BAO_0000019,,,
1024,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,,,1,4540,BAO_0000219,,HEK293,
1025,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,,,1,17296,BAO_0000219,,HEK293,
1026,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,,,1,17296,BAO_0000219,,HEK293,
1027,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,1,15779,BAO_0000219,,HEK293,
1028,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,,,1,15779,BAO_0000219,,HEK293,
1029,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,,,1,15779,BAO_0000219,,HEK293,
1030,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,1,6166,BAO_0000357,,,
1031,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,1,15779,BAO_0000219,,HEK293,
1032,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,,,1,4199,BAO_0000219,,HEK293,
1033,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,,,1,15316,BAO_0000219,,,
1034,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,1,14875,BAO_0000357,,,
1035,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,1,14727,BAO_0000219,,HeLa,
1036,,,,B,H,Expert,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,1,14727,BAO_0000019,,,
1037,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,,,1,15146,BAO_0000219,,HEK293,
1038,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,,,1,5213,BAO_0000219,,HEK293,
1039,,,,B,H,Autocuration,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,,,1,16429,BAO_0000219,,,
1040,,Homo sapiens,,B,D,Expert,,9606.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,,,1,15042,BAO_0000219,,HeLa,
1041,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,,,1,14818,BAO_0000219,,HEK293,
1042,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,,,1,4829,BAO_0000219,,HEK293,
1043,,,,B,D,Expert,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000357,,,
1044,,Homo sapiens,,B,D,Autocuration,,9606.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,1,13051,BAO_0000357,,,
1045,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,,,1,5486,BAO_0000357,,,
1046,,,,B,H,Autocuration,,,Binding affinity against 5-HT1D receptor,105,,,1,5254,BAO_0000357,,,
1047,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,105,,,1,5254,BAO_0000357,,,
1048,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,,,1,15331,BAO_0000357,,,
1049,,Homo sapiens,,B,H,Autocuration,,9606.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,1,13506,BAO_0000357,,,
1050,,,,B,H,Autocuration,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,15267,BAO_0000357,,,
1051,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,,,1,16616,BAO_0000218,,,
1052,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,,,1,16616,BAO_0000218,,,
1053,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,,,1,16616,BAO_0000218,,,
1054,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,,,1,16616,BAO_0000218,,,
1055,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,,,1,16616,BAO_0000218,,,
1056,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,,,1,16616,BAO_0000218,,,
1057,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,,,1,16616,BAO_0000218,,,
1058,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,,,1,16616,BAO_0000218,,,
1059,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,,,1,16616,BAO_0000218,,,
1060,,,,B,H,Autocuration,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,,1,10297,BAO_0000221,,,
1061,,,,B,H,Expert,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,,,1,13704,BAO_0000357,,,
1062,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,,1,10297,BAO_0000221,,,
1063,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,1,10297,BAO_0000221,,,
1064,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,,1,10297,BAO_0000221,,,
1065,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,1,10297,BAO_0000221,,,
1066,,,,B,H,Autocuration,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,,,1,217,BAO_0000357,,,
1067,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,,1,10297,BAO_0000221,,,
1068,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,,,1,4921,BAO_0000357,,,
1069,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,,,1,4921,BAO_0000357,,,
1070,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,,,1,4996,BAO_0000019,,,
1071,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,,,1,12918,BAO_0000357,,,
1072,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,1,5333,BAO_0000019,,,
1073,,Sus scrofa,,B,H,Autocuration,,9823.0,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,1,4437,BAO_0000019,,,
1074,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,,,1,1742,BAO_0000019,,,
1075,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,,,1,16688,BAO_0000357,,,
1076,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity radioligand.,51,,,1,12861,BAO_0000357,,,
1077,,Sus scrofa,,B,H,Expert,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,1,12861,BAO_0000019,,,
1078,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,1,12861,BAO_0000019,,,
1079,,,,B,H,Expert,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,,,1,12490,BAO_0000019,,,
1080,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,,,1,11828,BAO_0000019,,,
1081,,Sus scrofa,,B,H,Autocuration,Hippocampus,9823.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,,,1,11866,BAO_0000221,,,
1082,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,,,1,12827,BAO_0000249,,,
1083,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,,,1,12918,BAO_0000019,,,
1084,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,,,1,12919,BAO_0000019,,,
1085,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,,,1,13047,BAO_0000019,,,
1086,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,,,1,15796,BAO_0000249,,,
1087,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,,,1,3651,BAO_0000221,,,
1088,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,,,1,188,BAO_0000357,,,
1089,,Rattus norvegicus,,F,D,Expert,,10116.0,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,1,16616,BAO_0000249,,,Membranes
1090,,Rattus norvegicus,,F,D,Expert,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,,1,16616,BAO_0000249,,,Membranes
1091,,,,B,H,Autocuration,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,,,
1092,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,,,1,17167,BAO_0000221,,,
1093,,,,B,H,Autocuration,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,,,1,14776,BAO_0000019,,,
1094,,,,B,H,Expert,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,,,1,12158,BAO_0000357,,,
1095,,,,B,H,Autocuration,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,,,1,13481,BAO_0000357,,,
1096,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,,,1,13427,BAO_0000219,,,
1097,,,,B,H,Autocuration,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,,,1,10210,BAO_0000357,,,
1098,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,1,10205,BAO_0000249,,,Membranes
1099,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,1,10205,BAO_0000249,,,Membranes
1100,,,,B,H,Expert,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,,,1,10205,BAO_0000249,,,Membranes
1101,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,,,1,12280,BAO_0000357,,,
1102,,,,B,H,Expert,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,,,1,17386,BAO_0000357,,,
1103,,,,B,H,Expert,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,,,1,13654,BAO_0000357,,,
1104,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,,,1,14423,BAO_0000221,,,
1105,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,,,1,15412,BAO_0000221,,,
1106,,,,B,H,Autocuration,Hippocampus,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,,,
1107,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,,,1,4101,BAO_0000357,,,
1108,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,,,1,10062,BAO_0000357,,,
1109,,,,B,H,Autocuration,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,6238,BAO_0000249,,,
1110,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,16273,BAO_0000357,,,
1111,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,,,1,11139,BAO_0000357,,,
1112,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,,,
1113,,Rattus norvegicus,,B,D,Expert,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,9548,BAO_0000221,,,
1114,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,10381,BAO_0000221,,,
1115,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,1,13408,BAO_0000249,,,
1116,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,,,1,13825,BAO_0000221,,,
1117,,,,B,H,Expert,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,,,1,11147,BAO_0000221,,,
1118,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,10552,BAO_0000249,,,
1119,,,,B,H,Autocuration,Striatum,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,,1,10552,BAO_0000249,,,
1120,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,,,1,17136,BAO_0000249,,,Membranes
1121,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,,,1,5778,BAO_0000249,,,Membranes
1122,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,,,1,13481,BAO_0000221,,,
1123,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,,,1,13481,BAO_0000221,,,
1124,,,,B,H,Intermediate,Hippocampus,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,,,1,13630,BAO_0000221,,,
1125,,,,B,H,Expert,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,1,16245,BAO_0000249,,,
1126,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,14509,BAO_0000221,,,
1127,,,,B,H,Expert,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,1,14509,BAO_0000221,,,
1128,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,,,1,14509,BAO_0000221,,,
1129,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,,,1,14509,BAO_0000221,,,
1130,,,,B,H,Expert,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,,,1,14256,BAO_0000019,,,
1131,,,,B,H,Autocuration,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,,,1,11139,BAO_0000357,,,
1132,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,,,1,11047,BAO_0000019,,,
1133,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,,,1,11047,BAO_0000019,,,
1134,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,,,1,11047,BAO_0000019,,,
1135,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,1,2395,BAO_0000219,,CHO-K1,
1136,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,9699,BAO_0000357,,,
1137,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,,1,12028,BAO_0000221,,,
1138,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,,1,12028,BAO_0000221,,,
1139,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,5815,BAO_0000019,,,
1140,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,,,1,16616,BAO_0000019,,,
1141,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,,,1,5815,BAO_0000019,,,
1142,,,,B,H,Autocuration,Hippocampus,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,,,1,2761,BAO_0000221,,,
1143,,,,B,H,Expert,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,,,1,13133,BAO_0000357,,,
1144,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,,,1,10444,BAO_0000019,,,
1145,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,,,1,13278,BAO_0000357,,,
1146,,,,B,H,Autocuration,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,,,1,15874,BAO_0000357,,,
1147,,,,B,H,Autocuration,Striatum,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,,1,10552,BAO_0000249,,,Membranes
1148,,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,,,1,11130,BAO_0000357,,,
1149,In vivo,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,,,1,11130,BAO_0000218,,,
1150,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,,,1,14542,BAO_0000221,,,
1151,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,1,13670,BAO_0000357,,,
1152,,,,B,H,Expert,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,,,1,9888,BAO_0000249,,,
1153,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,,,1,3678,BAO_0000249,,,Membranes
1154,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,11332,BAO_0000221,,,
1155,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,11332,BAO_0000221,,,
1156,,,,B,H,Expert,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,1,1185,BAO_0000357,,,
1157,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,,,1,2014,BAO_0000249,,,
1158,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,1,1185,BAO_0000357,,,
1159,,,,B,H,Expert,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,,,1,14429,BAO_0000019,,,
1160,,,,B,H,Expert,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,,,1,16288,BAO_0000019,,,
1161,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,,,1,5432,BAO_0000019,,,
1162,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,,,1,14429,BAO_0000019,,,
1163,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,,,1,13672,BAO_0000357,,,
1164,,,,B,H,Expert,Hippocampus,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,,,
1165,,,,B,H,Autocuration,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,,,1,11296,BAO_0000357,,,
1166,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,,,1,14749,BAO_0000219,,CHO,
1167,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,,,1,15086,BAO_0000019,,,
1168,,,,B,H,Autocuration,Hippocampus,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,,,1,13462,BAO_0000221,,,
1169,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,15363,BAO_0000019,,,
1170,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,15363,BAO_0000019,,,
1171,,,,B,H,Autocuration,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,,,1,10796,BAO_0000357,,,
1172,,,,B,H,Expert,Brain,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,,,1,12816,BAO_0000221,,,
1173,,,,B,H,Expert,Hippocampus,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,13542,BAO_0000221,,,
1174,,,,B,H,Expert,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,,,1,13308,BAO_0000019,,,
1175,,,,B,H,Expert,Hippocampus,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,,,1,13541,BAO_0000221,,,
1176,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,,,1,10058,BAO_0000221,,,
1177,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,10058,BAO_0000221,,,
1178,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,,,1,10058,BAO_0000221,,,
1179,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,,,1,10058,BAO_0000221,,,
1180,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,,,1,10058,BAO_0000221,,,
1181,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,,,1,10058,BAO_0000221,,,
1182,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,,,1,10058,BAO_0000221,,,
1183,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,,,1,10058,BAO_0000221,,,
1184,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,,,1,10058,BAO_0000221,,,
1185,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,,,1,10058,BAO_0000221,,,
1186,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,,,1,10058,BAO_0000221,,,
1187,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,,,1,10058,BAO_0000221,,,
1188,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,,,1,10058,BAO_0000221,,,
1189,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,10058,BAO_0000221,,,
1190,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,,,1,10058,BAO_0000221,,,
1191,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,,,1,10058,BAO_0000221,,,
1192,,,,B,H,Expert,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,,,1,12879,BAO_0000019,,,
1193,,,,B,H,Expert,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,,,1,11964,BAO_0000019,,,
1194,,,,B,H,Autocuration,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,,,1,11964,BAO_0000019,,,
1195,,,,B,H,Autocuration,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,,,1,11964,BAO_0000019,,,
1196,,,,B,H,Expert,Brain,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,9548,BAO_0000221,,,
1197,,,,B,H,Expert,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,,,1,9098,BAO_0000019,,,
1198,,,,B,H,Autocuration,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,,,1,9098,BAO_0000019,,,
1199,,,,B,H,Autocuration,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,,,1,9098,BAO_0000019,,,
1200,,,,B,H,Expert,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,,,1,13248,BAO_0000219,,CHO,
1201,,,,B,H,Expert,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,,,1,3147,BAO_0000249,,,
1202,,,,B,H,Expert,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,1,13949,BAO_0000019,,,
1203,,,,B,H,Autocuration,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,,,1,11883,BAO_0000218,,CHO,
1204,,,,B,H,Autocuration,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,,,1,11883,BAO_0000218,,,
1205,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,,,1,11883,BAO_0000357,,,
1206,,,,B,H,Expert,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,1,15535,BAO_0000249,,,Membranes
1207,,,,B,H,Autocuration,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,,,1,15535,BAO_0000249,,,
1208,,,,B,H,Autocuration,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,,,1,15535,BAO_0000249,,,
1209,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,16372,BAO_0000219,,CHO,
1210,,,,B,H,Expert,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,,,1,14608,BAO_0000249,,,
1211,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,4795,BAO_0000221,,,
1212,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,1,13863,BAO_0000357,,,
1213,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,,,1,13863,BAO_0000357,,,
1214,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,,,1,13863,BAO_0000357,,,
1215,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,,,1,13863,BAO_0000357,,,
1216,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,,,1,13863,BAO_0000357,,,
1217,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,,,1,13863,BAO_0000357,,,
1218,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,,,1,13863,BAO_0000357,,,
1219,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,,,1,13863,BAO_0000357,,,
1220,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,,,1,13863,BAO_0000357,,,
1221,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,,,1,13863,BAO_0000357,,,
1222,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,,,1,13863,BAO_0000357,,,
1223,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,,,1,13863,BAO_0000357,,,
1224,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,,,1,13863,BAO_0000357,,,
1225,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,,,1,13863,BAO_0000357,,,
1226,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,,,1,13863,BAO_0000357,,,
1227,,,,B,H,Autocuration,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,,,
1228,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,,,1,12073,BAO_0000357,,,
1229,,,,B,H,Autocuration,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,,,1,4101,BAO_0000357,,,
1230,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,,,1,15360,BAO_0000019,,,
1231,,,,B,H,Autocuration,Hippocampus,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,11576,BAO_0000221,,,
1232,,,,B,H,Expert,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,,,1,5834,BAO_0000019,,,
1233,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,1,2395,BAO_0000219,,CHO-K1,
1234,,,,B,H,Autocuration,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,,,1,1375,BAO_0000019,,,
1235,,,,B,H,Autocuration,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,,,1,1375,BAO_0000019,,,
1236,,,,B,H,Autocuration,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,,,1,3967,BAO_0000357,,,
1237,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,,,1,12884,BAO_0000357,,,
1238,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,,,1,2343,BAO_0000357,,,
1239,,,,B,H,Autocuration,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,1,11511,BAO_0000019,,,
1240,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,1,11511,BAO_0000019,,,
1241,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,,,1,16394,BAO_0000218,,,
1242,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,,,1,16394,BAO_0000218,,,
1243,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,,,1,16394,BAO_0000218,,,
1244,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,,,1,16394,BAO_0000218,,,
1245,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,,,1,16394,BAO_0000218,,,
1246,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,,,1,16394,BAO_0000218,,,
1247,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,,,1,16394,BAO_0000218,,,
1248,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,,,1,16394,BAO_0000218,,,
1249,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,,,1,16394,BAO_0000218,,,
1250,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,,,1,16394,BAO_0000218,,,
1251,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,,,1,16394,BAO_0000218,,,
1252,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,,,1,16394,BAO_0000218,,,
1253,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,,,1,16394,BAO_0000218,,,
1254,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,,,1,16394,BAO_0000218,,,
1255,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,,,1,16394,BAO_0000218,,,
1256,,Rattus norvegicus,,F,D,Expert,,10116.0,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,1,16616,BAO_0000249,,,Membranes
1257,,,,B,H,Autocuration,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,,,
1258,,,,B,H,Autocuration,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,,,
1259,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,,,1,15629,BAO_0000357,,,
1260,,,,F,H,Autocuration,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,1,13241,BAO_0000249,,,
1261,,,,B,H,Expert,Hippocampus,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,,,
1262,,,,B,H,Autocuration,Hippocampus,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,,,1,14286,BAO_0000249,,,
1263,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,,,1,14542,BAO_0000221,,,
1264,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1265,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1266,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1267,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,1,13630,BAO_0000019,,,
1268,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,1,13630,BAO_0000019,,,
1269,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1270,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,,,1,13630,BAO_0000019,,,
1271,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1272,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1273,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1274,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,,,1,13630,BAO_0000019,,,
1275,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1276,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,1,13630,BAO_0000019,,,
1277,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1278,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1279,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1280,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1281,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1282,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,,,1,13630,BAO_0000019,,,
1283,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,,,1,13630,BAO_0000019,,,
1284,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1285,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,,,1,13630,BAO_0000019,,,
1286,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1287,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,1,13630,BAO_0000019,,,
1288,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,,,1,9783,BAO_0000221,,,
1289,,,,B,H,Expert,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,,,1,9783,BAO_0000221,,,
1290,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,,,1,14331,BAO_0000249,,,Membranes
1291,,,,B,H,Expert,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,,,1,15260,BAO_0000221,,,
1292,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,,,1,15260,BAO_0000221,,,
1293,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,,,1,15260,BAO_0000221,,,
1294,,Rattus norvegicus,,F,D,Expert,,10116.0,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,1,16616,BAO_0000249,,,
1295,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,,,1,15629,BAO_0000357,,,
1296,,,,B,H,Autocuration,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,1,15086,BAO_0000019,,,
1297,,,,F,H,Expert,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,1,5717,BAO_0000019,,,
1298,,,,B,H,Autocuration,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,1,12652,BAO_0000357,,,
1299,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,,,1,14608,BAO_0000221,,,
1300,,,,B,H,Autocuration,Hippocampus,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,,,
1301,,,,B,H,Autocuration,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,,,
1302,,Rattus norvegicus,,B,D,Expert,,10116.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,1,15247,BAO_0000357,,,
1303,,,,B,H,Expert,Hippocampus,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,,,1,17529,BAO_0000221,,,
1304,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14826,BAO_0000221,,,
1305,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14826,BAO_0000221,,,
1306,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,13241,BAO_0000221,,,
1307,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,,,1,14093,BAO_0000221,,,
1308,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,,,1,14093,BAO_0000221,,,
1309,,,,B,H,Autocuration,Brain,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,,,1,14442,BAO_0000221,,,
1310,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,1,9919,BAO_0000357,,,
1311,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,1,9919,BAO_0000357,,,
1312,,,,B,H,Autocuration,Hippocampus,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,,,1,11440,BAO_0000221,,,
1313,,,,B,H,Autocuration,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,,,1,11257,BAO_0000357,,,
1314,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,,,1,10330,BAO_0000357,,,
1315,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,,,1,17331,BAO_0000221,,,
1316,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,,,1,16567,BAO_0000249,,,
1317,,Rattus norvegicus,,B,D,Expert,,10116.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,1,12058,BAO_0000019,,,
1318,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,,,1,9699,BAO_0000221,,,
1319,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,,,1,9547,BAO_0000357,,,
1320,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,,,1,10330,BAO_0000357,,,
1321,,,,B,H,Autocuration,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,1,14331,BAO_0000357,,,
1322,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,14060,BAO_0000019,,,
1323,,,,B,H,Autocuration,Hippocampus,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,,,1,14744,BAO_0000221,,,
1324,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,1,13506,BAO_0000357,,,
1325,,,,B,H,Expert,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,,,
1326,,,,B,H,Expert,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,,,
1327,,,,B,H,Expert,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,,,1,10062,BAO_0000357,,,
1328,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,,,1,12073,BAO_0000357,,,
1329,,,,B,H,Autocuration,,,GTPgammaS radioligand binding assay,106,,,1,14875,BAO_0000357,,,
1330,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,1,2391,BAO_0000357,,,
1331,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,,,1,2391,BAO_0000019,,,
1332,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,,,1,2391,BAO_0000019,,,
1333,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,1,2391,BAO_0000357,,,
1334,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,1,2391,BAO_0000357,,,
1335,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,,,1,2391,BAO_0000019,,,
1336,,,,B,H,Expert,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,,,1,17211,BAO_0000219,,HeLa,
1337,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,,,1,17211,BAO_0000219,,HeLa,
1338,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,,,1,6491,BAO_0000357,,,
1339,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,1,16190,BAO_0000219,,CHO,
1340,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,,,1,14165,BAO_0000019,,,
1341,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,,,1,14165,BAO_0000019,,,
1342,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,,,1,4234,BAO_0000357,,,
1343,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,,,1,6328,BAO_0000219,,,
1344,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,1,14770,BAO_0000357,,,
1345,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,,,1,2598,BAO_0000357,,,
1346,,,,B,H,Expert,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,1,6897,BAO_0000357,,,
1347,,,,B,H,Autocuration,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,1,6897,BAO_0000357,,,
1348,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,,,1,6013,BAO_0000357,,,
1349,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,1,5843,BAO_0000357,,,
1350,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,,,1,14454,BAO_0000357,,,
1351,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,,,1,16209,BAO_0000357,,,
1352,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,3935,BAO_0000357,,,
1353,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,,,1,13729,BAO_0000219,,CHO-K1,
1354,,,,F,H,Expert,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,,,1,14251,BAO_0000019,,,
1355,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,,,1,17085,BAO_0000019,,,
1356,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,,,1,3025,BAO_0000357,,,
1357,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,,,1,15315,BAO_0000357,,,
1358,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,,,1,14214,BAO_0000219,,,
1359,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,1,3804,BAO_0000357,,,
1360,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,,,1,2391,BAO_0000357,,,
1361,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,4175,BAO_0000357,,,
1362,,,,B,H,Autocuration,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,,,1,17296,BAO_0000219,,CHO,
1363,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,,,1,17085,BAO_0000019,,,
1364,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,1,17211,BAO_0000219,,HeLa,
1365,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,,,1,17211,BAO_0000219,,HeLa,
1366,,,,B,H,Autocuration,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,1,17211,BAO_0000219,,HeLa,
1367,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,,,1,15926,BAO_0000357,,,
1368,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,,,1,16312,BAO_0000219,,CHO-K1,
1369,,,,B,H,Expert,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,,,1,5843,BAO_0000357,,,
1370,,,,B,H,Autocuration,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,,,1,5843,BAO_0000357,,,
1371,,,,B,H,Expert,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,,,1,16312,BAO_0000219,,CHO-K1,
1372,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,1,15926,BAO_0000357,,,
1373,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,1,15926,BAO_0000357,,,
1374,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,1,4540,BAO_0000219,,CHO,
1375,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,,,1,6166,BAO_0000357,,,
1376,,,,B,H,Autocuration,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,,,1,17296,BAO_0000219,,CHO,
1377,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,,,1,17296,BAO_0000219,,CHO,
1378,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,,,1,17296,BAO_0000219,,CHO,
1379,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,1,15779,BAO_0000219,,CHO,
1380,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,1,15779,BAO_0000219,,CHO,
1381,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,,,1,15779,BAO_0000219,,CHO,
1382,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,,,1,4199,BAO_0000219,,CHO,
1383,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,14875,BAO_0000357,,,
1384,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,1,15146,BAO_0000219,,CHO,
1385,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,,,1,5213,BAO_0000357,,,
1386,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,1,14818,BAO_0000219,,CHO,
1387,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,,,1,4829,BAO_0000219,,CHO,
1388,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,,,1,14454,BAO_0000019,,,
1389,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,,,1,14454,BAO_0000019,,,
1390,,,,F,H,Autocuration,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,1,14875,BAO_0000219,,CHO,
1391,,,,F,H,Autocuration,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,1,14875,BAO_0000219,,CHO,
1392,,,,F,H,Autocuration,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,,,1,15250,BAO_0000019,,,
1393,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,,,1,15250,BAO_0000219,,CHO,
1394,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,,,1,15086,BAO_0000357,,,
1395,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,,,1,3025,BAO_0000019,,,
1396,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,,,1,14998,BAO_0000019,,,
1397,,Oryctolagus cuniculus,,B,H,Intermediate,,9986.0,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,,,1,14998,BAO_0000019,,,
1398,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,,,1,14998,BAO_0000019,,,
1399,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,,,1,13969,BAO_0000357,,,
1400,,,,B,D,Intermediate,,,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,,,1,13392,BAO_0000357,,,
1401,,Rattus norvegicus,,B,D,Expert,Striatum,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,,,1,3651,BAO_0000019,,,
1402,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,1,10025,BAO_0000357,,,
1403,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,,,1,13863,BAO_0000357,,,
1404,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,,,1,13863,BAO_0000357,,,
1405,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,,,1,13863,BAO_0000357,,,
1406,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,,,1,13863,BAO_0000357,,,
1407,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,,,1,13863,BAO_0000357,,,
1408,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,,,1,13863,BAO_0000357,,,
1409,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,,,1,4622,BAO_0000249,,,
1410,,,,B,H,Intermediate,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,1,14911,BAO_0000019,,,
1411,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,1,12678,BAO_0000221,,,
1412,,,,B,H,Expert,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,,,1,12678,BAO_0000221,,,
1413,,,,B,H,Expert,Hippocampus,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,1,14235,BAO_0000221,,,
1414,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,1,14949,BAO_0000221,,,
1415,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,1,14949,BAO_0000221,,,
1416,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,,,1,14949,BAO_0000221,,,
1417,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,,,1,14949,BAO_0000221,,,
1418,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,,,1,14949,BAO_0000221,,,
1419,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,1,16118,BAO_0000249,,,
1420,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,,,1,3268,BAO_0000249,,,
1421,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,,,1,3268,BAO_0000249,,,
1422,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,,,1,16117,BAO_0000357,,,
1423,,,,B,H,Expert,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,,,1,9783,BAO_0000221,,,
1424,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,,,1,9783,BAO_0000221,,,
1425,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,14356,BAO_0000221,,,
1426,,,,F,H,Autocuration,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,,,1,15740,BAO_0000019,,,
1427,,,,B,H,Autocuration,Hippocampus,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,,,
1428,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,,,1,13348,BAO_0000221,,,
1429,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,,,1,10394,BAO_0000249,,,
1430,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,,,1,15260,BAO_0000221,,,
1431,,,,B,H,Expert,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,1,10046,BAO_0000221,,,
1432,,,,F,H,Intermediate,Hippocampus,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,,,1,15260,BAO_0000221,,,
1433,,,,B,H,Autocuration,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,,,1,12851,BAO_0000357,,,
1434,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,,,1,2148,BAO_0000221,,,
1435,,,,B,H,Expert,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,,,1,13134,BAO_0000357,,,
1436,,,,B,H,Autocuration,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,,,1,12462,BAO_0000019,,,
1437,,,,B,H,Expert,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,,,1,12462,BAO_0000019,,,
1438,,,,B,H,Autocuration,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,,,1,12462,BAO_0000219,,CHO,
1439,,,,B,H,Expert,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,,,1,11933,BAO_0000357,,,
1440,,,,B,H,Autocuration,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,,,1,11933,BAO_0000357,,,
1441,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,403,BAO_0000221,,,
1442,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,15538,BAO_0000221,,,
1443,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,,,1,15538,BAO_0000221,,,
1444,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,,,1,15538,BAO_0000221,,,
1445,,,,B,H,Intermediate,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,,,1,12464,BAO_0000019,,,
1446,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,,,1,1455,BAO_0000357,,,
1447,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,1,12652,BAO_0000357,,,
1448,,,,B,H,Autocuration,Hippocampus,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,,,1,12639,BAO_0000221,,,
1449,,,,B,H,Expert,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,,,1,13949,BAO_0000249,,,
1450,,Rattus norvegicus,,B,D,Expert,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,,,1,12463,BAO_0000357,,,
1451,,,,B,H,Expert,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,,,1,14829,BAO_0000221,,,
1452,,,,B,H,Autocuration,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,,,1,14829,BAO_0000221,,,
1453,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,,,1,12092,BAO_0000357,,,
1454,,,,B,H,Autocuration,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,,,1,403,BAO_0000249,,,
1455,,,,B,H,Autocuration,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,,,1,403,BAO_0000249,,,
1456,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,,,1,3967,BAO_0000357,,,
1457,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,,,1,12771,BAO_0000019,,,
1458,,,,B,H,Autocuration,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,1,15086,BAO_0000019,,,
1459,,,,B,H,Autocuration,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14909,BAO_0000221,,,
1460,,,,B,H,Expert,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14949,BAO_0000221,,,
1461,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,,,1,2309,BAO_0000221,,,
1462,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,4170,BAO_0000357,,,
1463,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,,,1,11642,BAO_0000221,,,
1464,,,,B,H,Autocuration,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,,,1,11642,BAO_0000221,,,
1465,,,,B,H,Autocuration,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,,,1,12953,BAO_0000221,,,
1466,,,,B,H,Autocuration,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,1,12953,BAO_0000221,,,
1467,,,,B,H,Expert,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,12953,BAO_0000221,,,
1468,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,,,1,12903,BAO_0000219,,CHO,
1469,,,,B,H,Expert,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,1,12536,BAO_0000357,,,
1470,,,,B,H,Autocuration,,,The inhibition activity of 5-HT1A at 1 uM,10576,,,1,10058,BAO_0000357,,,
1471,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,,,1,12902,BAO_0000219,,CHO-K1,
1472,,,,B,H,Expert,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,,,1,14057,BAO_0000249,,,
1473,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,,,1,11296,BAO_0000357,,,
1474,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,,,
1475,,,,B,H,Expert,Hippocampus,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,,,
1476,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,,,1,16616,BAO_0000249,,,Membranes
1477,,Rattus norvegicus,,F,D,Expert,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,,1,16616,BAO_0000249,,,Membranes
1478,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,,,1,16567,BAO_0000019,,,
1479,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,,,1,16567,BAO_0000019,,,
1480,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,,,1,16567,BAO_0000019,,,
1481,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,,,1,16567,BAO_0000019,,,
1482,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,,,1,17136,BAO_0000249,,,
1483,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,,,1,17136,BAO_0000249,,,
1484,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,,,1,16616,BAO_0000019,,,
1485,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,,,1,17331,BAO_0000221,,,
1486,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,,,1,17331,BAO_0000221,,,
1487,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,,,1,17167,BAO_0000221,,,
1488,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,1,15740,BAO_0000019,,,
1489,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,,,1,15740,BAO_0000019,,,
1490,,,,B,H,Autocuration,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,,,1,4671,BAO_0000357,,,
1491,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,1,10058,BAO_0000221,,,
1492,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,1,10058,BAO_0000221,,,
1493,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,,,1,10058,BAO_0000221,,,
1494,,,,B,H,Autocuration,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,,,1,12073,BAO_0000357,,,
1495,,,,B,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,1,2759,BAO_0000249,,,
1496,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,1,2759,BAO_0000249,,,
1497,,,,B,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,1,2759,BAO_0000249,,,
1498,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,1,2759,BAO_0000249,,,
1499,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,1,2759,BAO_0000249,,,
1500,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,,,1,9737,BAO_0000249,,,
1501,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,,,1,9737,BAO_0000019,,,
1502,,,,F,H,Expert,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,,,1,5717,BAO_0000019,,,
1503,,,,B,H,Autocuration,Hippocampus,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,12253,BAO_0000221,,,
1504,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,,,1,14025,BAO_0000019,,,
1505,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,,,1,10425,BAO_0000249,,,
1506,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,,,1,14998,BAO_0000019,,,
1507,,,,B,H,Autocuration,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,,,1,13694,BAO_0000221,,,
1508,,,,B,H,Autocuration,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,,,1,13694,BAO_0000221,,,
1509,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,,,1,4342,BAO_0000357,,,
1510,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,1,12936,BAO_0000357,,,
1511,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,,,1,13144,BAO_0000019,,,
1512,,,,B,H,Expert,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,,,1,13343,BAO_0000019,,,
1513,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,12132,BAO_0000357,,,
1514,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,,,1,15419,BAO_0000019,,,
1515,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,1479,BAO_0000221,,,
1516,,,,B,H,Expert,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,,,1,14287,BAO_0000019,,,
1517,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,,,1,13116,BAO_0000357,,,
1518,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,,,1,2759,BAO_0000249,,,Membranes
1519,,,,B,H,Autocuration,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,1,2759,BAO_0000249,,,
1520,,,,B,H,Expert,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,,,1,14748,BAO_0000019,,,
1521,,,,B,H,Autocuration,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,12304,BAO_0000019,,,
1522,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,,,1,12409,BAO_0000221,,,
1523,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,,,1,12409,BAO_0000221,,,
1524,,,,B,H,Autocuration,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,,,1,13267,BAO_0000221,,,
1525,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,15194,BAO_0000357,,,
1526,,,,B,H,Expert,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,,,1,14256,BAO_0000357,,,
1527,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,,,1,16567,BAO_0000019,,,
1528,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,1,15740,BAO_0000019,,,
1529,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,1,13278,BAO_0000357,,,
1530,,,,B,H,Expert,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,,,1,1970,BAO_0000249,,,Membranes
1531,,,,B,H,Autocuration,Brain,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,,,1,10034,BAO_0000221,,,
1532,,Rattus norvegicus,,B,H,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,,,1,13348,BAO_0000019,,,
1533,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,,,
1534,,,,B,H,Autocuration,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,,,
1535,,,,B,H,Autocuration,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,1,12058,BAO_0000019,,,
1536,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,4639,BAO_0000357,,,
1537,,,,B,H,Expert,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,,,1,15453,BAO_0000357,,,
1538,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,4820,BAO_0000357,,,
1539,,,,B,H,Autocuration,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,,,1,1089,BAO_0000357,,,
1540,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,,,1,386,BAO_0000249,,,Brain membranes
1541,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,,,1,6011,BAO_0000357,,,
1542,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,,,1,5014,BAO_0000357,,,
1543,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,,,1,4402,BAO_0000357,,,
1544,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,17066,BAO_0000357,,,
1545,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,,,1,17515,BAO_0000357,,,
1546,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,2474,BAO_0000357,,,
1547,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,,,1,4775,BAO_0000357,,,
1548,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,,,1,14294,BAO_0000357,,,
1549,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,,,1,14294,BAO_0000357,,,
1550,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,12249,BAO_0000219,,CHO,
1551,,,,B,H,Expert,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,,,1,11376,BAO_0000219,,,
1552,In vivo,,,B,H,Autocuration,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,2474,BAO_0000218,,,
1553,,,,B,H,Autocuration,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,13311,BAO_0000221,,,
1554,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,,,1,4373,BAO_0000357,,,
1555,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,,,1,1633,BAO_0000357,,,
1556,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,1,11866,BAO_0000357,,,
1557,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,1,4373,BAO_0000357,,,
1558,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,,,1,4687,BAO_0000357,,,
1559,,,,B,H,Autocuration,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,,,1,16946,BAO_0000357,,,
1560,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,,,1,13291,BAO_0000357,,,
1561,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,,,1,14159,BAO_0000357,,,
1562,,,,B,H,Autocuration,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,,,1,10812,BAO_0000357,,,
1563,,Mus musculus,,B,D,Expert,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,,,1,3032,BAO_0000219,,CHO,
1564,,,,B,H,Autocuration,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,,,1,16655,BAO_0000357,,,
1565,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,,,1,14532,BAO_0000357,,,
1566,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,13944,BAO_0000357,,,
1567,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT1a receptor,11863,,,1,13033,BAO_0000357,,,
1568,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,,,1,10321,BAO_0000357,,,
1569,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,,,1,2968,BAO_0000357,,,
1570,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,,,1,13964,BAO_0000357,,,
1571,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,,,1,15527,BAO_0000357,,,
1572,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,1,12248,BAO_0000219,,CHO,
1573,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,1,12249,BAO_0000219,,CHO,
1574,,,,B,H,Autocuration,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,,,1,15120,BAO_0000357,,,
1575,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,,,1,13313,BAO_0000357,,,
1576,,,,B,H,Autocuration,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,,,1,2613,BAO_0000218,,,
1577,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,,,1,16700,BAO_0000357,,,
1578,,,,B,H,Autocuration,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,,,1,2201,BAO_0000357,,,
1579,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,1274,BAO_0000357,,,
1580,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,,,1,1317,BAO_0000357,,,
1581,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 1A receptor,11863,,,1,12146,BAO_0000357,,,
1582,,,,B,H,Autocuration,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,14059,BAO_0000357,,,
1583,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,,,1,14025,BAO_0000019,,,
1584,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,,,1,14025,BAO_0000019,,,
1585,,Gorilla gorilla,,B,D,Intermediate,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,,,1,14447,BAO_0000219,,HEK293,
1586,In vivo,Cavia porcellus,,F,H,Autocuration,,10141.0,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,,,1,3025,BAO_0000218,,,
1587,In vivo,Cavia porcellus,,F,H,Autocuration,,10141.0,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,,,1,3025,BAO_0000218,,,
1588,,Cavia porcellus,,F,H,Autocuration,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,,,1,15329,BAO_0000019,,,
1589,,Cavia porcellus,,F,H,Autocuration,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,,,1,15329,BAO_0000019,,,
1590,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,,,1,15847,BAO_0000019,,,
1591,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,,,1,15847,BAO_0000019,,,
1592,,,,F,H,Autocuration,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,,,1,14165,BAO_0000019,,,
1593,,,,F,H,Autocuration,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,,,1,14214,BAO_0000019,,,
1594,,,,F,H,Autocuration,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,,,1,14214,BAO_0000019,,,
1595,,Homo sapiens,,F,D,Expert,,9606.0,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,,,1,14214,BAO_0000019,,,
1596,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,,,1,13729,BAO_0000219,,CHO-K1,
1597,,,,F,H,Autocuration,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,,,1,3025,BAO_0000219,,CHO,
1598,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,1,2391,BAO_0000357,,,
1599,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,,,1,2391,BAO_0000019,,,
1600,,,,F,H,Expert,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,,,1,14956,BAO_0000219,,CHO,
1601,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,,,1,2598,BAO_0000219,,CHO,
1602,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,,,1,2598,BAO_0000219,,CHO,
1603,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,,,1,2598,BAO_0000219,,CHO,
1604,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,,,1,2598,BAO_0000219,,CHO,
1605,,,,F,H,Expert,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,1,14956,BAO_0000019,,,
1606,,,,F,H,Autocuration,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,1,14956,BAO_0000019,,,
1607,,Homo sapiens,,B,D,Expert,,9606.0,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,,,1,14214,BAO_0000357,,,
1608,,,,B,H,Expert,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,,,1,3463,BAO_0000219,,CHO,
1609,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,,,1,15331,BAO_0000357,,,
1610,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,16146,BAO_0000357,,,
1611,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,1,14159,BAO_0000219,,CHO,
1612,,,,B,H,Expert,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,,,1,14158,BAO_0000219,,CHO,
1613,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,,,1,14159,BAO_0000357,,,
1614,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,1,15250,BAO_0000219,,CHO,
1615,,,,B,H,Expert,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,,,1,15250,BAO_0000219,,CHO,
1616,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,1,15331,BAO_0000219,,CHO,
1617,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,,,1,15332,BAO_0000219,,CHO,
1618,,,,B,H,Expert,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,1,14956,BAO_0000219,,CHO,
1619,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,,,1,3805,BAO_0000357,,,
1620,,,,B,H,Autocuration,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,,,1,14875,BAO_0000357,,,
1621,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,,,
1622,,Oryctolagus cuniculus,,F,H,Expert,,9986.0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,,,
1623,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,,,1,16288,BAO_0000357,,,
1624,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,,,1,16288,BAO_0000357,,,
1625,,,,B,H,Autocuration,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,,,1,16312,BAO_0000357,,,
1626,,Bos taurus,,B,H,Expert,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,,,1,1348,BAO_0000357,,,
1627,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,,,1,5834,BAO_0000357,,,
1628,,Bos taurus,,B,H,Autocuration,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,,1,13366,BAO_0000019,,,
1629,,Bos taurus,,B,H,Expert,,9913.0,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,,,1,1414,BAO_0000357,,,
1630,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,,,1,14998,BAO_0000019,,,
1631,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,1,11473,BAO_0000357,,,
1632,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,1,11473,BAO_0000357,,,
1633,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,1,10639,BAO_0000357,,,
1634,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,1,10639,BAO_0000357,,,
1635,,Bos taurus,,B,H,Autocuration,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,,,1,1375,BAO_0000357,,,
1636,,Bos taurus,,B,H,Autocuration,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,,,1,1375,BAO_0000357,,,
1637,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,1,16532,BAO_0000357,,,
1638,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,,,1,11147,BAO_0000357,,,
1639,,Bos taurus,,B,H,Autocuration,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,,1,13366,BAO_0000019,,,
1640,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,,,1,10444,BAO_0000019,,,
1641,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,,,1,16532,BAO_0000357,,,
1642,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,1,16532,BAO_0000357,,,
1643,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,,,1,12827,BAO_0000249,,,
1644,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,,,1,12827,BAO_0000249,,,
1645,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,,,
1646,,Bos taurus,,B,H,Autocuration,,9913.0,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,,,1,14025,BAO_0000019,,,
1647,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,,,
1648,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,,,
1649,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,,,
1650,,Gorilla gorilla,,B,H,Autocuration,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,,,1,14447,BAO_0000219,,HEK293,
1651,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,,,1,1375,BAO_0000019,,,
1652,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,,,1,1375,BAO_0000019,,,
1653,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,,,1,12409,BAO_0000019,,,
1654,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000019,,,
1655,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,,,1,12409,BAO_0000019,,,
1656,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,,,1,12409,BAO_0000019,,,
1657,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,,,1,12409,BAO_0000019,,,
1658,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,,,1,11574,BAO_0000357,,,
1659,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,,,1,1558,BAO_0000357,,,
1660,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,,,
1661,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,,,
1662,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,,,
1663,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,,,1,12409,BAO_0000218,,,
1664,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,,,1,12253,BAO_0000019,,,
1665,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,,,1,12936,BAO_0000357,,,
1666,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,,,1,13181,BAO_0000019,,,
1667,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,,,1,12409,BAO_0000357,,,
1668,,Cavia porcellus,,B,D,Intermediate,,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,,,1,10639,BAO_0000357,,,
1669,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor,51,,,1,5254,BAO_0000357,,,
1670,,,,B,H,Autocuration,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,,,1,13051,BAO_0000357,,,
1671,,,,F,H,Expert,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,,,1,3463,BAO_0000019,,,
1672,,,,F,H,Autocuration,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000019,,,
1673,,,,F,H,Autocuration,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,,,1,6011,BAO_0000019,,,
1674,,Homo sapiens,,F,D,Expert,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,,,1,14159,BAO_0000219,,CHO,
1675,,,,F,H,Autocuration,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,,,1,14159,BAO_0000219,,CHO,
1676,,,,B,H,Expert,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,1,15250,BAO_0000219,,CHO,
1677,,,,B,H,Autocuration,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,,,1,15250,BAO_0000219,,CHO,
1678,,,,F,H,Expert,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,1,15331,BAO_0000219,,CHO,
1679,,Homo sapiens,,F,D,Expert,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,1,15332,BAO_0000219,,CHO,
1680,,,,F,H,Expert,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,,,1,15332,BAO_0000219,,CHO,
1681,,,,F,H,Autocuration,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,,,1,3294,BAO_0000219,,CHO,
1682,,,,F,H,Expert,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,,,1,14158,BAO_0000219,,CHO,
1683,,,,F,H,Expert,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,,,1,14956,BAO_0000219,,CHO,
1684,,,,F,H,Autocuration,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,,,1,12469,BAO_0000019,,,
1685,,,,F,H,Expert,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,1,3463,BAO_0000219,,CHO,
1686,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,1,15250,BAO_0000219,,CHO,
1687,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,1,15250,BAO_0000219,,CHO,
1688,,,,F,H,Expert,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,,,1,14956,BAO_0000019,,,
1689,,,,F,H,Autocuration,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,,,1,14159,BAO_0000019,,,
1690,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,,,1,14159,BAO_0000019,,,
1691,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,,,1,14499,BAO_0000219,,CHO,
1692,,,,F,H,Autocuration,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000019,,,
1693,In vitro,,,B,H,Autocuration,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,,,1,3294,BAO_0000219,,,
1694,,,,B,H,Expert,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,,,1,3463,BAO_0000219,,CHO,
1695,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,,,1,15331,BAO_0000357,,,
1696,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14159,BAO_0000219,,CHO,
1697,,,,B,H,Expert,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,,,1,14158,BAO_0000219,,CHO,
1698,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,,,1,14159,BAO_0000357,,,
1699,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,,,1,15250,BAO_0000219,,CHO,
1700,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15250,BAO_0000219,,CHO,
1701,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15331,BAO_0000219,,CHO,
1702,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,15332,BAO_0000219,,CHO,
1703,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14499,BAO_0000219,,CHO,
1704,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15332,BAO_0000219,,CHO,
1705,,,,B,H,Expert,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14956,BAO_0000219,,CHO,
1706,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,,,1,3805,BAO_0000357,,,
1707,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,,,1,6011,BAO_0000219,,CHO,
1708,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,1,16190,BAO_0000219,,CHO,
1709,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,,,1,14165,BAO_0000019,,,
1710,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,,,1,4234,BAO_0000357,,,
1711,,,,B,H,Autocuration,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,,,1,15527,BAO_0000357,,,
1712,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,,,1,6328,BAO_0000219,,,
1713,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,,,1,16209,BAO_0000357,,,
1714,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,,,1,14770,BAO_0000357,,,
1715,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,,,1,2598,BAO_0000357,,,
1716,,,,B,H,Expert,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,,,1,6897,BAO_0000357,,,
1717,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,,,1,6013,BAO_0000357,,,
1718,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,1,5843,BAO_0000357,,,
1719,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,,,1,14454,BAO_0000357,,,
1720,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,,,1,14454,BAO_0000357,,,
1721,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,,,1,14454,BAO_0000357,,,
1722,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,,,1,15818,BAO_0000357,,,
1723,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,,,1,13729,BAO_0000219,,CHO-K1,
1724,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,,,1,6011,BAO_0000219,,,
1725,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,,,1,4234,BAO_0000357,,,
1726,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,17085,BAO_0000019,,,
1727,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,,,1,3025,BAO_0000357,,,
1728,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000357,,,
1729,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,,,1,14214,BAO_0000219,,,
1730,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,3804,BAO_0000357,,,
1731,,,,B,H,Autocuration,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,,,1,16700,BAO_0000357,,,
1732,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,,,1,2391,BAO_0000357,,,
1733,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,4175,BAO_0000357,,,
1734,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,17085,BAO_0000019,,,
1735,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,,,1,17085,BAO_0000019,,,
1736,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,,,1,15926,BAO_0000357,,,
1737,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,,,1,16312,BAO_0000219,,CHO-K1,
1738,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,,,1,16312,BAO_0000219,,CHO-K1,
1739,,,,B,H,Autocuration,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,,,1,14956,BAO_0000219,,CHO,
1740,,,,F,H,Autocuration,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,,,1,3294,BAO_0000019,,,
1741,,,,B,H,Autocuration,,,Binding activity radioligand.,105,,,1,12861,BAO_0000357,,,
1742,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,,,1,12861,BAO_0000019,,,
1743,,,,B,H,Expert,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,,,1,16312,BAO_0000219,,CHO-K1,
1744,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,1,5104,BAO_0000357,,,
1745,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,1,5105,BAO_0000357,,,
1746,,,,B,H,Autocuration,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,,,1,14499,BAO_0000357,,,
1747,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor,105,,,1,15926,BAO_0000357,,,
1748,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,1,4540,BAO_0000219,,CHO,
1749,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,,,1,15779,BAO_0000219,,CHO,
1750,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,,,1,15779,BAO_0000219,,CHO,
1751,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,1,6166,BAO_0000357,,,
1752,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,,,1,15779,BAO_0000219,,CHO,
1753,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,,,1,15779,BAO_0000219,,CHO,
1754,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,1,17451,BAO_0000219,,HEK293,
1755,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,1,17451,BAO_0000219,,HEK293,
1756,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,,,1,17451,BAO_0000219,,HEK293,
1757,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,,,1,4199,BAO_0000219,,CHO,
1758,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,14875,BAO_0000357,,,
1759,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,,,1,15146,BAO_0000219,,CHO,
1760,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,,,1,5213,BAO_0000357,,,
1761,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,,,1,14818,BAO_0000219,,CHO,
1762,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,,,1,4829,BAO_0000219,,CHO,
1763,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,,,1,14454,BAO_0000019,,,
1764,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,,,1,14454,BAO_0000019,,,
1765,,,,B,H,Autocuration,,,Binding affinity against 5-HT2C receptor,108,,,1,5254,BAO_0000357,,,
1766,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor,108,,,1,5254,BAO_0000357,,,
1767,,,,B,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,1,10639,BAO_0000357,,,
1768,,,,F,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,1,10639,BAO_0000019,,,
1769,,,,B,H,Expert,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,,,1,12352,BAO_0000019,,,
1770,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1B was determined,10577,,,1,9098,BAO_0000357,,,
1771,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,,,1,14430,BAO_0000019,,,
1772,,,,B,H,Expert,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,,,1,13657,BAO_0000019,,,
1773,,,,B,H,Autocuration,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,,,1,13657,BAO_0000019,,,
1774,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,,,1,15854,BAO_0000019,,,
1775,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,,,1,10639,BAO_0000019,,,
1776,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,1,10025,BAO_0000357,,,
1777,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,,,1,10025,BAO_0000357,,,
1778,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,1,14286,BAO_0000249,,,
1779,,,,B,H,Autocuration,Striatum,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,,,1,3651,BAO_0000019,,,
1780,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,,,1,14178,BAO_0000357,,,
1781,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,,,1,10639,BAO_0000019,,,
1782,,,,B,H,Autocuration,Striatum,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,,,1,13605,BAO_0000019,,,
1783,,,,B,H,Autocuration,Striatum,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,,,1,5834,BAO_0000019,,,
1784,,,,B,H,Autocuration,Striatum,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,,,1,10922,BAO_0000357,,,
1785,,,,B,H,Autocuration,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,1,14286,BAO_0000249,,,
1786,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,,,1,11825,BAO_0000357,,,
1787,,,,B,H,Autocuration,Striatum,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,,,1,14826,BAO_0000019,,,
1788,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,,,1,9699,BAO_0000019,,,
1789,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,,,1,14423,BAO_0000019,,,
1790,,,,B,H,Expert,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,,,1,10062,BAO_0000357,,,
1791,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,1,10062,BAO_0000357,,,
1792,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,,,1,12280,BAO_0000357,,,
1793,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,,,1,15412,BAO_0000357,,,
1794,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,,,1,15412,BAO_0000357,,,
1795,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,1,10062,BAO_0000357,,,
1796,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,1,11147,BAO_0000357,,,
1797,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,,,1,9547,BAO_0000019,,,
1798,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,,,1,10444,BAO_0000019,,,
1799,,,,B,H,Autocuration,Striatum,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,,,1,12469,BAO_0000019,,,
1800,,,,B,H,Expert,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,,,1,9098,BAO_0000019,,,
1801,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,,,1,9098,BAO_0000019,,,
1802,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,1,9699,BAO_0000357,,,
1803,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,,,1,10394,BAO_0000249,,,
1804,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,,,1,12092,BAO_0000357,,,
1805,,,,B,H,Autocuration,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,,,1,16700,BAO_0000357,,,
1806,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,,,1,403,BAO_0000249,,,
1807,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,1,12771,BAO_0000357,,,
1808,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,,,1,11642,BAO_0000019,,,
1809,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,,,1,12953,BAO_0000357,,,
1810,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,,,1,12953,BAO_0000357,,,
1811,,,,B,H,Expert,Striatum,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,,,1,12953,BAO_0000019,,,
1812,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,,,1,12953,BAO_0000357,,,
1813,,,,B,H,Autocuration,Brain,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,1,9737,BAO_0000249,,,
1814,,,,B,H,Autocuration,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,,,1,9737,BAO_0000019,,,
1815,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,1,9737,BAO_0000249,,,
1816,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,,,1,12827,BAO_0000357,,,
1817,,,,B,H,Autocuration,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,,,1,5033,BAO_0000357,,,
1818,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,,,1,9786,BAO_0000019,,,
1819,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,,,1,13116,BAO_0000357,,,
1820,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,,,1,16429,BAO_0000019,,,
1821,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,,,1,12409,BAO_0000249,,,
1822,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,1,15194,BAO_0000357,,,
1823,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,,,1,15194,BAO_0000357,,,
1824,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,,,1,5486,BAO_0000019,,,
1825,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,4639,BAO_0000357,,,
1826,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,,,1,386,BAO_0000249,,,Brain membranes
1827,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,,,1,2474,BAO_0000357,,,
1828,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,,,1,6011,BAO_0000357,,,
1829,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,,,1,5014,BAO_0000357,,,
1830,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,,,1,17515,BAO_0000357,,,
1831,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,,,1,4373,BAO_0000357,,,
1832,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,,,1,1633,BAO_0000357,,,
1833,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,,,1,1633,BAO_0000357,,,
1834,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,,,1,4373,BAO_0000357,,,
1835,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,,,1,4687,BAO_0000357,,,
1836,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,11574,BAO_0000357,,,
1837,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,,,1,10321,BAO_0000357,,,
1838,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,1,15527,BAO_0000357,,,
1839,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,,,1,17200,BAO_0000357,,,
1840,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,,,1,14423,BAO_0000224,,,
1841,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,,,1,5834,BAO_0000357,,,
1842,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,,,1,11473,BAO_0000357,,,
1843,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,,,1,11473,BAO_0000357,,,
1844,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,1,10639,BAO_0000357,,,
1845,,Sus scrofa,,B,H,Autocuration,,9823.0,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,1,10639,BAO_0000357,,,
1846,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,,,1,14331,BAO_0000357,,,
1847,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,,,1,10796,BAO_0000357,,,
1848,,Sus scrofa,,B,H,Expert,,9823.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,,,1,9098,BAO_0000357,,,
1849,,Sus scrofa,,B,H,Expert,,9823.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,,,1,14331,BAO_0000357,,,
1850,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,,,1,11828,BAO_0000019,,,
1851,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,,,1,11866,BAO_0000357,,,
1852,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,,,1,13047,BAO_0000019,,,
1853,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,,,1,188,BAO_0000357,,,
1854,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,1,11825,BAO_0000357,,,
1855,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,1,11825,BAO_0000357,,,
1856,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,,,1,11624,BAO_0000019,,,
1857,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,,,1,11139,BAO_0000357,,,
1858,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,,,1,11147,BAO_0000357,,,
1859,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,,,1,10444,BAO_0000019,,,
1860,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,11624,BAO_0000357,,,
1861,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,,,
1862,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,,,
1863,,Rattus norvegicus,,B,D,Expert,,10116.0,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,,,
1864,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,,,
1865,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,,,1,9098,BAO_0000357,,,
1866,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,,,1,10394,BAO_0000249,,,
1867,,,,B,H,Expert,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,,,1,11933,BAO_0000357,,,
1868,,Rattus norvegicus,,B,D,Autocuration,,10116.0,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,,,1,12092,BAO_0000357,,,
1869,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,,,1,12253,BAO_0000019,,,
1870,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,,,1,12253,BAO_0000219,,HEK293,
1871,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,,,1,1558,BAO_0000357,,,
1872,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,1,2474,BAO_0000357,,,
1873,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,1,2474,BAO_0000357,,,
1874,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,11574,BAO_0000357,,,
1875,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,,,1,1558,BAO_0000357,,,
1876,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,13944,BAO_0000357,,,
1877,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT1c receptor,12689,,,1,13033,BAO_0000357,,,
1878,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,,,1,10321,BAO_0000357,,,
1879,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,,,1,11866,BAO_0000357,,,
1880,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,,,
1881,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,,,1,11574,BAO_0000224,,,
1882,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,,,1,11574,BAO_0000224,,,
1883,,,,B,H,Autocuration,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,,,1,13631,BAO_0000019,,,
1884,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,,,1,9630,BAO_0000019,,,
1885,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,,,1,8822,BAO_0000249,,,
1886,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,,,
1887,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,,,1,8868,BAO_0000224,,,
1888,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,,,1,9064,BAO_0000224,,,
1889,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,,,1,9806,BAO_0000019,,,
1890,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,1,9098,BAO_0000224,,,
1891,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,,,1,8868,BAO_0000224,,,
1892,,,,B,H,Autocuration,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,1,12765,BAO_0000224,,,
1893,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,,,
1894,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,,,
1895,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,,,1,11049,BAO_0000019,,,
1896,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,,,1,11049,BAO_0000019,,,
1897,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,,,
1898,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,,,1,11473,BAO_0000019,,,
1899,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,,,1,11473,BAO_0000019,,,
1900,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,,,1,3086,BAO_0000019,,,
1901,,,,B,H,Autocuration,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,,,
1902,,,,B,H,Autocuration,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,,,
1903,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,,,1,10639,BAO_0000019,,,
1904,,,,B,H,Autocuration,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,,,1,10922,BAO_0000019,,,
1905,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,,,
1906,,,,B,H,Autocuration,Brain,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,,,1,10748,BAO_0000221,,,
1907,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,1,11614,BAO_0000249,,,Membranes
1908,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,1,11615,BAO_0000249,,,Membranes
1909,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,,,1,11615,BAO_0000224,,,
1910,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,1,11614,BAO_0000249,,,Membranes
1911,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,,,1,11702,BAO_0000224,,,
1912,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,,,
1913,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,,,1,11702,BAO_0000224,,,
1914,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,,,
1915,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,,,1,13346,BAO_0000019,,,
1916,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,1,10025,BAO_0000224,,,
1917,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,1,10025,BAO_0000224,,,
1918,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,1,10025,BAO_0000224,,,
1919,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,,,1,9036,BAO_0000224,,,
1920,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,,,1,9036,BAO_0000224,,,
1921,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,,,1,9161,BAO_0000019,,,
1922,,,,B,H,Autocuration,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,,,1,12304,BAO_0000019,,,
1923,,,,B,H,Autocuration,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,,,1,13276,BAO_0000224,,,
1924,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,1,11825,BAO_0000224,,,
1925,,,,B,H,Autocuration,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,,,1,12443,BAO_0000224,,,
1926,,,,B,H,Autocuration,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,1,13830,BAO_0000224,,,
1927,,,,B,H,Autocuration,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,,,1,9592,BAO_0000249,,,Membranes
1928,,,,B,H,Autocuration,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,,,1,9592,BAO_0000249,,,Membranes
1929,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,,,1,10881,BAO_0000224,,,
1930,,,,B,H,Autocuration,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,,,1,13605,BAO_0000019,,,
1931,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,,,1,11624,BAO_0000224,,,
1932,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,1,4101,BAO_0000224,,,
1933,,,,B,H,Autocuration,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,1,4101,BAO_0000224,,,
1934,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,,,1,15360,BAO_0000019,,,
1935,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,11576,BAO_0000019,,,
1936,,,,B,H,Autocuration,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,,,1,5834,BAO_0000019,,,
1937,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,,CHO-K1,
1938,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,1,11965,BAO_0000249,,,Membranes
1939,,,,B,H,Autocuration,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,,,1,3967,BAO_0000224,,,
1940,,,,B,H,Autocuration,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,,,1,11130,BAO_0000249,,,Brain membranes
1941,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,1,13427,BAO_0000219,,,
1942,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,9443,BAO_0000224,,,
1943,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,1,9443,BAO_0000224,,,
1944,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,1,11825,BAO_0000224,,,
1945,,,,B,H,Autocuration,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,,,1,12120,BAO_0000249,,,Membranes
1946,,,,B,H,Autocuration,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,,,1,12120,BAO_0000249,,,Membranes
1947,,,,F,H,Autocuration,Thoracic aorta,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,,,1,11963,BAO_0000019,,,
1948,,,,B,H,Autocuration,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000019,,,
1949,,,,B,H,Autocuration,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,1,8868,BAO_0000224,,,
1950,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,,,1,17200,BAO_0000357,,,
1951,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,,,1,17200,BAO_0000357,,,
1952,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,,,1,13969,BAO_0000357,,,
1953,,,,B,D,Expert,,,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,,,1,13392,BAO_0000357,,,
1954,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,1742,BAO_0000249,,,
1955,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,1742,BAO_0000249,,,
1956,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,,,1,14331,BAO_0000357,,,
1957,,,,F,H,Autocuration,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,,,1,12861,BAO_0000019,,,
1958,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,,,1,12861,BAO_0000019,,,
1959,,,,B,H,Autocuration,,,Binding activity radioligand.,17106,,,1,12861,BAO_0000357,,,
1960,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,,,1,12861,BAO_0000019,,,
1961,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,1,12861,BAO_0000019,,,
1962,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,,,1,12861,BAO_0000019,,,
1963,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,675,BAO_0000249,,,
1964,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,,,1,12490,BAO_0000019,,,
1965,,,,B,H,Expert,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,,,1,11828,BAO_0000249,,,
1966,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,,,1,11866,BAO_0000357,,,
1967,,Sus scrofa,,B,H,Autocuration,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,,,1,773,BAO_0000357,,,
1968,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for intrinsic activity against 5-HT1D receptor,105,,,1,13047,BAO_0000357,,,
1969,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,,,
1970,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for binding affinity against 5-HT1D receptor,105,,,1,13047,BAO_0000357,,,
1971,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,,,1,188,BAO_0000357,,,
1972,,,,F,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,,,1,10639,BAO_0000019,,,
1973,,,,F,H,Autocuration,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,,,1,12438,BAO_0000019,,,
1974,,,,B,H,Autocuration,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,,,1,12438,BAO_0000357,,,
1975,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,,,1,15854,BAO_0000019,,,
1976,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,,,1,10394,BAO_0000249,,,
1977,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,,,1,12092,BAO_0000357,,,
1978,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,,,1,3389,BAO_0000019,,,
1979,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,,,1,6011,BAO_0000357,,,
1980,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,,,1,4639,BAO_0000357,,,
1981,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,,,1,2474,BAO_0000357,,,
1982,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,,,1,5014,BAO_0000357,,,
1983,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,,,1,17515,BAO_0000357,,,
1984,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,,,1,11866,BAO_0000357,,,
1985,,,,B,H,Autocuration,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,,,1,4687,BAO_0000357,,,
1986,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 1D receptor,105,,,1,12146,BAO_0000357,,,
1987,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,,,1,10321,BAO_0000357,,,
1988,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,,,1,13267,BAO_0000219,,HEK293,
1989,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,,,1,1274,BAO_0000357,,,
1990,,,,B,H,Autocuration,,,,105,,,1,15250,BAO_0000357,,,
1991,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,,CHO-K1,
1992,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,1,13706,BAO_0000219,,CHO-K1,
1993,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,,,1,13706,BAO_0000219,,HEK293,
1994,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,,,1,13706,BAO_0000219,,HEK293,
1995,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,,,
1996,,,,B,H,Autocuration,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,,,1,13366,BAO_0000357,,,
1997,,,,B,H,Expert,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,,,1,13366,BAO_0000357,,,
1998,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,,,1,1558,BAO_0000357,,,
1999,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,,,1,12902,BAO_0000219,,CHO-K1,
2000,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,1,13706,BAO_0000219,,CHO-K1,
2001,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,,,1,13706,BAO_0000019,,,
2002,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,,,1,13706,BAO_0000019,,,
2003,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,,,
2004,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,,,
2005,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,,,
2006,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,,,
2007,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,,,
2008,,,,B,H,Autocuration,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,,,1,13366,BAO_0000357,,,
2009,,,,B,H,Expert,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,,,1,13051,BAO_0000357,,,
2010,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,,,1,12903,BAO_0000219,,CHO,
2011,,Homo sapiens,,B,D,Autocuration,,9606.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,,,1,12469,BAO_0000219,,,
2012,,,,B,H,Autocuration,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,,,1,5619,BAO_0000357,,,
2013,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,,,
2014,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,,,
2015,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,,,
2016,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,,,
2017,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,,,1,16633,BAO_0000357,,,
2018,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,1,3269,BAO_0000357,,,
2019,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,1,12409,BAO_0000357,,,
2020,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,1,13706,BAO_0000019,,,
2021,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,,,1,13706,BAO_0000219,,HEK293,
2022,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,,,1,13706,BAO_0000219,,HEK293,
2023,,,,B,H,Autocuration,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,1,12903,BAO_0000219,,CHO,
2024,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,,,1,13047,BAO_0000019,,,
2025,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,,,
2026,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,,,
2027,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,,,
2028,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,,,1,13366,BAO_0000357,,,
2029,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,,,1,13366,BAO_0000357,,,
2030,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,,,1,12469,BAO_0000219,,CHO,
2031,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,,CHO-K1,
2032,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,,CHO-K1,
2033,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,1,13706,BAO_0000019,,,
2034,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,,,1,12902,BAO_0000219,,CHO-K1,
2035,,,,B,H,Expert,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,,,1,13051,BAO_0000357,,,
2036,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,1,12903,BAO_0000219,,CHO,
2037,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,,,1,1558,BAO_0000219,,CHO-K1,
2038,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,,,1,1558,BAO_0000219,,CHO-K1,
2039,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,,,1,1558,BAO_0000219,,CHO-K1,
2040,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,,,1,1558,BAO_0000219,,CHO-K1,
2041,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,,,1,1558,BAO_0000357,,,
2042,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,,,1,13047,BAO_0000019,,,
2043,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,,,1,13313,BAO_0000357,,,
2044,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,,,
2045,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,,,1,12409,BAO_0000357,,,
2046,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,,,1,15250,BAO_0000219,,CHO,
2047,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,,,1,1348,BAO_0000357,,,
2048,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,,,1,1348,BAO_0000357,,,
2049,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,,,1,4234,BAO_0000357,,,
2050,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,,,1,16209,BAO_0000357,,,
2051,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,,,1,10444,BAO_0000019,,,
2052,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,,,1,3935,BAO_0000357,,,
2053,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,,,1,15818,BAO_0000357,,,
2054,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,,,1,17085,BAO_0000019,,,
2055,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,,,1,12936,BAO_0000219,,CHO,
2056,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,,,1,6166,BAO_0000357,,,
2057,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,,,1,15779,BAO_0000219,,CHO,
2058,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,,,1,15779,BAO_0000219,,CHO,
2059,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,,,1,15779,BAO_0000219,,CHO,
2060,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,,,1,13181,BAO_0000357,,,
2061,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,,,1,4199,BAO_0000219,,CHO,
2062,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,,,1,14875,BAO_0000357,,,
2063,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,,,1,15146,BAO_0000219,,CHO,
2064,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,,,1,5213,BAO_0000357,,,
2065,,,,B,H,Autocuration,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,,,1,12146,BAO_0000357,,,
2066,,,,B,H,Autocuration,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,,,1,13267,BAO_0000219,,CHO,
2067,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,,,1,14818,BAO_0000219,,CHO,
2068,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,,,1,4829,BAO_0000219,,CHO,
2069,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,,,1,4373,BAO_0000357,,,
2070,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,,,1,4373,BAO_0000357,,,
2071,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,,,1,14159,BAO_0000357,,,
2072,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,,,1,16633,BAO_0000357,,,
2073,,,,F,H,Autocuration,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,,,1,17085,BAO_0000019,,,
2074,,,,F,H,Expert,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,,,1,17085,BAO_0000019,,,
2075,,,,F,H,Autocuration,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000019,,,
2076,,,,F,H,Autocuration,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000019,,,
2077,,,,F,H,Expert,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,,,1,17085,BAO_0000019,,,
2078,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,,,1,14159,BAO_0000357,,,
2079,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,,,1,15250,BAO_0000219,,CHO,
2080,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,,,1,3805,BAO_0000357,,,
2081,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,,,1,16190,BAO_0000219,,CHO,
2082,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,,,1,16190,BAO_0000357,,,
2083,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000357,,,
2084,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,,,1,16209,BAO_0000357,,,
2085,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,,,1,16209,BAO_0000357,,,
2086,,,,B,H,Autocuration,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,,,1,6866,BAO_0000357,,,
2087,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,1,17085,BAO_0000019,,,
2088,,,,B,H,Autocuration,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,,,1,16312,BAO_0000357,,,
2089,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,,,1,6166,BAO_0000357,,,
2090,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,1,15779,BAO_0000219,,CHO,
2091,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,,,1,4199,BAO_0000219,,CHO,
2092,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,,,1,14875,BAO_0000357,,,
2093,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,,,1,15146,BAO_0000219,,CHO,
2094,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,,,1,5213,BAO_0000357,,,
2095,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,,,1,14818,BAO_0000219,,CHO,
2096,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,1,4829,BAO_0000219,,CHO,
2097,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,1,4829,BAO_0000219,,CHO,
2098,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,,,1,4373,BAO_0000357,,,
2099,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,,,1,4373,BAO_0000357,,,
2100,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,,,1,5014,BAO_0000357,,,
2101,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,,,1,11662,BAO_0000019,,,
2102,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,1,11662,BAO_0000019,,,
2103,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,,,
2104,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,,,
2105,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,,,
2106,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2107,,,,B,H,Intermediate,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,,,1,12352,BAO_0000019,,,
2108,,Bos taurus,,B,U,Autocuration,,9913.0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,,,1,13657,BAO_0000019,,,
2109,,Bos taurus,,B,U,Autocuration,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,,,1,14331,BAO_0000019,,,
2110,,Bos taurus,,B,U,Autocuration,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,,,1,14331,BAO_0000019,,,
2111,,,,B,U,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,,,1,14331,BAO_0000019,,,
2112,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,,,1,12685,BAO_0000019,,,
2113,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,,,1,14389,BAO_0000019,,,
2114,,Cavia porcellus,,B,H,Autocuration,,10141.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,,,1,14386,BAO_0000019,,,
2115,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,,,1,5732,BAO_0000224,,,
2116,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,,,1,16293,BAO_0000224,,,
2117,,,,B,H,Autocuration,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,,,1,2078,BAO_0000224,,,
2118,,,,B,H,Autocuration,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,,,1,5486,BAO_0000357,,,
2119,In vivo,,,B,H,Autocuration,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,1,11820,BAO_0000218,,,
2120,,,,B,H,Autocuration,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,,,
2121,,,,B,H,Autocuration,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,,,1,13704,BAO_0000224,,,
2122,,Mus musculus,,B,D,Autocuration,,10090.0,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,,,
2123,In vivo,,,B,H,Autocuration,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,1,11820,BAO_0000218,,,
2124,,Mus musculus,,B,D,Autocuration,,10090.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,,,
2125,,,,B,H,Autocuration,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,,,1,11555,BAO_0000224,,,
2126,,,,B,H,Autocuration,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,,,1,11555,BAO_0000224,,,
2127,,,,B,H,Autocuration,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,,,1,11555,BAO_0000224,,,
2128,,Mus musculus,,B,D,Autocuration,,10090.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,,,
2129,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,,,1,16688,BAO_0000224,,,
2130,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,,,1,16688,BAO_0000224,,,
2131,,,,B,U,Autocuration,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,1,5333,BAO_0000221,,,
2132,,,,B,U,Autocuration,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,1,4437,BAO_0000221,,,
2133,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,,,1,5033,BAO_0000357,,,
2134,,,,B,H,Autocuration,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15267,BAO_0000019,,,
2135,,,,B,H,Autocuration,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15267,BAO_0000019,,,
2136,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,,,1,11820,BAO_0000019,,,
2137,,,,B,H,Autocuration,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000224,,,
2138,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,,,1,9162,BAO_0000019,,,
2139,,,,B,H,Autocuration,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,,,1,9162,BAO_0000019,,,
2140,,,,B,H,Autocuration,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,,,1,9162,BAO_0000019,,,
2141,,,,F,H,Autocuration,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,,,1,10428,BAO_0000019,,,
2142,,,,B,H,Autocuration,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,,,1,9628,BAO_0000019,,,
2143,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,,,1,12704,BAO_0000224,,,
2144,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,,,1,15453,BAO_0000224,,,
2145,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,,,1,188,BAO_0000224,,,
2146,,,,B,H,Autocuration,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,,,1,10349,BAO_0000224,,,
2147,,,,B,H,Autocuration,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,,,1,10349,BAO_0000224,,,
2148,,,,B,H,Autocuration,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,1,8868,BAO_0000224,,,
2149,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,1,10025,BAO_0000224,,,
2150,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,1,10025,BAO_0000224,,,
2151,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,,,1,11702,BAO_0000224,,,
2152,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,,,1,11702,BAO_0000224,,,
2153,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,,,
2154,,,,F,H,Autocuration,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,,,1,11702,BAO_0000019,,,
2155,,,,F,H,Autocuration,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,,,1,11702,BAO_0000019,,,
2156,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,,,1,10085,BAO_0000221,,,
2157,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,,,1,10085,BAO_0000221,,,
2158,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,,,1,9630,BAO_0000221,,,
2159,,,,B,H,Autocuration,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,11070,BAO_0000019,,,
2160,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,1,9841,BAO_0000249,,,Membranes
2161,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,1,9841,BAO_0000249,,,Membranes
2162,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,,,1,13291,BAO_0000019,,,
2163,,,,F,H,Autocuration,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,,,1,10590,BAO_0000019,,,
2164,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,,,
2165,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,,,1,12268,BAO_0000249,,,Membranes
2166,,,,B,H,Autocuration,Brain,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,,,1,13508,BAO_0000221,,,
2167,,,,F,H,Autocuration,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,1,11279,BAO_0000019,,,
2168,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2169,,,,F,H,Autocuration,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2170,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,1,11200,BAO_0000019,,,
2171,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,1,11200,BAO_0000019,,,
2172,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2173,,,,B,H,Autocuration,Brain,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,,,1,9231,BAO_0000220,,,
2174,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,1,9737,BAO_0000019,,,
2175,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,,,1,9737,BAO_0000249,,,
2176,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,,,1,9737,BAO_0000019,,,
2177,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,1,9737,BAO_0000019,,,
2178,,Rattus norvegicus,,B,D,Autocuration,,10116.0,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,,,1,11828,BAO_0000019,,,
2179,,,,B,H,Autocuration,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,,,1,12253,BAO_0000019,,,
2180,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,,,1,12253,BAO_0000019,,,
2181,,,,F,H,Autocuration,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,,,1,11279,BAO_0000019,,,
2182,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,,,1,11866,BAO_0000019,,,
2183,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,,,1,14424,BAO_0000224,,,
2184,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15180,BAO_0000019,,,
2185,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15180,BAO_0000019,,,
2186,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,,,1,9786,BAO_0000019,,,
2187,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,,,1,12132,BAO_0000224,,,
2188,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,,,1,5486,BAO_0000249,,,
2189,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,,,1,15316,BAO_0000019,,,
2190,,,,B,H,Autocuration,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,,,1,16429,BAO_0000019,,,
2191,,,,B,H,Autocuration,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,,,1,14617,BAO_0000224,,,
2192,,,,B,H,Autocuration,Brain,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,,,1,11351,BAO_0000221,,,
2193,,,,F,H,Autocuration,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,1,11279,BAO_0000019,,,
2194,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2195,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2196,,,,B,H,Autocuration,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2197,,,,B,H,Autocuration,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2198,,,,B,H,Autocuration,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2199,,,,B,H,Autocuration,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,,,
2200,,,,B,H,Autocuration,,,Hill coefficient of compound was determined,105075,,,1,9523,BAO_0000224,,,
2201,,,,B,U,Autocuration,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,,,1,4771,BAO_0000019,,,
2202,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,,,1,5033,BAO_0000019,,,
2203,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,,,1,10845,BAO_0000019,,,
2204,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,,,1,10845,BAO_0000019,,,
2205,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,,,1,16288,BAO_0000357,,,
2206,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,,,1,16288,BAO_0000019,,,
2207,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,,,1,16190,BAO_0000019,,,
2208,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,,,1,12463,BAO_0000224,,,
2209,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,,,1,9699,BAO_0000224,,,
2210,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,,,1,9699,BAO_0000224,,,
2211,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,,,
2212,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,,,1,1205,BAO_0000224,,,
2213,,,,B,U,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,,,1,11376,BAO_0000219,,,
2214,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,,,1,11376,BAO_0000219,,,
2215,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,,,1,4639,BAO_0000224,,,
2216,,,,B,H,Autocuration,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,,,1,2222,BAO_0000224,,,
2217,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,,,1,1558,BAO_0000224,,,
2218,,,,B,H,Autocuration,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,1089,BAO_0000224,,,
2219,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,,,1,386,BAO_0000249,,,Brain membranes
2220,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,,,1,2474,BAO_0000224,,,
2221,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2 receptor,104784,,,1,17066,BAO_0000224,,,
2222,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,,,1,959,BAO_0000224,,,
2223,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,,,1,6398,BAO_0000224,,,
2224,,,,B,H,Autocuration,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,,,1,11889,BAO_0000224,,,
2225,,,,B,H,Autocuration,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,4221,BAO_0000224,,,
2226,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,,,1,11026,BAO_0000224,,,
2227,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,,,1,11866,BAO_0000224,,,
2228,,,,B,H,Autocuration,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,4221,BAO_0000224,,,
2229,,,,B,U,Autocuration,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,,,1,13950,BAO_0000019,,,
2230,,,,B,H,Autocuration,,,5-hydroxytryptamine 2 receptor binding affinity,104784,,,1,1263,BAO_0000224,,,
2231,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,,,1,13291,BAO_0000357,,,
2232,,,,B,H,Autocuration,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,,,1,10812,BAO_0000357,,,
2233,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,1,13020,BAO_0000224,,,
2234,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,,,1,13021,BAO_0000224,,,
2235,,,,B,H,Autocuration,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,1,13020,BAO_0000224,,,
2236,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,,,1,14532,BAO_0000357,,,
2237,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,1,13944,BAO_0000357,,,
2238,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,1,14331,BAO_0000357,,,
2239,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,,,1,14118,BAO_0000357,,,
2240,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT2 receptor,17005,,,1,13033,BAO_0000357,,,
2241,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,,,1,10321,BAO_0000357,,,
2242,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,,,1,12918,BAO_0000357,,,
2243,,,,B,H,Autocuration,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,,,1,15120,BAO_0000357,,,
2244,,,,B,H,Autocuration,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,,,1,2613,BAO_0000218,,,
2245,,Homo sapiens,,B,D,Autocuration,,9606.0,Inhibitory activity against cloned human 5-HT2 receptor,104784,,,1,13378,BAO_0000224,,,
2246,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,,,1,2331,BAO_0000219,,CHO,
2247,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,,,1,2331,BAO_0000219,,CHO,
2248,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,,,1,2331,BAO_0000219,,CHO,
2249,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,,,1,2331,BAO_0000219,,CHO,
2250,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,,,1,4170,BAO_0000224,,,
2251,,,,B,H,Autocuration,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,,,1,15453,BAO_0000224,,,
2252,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,,,1,1479,BAO_0000357,,,
2253,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,,,1,11139,BAO_0000224,,,
2254,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,,,1,13969,BAO_0000357,,,
2255,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,,,1,13392,BAO_0000357,,,
2256,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,,,1,14430,BAO_0000019,,,
2257,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,,,1,13181,BAO_0000357,,,
2258,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,1,17200,BAO_0000357,,,
2259,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,,,
2260,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,1,17200,BAO_0000357,,,
2261,,,,B,H,Autocuration,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,,,1,13463,BAO_0000357,,,
2262,,,,B,H,Autocuration,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,1,6347,BAO_0000219,,CHO,
2263,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,,,1,6857,BAO_0000219,,CHO,
2264,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,1,4176,BAO_0000219,,,
2265,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,,,1,4176,BAO_0000219,,,
2266,,,,F,H,Autocuration,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,1,4176,BAO_0000219,,,
2267,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,,,1,6347,BAO_0000219,,CHO,
2268,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,,,1,6347,BAO_0000219,,CHO,
2269,,,,B,H,Autocuration,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,,,1,15331,BAO_0000357,,,
2270,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 2A receptor,107,,,1,16146,BAO_0000357,,,
2271,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,15250,BAO_0000219,,CHO,
2272,,,,B,H,Expert,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,,,1,13631,BAO_0000219,,,
2273,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,,,1,3805,BAO_0000357,,,
2274,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,,,1,4011,BAO_0000219,,CHO,
2275,,,,B,H,Expert,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,,,1,4012,BAO_0000219,,CHO,
2276,,,,B,H,Expert,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,,,1,6366,BAO_0000219,,L929,
2277,,,,B,H,Expert,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,15949,BAO_0000219,,CHO,
2278,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,,,1,14093,BAO_0000019,,,
2279,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,1,13481,BAO_0000019,,,
2280,,,,B,H,Autocuration,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,1,6347,BAO_0000219,,CHO,
2281,,,,B,H,Autocuration,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,,,1,6347,BAO_0000219,,CHO,
2282,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,,,1,14093,BAO_0000019,,,
2283,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,,,1,14093,BAO_0000019,,,
2284,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,1,13481,BAO_0000019,,,
2285,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,,,1,14442,BAO_0000357,,,
2286,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,1,14442,BAO_0000357,,,
2287,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,,,1,14755,BAO_0000357,,,
2288,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,,,1,16441,BAO_0000357,,,
2289,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,,,1,14744,BAO_0000357,,,
2290,,,,B,H,Expert,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,16659,BAO_0000219,,CHO,
2291,,,,B,H,Autocuration,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,,,1,3307,BAO_0000357,,,
2292,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,,,1,6857,BAO_0000019,,,
2293,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,,,1,5635,BAO_0000357,,,
2294,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,,,1,4234,BAO_0000357,,,
2295,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,1,15527,BAO_0000357,,,
2296,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,,,1,6588,BAO_0000219,,CHO,
2297,,,,B,H,Expert,,,Binding affinity towards human 5-HT2A receptor in BEK cells,107,,,1,13631,BAO_0000219,,,
2298,,,,B,H,Autocuration,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,,,1,17723,BAO_0000357,,,
2299,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,1,14770,BAO_0000357,,,
2300,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,1,16293,BAO_0000357,,,
2301,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,1,16209,BAO_0000357,,,
2302,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,,,1,12469,BAO_0000219,,,
2303,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,,,
2304,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,,,
2305,,,,B,H,Expert,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,,,1,16441,BAO_0000019,,,
2306,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,,,1,8,BAO_0000357,,,
2307,,,,B,H,Autocuration,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,,,1,4176,BAO_0000219,,HEK293,
2308,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,,,1,17085,BAO_0000019,,,
2309,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,,,
2310,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,,,
2311,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,,,1,4013,BAO_0000219,,CHO,
2312,,,,B,H,Autocuration,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,,,
2313,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,,,
2314,,,,B,H,Autocuration,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,,,1,5088,BAO_0000357,,,
2315,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,,,
2316,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,,,1,5088,BAO_0000357,,,
2317,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,,,1,5088,BAO_0000357,,,
2318,,,,B,H,Autocuration,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,,,1,9786,BAO_0000019,,,
2319,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,,,1,9205,BAO_0000019,,,
2320,,,,B,H,Autocuration,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,,,1,11257,BAO_0000224,,,
2321,,,,B,H,Autocuration,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,1,9362,BAO_0000019,,,
2322,,,,B,H,Autocuration,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,1,9362,BAO_0000019,,,
2323,,,,B,H,Autocuration,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,,,1,10590,BAO_0000224,,,
2324,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,1,10468,BAO_0000019,,,
2325,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,,,1,13050,BAO_0000019,,,
2326,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,,,1,11624,BAO_0000019,,,
2327,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,1,10468,BAO_0000019,,,
2328,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,,,1,10330,BAO_0000224,,,
2329,,,,B,H,Autocuration,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,1,10062,BAO_0000224,,,
2330,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,11642,BAO_0000224,,,
2331,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,10062,BAO_0000224,,,
2332,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,1,13427,BAO_0000219,,,
2333,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,12280,BAO_0000224,,,
2334,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,,,1,4101,BAO_0000224,,,
2335,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,10062,BAO_0000224,,,
2336,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,,,1,11147,BAO_0000224,,,
2337,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,,CHO-K1,
2338,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,,CHO-K1,
2339,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,,,1,9098,BAO_0000019,,,
2340,,,,B,H,Autocuration,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,,,1,9098,BAO_0000019,,,
2341,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,,,1,9098,BAO_0000019,,,
2342,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,9443,BAO_0000224,,,
2343,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,1,9443,BAO_0000224,,,
2344,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,,,1,9699,BAO_0000019,,,
2345,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,,,1,9699,BAO_0000019,,,
2346,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,1,9098,BAO_0000224,,,
2347,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity for 5-hydroxytryptamine 2 receptor,104686,,,1,3070,BAO_0000224,,,
2348,,,,B,H,Autocuration,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,,,1,9547,BAO_0000224,,,
2349,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,,,1,10444,BAO_0000019,,,
2350,,,,B,H,Autocuration,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,,,1,14617,BAO_0000019,,,
2351,,,,B,H,Autocuration,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,,,1,14617,BAO_0000019,,,
2352,,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,,,1,11130,BAO_0000224,,,
2353,In vivo,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,,,1,11130,BAO_0000218,,,
2354,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,,,1,14542,BAO_0000221,,,
2355,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,,,1,2797,BAO_0000224,,,
2356,,,,B,H,Autocuration,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,1,11332,BAO_0000019,,,
2357,,,,B,H,Autocuration,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,1,11332,BAO_0000019,,,
2358,,,,B,H,Autocuration,Frontal cortex,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,,,1,10752,BAO_0000019,,,
2359,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,1,1185,BAO_0000224,,,
2360,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,1,1185,BAO_0000224,,,
2361,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,,,1,11624,BAO_0000224,,,
2362,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,,,1,1344,BAO_0000019,,,
2363,,Rattus norvegicus,,B,D,Autocuration,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,,,1,15453,BAO_0000019,,,
2364,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,1,11662,BAO_0000019,,,
2365,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,,,
2366,,,,B,H,Autocuration,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,,,1,10796,BAO_0000224,,,
2367,,,,B,H,Autocuration,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000224,,,
2368,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,,,1,8814,BAO_0000019,,,
2369,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,,,1,8908,BAO_0000019,,,
2370,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,1,9098,BAO_0000019,,,
2371,,,,B,H,Autocuration,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,,,1,9098,BAO_0000019,,,
2372,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,1,9098,BAO_0000019,,,
2373,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,,,1,9098,BAO_0000019,,,
2374,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,,,1,9098,BAO_0000249,,,
2375,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,,,1,9098,BAO_0000019,,,
2376,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,,,1,9098,BAO_0000019,,,
2377,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,,,1,9161,BAO_0000019,,,
2378,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,,,1,9161,BAO_0000019,,,
2379,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,,,1,9161,BAO_0000019,,,
2380,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,,,1,9161,BAO_0000019,,,
2381,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,,,1,9161,BAO_0000019,,,
2382,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,,,1,9161,BAO_0000019,,,
2383,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,,,1,9161,BAO_0000019,,,
2384,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,,,1,9161,BAO_0000019,,,
2385,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,,,1,9161,BAO_0000019,,,
2386,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,,,1,9161,BAO_0000019,,,
2387,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,,,1,9161,BAO_0000019,,,
2388,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,,,1,9161,BAO_0000019,,,
2389,,,,B,H,Autocuration,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,,,1,12094,BAO_0000019,,,
2390,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,,,1,12018,BAO_0000249,,,
2391,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,,,1,10394,BAO_0000249,,,
2392,,,,B,H,Autocuration,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,,,1,15260,BAO_0000224,,,
2393,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,,,1,11624,BAO_0000224,,,
2394,,,,B,H,Autocuration,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,13654,BAO_0000224,,,
2395,,,,B,H,Autocuration,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,,,1,9541,BAO_0000019,,,
2396,,,,B,H,Autocuration,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,,,1,11933,BAO_0000224,,,
2397,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,15538,BAO_0000019,,,
2398,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,,,1,15538,BAO_0000019,,,
2399,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,,,1,15538,BAO_0000019,,,
2400,,,,B,D,Autocuration,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,,,1,8841,BAO_0000019,,,
2401,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,,,1,1455,BAO_0000224,,,
2402,,,,B,H,Autocuration,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,,,1,1455,BAO_0000224,,,
2403,,,,B,H,Autocuration,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,,,1,11752,BAO_0000019,,,
2404,,,,B,H,Autocuration,Brain,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,,,1,11642,BAO_0000221,,,
2405,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,,,1,12092,BAO_0000224,,,
2406,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,,,1,3967,BAO_0000224,,,
2407,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,12771,BAO_0000224,,,
2408,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,,,1,11642,BAO_0000019,,,
2409,,,,B,H,Autocuration,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,,,1,11628,BAO_0000224,,,
2410,,,,B,H,Autocuration,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,13654,BAO_0000224,,,
2411,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2412,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,,,
2413,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,,,
2414,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,1,11200,BAO_0000218,,,
2415,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,,,
2416,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,1,11200,BAO_0000218,,,
2417,,,,B,H,Expert,Brain,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000221,,,
2418,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,,,
2419,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,,,1,14025,BAO_0000019,,,
2420,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,,,1,4342,BAO_0000357,,,
2421,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,,,1,13735,BAO_0000019,,,
2422,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,,,1,5816,BAO_0000357,,,
2423,,,,B,H,Expert,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,,,1,14287,BAO_0000019,,,
2424,,,,B,H,Autocuration,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,,,1,15738,BAO_0000357,,,
2425,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,,,1,15738,BAO_0000357,,,
2426,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,,,1,15026,BAO_0000019,,,
2427,,,,B,H,Expert,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,1,16647,BAO_0000019,,,
2428,,,,B,H,Autocuration,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,,,1,16647,BAO_0000019,,,
2429,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,,,1,13345,BAO_0000019,,,
2430,,,,B,H,Autocuration,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,,,1,1543,BAO_0000249,,,Membranes
2431,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,,,1,12444,BAO_0000019,,,
2432,,,,B,H,Expert,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,,,1,16404,BAO_0000019,,,
2433,,,,B,H,Autocuration,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,,,1,16404,BAO_0000219,,CHO,
2434,,,,B,H,Expert,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,,,1,15577,BAO_0000357,,,
2435,,,,B,H,Autocuration,,,Serotonergic activity of the compound.,12687,,,1,15577,BAO_0000357,,,
2436,,,,B,H,Autocuration,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,,,1,2495,BAO_0000249,,,
2437,,Rattus norvegicus,,B,D,Expert,,10116.0,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,,,1,15042,BAO_0000019,,,
2438,,,,B,H,Expert,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,,,1,15026,BAO_0000249,,,
2439,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,,,
2440,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,,,
2441,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,,,
2442,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,15194,BAO_0000357,,,
2443,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,,,1,15194,BAO_0000357,,,
2444,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,4820,BAO_0000357,,,
2445,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,,,1,6736,BAO_0000357,,,
2446,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,,,1,5163,BAO_0000357,,,
2447,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,,,1,5163,BAO_0000357,,,
2448,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,,,1,6011,BAO_0000357,,,
2449,,Homo sapiens,,B,D,Expert,,9606.0,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,,,1,14294,BAO_0000357,,,
2450,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,,,1,5014,BAO_0000357,,,
2451,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,17066,BAO_0000357,,,
2452,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,,,1,17515,BAO_0000357,,,
2453,,,,B,H,Expert,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,,,1,6736,BAO_0000357,,,
2454,,,,B,H,Expert,,,Affinity for 5-hydroxytryptamine 2A receptor,107,,,1,5163,BAO_0000357,,,
2455,,,,B,H,Expert,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,,,1,16911,BAO_0000219,,NIH3T3,
2456,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,,,1,6841,BAO_0000357,,,
2457,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,,,1,6119,BAO_0000357,,,
2458,,,,B,H,Autocuration,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,,,1,3962,BAO_0000357,,,
2459,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,,,
2460,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,,,
2461,,,,F,H,Autocuration,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,,,1,3962,BAO_0000019,,,
2462,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,,,1,1633,BAO_0000357,,,
2463,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,,,
2464,,,,B,H,Expert,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,,,1,6576,BAO_0000357,,,
2465,,,,B,H,Autocuration,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,4687,BAO_0000357,,,
2466,,,,B,H,Autocuration,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,,,1,16946,BAO_0000357,,,
2467,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,,,1,14159,BAO_0000357,,,
2468,,Mus musculus,,B,H,Expert,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,,,1,3032,BAO_0000219,,CHO,
2469,,,,B,H,Autocuration,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,,,1,16655,BAO_0000357,,,
2470,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2A receptor,107,,,1,13964,BAO_0000357,,,
2471,,,,B,H,Expert,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,,,1,16989,BAO_0000357,,,
2472,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,,,1,16117,BAO_0000357,,,
2473,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,,,1,16700,BAO_0000357,,,
2474,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 2A receptor,107,,,1,3269,BAO_0000357,,,
2475,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,,,1,1274,BAO_0000357,,,
2476,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,,,1,1317,BAO_0000357,,,
2477,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 2A receptor,107,,,1,12146,BAO_0000357,,,
2478,,,,B,H,Autocuration,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,1,12652,BAO_0000224,,,
2479,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,,,1,12652,BAO_0000224,,,
2480,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,,,1,12652,BAO_0000224,,,
2481,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,1,12652,BAO_0000224,,,
2482,,,,B,H,Autocuration,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,,,1,16647,BAO_0000357,,,
2483,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,,,1,15851,BAO_0000219,,HEK293,
2484,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,,,1,6857,BAO_0000219,,CHO,
2485,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,,,1,3805,BAO_0000357,,,
2486,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,,,1,6491,BAO_0000357,,,
2487,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,,,1,14093,BAO_0000019,,,
2488,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,,,1,13481,BAO_0000019,,,
2489,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,,,1,14093,BAO_0000019,,,
2490,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,,,1,14093,BAO_0000019,,,
2491,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,,,1,14093,BAO_0000019,,,
2492,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,1,13481,BAO_0000019,,,
2493,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,,,1,14442,BAO_0000357,,,
2494,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,,,1,14442,BAO_0000357,,,
2495,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,1,14442,BAO_0000357,,,
2496,,,,B,H,Autocuration,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,,,1,12369,BAO_0000357,,,
2497,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,,,1,12369,BAO_0000357,,,
2498,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,,,1,12369,BAO_0000357,,,
2499,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,,,1,14447,BAO_0000019,,,
2500,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,,,1,14447,BAO_0000019,,,
2501,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,,NIH3T3,
2502,,,,F,H,Autocuration,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,1,6857,BAO_0000219,,CHO,
2503,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,1,6857,BAO_0000219,,CHO,
2504,,,,B,H,Autocuration,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,,,1,5635,BAO_0000224,,,
2505,,,,B,H,Autocuration,,,Binding activity radioligand.,107,,,1,12861,BAO_0000357,,,
2506,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,,,1,12861,BAO_0000019,,,
2507,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,1,5105,BAO_0000219,,L929,
2508,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,1,5104,BAO_0000219,,L929,
2509,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,,,1,5105,BAO_0000219,,L929,
2510,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,,,1,5105,BAO_0000219,,L929,
2511,,,,B,H,Autocuration,,,Binding affinity against 5-HT2A receptor,107,,,1,5254,BAO_0000357,,,
2512,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor,107,,,1,5254,BAO_0000357,,,
2513,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,,,1,13267,BAO_0000219,,HEK293,
2514,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,,,1,13267,BAO_0000219,,HEK293,
2515,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,,,1,14157,BAO_0000219,,HEK293,
2516,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,,HEK293,
2517,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,,,1,14068,BAO_0000357,,,
2518,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,,HEK293,
2519,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,,HEK293,
2520,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,,,1,4540,BAO_0000219,,HEK293,
2521,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,,,1,6166,BAO_0000357,,,
2522,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,,HEK293,
2523,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,,HEK293,
2524,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,,HEK293,
2525,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,,,1,15779,BAO_0000219,,HEK293,
2526,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,14391,BAO_0000219,,HEK293,
2527,,,,B,H,Expert,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,,,1,15851,BAO_0000219,,HEK293,
2528,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,,,1,15851,BAO_0000219,,HEK293,
2529,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,,,1,3832,BAO_0000219,,HEK293,
2530,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,,,1,3833,BAO_0000219,,HEK293,
2531,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,,HEK293,
2532,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,,,1,17451,BAO_0000219,,NIH3T3,
2533,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,,NIH3T3,
2534,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,,NIH3T3,
2535,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,,,1,4199,BAO_0000219,,HEK293,
2536,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,,,1,1883,BAO_0000219,,CHO-K1,
2537,,,,B,H,Expert,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,,,1,1883,BAO_0000219,,CHO-K1,
2538,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,1,14875,BAO_0000357,,,
2539,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,,,1,15146,BAO_0000219,,HEK293,
2540,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,,,1,5213,BAO_0000219,,HEK293,
2541,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,,,1,16404,BAO_0000219,,CHO,
2542,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,,,1,14818,BAO_0000219,,HEK293,
2543,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,,,1,4829,BAO_0000219,,HEK293,
2544,,,,F,H,Autocuration,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,,,1,12652,BAO_0000219,,NIH3T3,
2545,,,,B,H,Expert,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,,,1,4682,BAO_0000219,,NIH3T3,
2546,,,,F,H,Autocuration,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,,,1,12652,BAO_0000019,,,
2547,,,,B,H,Autocuration,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,,,1,4921,BAO_0000357,,,
2548,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,,,1,4921,BAO_0000357,,,
2549,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against rabbit aorta 5-HT2A receptor,107,,,1,16312,BAO_0000357,,,
2550,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,,,1,14998,BAO_0000357,,,
2551,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,,,1,14025,BAO_0000357,,,
2552,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,,,1,13047,BAO_0000019,,,
2553,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for binding affinity against 5-HT2A receptor,107,,,1,13047,BAO_0000357,,,
2554,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,,,1,1883,BAO_0000219,,CHO-K1,
2555,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,,,1,13463,BAO_0000019,,,
2556,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,1,13463,BAO_0000019,,,
2557,,,,B,H,Autocuration,Stomach,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,,,1,13463,BAO_0000019,,,
2558,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Binding affinity for 5-HT 2A in rat stomach fundus,12687,,,1,13463,BAO_0000019,,,
2559,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,1,13463,BAO_0000019,,,
2560,,,,B,H,Expert,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,,,1,16326,BAO_0000219,,NIH3T3,
2561,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,,,
2562,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,,,
2563,,,,B,H,Autocuration,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,1,15740,BAO_0000357,,,
2564,,,,B,H,Autocuration,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,,,1,16633,BAO_0000357,,,
2565,,Rattus norvegicus,,F,D,Expert,,10116.0,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,,,1,17200,BAO_0000019,,,
2566,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,,,
2567,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,,,
2568,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,,,
2569,,,,F,H,Autocuration,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,,,
2570,,,,F,H,Autocuration,,,Efficacy at 5-hydroxytryptamine 2A receptor,12687,,,1,15363,BAO_0000019,,,
2571,,,,B,H,Autocuration,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,1,17200,BAO_0000357,,,
2572,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,1,17200,BAO_0000357,,,
2573,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,,,1,17200,BAO_0000357,,,
2574,,Rattus norvegicus,,F,D,Expert,,10116.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,,,
2575,,,,F,H,Autocuration,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,,,
2576,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,,,1,17211,BAO_0000019,,,
2577,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,1,17331,BAO_0000019,,,
2578,,,,B,H,Expert,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,,,1,13565,BAO_0000249,,,
2579,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,,,1,13730,BAO_0000357,,,
2580,,,,B,H,Expert,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,,,1,12416,BAO_0000019,,,
2581,,,,B,H,Autocuration,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,1,15295,BAO_0000357,,,
2582,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,,,1,1742,BAO_0000019,,,
2583,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,,,1,15295,BAO_0000357,,,
2584,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,,,1,14970,BAO_0000019,,,
2585,,,,B,H,Expert,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,,,1,16693,BAO_0000019,,,
2586,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,,,1,14776,BAO_0000019,,,
2587,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,14286,BAO_0000249,,,
2588,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,1,17200,BAO_0000019,,,
2589,,,,B,H,Expert,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,,,1,15306,BAO_0000357,,,
2590,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,,,1,14178,BAO_0000357,,,
2591,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,,,1,14229,BAO_0000019,,,
2592,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,,,1,12884,BAO_0000357,,,
2593,,,,B,H,Expert,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,,,1,13149,BAO_0000357,,,
2594,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,,,1,15295,BAO_0000019,,,
2595,,,,B,H,Autocuration,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,,,1,15740,BAO_0000357,,,
2596,,,,B,H,Autocuration,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,,,1,15185,BAO_0000019,,,
2597,,,,B,H,Autocuration,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,,,1,15185,BAO_0000019,,,
2598,,,,B,H,Expert,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,,,1,17529,BAO_0000019,,,
2599,,,,B,H,Autocuration,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,1,14826,BAO_0000019,,,
2600,,,,B,H,Expert,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,,,1,17211,BAO_0000019,,,
2601,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,1,14826,BAO_0000019,,,
2602,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,,,
2603,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,,,1,14093,BAO_0000019,,,
2604,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,,,1,13246,BAO_0000219,,NIH3T3,
2605,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,,,1,13246,BAO_0000357,,,
2606,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,,,
2607,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,,,
2608,,,,B,H,Autocuration,Brain,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,,,1,14442,BAO_0000221,,,
2609,,,,B,H,Expert,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,,,1,12457,BAO_0000357,,,
2610,,,,B,H,Expert,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,12457,BAO_0000219,,NIH3T3,
2611,,,,F,H,Autocuration,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,,,1,14755,BAO_0000221,,,
2612,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,,,1,4707,BAO_0000357,,,
2613,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,1,13297,BAO_0000357,,,
2614,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,1,17331,BAO_0000019,,,
2615,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,,,1,4664,BAO_0000019,,,
2616,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,1,16633,BAO_0000357,,,
2617,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,,,1,4664,BAO_0000219,,NIH3T3,
2618,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,16133,BAO_0000357,,,
2619,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,16133,BAO_0000357,,,
2620,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,,,1,14060,BAO_0000019,,,
2621,,,,B,H,Expert,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,16326,BAO_0000357,,,
2622,,,,B,H,Expert,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,,,1,16659,BAO_0000219,,CHO,
2623,,,,B,H,Autocuration,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,,,1,14776,BAO_0000019,,,
2624,,,,B,H,Autocuration,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,,,1,13481,BAO_0000357,,,
2625,,,,B,H,Autocuration,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,,,1,17386,BAO_0000357,,,
2626,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,,,1,6611,BAO_0000357,,,
2627,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,,,1,14423,BAO_0000019,,,
2628,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,,,1,15412,BAO_0000019,,,
2629,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,,,1,15412,BAO_0000019,,,
2630,,,,B,H,Autocuration,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,,,1,6238,BAO_0000019,,,
2631,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,,,1,6648,BAO_0000357,,,
2632,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,,,1,5667,BAO_0000357,,,
2633,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,,,1,6611,BAO_0000357,,,
2634,,,,B,H,Autocuration,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,13481,BAO_0000357,,,
2635,,,,B,H,Autocuration,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,,,1,13481,BAO_0000357,,,
2636,,,,B,H,Expert,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,,,1,15558,BAO_0000219,,NIH3T3,
2637,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,1,6013,BAO_0000357,,,
2638,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,1,16633,BAO_0000357,,,
2639,,,,B,H,Autocuration,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,,,1,6013,BAO_0000357,,,
2640,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,,,1,6013,BAO_0000357,,,
2641,,,,B,H,Autocuration,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,,,1,6013,BAO_0000357,,,
2642,,,,B,H,Expert,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,,,1,6013,BAO_0000357,,,
2643,,,,B,H,Autocuration,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,,,1,6013,BAO_0000357,,,
2644,,,,B,H,Autocuration,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,,,1,6013,BAO_0000357,,,
2645,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,1,16293,BAO_0000357,,,
2646,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,,,1,17175,BAO_0000219,,NIH3T3,
2647,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,1,13278,BAO_0000357,,,
2648,,,,B,H,Autocuration,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,,,1,3682,BAO_0000019,,,
2649,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,,,1,2014,BAO_0000357,,,
2650,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,,,1,2014,BAO_0000357,,,
2651,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,,,1,4932,BAO_0000357,,,
2652,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,,,1,4932,BAO_0000019,,,
2653,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,,,1,3935,BAO_0000357,,,
2654,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,,,1,5432,BAO_0000221,,,
2655,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,1,15818,BAO_0000357,,,
2656,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,,,1,13672,BAO_0000357,,,
2657,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,,,1,13672,BAO_0000357,,,
2658,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,,,1,14749,BAO_0000219,,NIH3T3,
2659,,,,B,H,Autocuration,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,,,1,13462,BAO_0000019,,,
2660,,,,B,H,Autocuration,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,1,15740,BAO_0000357,,,
2661,,,,B,H,Expert,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,1,16647,BAO_0000019,,,
2662,,,,B,H,Autocuration,Brain,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,,,1,13345,BAO_0000221,,,
2663,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,,,
2664,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,,,
2665,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,,,1,15535,BAO_0000019,,,
2666,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,,,
2667,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,,,
2668,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,,,
2669,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,,,1,4795,BAO_0000019,,,
2670,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,,,1,8,BAO_0000019,,,
2671,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,,,1,8,BAO_0000019,,,
2672,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,1,17200,BAO_0000019,,,
2673,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,,,1,2148,BAO_0000019,,,
2674,,Rattus norvegicus,,B,D,Expert,,10116.0,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,,,1,13345,BAO_0000224,,,
2675,,,,B,H,Autocuration,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,5088,BAO_0000357,,,
2676,,,,B,H,Autocuration,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,5088,BAO_0000357,,,
2677,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,,,1,17133,BAO_0000357,,,
2678,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,,,1,17133,BAO_0000357,,,
2679,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,,,1,16532,BAO_0000357,,,
2680,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,1,15086,BAO_0000357,,,
2681,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,2309,BAO_0000019,,,
2682,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,,,1,12953,BAO_0000019,,,
2683,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,,,1,12953,BAO_0000019,,,
2684,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,,,1,12953,BAO_0000019,,,
2685,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,,,1,16659,BAO_0000219,,CHO,
2686,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,1,16740,BAO_0000019,,,
2687,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,1,16740,BAO_0000019,,,
2688,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,,,1,17133,BAO_0000357,,,
2689,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,,,1,17211,BAO_0000019,,,
2690,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,,,1,17331,BAO_0000019,,,
2691,,,,B,H,Autocuration,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,,,1,16633,BAO_0000218,,,
2692,,,,B,H,Autocuration,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,,,1,16633,BAO_0000218,,,
2693,,,,B,H,Autocuration,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,,,1,16633,BAO_0000218,,,
2694,,,,B,H,Expert,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,,,1,15026,BAO_0000357,,,
2695,,,,B,H,Expert,,,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,,,1,15026,BAO_0000357,,,
2696,,,,B,H,Expert,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,1,16404,BAO_0000224,,,
2697,,,,B,H,Expert,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,1,16404,BAO_0000224,,,
2698,,,,B,H,Expert,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,,,1,16404,BAO_0000224,,,
2699,,,,B,H,Autocuration,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,,,1,16404,BAO_0000357,,,
2700,,,,B,H,Expert,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,,,1,16326,BAO_0000357,,,
2701,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,,,1,15847,BAO_0000019,,,
2702,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,,,1,15847,BAO_0000019,,,
2703,,,,F,H,Autocuration,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,,,
2704,,,,F,H,Expert,Thoracic aorta,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,,,1,16404,BAO_0000019,,,
2705,,,,F,H,Expert,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,,,1,16404,BAO_0000019,,,
2706,,,,F,H,Autocuration,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,,,1,16404,BAO_0000019,,,
2707,,,,B,H,Autocuration,,,Binding activity radioligand.,12687,,,1,12861,BAO_0000357,,,
2708,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,1,12861,BAO_0000019,,,
2709,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,,,1,12861,BAO_0000019,,,
2710,,,,B,H,Expert,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,,,1,12490,BAO_0000019,,,
2711,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,,,1,12827,BAO_0000219,,N1E-115,
2712,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,,,1,12827,BAO_0000219,,N1E-115,
2713,,,,B,H,Autocuration,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,,,1,12918,BAO_0000019,,,
2714,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,,,1,12919,BAO_0000019,,,
2715,,,,B,H,Autocuration,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,,,1,17723,BAO_0000357,,,
2716,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,6013,BAO_0000357,,,
2717,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,,,1,16293,BAO_0000357,,,
2718,,,,B,H,Expert,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,1,3857,BAO_0000019,,,
2719,,,,B,H,Expert,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,,,1,3857,BAO_0000019,,,
2720,,,,B,H,Expert,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,1,3857,BAO_0000019,,,
2721,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,1,15363,BAO_0000357,,,
2722,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,1,15363,BAO_0000357,,,
2723,,,,B,H,Expert,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,,,1,16441,BAO_0000019,,,
2724,,,,B,H,Expert,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,,,1,16441,BAO_0000019,,,
2725,,,,B,H,Autocuration,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,,,1,4176,BAO_0000219,,HEK293,
2726,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,,,1,17085,BAO_0000019,,,
2727,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,,,1,17200,BAO_0000357,,,
2728,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,,,1,5088,BAO_0000357,,,
2729,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,,,1,5088,BAO_0000357,,,
2730,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,5088,BAO_0000357,,,
2731,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,,,1,5088,BAO_0000357,,,
2732,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,16659,BAO_0000219,,CHO,
2733,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,,,1,16659,BAO_0000219,,CHO,
2734,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,,,1,17451,BAO_0000219,,NIH3T3,
2735,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,,,1,6857,BAO_0000219,,CHO,
2736,,,,B,H,Expert,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,1,3857,BAO_0000019,,,
2737,,,,B,H,Autocuration,,,Binding activity radioligand.,108,,,1,12861,BAO_0000357,,,
2738,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,,,1,12861,BAO_0000019,,,
2739,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,,,1,5104,BAO_0000219,,CHO,
2740,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,,,1,5105,BAO_0000219,,CHO,
2741,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,,,1,5105,BAO_0000219,,CHO,
2742,,,,B,H,Autocuration,,,Binding affinity against 5-HT2C receptor,108,,,1,5254,BAO_0000357,,,
2743,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,,,1,13267,BAO_0000219,,HEK293,
2744,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,,,1,14157,BAO_0000219,,HEK293,
2745,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,1,12936,BAO_0000219,,HEK293,
2746,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,,,1,14068,BAO_0000357,,,
2747,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,1,12936,BAO_0000219,,HEK293,
2748,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,,,1,4540,BAO_0000219,,HEK293,
2749,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,,,1,4540,BAO_0000219,,HEK293,
2750,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,,,1,6166,BAO_0000357,,,
2751,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,17296,BAO_0000219,,HEK293,
2752,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,17296,BAO_0000219,,HEK293,
2753,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,1,15779,BAO_0000219,,HEK293,
2754,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,1,15779,BAO_0000219,,HEK293,
2755,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,14391,BAO_0000219,,HEK293,
2756,,,,B,H,Autocuration,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,,,1,15779,BAO_0000219,,HEK293,
2757,,,,B,H,Expert,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,,,1,15851,BAO_0000219,,HEK293,
2758,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,,,1,15851,BAO_0000219,,HEK293,
2759,,,,B,H,Autocuration,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,,,1,15779,BAO_0000219,,HEK293,
2760,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,,,1,3832,BAO_0000219,,HEK293,
2761,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,,,1,3833,BAO_0000219,,HEK293,
2762,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,,,1,17451,BAO_0000219,,NIH3T3,
2763,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,,,1,4199,BAO_0000219,,HEK293,
2764,,,,B,H,Expert,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,,,1,1883,BAO_0000219,,CHO-K1,
2765,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,4321,BAO_0000357,,,
2766,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,,,1,14875,BAO_0000357,,,
2767,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,,,1,15146,BAO_0000219,,HEK293,
2768,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,,,1,5213,BAO_0000219,,HEK293,
2769,,,,B,H,Autocuration,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,,,1,16404,BAO_0000219,,HeLa,
2770,,,,F,H,Autocuration,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,,,1,13267,BAO_0000019,,,
2771,,,,F,H,Autocuration,Hippocampus,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,,,1,13267,BAO_0000221,,,
2772,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,,,1,14818,BAO_0000219,,HEK293,
2773,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,,,1,4829,BAO_0000219,,HEK293,
2774,,,,B,H,Autocuration,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,,,1,13463,BAO_0000357,,,
2775,,,,B,H,Autocuration,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,,,1,13463,BAO_0000019,,,
2776,,,,B,H,Autocuration,Stomach,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,,,1,13463,BAO_0000019,,,
2777,,,,F,H,Autocuration,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,,,1,12652,BAO_0000219,,A9,
2778,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,,NIH3T3,
2779,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,,NIH3T3,
2780,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,,NIH3T3,
2781,,,,F,H,Autocuration,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,,,1,12652,BAO_0000019,,,
2782,,Mus musculus,,B,H,Autocuration,Stomach,10090.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,,,1,13463,BAO_0000019,,,
2783,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,,,1,13463,BAO_0000019,,,
2784,,,,B,H,Expert,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,,,1,13969,BAO_0000357,,,
2785,,Sus scrofa,,B,H,Expert,,9823.0,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,,,
2786,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,,,
2787,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,,,1,14430,BAO_0000019,,,
2788,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,,,1,1742,BAO_0000019,,,
2789,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,,,1,14286,BAO_0000249,,,
2790,,,,B,H,Autocuration,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,,,1,5619,BAO_0000357,,,
2791,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,15086,BAO_0000357,,,
2792,,,,B,H,Autocuration,,,Binding activity radioligand.,108,,,1,12861,BAO_0000357,,,
2793,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,,,1,12861,BAO_0000019,,,
2794,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,,,1,12861,BAO_0000019,,,
2795,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,,,1,12827,BAO_0000249,,,
2796,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,,,1,12827,BAO_0000249,,,
2797,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,1,12919,BAO_0000019,,,
2798,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,1,12919,BAO_0000019,,,
2799,,Sus scrofa,,B,H,Autocuration,,9823.0,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,,,1,16429,BAO_0000357,,,
2800,,Sus scrofa,,B,H,Autocuration,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,,,1,773,BAO_0000019,,,
2801,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,,,1,5033,BAO_0000357,,,
2802,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,1,12861,BAO_0000019,,,
2803,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,,,1,14093,BAO_0000019,,,
2804,,,,B,H,Expert,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,,,1,14970,BAO_0000357,,,
2805,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,,,1,14970,BAO_0000357,,,
2806,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,,,1,14970,BAO_0000357,,,
2807,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,1,14178,BAO_0000357,,,
2808,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,1,14178,BAO_0000357,,,
2809,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,,,1,14229,BAO_0000249,,,Brain membranes
2810,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,,,1,16532,BAO_0000357,,,
2811,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,,,1,14826,BAO_0000019,,,
2812,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,,,1,17211,BAO_0000019,,,
2813,In vitro,,,B,H,Expert,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,,,1,17211,BAO_0000219,,,
2814,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,,,1,13246,BAO_0000219,,NIH3T3,
2815,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,,,1,13246,BAO_0000357,,,
2816,,,,B,H,Expert,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,,,1,12457,BAO_0000357,,,
2817,,,,B,H,Expert,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,,,1,12457,BAO_0000219,,NIH3T3,
2818,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,,,1,4707,BAO_0000357,,,
2819,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,,,1,13297,BAO_0000357,,,
2820,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,1,16633,BAO_0000357,,,
2821,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,1,16133,BAO_0000357,,,
2822,,,,B,H,Expert,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,,,1,16326,BAO_0000357,,,
2823,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,,,1,14423,BAO_0000019,,,
2824,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,,,1,15412,BAO_0000019,,,
2825,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,,,1,15412,BAO_0000019,,,
2826,,,,B,H,Expert,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,,,1,15558,BAO_0000219,,A9,
2827,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,1,16633,BAO_0000357,,,
2828,,,,B,H,Expert,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,,,1,6013,BAO_0000357,,,
2829,In vitro,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,,,1,17175,BAO_0000219,,,
2830,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,,,1,12469,BAO_0000219,,,
2831,,,,B,H,Autocuration,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,,,1,3682,BAO_0000019,,,
2832,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,,,1,4932,BAO_0000357,,,
2833,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,,,1,4932,BAO_0000019,,,
2834,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,,,1,3935,BAO_0000357,,,
2835,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,,,1,15818,BAO_0000357,,,
2836,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,,,1,15818,BAO_0000357,,,
2837,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,,,1,14749,BAO_0000219,,,
2838,,,,B,H,Autocuration,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,,,1,15740,BAO_0000357,,,
2839,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,,,1,17133,BAO_0000357,,,
2840,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,,,1,16532,BAO_0000357,,,
2841,,,,B,H,Autocuration,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,,,1,12369,BAO_0000357,,,
2842,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,,,1,12369,BAO_0000219,,,
2843,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,,,1,2309,BAO_0000019,,,
2844,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,,,1,12953,BAO_0000357,,,
2845,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,,,1,12953,BAO_0000019,,,
2846,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,,,1,12953,BAO_0000357,,,
2847,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,,,1,12953,BAO_0000357,,,
2848,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,,,1,17133,BAO_0000357,,,
2849,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,,,1,17211,BAO_0000019,,,
2850,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,,,1,17211,BAO_0000019,,,
2851,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,,,1,14025,BAO_0000019,,,
2852,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,,,1,14998,BAO_0000019,,,
2853,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,,,1,4342,BAO_0000357,,,
2854,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,,,1,13735,BAO_0000019,,,
2855,,,,B,H,Autocuration,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,,,1,13181,BAO_0000357,,,
2856,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,,,1,1883,BAO_0000219,,CHO-K1,
2857,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,1,15194,BAO_0000357,,,
2858,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,,,1,15194,BAO_0000357,,,
2859,,,,F,H,Autocuration,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,,,1,14579,BAO_0000019,,,
2860,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,4639,BAO_0000357,,,
2861,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,4820,BAO_0000357,,,
2862,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,,,1,14442,BAO_0000357,,,
2863,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,,,1,14755,BAO_0000357,,,
2864,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,,,1,14744,BAO_0000357,,,
2865,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,,,1,6857,BAO_0000019,,,
2866,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,,,1,16209,BAO_0000357,,,
2867,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,,,
2868,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,,,
2869,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,,,
2870,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,,,1,17085,BAO_0000019,,,
2871,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,,,1,17200,BAO_0000357,,,
2872,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,1,15851,BAO_0000219,,HEK293,
2873,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,1,15851,BAO_0000219,,HEK293,
2874,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,1,6857,BAO_0000219,,CHO,
2875,,Homo sapiens,,F,D,Expert,,9606.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,1,6857,BAO_0000219,,CHO,
2876,,,,B,H,Autocuration,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,15779,BAO_0000219,,HEK293,
2877,,,,B,H,Expert,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,,,1,15851,BAO_0000219,,HEK293,
2878,,,,B,H,Autocuration,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,,,1,15779,BAO_0000219,,HEK293,
2879,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,,,1,14157,BAO_0000219,,HEK293,
2880,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,,,1,4540,BAO_0000219,,HEK293,
2881,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,,,1,6166,BAO_0000357,,,
2882,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,,,1,15779,BAO_0000219,,HEK293,
2883,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,,,1,14391,BAO_0000219,,HEK293,
2884,,,,B,H,Expert,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,,,1,3832,BAO_0000219,,HEK293,
2885,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,,,1,3833,BAO_0000219,,HEK293,
2886,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,,,1,15851,BAO_0000219,,HEK293,
2887,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,,,1,15851,BAO_0000219,,HEK293,
2888,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,,,1,4199,BAO_0000219,,HEK293,
2889,,,,B,H,Expert,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,,,1,1883,BAO_0000219,,CHO-K1,
2890,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2B receptor,227,,,1,4321,BAO_0000357,,,
2891,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,,,1,15146,BAO_0000219,,HEK293,
2892,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,,,1,5213,BAO_0000219,,HEK293,
2893,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,,,1,14818,BAO_0000219,,HEK293,
2894,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,4829,BAO_0000219,,HEK293,
2895,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,4829,BAO_0000219,,HEK293,
2896,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,,,1,14025,BAO_0000019,,,
2897,,,,B,H,Expert,Stomach,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,,,1,13463,BAO_0000019,,,
2898,,,,B,H,Expert,Stomach,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,,,1,7259,BAO_0000357,,,
2899,,,,B,H,Autocuration,Stomach,,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,,,1,7259,BAO_0000357,,,
2900,,Rattus norvegicus,,F,D,Expert,Stomach,10116.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,,,1,7185,BAO_0000019,,,
2901,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,,,1,7185,BAO_0000019,,,
2902,,,,F,H,Autocuration,Stomach,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,,,1,13267,BAO_0000019,,,
2903,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,,,1,13735,BAO_0000357,,,
2904,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,,,1,15738,BAO_0000019,,,
2905,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,,,1,15738,BAO_0000019,,,
2906,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,,,1,15738,BAO_0000019,,,
2907,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,,,
2908,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,,,
2909,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,,,
2910,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,,,
2911,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,,,
2912,,,,F,H,Expert,Stomach,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,,,
2913,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,,,1,16404,BAO_0000019,,,
2914,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,,,1,16404,BAO_0000019,,,
2915,,Rattus norvegicus,,F,D,Expert,Stomach,10116.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,,,1,16404,BAO_0000019,,,
2916,,,,F,H,Autocuration,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,,,1,16404,BAO_0000019,,,
2917,,,,B,H,Autocuration,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,,,
2918,,,,B,H,Expert,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,,,1,7483,BAO_0000357,,,
2919,,,,B,H,Autocuration,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,,,
2920,,,,B,H,Autocuration,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,,,
2922,,Rattus norvegicus,,F,D,Autocuration,Stomach,10116.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,,,
2923,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,227,,,1,6347,BAO_0000357,,,
2924,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,,,1,4373,BAO_0000357,,,
2925,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,,,1,4373,BAO_0000357,,,
2926,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-HT 2B receptor,227,,,1,4687,BAO_0000357,,,
2927,,,,B,H,Autocuration,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,,,1,16946,BAO_0000357,,,
2928,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 2B receptor,227,,,1,16633,BAO_0000357,,,
2929,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,,,1,16633,BAO_0000357,,,
2930,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,,,1,16633,BAO_0000357,,,
2931,,,,B,H,Expert,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,1,15026,BAO_0000357,,,
2932,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,1,15738,BAO_0000357,,,
2933,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,,,1,15738,BAO_0000357,,,
2934,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,,,1,15738,BAO_0000357,,,
2935,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,,,1,15738,BAO_0000357,,,
2936,,Bos taurus,,B,H,Expert,,9913.0,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,,,1,16404,BAO_0000357,,,
2937,,Bos taurus,,B,H,Expert,,9913.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,1,15026,BAO_0000357,,,
2938,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,1,15738,BAO_0000357,,,
2939,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,,,1,16312,BAO_0000019,,,
2940,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,,,1,5486,BAO_0000357,,,
2941,,,,B,H,Autocuration,,,Binding affinity against 5-HT1A receptor,51,,,1,5254,BAO_0000357,,,
2942,,,,F,H,Expert,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,,,1,3857,BAO_0000219,,CHO,
2943,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,,,1,6857,BAO_0000219,,CHO,
2944,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,,,1,4176,BAO_0000219,,,
2945,,,,B,H,Autocuration,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,,,1,6347,BAO_0000219,,CHO,
2946,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,,,1,6347,BAO_0000219,,CHO,
2947,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 2C receptor,108,,,1,16146,BAO_0000357,,,
2948,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,,,1,3805,BAO_0000357,,,
2949,,,,B,H,Autocuration,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,1,3857,BAO_0000019,,,
2950,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,,,1,5635,BAO_0000357,,,
2951,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,1,5635,BAO_0000357,,,
2952,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,1,5635,BAO_0000357,,,
2953,,,,B,H,Expert,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,,,1,4012,BAO_0000219,,CHO,
2954,,,,B,H,Expert,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,,,1,6366,BAO_0000219,,CHO,
2955,,,,B,H,Expert,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,15949,BAO_0000219,,CHO,
2956,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,,,1,17211,BAO_0000219,,CHO,
2957,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,,,1,6491,BAO_0000357,,,
2958,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,,,1,14093,BAO_0000019,,,
2959,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,,,1,13481,BAO_0000019,,,
2960,,Rattus norvegicus,,B,H,Expert,,10116.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,,,1,6347,BAO_0000219,,CHO,
2961,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,,,1,14093,BAO_0000019,,,
2962,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,,,1,14093,BAO_0000019,,,
2963,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,13481,BAO_0000019,,,
2964,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,,,1,14442,BAO_0000357,,,
2965,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,,,1,14442,BAO_0000357,,,
2966,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,,,1,14442,BAO_0000357,,,
2967,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,,,1,14755,BAO_0000357,,,
2968,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,,,1,14744,BAO_0000357,,,
2969,,,,B,H,Expert,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,16659,BAO_0000219,,CHO,
2970,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,,,1,6857,BAO_0000019,,,
2971,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,,,1,5635,BAO_0000357,,,
2972,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,,,1,4234,BAO_0000357,,,
2973,,,,B,H,Autocuration,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,,,1,16209,BAO_0000357,,,
2974,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,,,1,5778,BAO_0000249,,,Membranes
2975,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,,,1,5094,BAO_0000223,,,
2976,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,,,1,809,BAO_0000019,,,
2977,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,,,1,1578,BAO_0000019,,,
2978,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,,,1,809,BAO_0000019,,,
2979,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,,,1,12469,BAO_0000219,,,
2980,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,,,1,14290,BAO_0000019,,,
2981,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,,,1,14290,BAO_0000019,,,
2982,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,,,1,10609,BAO_0000223,,,
2983,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,,,1,10609,BAO_0000223,,,
2984,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,,,1,10609,BAO_0000223,,,
2985,,,,B,H,Autocuration,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,1,15253,BAO_0000249,,,
2986,,,,B,H,Autocuration,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,1,15253,BAO_0000249,,,
2987,,,,B,H,Autocuration,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,,,1,11683,BAO_0000249,,,Membranes
2988,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,,,1,12092,BAO_0000223,,,
2989,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,1,1946,BAO_0000019,,,
2990,,,,B,H,Autocuration,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,,,1,11623,BAO_0000223,,,
2991,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,,,1,11623,BAO_0000223,,,
2992,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,,,1,14788,BAO_0000019,,,
2993,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,,,1,5432,BAO_0000019,,,
2994,,,,B,H,Autocuration,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,14826,BAO_0000249,,,
2995,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,,,1,2222,BAO_0000223,,,
2996,,,,B,H,Autocuration,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,,,1,11963,BAO_0000019,,,
2997,,,,B,H,Autocuration,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,,,1,14145,BAO_0000019,,,
2998,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,,,1,17819,BAO_0000019,,,
2999,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,1,10394,BAO_0000249,,,
3000,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,1,10394,BAO_0000249,,,
3001,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,1,15034,BAO_0000019,,,
3002,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,1,691,BAO_0000019,,,
3003,,,,B,H,Autocuration,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,,,1,12092,BAO_0000249,,,Membranes
3004,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,,,1,11752,BAO_0000223,,,
3005,,,,B,H,Autocuration,Brain,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,,,1,11752,BAO_0000221,,,
3006,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,,,1,301,BAO_0000019,,,
3007,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,,,1,16532,BAO_0000223,,,
3008,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,1,16532,BAO_0000223,,,
3009,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,,,1,12092,BAO_0000223,,,
3010,,,,B,H,Autocuration,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,,,1,11684,BAO_0000223,,,
3011,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,,,1,11684,BAO_0000223,,,
3012,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,,,1,12953,BAO_0000019,,,
3013,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,,,1,12953,BAO_0000019,,,
3014,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,,,1,12953,BAO_0000223,,,
3015,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,,,1,12861,BAO_0000019,,,
3016,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3017,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3018,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3019,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3020,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3021,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3022,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3023,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3024,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3025,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3026,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3027,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3028,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3029,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3030,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3031,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3032,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3033,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3034,,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,,,1,10609,BAO_0000019,,,
3035,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,,,1,12861,BAO_0000019,,,
3036,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,1,12861,BAO_0000019,,,
3037,,,,B,H,Autocuration,,,Binding activity radioligand.,104698,,,1,12861,BAO_0000223,,,
3038,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,,,1,10728,BAO_0000249,,,Brain membranes
3039,,,,B,H,Autocuration,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,,,1,10728,BAO_0000249,,,Brain membranes
3040,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,,,1,5163,BAO_0000357,,,
3041,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,,,1,5163,BAO_0000357,,,
3042,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,,,1,6011,BAO_0000357,,,
3043,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,,,1,5014,BAO_0000357,,,
3044,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,,,1,5635,BAO_0000357,,,
3045,,,,B,H,Expert,,,Affinity for 5-hydroxytryptamine 2C receptor,108,,,1,5163,BAO_0000357,,,
3046,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,6841,BAO_0000357,,,
3047,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,,,1,6119,BAO_0000357,,,
3048,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,,,1,4373,BAO_0000357,,,
3049,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,,,1,1633,BAO_0000357,,,
3050,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,,,1,1633,BAO_0000357,,,
3051,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,,,1,4373,BAO_0000357,,,
3052,,,,B,H,Expert,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,,,1,6576,BAO_0000357,,,
3053,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,,,1,4687,BAO_0000357,,,
3054,,,,B,H,Autocuration,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,,,1,12146,BAO_0000357,,,
3055,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,,,1,12146,BAO_0000357,,,
3056,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,,,1,16946,BAO_0000357,,,
3057,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,,,1,14159,BAO_0000357,,,
3058,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,,,1,16700,BAO_0000357,,,
3059,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 2C receptor,108,,,1,3269,BAO_0000357,,,
3060,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,1274,BAO_0000357,,,
3061,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,,,1,1317,BAO_0000357,,,
3062,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,,,1,5834,BAO_0000357,,,
3063,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,,,1,11147,BAO_0000357,,,
3064,,Cavia porcellus,,F,H,Expert,,10141.0,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,,,1,14145,BAO_0000019,,,
3065,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,,1,10561,BAO_0000221,,,
3066,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,,,1,15847,BAO_0000019,,,
3067,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,,,1,15847,BAO_0000019,,,
3068,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,,1,10561,BAO_0000221,,,
3069,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,,,1,11454,BAO_0000221,,,
3070,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,,,
3071,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,,,1,4639,BAO_0000019,,,
3072,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,,,1,4639,BAO_0000019,,,
3073,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,,,1,4639,BAO_0000019,,,
3074,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,,,
3075,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,,,1,4639,BAO_0000019,,,
3076,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,,,1,15253,BAO_0000221,,,
3077,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,,,1,15253,BAO_0000221,,,
3078,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,,,1,11963,BAO_0000221,,,
3079,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,,,1,1946,BAO_0000221,,,
3080,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,,,1,1946,BAO_0000221,,,
3081,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,,,1,12045,BAO_0000223,,,
3082,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,,,
3083,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,,,
3084,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,,,
3085,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,,,1,188,BAO_0000221,,,
3086,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,,,1,12919,BAO_0000221,,,
3087,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,,,1,12918,BAO_0000221,,,
3088,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,,,
3089,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,,,
3090,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,,,
3091,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,,,1,1559,BAO_0000221,,,
3092,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,,,1,1559,BAO_0000221,,,
3093,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,,,1,14424,BAO_0000221,,,
3094,,Cavia porcellus,,B,U,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,,,1,13181,BAO_0000019,,,
3095,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,,,1,5486,BAO_0000357,,,
3096,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,,,1,6491,BAO_0000223,,,
3097,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor,104714,,,1,6013,BAO_0000223,,,
3098,,,,B,H,Autocuration,,,Binding activity radioligand.,104714,,,1,12861,BAO_0000223,,,
3099,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,,,1,12861,BAO_0000019,,,
3100,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,1,5104,BAO_0000223,,,
3101,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,1,5105,BAO_0000223,,,
3102,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,,,1,5104,BAO_0000223,,,
3103,,,,B,U,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,,,1,3935,BAO_0000019,,,
3104,,,,B,H,Expert,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,,,1,13657,BAO_0000219,,NG108-15,
3105,In vivo,,,B,H,Autocuration,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,,,1,10369,BAO_0000218,,,
3106,,,,B,H,Autocuration,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,1,10369,BAO_0000019,,,
3107,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,,,1,12918,BAO_0000224,,,
3108,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,,,1,12918,BAO_0000224,,,
3109,,,,B,H,Autocuration,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,1,10369,BAO_0000019,,,
3110,,,,B,H,Autocuration,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,,,1,773,BAO_0000019,,,
3111,,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor agonism in mouse,105030,,,1,12918,BAO_0000218,,,
3112,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,,,1,10561,BAO_0000219,,,
3113,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,1,12827,BAO_0000019,,,
3114,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,1,12827,BAO_0000019,,,
3115,,,,B,H,Autocuration,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,,,1,12918,BAO_0000224,,,
3116,,,,B,H,Autocuration,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,1,273,BAO_0000219,,,
3117,,,,B,H,Autocuration,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,1,273,BAO_0000219,,,
3118,,,,B,H,Autocuration,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,,,1,10561,BAO_0000224,,,
3119,In vitro,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,,,1,5033,BAO_0000219,,,
3120,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,,,1,16429,BAO_0000219,,N1E-115,
3121,,,,B,H,Autocuration,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,,,1,10322,BAO_0000019,,,
3122,,,,B,H,Autocuration,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,,,1,14331,BAO_0000219,,,
3123,,Mus musculus,,B,D,Autocuration,,10090.0,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,,,1,13462,BAO_0000357,,,
3124,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,1,12861,BAO_0000019,,,
3125,,Sus scrofa,,B,H,Autocuration,,9823.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,,,1,15086,BAO_0000357,,,
3126,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity radioligand.,144,,,1,12861,BAO_0000357,,,
3127,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,,,1,10561,BAO_0000223,,,
3128,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,,,1,10561,BAO_0000223,,,
3129,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,,,1,10561,BAO_0000223,,,
3130,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,,,1,10561,BAO_0000019,,,
3131,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,,,
3132,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,,,
3133,,Oryctolagus cuniculus,,F,H,Autocuration,Ileum,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,,,
3134,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,,,
3135,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,,,
3136,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,,,
3137,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,,,
3138,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,,,1,13047,BAO_0000219,,CHO,
3139,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,,,1,1650,BAO_0000019,,,
3140,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,,,1,16288,BAO_0000019,,,
3141,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,,,1,16288,BAO_0000357,,,
3142,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,,,1,10254,BAO_0000019,,,
3143,,,,B,H,Autocuration,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,,,1,14532,BAO_0000019,,,
3144,In vivo,,,F,H,Autocuration,Heart,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000218,,,
3145,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,,,
3146,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,,,
3147,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,,,
3148,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,,,
3149,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,,,
3150,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,,,
3151,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,,,
3152,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,,,
3153,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,,,1,1089,BAO_0000218,,,
3154,In vivo,,,F,H,Autocuration,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,,,1,1089,BAO_0000218,,,
3155,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3156,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,,,1,11454,BAO_0000019,,,
3157,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,,,1,12205,BAO_0000218,,,
3158,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,,,1,1089,BAO_0000019,,,
3159,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,1,5094,BAO_0000019,,,
3160,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,,,1,2622,BAO_0000019,,,
3161,,,,B,H,Autocuration,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,,,1,245,BAO_0000223,,,
3162,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,,,1,14788,BAO_0000019,,,
3163,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,,,1,14788,BAO_0000019,,,
3164,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,,,1,3020,BAO_0000249,,,
3165,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,,,1,1742,BAO_0000019,,,
3166,,,,B,H,Autocuration,Brain,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,,,1,17394,BAO_0000249,,,
3167,,,,B,H,Autocuration,Brain,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,,,1,17394,BAO_0000221,,,
3168,,,,B,H,Autocuration,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,17394,BAO_0000249,,,
3169,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,14286,BAO_0000249,,,
3170,,,,B,H,Autocuration,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,,,1,14178,BAO_0000019,,,
3171,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,,,1,14178,BAO_0000019,,,
3172,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,,,1,14178,BAO_0000019,,,
3173,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,,,1,14178,BAO_0000223,,,
3174,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,1,15034,BAO_0000019,,,
3175,,,,B,H,Autocuration,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,,,1,1089,BAO_0000249,,,Membranes
3176,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,,,1,1089,BAO_0000019,,,
3177,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,1,16532,BAO_0000223,,,
3178,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,,,1,12801,BAO_0000223,,,
3179,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,,,1,15194,BAO_0000219,,NG108-15,
3180,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000219,,NG108-15,
3181,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000019,,,
3182,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,,,1,15194,BAO_0000019,,,
3183,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,,,1,15194,BAO_0000019,,,
3184,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,,,1,15194,BAO_0000019,,,
3185,,,,F,H,Autocuration,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,,,1,10610,BAO_0000019,,,
3186,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,,,1,10355,BAO_0000019,,,
3187,,,,F,H,Autocuration,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,,,1,691,BAO_0000019,,,
3188,,,,F,H,Autocuration,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,,,1,10611,BAO_0000218,,,
3189,In vivo,,,F,H,Autocuration,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,,,1,12801,BAO_0000218,,,
3190,,,,F,H,Autocuration,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,,,1,10609,BAO_0000218,,,
3191,In vivo,,,F,H,Autocuration,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3192,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3193,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,,,1,11454,BAO_0000218,,,
3194,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3195,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3196,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,,,1,11454,BAO_0000218,,,
3197,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3198,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3199,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3200,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3201,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3202,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3203,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3204,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3205,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3206,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3207,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3208,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,,,1,11454,BAO_0000218,,,
3209,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,,,1,11454,BAO_0000218,,,
3210,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,,,1,11454,BAO_0000218,,,
3211,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,,,1,11454,BAO_0000218,,,
3212,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,,,1,11454,BAO_0000218,,,
3213,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3214,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3215,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3216,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3217,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3218,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3219,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,,,
3220,,,,F,H,Autocuration,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,,,1,670,BAO_0000218,,,
3221,,,,F,H,Autocuration,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,,,1,670,BAO_0000218,,,
3222,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,,,1,10321,BAO_0000218,,,
3223,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,,,1,10321,BAO_0000218,,,
3224,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,,,1,10321,BAO_0000218,,,
3225,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,,,1,10321,BAO_0000218,,,
3226,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,,,1,10321,BAO_0000218,,,
3227,In vivo,,,F,H,Autocuration,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,,,1,10322,BAO_0000218,,,
3228,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,1,15412,BAO_0000019,,,
3229,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,1,15412,BAO_0000019,,,
3230,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,,,1,15412,BAO_0000223,,,
3231,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,,,1,15412,BAO_0000019,,,
3232,,,,B,D,Intermediate,Hippocampus,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,,,1,15412,BAO_0000221,,,
3233,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,,,1,15412,BAO_0000019,,,
3234,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,,,1,17394,BAO_0000019,,,
3235,,,,B,H,Autocuration,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,,,1,12457,BAO_0000223,,,
3236,,,,B,H,Autocuration,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,,,1,12457,BAO_0000019,,,
3237,,,,B,H,Autocuration,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,,,1,12205,BAO_0000019,,,
3238,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,,,1,14532,BAO_0000019,,,
3239,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,,,1,1122,BAO_0000019,,,
3240,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,1,5094,BAO_0000019,,,
3241,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,,,1,809,BAO_0000221,,,
3242,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,,,1,809,BAO_0000221,,,
3243,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,,,1,14290,BAO_0000221,,,
3244,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,,,1,14290,BAO_0000221,,,
3245,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,,,
3246,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,,,
3247,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,,,1,14290,BAO_0000221,,,
3248,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,,,1,13961,BAO_0000221,,,
3249,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,,,1,13961,BAO_0000221,,,
3250,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,,,1,809,BAO_0000221,,,
3251,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,,,1,809,BAO_0000221,,,
3252,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,,,1,809,BAO_0000221,,,
3253,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,,,1,14290,BAO_0000221,,,
3254,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,,,1,14290,BAO_0000221,,,
3255,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,,,1,14290,BAO_0000221,,,
3256,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,,,1,14290,BAO_0000221,,,
3257,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,,,
3258,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,,,
3259,,Cavia porcellus,,B,D,Intermediate,,10141.0,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,,1,15034,BAO_0000357,,,
3260,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,,,
3261,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,,,
3262,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,,,1,5399,BAO_0000357,,,
3263,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,,1,17394,BAO_0000357,,,
3264,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,,1,17394,BAO_0000357,,,
3265,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,,1,17394,BAO_0000357,,,
3266,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,,,1,13961,BAO_0000221,,,
3267,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,,,1,13961,BAO_0000221,,,
3268,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,,1,13961,BAO_0000221,,,
3269,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,,,1,16946,BAO_0000357,,,
3270,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,,,1,16946,BAO_0000357,,,
3271,,Cavia porcellus,,F,D,Intermediate,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,1,15034,BAO_0000019,,,
3272,,Cavia porcellus,,F,D,Intermediate,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,,,1,15034,BAO_0000019,,,
3273,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,,,1,12918,BAO_0000019,,,
3274,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,,,1,16946,BAO_0000357,,,
3275,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,,1,17394,BAO_0000357,,,
3276,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,,,1,15034,BAO_0000357,,,
3277,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,,,
3278,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,,,
3279,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,,,1,17358,BAO_0000221,,,
3280,,Cavia porcellus,,B,D,Expert,,10141.0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,,,1,12953,BAO_0000357,,,
3281,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,1,12953,BAO_0000357,,,
3282,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,,,1,12953,BAO_0000357,,,
3283,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,1,12953,BAO_0000357,,,
3284,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,,,
3285,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,,,1,12918,BAO_0000221,,,
3286,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,,,1,12919,BAO_0000221,,,
3287,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,,,1,273,BAO_0000221,,,
3288,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,,,
3289,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,,,1,13181,BAO_0000357,,,
3290,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,,,1,13181,BAO_0000357,,,
3291,,Cavia porcellus,,F,D,Intermediate,,10141.0,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,1,15034,BAO_0000019,,,
3292,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,,1,5033,BAO_0000357,,,
3293,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,,,1,1980,BAO_0000019,,,
3294,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,,,1,13181,BAO_0000219,,HEK293,
3295,,Cavia porcellus,,B,D,Intermediate,,10141.0,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,,,1,14287,BAO_0000019,,,
3296,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,,,1,1317,BAO_0000357,,,
3297,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,,,1,15316,BAO_0000357,,,
3298,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,,,1,16429,BAO_0000357,,,
3299,,Cavia porcellus,,B,D,Intermediate,Hippocampus,10141.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,,,1,14818,BAO_0000221,,,
3300,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,,,1,15194,BAO_0000357,,,
3301,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,,,1,15194,BAO_0000357,,,
3302,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,,1,13961,BAO_0000221,,,
3303,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,,,1,5486,BAO_0000357,,,
3304,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,,,1,16209,BAO_0000357,,,
3305,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,,,1,17085,BAO_0000019,,,
3306,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,,,1,4199,BAO_0000219,,HeLa,
3307,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,15146,BAO_0000357,,,
3308,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,,,1,5213,BAO_0000357,,,
3309,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,,,1,4829,BAO_0000219,,HeLa,
3310,,,,B,H,Autocuration,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,,,1,17358,BAO_0000357,,,
3311,,,,B,H,Autocuration,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,,,1,17358,BAO_0000357,,,
3312,,,,B,H,Autocuration,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,,,1,16946,BAO_0000219,,,
3313,,,,B,H,Autocuration,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,,,1,17358,BAO_0000357,,,
3314,,,,F,H,Autocuration,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,,,1,268,BAO_0000019,,,
3315,,,,F,H,Autocuration,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,,,1,268,BAO_0000019,,,
3316,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,,,1,15086,BAO_0000357,,,
3317,,,,B,H,Autocuration,Hippocampus,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,,,1,14875,BAO_0000221,,,
3318,,Sus scrofa,,B,H,Autocuration,Hippocampus,9823.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,,,1,13267,BAO_0000221,,,
3319,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,,,1,13047,BAO_0000019,,,
3320,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,,,1,1650,BAO_0000357,,,
3321,,,,F,H,Autocuration,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,1,567,BAO_0000019,,,
3322,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,,,1,17358,BAO_0000357,,,
3323,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,,,1,188,BAO_0000357,,,
3324,,,,F,H,Autocuration,,,lntrinsic activity relative to 5-HT receptor,10623,,,1,670,BAO_0000019,,,
3325,,,,F,H,Autocuration,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,,,1,204,BAO_0000019,,,
3326,,,,F,H,Expert,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,,,1,1946,BAO_0000019,,,
3327,,,,F,H,Autocuration,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,,,1,6398,BAO_0000019,,,
3328,,,,F,H,Autocuration,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,,,1,6398,BAO_0000019,,,
3329,,,,F,H,Autocuration,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,,,1,17358,BAO_0000019,,,
3330,,,,F,H,Autocuration,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,,,1,6398,BAO_0000019,,,
3331,,,,B,H,Expert,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,,,1,11752,BAO_0000357,,,
3332,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,,,1,809,BAO_0000019,,,
3333,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,,,1,14178,BAO_0000357,,,
3334,,,,B,H,Autocuration,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,1,567,BAO_0000357,,,
3335,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,,,1,1946,BAO_0000357,,,
3336,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,,,1,1946,BAO_0000357,,,
3337,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,,,1,13961,BAO_0000019,,,
3338,,,,B,H,Autocuration,Striatum,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,,,1,6238,BAO_0000249,,,
3339,,,,B,H,Autocuration,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,,,1,14290,BAO_0000249,,,
3340,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,,,1,14290,BAO_0000249,,,
3341,,Rattus norvegicus,,B,D,Expert,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,,1,809,BAO_0000019,,,
3342,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,,1,1578,BAO_0000019,,,
3343,,,,B,H,Expert,Striatum,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,,,1,16709,BAO_0000249,,,
3344,,,,B,H,Expert,Striatum,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,,,1,1946,BAO_0000019,,,
3345,,,,B,H,Expert,Striatum,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,,,1,15253,BAO_0000249,,,
3346,,,,B,H,Expert,Striatum,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,1,4535,BAO_0000249,,,
3347,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,,,1,13961,BAO_0000249,,,
3348,,,,F,H,Autocuration,Brain,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,,,1,17358,BAO_0000221,,,
3349,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,,,1,15847,BAO_0000019,,,
3350,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,,,1,15847,BAO_0000019,,,
3351,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,,,1,670,BAO_0000019,,,
3352,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,,,1,670,BAO_0000019,,,
3353,,,,F,H,Autocuration,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,1,1317,BAO_0000019,,,
3354,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,,,1,12936,BAO_0000357,,,
3355,,,,B,H,Expert,Striatum,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,1,4535,BAO_0000249,,,
3356,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,,,1,14424,BAO_0000019,,,
3357,,,,F,H,Expert,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,,,1,14424,BAO_0000019,,,
3358,,,,F,H,Expert,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,1,14424,BAO_0000019,,,
3359,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,,,1,14424,BAO_0000019,,,
3360,,,,F,H,Autocuration,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,,,1,14424,BAO_0000019,,,
3361,,,,F,H,Expert,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,,,1,14424,BAO_0000019,,,
3362,,,,F,H,Expert,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,,,1,14424,BAO_0000218,,,
3363,,,,F,H,Autocuration,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,1,14424,BAO_0000019,,,
3364,,Rattus norvegicus,,F,H,Autocuration,,10116.0,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,,,1,1980,BAO_0000019,,,
3365,,,,F,H,Autocuration,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,,,1,4639,BAO_0000019,,,
3366,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000357,,,
3367,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,,,1,17358,BAO_0000357,,,
3368,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,,,1,17358,BAO_0000357,,,
3369,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,1558,BAO_0000357,,,
3370,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,,,
3371,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-HT4 receptor was determined,168,,,1,16117,BAO_0000357,,,
3372,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,,,
3373,,,,F,H,Autocuration,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000019,,,
3374,,,,B,H,Autocuration,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000357,,,
3375,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,,,1,17358,BAO_0000357,,,
3376,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,,,1,17358,BAO_0000357,,,
3377,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,,,1,17358,BAO_0000357,,,
3378,,,,B,H,Expert,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,,,1,1274,BAO_0000357,,,
3379,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,,,1,10728,BAO_0000249,,,Brain membranes
3380,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,,,1,11695,BAO_0000249,,,Brain membranes
3381,,,,B,H,Autocuration,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,,,1,11695,BAO_0000249,,,Brain membranes
3382,,,,B,H,Autocuration,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,,,1,12490,BAO_0000019,,,
3383,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,1,11828,BAO_0000019,,,
3384,,,,B,H,Autocuration,Hippocampus,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,,,1,12253,BAO_0000221,,,
3385,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,,,1,10561,BAO_0000019,,,
3386,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,,,1,10561,BAO_0000019,,,
3387,,,,F,H,Autocuration,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,,,1,14432,BAO_0000019,,,
3388,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,,,1,12936,BAO_0000223,,,
3389,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,,,1,1274,BAO_0000223,,,
3390,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,,,1,1980,BAO_0000019,,,
3391,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,,,1,670,BAO_0000249,,,
3392,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,,,1,968,BAO_0000019,,,
3393,,,,B,H,Autocuration,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,,,1,14287,BAO_0000019,,,
3394,,,,B,H,Autocuration,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,,,1,567,BAO_0000019,,,
3395,,,,B,H,Autocuration,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,,,1,13267,BAO_0000019,,,
3396,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,,,1,14826,BAO_0000249,,,
3397,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000223,,,
3398,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,,,1,15194,BAO_0000223,,,
3399,,Rattus norvegicus,,B,D,Autocuration,,10116.0,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,,,1,10394,BAO_0000223,,,
3400,,,,B,D,Expert,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,,,1,13657,BAO_0000249,,,
3401,,,,F,H,Autocuration,Brain,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,,,1,1879,BAO_0000221,,,
3402,,,,F,H,Autocuration,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,,,1,1879,BAO_0000019,,,
3403,,,,F,H,Autocuration,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,,,1,1879,BAO_0000019,,,
3404,In vivo,,,F,H,Autocuration,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,,,1,204,BAO_0000218,,,
3405,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,1,1879,BAO_0000019,,,
3406,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,,,1,1879,BAO_0000357,,,
3407,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,1,1879,BAO_0000019,,,
3408,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,,,1,1879,BAO_0000019,,,
3409,,,,B,H,Autocuration,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,,,1,10641,BAO_0000019,,,
3410,,,,B,H,Autocuration,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,,,1,773,BAO_0000019,,,
3411,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,,,1,11952,BAO_0000249,,,
3412,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,,,1,14145,BAO_0000019,,,
3413,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,17066,BAO_0000357,,,
3414,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,,,1,6398,BAO_0000223,,,
3415,,,,B,U,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,,,1,10321,BAO_0000019,,,
3416,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,,,1,511,BAO_0000019,,,
3417,,,,B,H,Autocuration,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,4639,BAO_0000223,,,
3418,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,4639,BAO_0000223,,,
3419,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,,,1,4639,BAO_0000019,,,
3420,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,1,4639,BAO_0000019,,,
3421,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,,,1,4639,BAO_0000019,,,
3422,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,1558,BAO_0000223,,,
3423,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,,,1,268,BAO_0000019,,,
3424,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,,,1,2474,BAO_0000223,,,
3425,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,,,1,5067,BAO_0000019,,,
3426,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,,,1,5067,BAO_0000019,,,
3427,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,,,1,5067,BAO_0000019,,,
3428,,,,B,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,,,1,5067,BAO_0000223,,,
3429,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,,,1,5067,BAO_0000019,,,
3430,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,,,1,5067,BAO_0000019,,,
3431,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,,,1,5067,BAO_0000019,,,
3432,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,,,1,5067,BAO_0000223,,,
3433,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,,,1,5067,BAO_0000223,,,
3434,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,,,1,5067,BAO_0000019,,,
3435,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,,,1,5067,BAO_0000223,,,
3436,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,5067,BAO_0000223,,,
3437,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,,,1,14331,BAO_0000219,,,
3438,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,,,1,5067,BAO_0000223,,,
3439,,,,B,H,Autocuration,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,,,1,6179,BAO_0000219,,NG108-15,
3440,,,,B,H,Autocuration,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,,,1,4265,BAO_0000019,,,
3441,,,,B,H,Autocuration,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,,,1,4265,BAO_0000219,,NG108-15,
3442,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,,,1,17358,BAO_0000223,,,
3443,,,,B,H,Autocuration,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,,,1,17358,BAO_0000223,,,
3444,In vitro,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,,,1,13628,BAO_0000219,,,
3445,,,,B,H,Autocuration,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,,,1,4612,BAO_0000223,,,
3446,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,,,1,17358,BAO_0000019,,,
3447,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,,,1,4639,BAO_0000019,,,
3448,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,,,1,4639,BAO_0000019,,,
3449,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,,,1,4639,BAO_0000019,,,
3450,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,1,4639,BAO_0000019,,,
3451,,,,B,H,Autocuration,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,,,1,511,BAO_0000223,,,
3452,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,1479,BAO_0000223,,,
3453,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,,,1,1317,BAO_0000223,,,
3454,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,,,1,12146,BAO_0000223,,,
3455,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,,,1,12146,BAO_0000223,,,
3456,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,,,1,13969,BAO_0000223,,,
3457,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,,,
3458,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,,,1,13392,BAO_0000223,,,
3459,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,,,1,14159,BAO_0000357,,,
3460,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,1558,BAO_0000357,,,
3461,,,,B,H,Autocuration,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,,,1,16655,BAO_0000357,,,
3462,,,,B,H,Autocuration,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,1,13020,BAO_0000223,,,
3463,,,,B,H,Autocuration,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,,,1,13021,BAO_0000223,,,
3464,,,,B,H,Autocuration,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,1,13020,BAO_0000223,,,
3465,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,,,1,10321,BAO_0000019,,,
3466,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,15818,BAO_0000357,,,
3467,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,15818,BAO_0000357,,,
3468,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,,,1,17358,BAO_0000357,,,
3469,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,,,1,2222,BAO_0000357,,,
3470,,,,B,H,Autocuration,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,,,1,10322,BAO_0000019,,,
3471,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,,,1,16117,BAO_0000357,,,
3472,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,,,1,17200,BAO_0000357,,,
3473,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,,,1,17358,BAO_0000019,,,
3474,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,,,1,16700,BAO_0000357,,,
3475,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,,,1,1980,BAO_0000019,,,
3476,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,,,1,1980,BAO_0000019,,,
3477,,,,B,H,Autocuration,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,,,1,12409,BAO_0000223,,,
3478,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000357,,,
3479,,,,F,H,Autocuration,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000019,,,
3480,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000357,,,
3481,,Rattus norvegicus,,F,D,Expert,,10116.0,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,,,1,6769,BAO_0000219,,Oocytes,
3482,,Rattus norvegicus,,F,D,Expert,,10116.0,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,,,1,6769,BAO_0000219,,Oocytes,
3483,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,,,1,6769,BAO_0000219,,Oocytes,
3484,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,,,1,809,BAO_0000221,,,
3485,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,,,1,809,BAO_0000221,,,
3486,,Cavia porcellus,,F,D,Intermediate,,10141.0,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,,,1,14290,BAO_0000019,,,
3487,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,,,1,17358,BAO_0000221,,,
3488,,Cavia porcellus,,B,D,Intermediate,,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,,,1,17358,BAO_0000357,,,
3489,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,,,1,17358,BAO_0000221,,,
3490,,,,B,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,,,1,17386,BAO_0000221,,,
3491,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 7 receptor,10209,,,1,3269,BAO_0000357,,,
3492,,Cavia porcellus,,B,H,Autocuration,,10141.0,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,1,7721,BAO_0000224,,,
3493,,Cavia porcellus,,B,H,Autocuration,,10141.0,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,1,7721,BAO_0000224,,,
3494,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,,,1,9117,BAO_0000221,,,
3495,,Cavia porcellus,,B,H,Autocuration,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,1,7721,BAO_0000224,,,
3496,,Cavia porcellus,,B,H,Autocuration,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,1,7721,BAO_0000224,,,
3497,,Cavia porcellus,,F,H,Autocuration,,10141.0,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,1,15796,BAO_0000019,,,
3498,,Cavia porcellus,,F,H,Autocuration,,10141.0,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,1,15796,BAO_0000019,,,
3499,,Homo sapiens,,B,D,Expert,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,,,1,15650,BAO_0000219,,,
3500,,Homo sapiens,,B,D,Expert,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,,,1,15650,BAO_0000219,,,
3501,,Homo sapiens,,F,D,Autocuration,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,,,1,6866,BAO_0000019,,,
3502,,Homo sapiens,,F,D,Expert,Cardiac atrium,9606.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,,,1,15650,BAO_0000219,,,
3503,,Mus musculus,,B,U,Autocuration,,10090.0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,,,1,10063,BAO_0000019,,,
3504,,Mus musculus,,B,U,Autocuration,,10090.0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,,,1,12665,BAO_0000019,,,
3505,,,,B,H,Autocuration,,,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,,,1,7504,BAO_0000019,,,
3506,,,,B,H,Autocuration,,,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,,,1,7504,BAO_0000224,,,
3507,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,,,1,7038,BAO_0000019,,,
3508,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,,,1,7626,BAO_0000224,,,
3509,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,,,1,7626,BAO_0000224,,,
3510,,,,F,H,Autocuration,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,,,1,7185,BAO_0000019,,,
3511,,,,F,H,Autocuration,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,,,1,7185,BAO_0000019,,,
3512,,,,F,H,Autocuration,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,,,1,7185,BAO_0000019,,,
3513,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,,,1,6960,BAO_0000224,,,
3514,,,,B,H,Autocuration,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,,,1,6960,BAO_0000224,,,
3515,,,,B,H,Autocuration,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,1,12416,BAO_0000221,,,
3516,,,,B,H,Expert,,,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,,,1,15753,BAO_0000357,,,
3517,,,,B,H,Autocuration,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,,,1,8062,BAO_0000019,,,
3518,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,,,1,9036,BAO_0000019,,,
3519,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,,,1,15067,BAO_0000224,,,
3520,,Rattus norvegicus,,F,D,Expert,Brain,10116.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,,,1,15753,BAO_0000019,,,
3521,,Rattus norvegicus,,F,D,Expert,Cerebellum,10116.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,,,1,15753,BAO_0000221,,,
3522,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,,,1,15295,BAO_0000019,,,
3523,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Percent binding affinity against 5-hydroxytryptamine receptor,104705,,,1,6347,BAO_0000224,,,
3524,,,,B,U,Autocuration,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,,,1,6763,BAO_0000019,,,
3525,,Rattus norvegicus,,B,D,Autocuration,,10116.0,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,,,1,12092,BAO_0000224,,,
3526,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity against 5-hydroxytryptamine receptor was determined,104705,,,1,1579,BAO_0000224,,,
3527,,Rattus norvegicus,,B,D,Autocuration,Stomach,10116.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,,,1,1579,BAO_0000019,,,
3528,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,,,1,5963,BAO_0000219,,,
3529,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,,,1,5963,BAO_0000219,,,
3530,,,,B,H,Autocuration,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,,,1,5030,BAO_0000357,,,
3531,,,,B,H,Expert,,,Inhibition of 5-hydroxytryptamine reuptake,121,,,1,15796,BAO_0000357,,,
3532,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,,,1,15413,BAO_0000019,,,
3533,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,,,1,15413,BAO_0000019,,,
3534,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,,,1,15413,BAO_0000019,,,
3535,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine receptor uptake,18065,,,1,12409,BAO_0000019,,,
3536,,Homo sapiens,,B,D,Expert,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,1,16909,BAO_0000219,,CHO,
3537,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,,,1,16909,BAO_0000019,,,
3538,,Homo sapiens,,B,H,Autocuration,,9606.0,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,,,1,15629,BAO_0000249,,,
3539,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,,,1,15629,BAO_0000357,,,
3540,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,,,1,15629,BAO_0000249,,,
3541,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3542,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3543,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,,,1,10034,BAO_0000019,,,
3544,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,,,
3545,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,1,10034,BAO_0000019,,,
3546,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,,,1,10034,BAO_0000019,,,
3547,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,,,1,10034,BAO_0000019,,,
3548,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3549,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,,,1,10034,BAO_0000019,,,
3550,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,,,
3551,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,1,10034,BAO_0000019,,,
3552,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,,,1,10034,BAO_0000019,,,
3553,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3554,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,,,1,10034,BAO_0000019,,,
3555,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,,,1,10034,BAO_0000019,,,
3556,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3557,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,,,1,10034,BAO_0000019,,,
3558,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,,,
3559,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,1274,BAO_0000357,,,
3560,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,,,
3561,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,,,1,14532,BAO_0000357,,,
3562,,,,B,H,Expert,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,,,1,16989,BAO_0000357,,,
3563,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,,,1,17200,BAO_0000357,,,
3564,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,15779,BAO_0000357,,,
3565,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,1,15779,BAO_0000357,,,
3566,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,1,15779,BAO_0000357,,,
3567,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,,COS-7,
3568,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,,COS-7,
3569,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,,COS-7,
3570,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,,COS-7,
3571,,,,B,H,Autocuration,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,1,17046,BAO_0000219,,C6,
3572,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,1,17046,BAO_0000219,,C6,
3573,,,,B,H,Expert,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,,,1,15650,BAO_0000219,,C6,
3574,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,,,1,17046,BAO_0000219,,C6,
3575,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,,,1,17066,BAO_0000357,,,
3576,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,,,1,17200,BAO_0000357,,,
3577,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,,,1,16146,BAO_0000357,,,
3578,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,,,1,15250,BAO_0000219,,CHO,
3579,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,,,1,6491,BAO_0000357,,,
3580,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,,,
3581,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,,,1,17066,BAO_0000357,,,
3582,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,,,1,4234,BAO_0000357,,,
3583,,,,B,H,Autocuration,,,Binding affinity towards 5-HT5A receptor,10624,,,1,6013,BAO_0000357,,,
3584,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,,,1,17175,BAO_0000357,,,
3585,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,1,15818,BAO_0000357,,,
3586,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,,,1,6166,BAO_0000357,,,
3587,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,,,1,15779,BAO_0000219,,HEK293,
3588,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,,,1,15779,BAO_0000219,,HEK293,
3589,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,,,1,5213,BAO_0000219,,HEK293,
3590,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,,,1,17066,BAO_0000357,,,
3591,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,,,1,17066,BAO_0000357,,,
3592,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,,,1,17066,BAO_0000357,,,
3593,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,,,1,17066,BAO_0000357,,,
3594,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,,,1,17066,BAO_0000357,,,
3595,,,,B,H,Expert,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,,,1,17175,BAO_0000357,,,
3596,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,,,1,16190,BAO_0000219,,HEK293,
3597,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,,,1,16190,BAO_0000219,,HEK293,
3598,,,,B,H,Expert,,,Binding affinity towards 5-HT5a receptor,10624,,,1,4820,BAO_0000357,,,
3599,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,,,
3600,,,,B,H,Expert,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,,,
3601,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,,,1,17175,BAO_0000357,,,
3602,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,,,1,16633,BAO_0000357,,,
3603,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,,,1,16633,BAO_0000357,,,
3604,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,,,1,16700,BAO_0000357,,,
3605,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,,,
3606,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,,,1,5486,BAO_0000223,,,
3607,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,,,1,16146,BAO_0000357,,,
3608,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,,,1,17273,BAO_0000357,,,
3609,,,,B,H,Autocuration,,,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,,,1,17687,BAO_0000357,,,
3610,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,,,1,6491,BAO_0000357,,,
3611,,,,B,H,Expert,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,,,1,16190,BAO_0000219,,HeLa,
3612,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,,,
3613,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,,,
3614,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,,,1,17066,BAO_0000357,,,
3615,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,,,1,17066,BAO_0000357,,,
3616,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,,,1,3555,BAO_0000357,,,
3617,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,5808,BAO_0000357,,,
3618,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,6013,BAO_0000357,,,
3619,,,,B,H,Expert,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,,,1,15818,BAO_0000219,,HEK293,
3620,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,,,1,16209,BAO_0000357,,,
3621,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,,,1,3935,BAO_0000219,,HEK293,
3622,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,15818,BAO_0000357,,,
3623,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,1,3805,BAO_0000219,,HEK293,
3624,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,,,1,16441,BAO_0000019,,,
3625,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,,,1,16441,BAO_0000019,,,
3626,,,,B,H,Expert,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,,,1,6786,BAO_0000219,,COS-7,
3627,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,,,1,4234,BAO_0000357,,,
3628,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,,,1,17085,BAO_0000019,,,
3629,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,,,1,17200,BAO_0000357,,,
3630,,,,B,H,Autocuration,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,1,17451,BAO_0000219,,HEK293,
3631,,,,F,H,Autocuration,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,,,1,3935,BAO_0000019,,,
3632,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,,,1,5033,BAO_0000357,,,
3633,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,1,4540,BAO_0000357,,,
3634,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,1,4540,BAO_0000219,,HeLa,
3635,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,1,4540,BAO_0000219,,HeLa,
3636,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,,,1,17296,BAO_0000219,,HeLa,
3637,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,1,17296,BAO_0000219,,HeLa,
3638,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,1,17296,BAO_0000219,,HeLa,
3639,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,,,1,15779,BAO_0000219,,CHO,
3640,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,,,1,15779,BAO_0000219,,HEK293,
3641,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,,,1,15779,BAO_0000219,,HEK293,
3642,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,,,1,15779,BAO_0000219,,HEK293,
3643,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,,,1,15779,BAO_0000219,,HeLa,
3644,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,6166,BAO_0000357,,,
3645,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,,,1,17451,BAO_0000219,,HeLa,
3646,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,,,1,15316,BAO_0000357,,,
3647,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,1,4199,BAO_0000357,,,
3648,,,,B,H,Expert,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,,,1,15146,BAO_0000219,,HeLa,
3649,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,,,1,5213,BAO_0000357,,,
3650,,,,B,H,Autocuration,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,,,1,16429,BAO_0000219,,,
3651,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,,,1,14818,BAO_0000219,,HeLa,
3652,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,,,1,4829,BAO_0000219,,HeLa,
3653,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,,,1,4829,BAO_0000219,,HeLa,
3654,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,,,1,4829,BAO_0000219,,HeLa,
3655,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,,,1,15250,BAO_0000219,,CHO,
3656,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,,,1,14423,BAO_0000019,,,
3657,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,,,1,15086,BAO_0000357,,,
3658,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,,,1,4342,BAO_0000357,,,
3659,,Homo sapiens,,B,D,Autocuration,,9606.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,,,1,16190,BAO_0000219,,HeLa,
3660,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,4820,BAO_0000357,,,
3661,,,,B,H,Autocuration,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,,,1,4639,BAO_0000357,,,
3662,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,1,17066,BAO_0000019,,,
3663,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,,,1,6011,BAO_0000357,,,
3664,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,,,
3665,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,,,1,17515,BAO_0000357,,,
3666,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,5014,BAO_0000357,,,
3667,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,,,1,4373,BAO_0000357,,,
3668,,,,F,H,Expert,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000019,,,
3669,,,,F,H,Expert,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,1,17066,BAO_0000019,,,
3670,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,,,1,4373,BAO_0000357,,,
3671,,,,B,H,Autocuration,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,4687,BAO_0000357,,,
3672,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,,,1,16946,BAO_0000357,,,
3673,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,,,1,16946,BAO_0000357,,,
3674,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,,,1,16633,BAO_0000357,,,
3675,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,,,1,16633,BAO_0000357,,,
3676,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,,,
3677,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,,,1,16700,BAO_0000357,,,
3678,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 6 receptor,10627,,,1,3269,BAO_0000357,,,
3679,,,,B,H,Autocuration,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,,,1,5486,BAO_0000357,,,
3680,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,,,1,16146,BAO_0000357,,,
3681,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,,,1,5014,BAO_0000219,,HEK293,
3682,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,,,1,15463,BAO_0000357,,,
3683,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,,,1,3805,BAO_0000357,,,
3684,,,,B,H,Expert,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,,,1,5014,BAO_0000219,,HEK293,
3685,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,,,1,6491,BAO_0000357,,,
3686,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,,,1,16190,BAO_0000219,,CHO,
3687,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,,,
3688,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,,,
3689,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,,,1,3555,BAO_0000357,,,
3690,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,,,1,6588,BAO_0000219,,CHO,
3691,,,,B,H,Autocuration,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,,,1,15463,BAO_0000357,,,
3692,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,1,6013,BAO_0000357,,,
3693,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,,,1,16209,BAO_0000357,,,
3694,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,,,1,3935,BAO_0000357,,,
3695,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,1,15818,BAO_0000357,,,
3696,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,,,1,5014,BAO_0000219,,HEK293,
3697,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,,,1,16441,BAO_0000019,,,
3698,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,,,1,16441,BAO_0000019,,,
3699,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,,,1,4234,BAO_0000357,,,
3700,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,,,1,17085,BAO_0000019,,,
3701,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,,,1,17200,BAO_0000357,,,
3702,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,,,1,17451,BAO_0000219,,CHO,
3703,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,,,1,17085,BAO_0000019,,,
3704,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,,,1,5104,BAO_0000357,,,
3705,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,,,1,5104,BAO_0000357,,,
3706,,Homo sapiens,,B,D,Expert,,9606.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,1,5033,BAO_0000219,,COS-7,
3707,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,1,5486,BAO_0000219,,COS-7,
3708,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,,,1,4540,BAO_0000219,,HEK293,
3709,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,,,1,6166,BAO_0000357,,,
3710,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,,,1,17342,BAO_0000219,,HEK293,
3711,,,,B,H,Expert,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,,,1,17342,BAO_0000357,,,
3712,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,,,1,17296,BAO_0000357,,,
3713,,,,B,H,Expert,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,,,1,16429,BAO_0000219,,,
3714,,,,B,H,Autocuration,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,,,1,15779,BAO_0000219,,HEK293,
3715,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,,HEK293,
3716,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,,HEK293,
3717,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,,HEK293,
3718,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,,HEK293,
3719,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,,,1,17451,BAO_0000219,,CHO,
3720,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,,,1,4199,BAO_0000219,,HEK293,
3721,,,,B,D,Expert,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,,,1,4199,BAO_0000219,,HEK293,
3722,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,,,1,4199,BAO_0000219,,HEK293,
3723,,,,B,D,Intermediate,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,,,1,3680,BAO_0000219,,HEK293,
3724,,,,B,D,Intermediate,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,,,1,3680,BAO_0000357,,,
3725,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,,,1,15316,BAO_0000219,,COS-7,
3726,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,,,1,15146,BAO_0000219,,HEK293,
3727,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,,,1,5213,BAO_0000219,,HEK293,
3728,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,,,1,5213,BAO_0000219,,HEK293,
3729,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,,,1,14818,BAO_0000219,,HEK293,
3730,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,,,1,14818,BAO_0000219,,HEK293,
3731,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,,,1,14818,BAO_0000219,,HEK293,
3732,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,,,1,4829,BAO_0000219,,HEK293,
3733,,Homo sapiens,,B,D,Autocuration,,9606.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,,,1,17200,BAO_0000357,,,
3734,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,,,1,17066,BAO_0000357,,,
3735,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,,,1,14025,BAO_0000019,,,
3736,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,,,1,15250,BAO_0000219,,CHO,
3737,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,,,1,16372,BAO_0000219,,CHO,
3738,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,,,1,16372,BAO_0000219,,CHO,
3739,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,,,1,16372,BAO_0000219,,CHO,
3740,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,,,1,16372,BAO_0000219,,CHO,
3741,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,,,1,16372,BAO_0000219,,CHO,
3742,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,,,1,16372,BAO_0000219,,CHO,
3743,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,,,1,16372,BAO_0000219,,CHO,
3744,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,,,1,16372,BAO_0000219,,CHO,
3745,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,,,1,16372,BAO_0000219,,CHO,
3746,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,,,1,16372,BAO_0000219,,CHO,
3747,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,,,1,16372,BAO_0000219,,CHO,
3748,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,,,1,16372,BAO_0000219,,CHO,
3749,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,,,1,17066,BAO_0000357,,,
3750,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,,,1,17066,BAO_0000357,,,
3751,,,,B,H,Expert,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,,,1,17386,BAO_0000357,,,
3752,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,,,1,14423,BAO_0000019,,,
3753,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,,,1,15874,BAO_0000357,,,
3754,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,,,1,15874,BAO_0000357,,,
3755,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,,,1,16372,BAO_0000219,,CHO,
3756,,,,B,H,Autocuration,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,,,1,4622,BAO_0000357,,,
3757,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,,,1,15086,BAO_0000357,,,
3758,,,,B,H,Autocuration,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,,,1,16372,BAO_0000219,,CHO,
3759,,,,B,H,Autocuration,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,,,1,16372,BAO_0000219,,CHO,
3760,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,,,1,16372,BAO_0000219,,CHO,
3761,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,,,1,16372,BAO_0000219,,CHO,
3762,,,,F,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,,,1,17386,BAO_0000221,,,
3763,,,,F,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,,,1,17386,BAO_0000221,,,
3764,,,,F,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,,,1,17386,BAO_0000221,,,
3765,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,,,1,5831,BAO_0000249,,,Membranes
3766,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,,,1,4342,BAO_0000357,,,
3767,,,,B,H,Expert,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,,,1,17319,BAO_0000357,,,
3768,,,,B,H,Expert,Hypothalamus,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,,,1,17342,BAO_0000019,,,
3769,,,,B,H,Autocuration,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,,,1,17342,BAO_0000357,,,
3770,,,,B,H,Expert,Hypothalamus,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,,,1,3680,BAO_0000249,,,
3771,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,,,1,3680,BAO_0000357,,,
3772,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,,,1,17319,BAO_0000219,,HEK293,
3773,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,,,1,17319,BAO_0000219,,HEK293,
3774,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,,,1,17319,BAO_0000219,,HEK293,
3775,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,1,4820,BAO_0000357,,,
3776,,,,B,H,Autocuration,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,,,1,4639,BAO_0000357,,,
3777,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,,,1,6011,BAO_0000357,,,
3778,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,,,
3779,,,,B,H,Expert,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,,,
3780,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,,,1,17515,BAO_0000357,,,
3781,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,1,4373,BAO_0000357,,,
3782,,,,F,H,Expert,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,,,1,17066,BAO_0000019,,,
3783,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,,,1,4373,BAO_0000357,,,
3784,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,,,1,4373,BAO_0000357,,,
3785,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,,,1,4687,BAO_0000357,,,
3786,,,,B,H,Expert,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,,,1,17342,BAO_0000357,,,
3787,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,,,1,16946,BAO_0000357,,,
3788,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,,,1,16946,BAO_0000357,,,
3789,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,,,1,16633,BAO_0000357,,,
3790,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,,,1,16633,BAO_0000357,,,
3791,,,,B,H,Expert,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,,,
3792,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,,,1,16700,BAO_0000357,,,
3793,,,,B,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,,,1,17386,BAO_0000221,,,
3794,,,,F,H,Autocuration,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,,,1,14080,BAO_0000019,,,
3795,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,,,1,14080,BAO_0000019,,,
3796,,,,B,H,Autocuration,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,,,1,409,BAO_0000357,,,
3797,,,,B,H,Autocuration,,,In vitro inhibition of human recombinant lipoxygenase enzyme,55,,,1,409,BAO_0000357,,,
3798,,,,B,H,Autocuration,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,,,1,409,BAO_0000357,,,
3799,,,,B,H,Expert,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,55,,,1,11090,BAO_0000357,,,
3800,,,,B,H,Expert,Blood,,Inhibition of 5-lipoxygenase in human whole blood.,55,,,1,11090,BAO_0000357,,,
3801,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,,,1,948,BAO_0000357,,,
3802,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,,,1,948,BAO_0000357,,,
3803,,,,F,H,Expert,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,,,1,13622,BAO_0000219,,,
3804,,,,F,H,Autocuration,Blood,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,,,1,13622,BAO_0000019,,,
3805,,,,B,H,Autocuration,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,,,1,9637,BAO_0000357,,,
3806,,,,B,H,Autocuration,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,,,1,11320,BAO_0000357,,,
3807,,,,B,H,Expert,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,,,1,11320,BAO_0000357,,,
3808,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,,,1,6838,BAO_0000357,,,
3809,,Homo sapiens,,B,D,Expert,Blood,9606.0,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,,,1,17667,BAO_0000357,,,
3810,,,,B,H,Autocuration,,,In vitro potency against human 5-Lipoxygenase,55,,,1,12703,BAO_0000357,,,
3811,,Homo sapiens,,F,D,Expert,,9606.0,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,,,1,14312,BAO_0000019,,,
3812,,,,F,H,Autocuration,Blood,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,,,1,14312,BAO_0000019,,,
3813,,,,F,H,Autocuration,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,1,5364,BAO_0000019,,,
3814,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,,,1,951,BAO_0000219,,,
3815,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,,,1,951,BAO_0000219,,,
3816,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,,,1,951,BAO_0000219,,,
3817,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,,,1,951,BAO_0000219,,,
3818,,,,B,H,Autocuration,,,Inhibition of human 5-lipoxygenase in human cells,55,,,1,12365,BAO_0000219,,,
3819,,,,B,H,Expert,,,Inhibition of human neutrophil 5-lipoxygenase,55,,,1,10603,BAO_0000357,,,
3820,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,,,1,10501,BAO_0000019,,,
3821,,,,B,H,Expert,Blood,,Inhibition of 5-lipoxygenase from human whole blood,55,,,1,12281,BAO_0000357,,,
3822,,,,B,H,Autocuration,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,1,2567,BAO_0000357,,,
3823,,,,B,H,Autocuration,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,,,1,2567,BAO_0000219,,,
3824,,,,B,H,Expert,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,,,1,10193,BAO_0000357,,,
3825,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,1,10193,BAO_0000357,,,
3826,,,,B,H,Expert,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,,,1,13623,BAO_0000357,,,
3827,,,,B,H,Autocuration,,,Tested against 5-lipoxygenase,55,,,1,12780,BAO_0000357,,,
3828,,,,B,H,Autocuration,,,Tested for activity against 5-Lipoxygenase (5-LO),55,,,1,12780,BAO_0000357,,,
3829,,,,B,H,Autocuration,,,Tested for activity against 5-lipoxygenase,55,,,1,12780,BAO_0000357,,,
3830,,,,B,H,Autocuration,,,Tested for inhibition of 5-HPETE production by human 5-LO,55,,,1,11966,BAO_0000357,,,
3831,,,,F,H,Autocuration,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,,,1,5364,BAO_0000019,,,
3832,,,,B,H,Expert,,,Inhibition of Human 5-lipoxygenase,55,,,1,13165,BAO_0000357,,,
3833,,,,B,H,Autocuration,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,,,1,5364,BAO_0000019,,,
3834,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,1,11311,BAO_0000219,,,
3835,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,,,1,11311,BAO_0000219,,,
3836,,,,B,H,Autocuration,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,,,1,14863,BAO_0000019,,,
3837,,,,B,H,Autocuration,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,,,1,14863,BAO_0000019,,,
3838,,,,B,H,Autocuration,Blood,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,,,1,11087,BAO_0000357,,,
3839,,,,B,H,Autocuration,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,,,1,455,BAO_0000357,,,
3840,,,,B,H,Autocuration,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,1,13183,BAO_0000357,,,
3841,,,,B,H,Expert,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,,,1,10319,BAO_0000019,,,
3842,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,1,10193,BAO_0000357,,,
3843,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,,,1,951,BAO_0000219,,,
3844,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,,,1,951,BAO_0000219,,,
3845,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,,,1,951,BAO_0000219,,,
3846,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,,,1,951,BAO_0000219,,,
3847,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,,,1,9859,BAO_0000357,,,
3848,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,,,1,9859,BAO_0000357,,,
3849,,,,B,H,Autocuration,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,,,1,9859,BAO_0000357,,,
3850,,,,B,H,Autocuration,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,,,1,2567,BAO_0000357,,,
3851,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,,,1,10193,BAO_0000357,,,
3852,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,,,1,10193,BAO_0000357,,,
3853,,,,B,H,Autocuration,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,,,1,949,BAO_0000019,,,
3854,,,,B,H,Autocuration,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,,,1,949,BAO_0000019,,,
3855,,,,B,H,Expert,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,,,1,10603,BAO_0000357,,,
3856,,,,B,H,Expert,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,1,10603,BAO_0000357,,,
3857,,,,F,H,Autocuration,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,,,1,10603,BAO_0000019,,,
3858,,,,B,H,Expert,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,,,1,10603,BAO_0000357,,,
3859,,,,B,H,Expert,,,Inhibition of lipoxygenase at the concentration of 1 uM,55,,,1,10603,BAO_0000357,,,
3860,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,,,1,10193,BAO_0000357,,,
3861,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of 5-Lipoxygenase (5-LOX),55,,,1,14580,BAO_0000357,,,
3862,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,1,11090,BAO_0000357,,,
3863,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,,,1,11090,BAO_0000357,,,
3864,,,,B,H,Autocuration,,,Inhibitory activity against lipoxygenase-2 in mice,17087,,,1,6339,BAO_0000357,,,
3865,,,,B,H,Expert,,,Inhibitory activity against murine lipoxygenase-2.,17087,,,1,6339,BAO_0000357,,,
3866,,Mus musculus,,B,D,Expert,,10090.0,Inhibition of 5-lipoxygenase from mouse macrophage,17087,,,1,12281,BAO_0000357,,,
3867,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,,,1,11311,BAO_0000357,,,
3868,,Sus scrofa,,B,H,Autocuration,,9823.0,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,,,1,11089,BAO_0000019,,,
3869,,Sus scrofa,,B,H,Autocuration,,9823.0,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,,,1,10091,BAO_0000019,,,
3870,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,,,1,14352,BAO_0000019,,,
3871,,Rattus norvegicus,,B,D,Expert,,10116.0,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,,,1,13329,BAO_0000019,,,
3872,,,,B,H,Autocuration,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,,,1,13329,BAO_0000019,,,
3873,,,,B,H,Autocuration,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,1,13329,BAO_0000019,,,
3874,,,,B,H,Autocuration,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,,,1,13329,BAO_0000019,,,
3875,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,,,1,13329,BAO_0000019,,,
3876,,,,B,H,Expert,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,,,1,13329,BAO_0000019,,,
3877,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,,,1,13329,BAO_0000019,,,
3878,,,,B,H,Autocuration,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,,,1,11311,BAO_0000019,,,
3879,,,,B,H,Autocuration,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,,,1,11311,BAO_0000019,,,
3880,,,,B,H,Autocuration,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,1,105,BAO_0000219,,RBL-1,
3881,,,,B,H,Autocuration,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,,,1,105,BAO_0000219,,RBL-1,
3882,,,,B,H,Autocuration,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,,,1,9138,BAO_0000357,,,
3883,,,,B,H,Autocuration,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,,,1,9138,BAO_0000357,,,
3884,,,,B,H,Autocuration,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,,,1,9138,BAO_0000357,,,
3885,,,,B,H,Autocuration,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,1,14427,BAO_0000357,,,
3886,,,,B,H,Autocuration,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,,,1,13329,BAO_0000019,,,
3887,,,,B,H,Autocuration,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,,,1,13329,BAO_0000019,,,
3888,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,,,1,14427,BAO_0000219,,RBL-2H3,
3889,,,,B,H,Autocuration,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,,,1,14427,BAO_0000357,,,
3890,,,,B,H,Autocuration,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,,,1,14427,BAO_0000357,,,
3891,,,,B,H,Expert,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,,,1,10293,BAO_0000219,,RBL-1,
3892,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,,,1,338,BAO_0000219,,RBL-1,
3893,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,,,1,303,BAO_0000357,,,
3894,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,,,1,303,BAO_0000219,,RBL-1,
3895,,,,B,H,Expert,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,,,1,9247,BAO_0000219,,RBL-1,
3896,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,1,9247,BAO_0000219,,RBL-1,
3897,,,,B,H,Autocuration,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,,,1,137,BAO_0000219,,RBL-1,
3898,,,,B,H,Expert,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,,,1,11481,BAO_0000357,,,
3899,,,,B,H,Expert,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,,,1,11481,BAO_0000357,,,
3900,,,,B,H,Expert,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,,,1,9029,BAO_0000357,,,
3901,,,,B,H,Autocuration,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,,,1,1701,BAO_0000019,,,
3902,,,,B,H,Autocuration,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,,,1,1701,BAO_0000019,,,
3903,,,,B,H,Autocuration,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,,,1,1701,BAO_0000019,,,
3904,,,,B,H,Autocuration,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,,,1,1701,BAO_0000019,,,
3905,,,,F,H,Expert,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,,,1,13358,BAO_0000219,,RBL-1,
3906,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,,,1,1175,BAO_0000219,,RBL-1,
3907,,,,B,H,Expert,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,,,1,8797,BAO_0000219,,RBL-1,
3908,,,,B,H,Autocuration,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,,,1,8797,BAO_0000019,,,
3909,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,,,1,577,BAO_0000357,,,
3910,,,,B,H,Expert,,,In vitro inhibitory activity against RBL-1 5-LO,12166,,,1,9295,BAO_0000219,,RBL-1,
3911,,,,B,H,Autocuration,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,,,1,9295,BAO_0000219,,RBL-1,
3912,,,,B,H,Autocuration,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,,,1,9295,BAO_0000219,,RBL-1,
3913,,,,B,H,Autocuration,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,,,1,9295,BAO_0000218,,,
3914,,,,B,H,Autocuration,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,,,1,9295,BAO_0000357,,,
3915,,,,B,H,Autocuration,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,,,1,216,BAO_0000218,,,
3916,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,,,1,11090,BAO_0000219,,RBL-1,
3917,,,,B,H,Autocuration,Blood,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,,,1,11090,BAO_0000019,,,
3918,,,,B,H,Expert,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,,,1,10091,BAO_0000357,,,
3919,,,,F,H,Autocuration,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,,,1,10274,BAO_0000019,,,
3920,,,,F,H,Autocuration,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,,,1,13622,BAO_0000219,,,
3921,,,,B,H,Expert,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,,,1,12118,BAO_0000219,,RBL-1,
3922,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,,,1,12576,BAO_0000357,,,
3923,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,,,1,9546,BAO_0000219,,RBL-1,
3924,,,,B,H,Autocuration,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,,,1,9521,BAO_0000219,,RBL-1,
3925,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,,,1,10626,BAO_0000219,,RBL-1,
3926,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase,12166,,,1,9225,BAO_0000219,,RBL-1,
3927,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,,,1,9225,BAO_0000219,,RBL-1,
3928,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,,,1,9225,BAO_0000219,,RBL-1,
3929,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,,,1,9225,BAO_0000219,,RBL-1,
3930,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,,,1,9225,BAO_0000219,,RBL-1,
3931,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,,,1,9225,BAO_0000219,,RBL-1,
3932,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,,,1,9225,BAO_0000219,,RBL-1,
3933,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,,,1,9225,BAO_0000219,,RBL-1,
3934,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,,,1,9225,BAO_0000219,,RBL-1,
3935,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,,,1,9225,BAO_0000219,,RBL-1,
3936,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,,,1,9225,BAO_0000219,,RBL-1,
3937,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,,,1,9225,BAO_0000219,,RBL-1,
3938,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,,,1,9225,BAO_0000219,,RBL-1,
3939,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,,,1,9225,BAO_0000219,,RBL-1,
3940,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,,,1,9225,BAO_0000219,,RBL-1,
3941,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,,,1,9225,BAO_0000219,,RBL-1,
3942,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,,,1,9225,BAO_0000219,,RBL-1,
3943,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,,,1,9225,BAO_0000219,,RBL-1,
3944,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,,,1,9225,BAO_0000219,,RBL-1,
3945,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,,,1,9225,BAO_0000219,,RBL-1,
3946,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,,,1,9225,BAO_0000219,,RBL-1,
3947,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,,,1,9225,BAO_0000219,,RBL-1,
3948,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,,,1,9225,BAO_0000219,,RBL-1,
3949,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,,,1,9225,BAO_0000219,,RBL-1,
3950,,,,B,H,Expert,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,,,1,9401,BAO_0000019,,,
3951,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,,,1,10325,BAO_0000019,,,
3952,,,,F,H,Expert,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,,,1,1556,BAO_0000219,,RBL-2H3,
3953,,,,F,H,Expert,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,,,1,1556,BAO_0000219,,RBL-2H3,
3954,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,,,1,961,BAO_0000219,,RBL-1,
3955,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,,,1,6838,BAO_0000019,,,
3956,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,,,1,10325,BAO_0000019,,,
3957,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,,1,9209,BAO_0000219,,RBL-1,
3958,,,,B,H,Expert,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,,,1,11520,BAO_0000219,,RBL-1,
3959,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,,,1,137,BAO_0000357,,,
3960,,,,B,H,Autocuration,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,,,1,4717,BAO_0000219,,RBL-1,
3961,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,,,1,10636,BAO_0000219,,RBL-1,
3962,,Rattus norvegicus,,F,D,Expert,,10116.0,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,,,1,14312,BAO_0000019,,,
3963,,,,B,H,Autocuration,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,,,1,1203,BAO_0000219,,RBL-1,
3964,,,,B,H,Autocuration,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,,,1,1203,BAO_0000019,,,
3965,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,,,1,13622,BAO_0000219,,RBL-1,
3966,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,,,1,9793,BAO_0000357,,,
3967,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,,,1,1143,BAO_0000219,,RBL-1,
3968,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,,,1,11854,BAO_0000219,,RBL-1,
3969,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,,RBL-1,
3970,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,,RBL-1,
3971,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,,,1,10501,BAO_0000219,,RBL-1,
3972,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,1,12526,BAO_0000219,,RBL-1,
3973,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,,,1,10034,BAO_0000019,,,
3974,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,,1,10034,BAO_0000019,,,
3975,,,,F,H,Autocuration,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,,,1,10034,BAO_0000019,,,
3976,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,1,10046,BAO_0000221,,,
3977,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,1,10046,BAO_0000221,,,
3978,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,1,10046,BAO_0000019,,,
3979,,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,,,1,12079,BAO_0000019,,,
3980,,,,F,H,Autocuration,Blood,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,,,1,12079,BAO_0000019,,,
3981,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,1,11311,BAO_0000219,,,
3982,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,,,1,12338,BAO_0000219,,,
3983,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,,,1,12143,BAO_0000219,,,
3984,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,,,1,12143,BAO_0000219,,,
3985,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,1,12143,BAO_0000219,,,
3986,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,,,1,12143,BAO_0000219,,,
3987,,,,B,H,Expert,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,,,1,12365,BAO_0000357,,,
3988,,,,B,H,Expert,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,,,1,13500,BAO_0000357,,,
3989,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3990,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3991,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3992,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3993,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3994,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3995,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3996,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3997,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3998,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
3999,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4000,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4001,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4002,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4003,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4004,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4005,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4006,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4007,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4008,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4009,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4010,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4011,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4012,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4013,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4014,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4015,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4016,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4017,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4018,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4019,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4020,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4021,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4022,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4023,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,,,1,12832,BAO_0000218,,,
4024,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4025,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4026,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4027,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4028,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4029,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4030,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4031,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4032,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4033,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4034,In vivo,Canis lupus familiaris,,F,H,Autocuration,Blood,9615.0,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4035,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,,,1,3595,BAO_0000218,,,
4036,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,,,1,3595,BAO_0000218,,,
4037,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,,,1,3595,BAO_0000218,,,
4038,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,,,1,3595,BAO_0000218,,,
4039,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,,,1,3595,BAO_0000218,,,
4040,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,,,1,3595,BAO_0000218,,,
4041,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,,,1,3595,BAO_0000218,,,
4042,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,,,1,3595,BAO_0000218,,,
4043,,Cavia porcellus,,B,H,Autocuration,,10141.0,Ability to inhibit 5-lipoxygenase in guinea pig,55,,,1,9203,BAO_0000357,,,
4044,,Cavia porcellus,,B,H,Expert,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,,,1,82,BAO_0000357,,,
4045,,Cavia porcellus,,B,H,Autocuration,,10141.0,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,,,1,11090,BAO_0000357,,,
4046,,Cavia porcellus,,B,H,Autocuration,Blood,10141.0,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,,,1,12832,BAO_0000218,,,
4047,,Cavia porcellus,,B,H,Autocuration,,10141.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,,,1,1065,BAO_0000357,,,
4048,,Cavia porcellus,,B,H,Autocuration,,10141.0,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,,,1,1065,BAO_0000357,,,
4049,,Cavia porcellus,,B,H,Expert,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,,,1,12832,BAO_0000019,,,
4050,,Cavia porcellus,,B,H,Expert,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,,,1,12832,BAO_0000019,,,
4051,,Cavia porcellus,,B,H,Autocuration,,10141.0,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,,,1,12832,BAO_0000019,,,
4052,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,,,1,10504,BAO_0000019,,,
4053,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase,55,,,1,7788,BAO_0000357,,,
4054,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,,,1,10001,BAO_0000357,,,
4055,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,,,1,10193,BAO_0000357,,,
4056,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,,,1,13243,BAO_0000357,,,
4057,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity uM,55,,,1,13243,BAO_0000357,,,
4058,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,,,1,969,BAO_0000219,,,
4059,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase at 10 uM,55,,,1,10001,BAO_0000357,,,
4060,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,,,1,7788,BAO_0000357,,,
4061,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,,,1,10001,BAO_0000357,,,
4062,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,,,1,10193,BAO_0000357,,,
4063,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity uM,55,,,1,13243,BAO_0000357,,,
4064,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,,,1,13243,BAO_0000357,,,
4065,,Cavia porcellus,,B,H,Expert,,10141.0,Inhibitory activity uM,55,,,1,13243,BAO_0000357,,,
4066,,Cavia porcellus,,F,H,Autocuration,,10141.0,Inhibitory activity uM,55,,,1,13243,BAO_0000019,,,
4067,,Cavia porcellus,,B,H,Autocuration,,10141.0,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,,,1,10504,BAO_0000019,,,
4068,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,,,1,7788,BAO_0000357,,,
4069,,Cavia porcellus,,F,H,Expert,Ileum,10141.0,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,,,1,10546,BAO_0000221,,,
4070,,,,B,H,Autocuration,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,1,13183,BAO_0000357,,,
4071,,,,B,H,Autocuration,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,,,1,13183,BAO_0000357,,,
4072,,,,B,H,Autocuration,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,,,1,2578,BAO_0000357,,,
4073,,,,B,H,Expert,,,In vitro inhibition of human 5-Lipoxygenase.,55,,,1,12780,BAO_0000357,,,
4074,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4075,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4076,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4077,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4078,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4079,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4080,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4081,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4082,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4083,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4084,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4085,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4086,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4087,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4088,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4089,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4090,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4091,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4092,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4093,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4094,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4095,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4096,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4097,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4098,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4099,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4100,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4101,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4102,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4103,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4104,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4105,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4106,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4107,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4108,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4109,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4110,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4111,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4112,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4113,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4114,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4115,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4116,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4117,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4118,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4119,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4120,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4121,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4122,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4123,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4124,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,,,1,7411,BAO_0000251,,,Microsomes
4125,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4126,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,,,1,7411,BAO_0000251,,,Microsomes
4127,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 7226/S myeloma cancer cell line,80433,,,1,10797,BAO_0000219,,RPMI-8226,
4128,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,,,1,6881,BAO_0000219,,BEL-7404 tumor cell line,
4129,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,,,1,3838,BAO_0000219,,786-0,
4130,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,,,1,3838,BAO_0000219,,786-0,
4131,,Cricetulus griseus,,F,N,Expert,,10029.0,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,,,1,12981,BAO_0000219,,V79,
4132,,Cricetulus griseus,,F,N,Expert,,10029.0,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,,,1,12981,BAO_0000219,,V79,
4133,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4134,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4135,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4136,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4137,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4138,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,,,1,7653,BAO_0000219,,7800C1 cell line,
4139,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,,,1,17229,BAO_0000219,,786-0,
4140,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against 786-0 Renal cancer cell line,80640,,,1,12858,BAO_0000219,,786-0,
4141,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,,,1,16325,BAO_0000219,,786-0,
4142,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,,,1,16325,BAO_0000219,,786-0,
4143,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against human renal 786-0 cell line,80640,,,1,5858,BAO_0000219,,786-0,
4144,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,,,1,16325,BAO_0000219,,786-0,
4145,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,,,1,14696,BAO_0000219,,786-0,
4146,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,,,1,3786,BAO_0000219,,786-0,
4147,,Homo sapiens,,F,N,Intermediate,,9606.0,inhibition of the growth of renal cancer(786-0) cell line,80640,,,1,14696,BAO_0000219,,786-0,
4148,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,,,1,14769,BAO_0000219,,786-0,
4149,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,,,1,15354,BAO_0000219,,786-0,
4150,,Homo sapiens,,F,N,Intermediate,,9606.0,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,,,1,14255,BAO_0000219,,786-0,
4151,,Homo sapiens,,F,N,Intermediate,,9606.0,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,,,1,14255,BAO_0000219,,786-0,
4152,,Homo sapiens,,F,N,Intermediate,,9606.0,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,,,1,14255,BAO_0000219,,786-0,
4153,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,,,1,14696,BAO_0000219,,786-0,
4154,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,,,1,12016,BAO_0000219,,786-0,
4155,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,,,1,2597,BAO_0000219,,786-0,
4156,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,,,1,12526,BAO_0000219,,RBL-1,
4157,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,,,1,12526,BAO_0000219,,RBL-1,
4158,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,,1,14799,BAO_0000019,,,
4159,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,,RBL-1,
4160,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,,RBL-1,
4161,,,,B,H,Autocuration,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,,,1,12767,BAO_0000357,,,
4162,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,,,1,10997,BAO_0000219,,,
4163,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,,,1,11388,BAO_0000219,,RBL-1,
4164,,,,B,H,Autocuration,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,,,1,167,BAO_0000357,,,
4165,,,,B,H,Autocuration,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,,,1,167,BAO_0000357,,,
4166,,,,B,H,Expert,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,,,1,13744,BAO_0000357,,,
4167,,,,B,H,Autocuration,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,,,1,1630,BAO_0000357,,,
4168,,,,B,H,Autocuration,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,,,1,1630,BAO_0000357,,,
4169,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,,,1,969,BAO_0000019,,,
4170,,,,B,H,Autocuration,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,,,1,13621,BAO_0000219,,RBL-1,
4171,,,,B,H,Autocuration,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,,,1,10089,BAO_0000357,,,
4172,,,,B,H,Expert,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,,,1,10193,BAO_0000357,,,
4173,,,,B,H,Autocuration,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,,,1,11966,BAO_0000357,,,
4174,,,,B,H,Autocuration,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,1,12251,BAO_0000019,,,
4175,,,,B,H,Autocuration,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,,,1,211,BAO_0000219,,RBL-1,
4176,,,,F,H,Expert,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,,,1,12251,BAO_0000019,,,
4177,,,,B,H,Autocuration,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,,,1,12495,BAO_0000219,,RBL-1,
4178,,,,B,H,Autocuration,,,Tested for its inhibitory activity against 5-lipoxygenase,12166,,,1,414,BAO_0000357,,,
4179,,,,B,H,Autocuration,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,,,1,414,BAO_0000357,,,
4180,,,,B,H,Expert,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,,,1,10325,BAO_0000019,,,
4181,,,,B,H,Expert,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,1,11966,BAO_0000019,,,
4182,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,1,165,BAO_0000219,,RBL-1,
4183,,,,B,H,Autocuration,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,,,1,165,BAO_0000219,,RBL-1,
4184,,,,B,H,Autocuration,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,1,165,BAO_0000219,,RBL-1,
4185,,,,B,H,Expert,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,,,1,165,BAO_0000219,,RBL-1,
4186,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,,,1,11311,BAO_0000218,,,
4187,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,,,1,11311,BAO_0000219,,RBL-1,
4188,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,,,1,11311,BAO_0000219,,RBL-1,
4189,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,,,1,11311,BAO_0000219,,,
4190,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,,,1,11311,BAO_0000219,,,
4191,In vivo,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,,,1,11311,BAO_0000218,,,
4192,,,,F,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4193,,,,F,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4194,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,,,1,11311,BAO_0000019,,,
4195,,,,B,H,Autocuration,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,,,1,11732,BAO_0000019,,,
4196,,,,B,H,Expert,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,,,1,11732,BAO_0000019,,,
4197,,,,B,H,Expert,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,,,1,11087,BAO_0000019,,,
4198,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,,,1,11087,BAO_0000019,,,
4199,,,,B,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,,,1,11087,BAO_0000219,,RBL-1,
4200,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,,,1,11087,BAO_0000357,,,
4201,,,,B,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,,,1,496,BAO_0000219,,RBL-1,
4202,,,,F,H,Expert,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,,,1,13986,BAO_0000219,,RBL-1,
4203,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,,,1,11520,BAO_0000357,,,
4204,,,,B,H,Autocuration,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,,,1,10293,BAO_0000219,,RBL-1,
4205,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,,,1,303,BAO_0000219,,RBL-1,
4206,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,,,1,303,BAO_0000219,,RBL-1,
4207,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4208,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4209,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,,,1,9247,BAO_0000219,,RBL-1,
4210,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4211,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4212,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4213,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4214,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,,,1,9247,BAO_0000219,,RBL-1,
4215,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,,,1,11481,BAO_0000357,,,
4216,,,,B,H,Autocuration,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,,,1,105,BAO_0000357,,,
4217,,,,B,H,Expert,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,,,1,9029,BAO_0000357,,,
4218,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,,,1,1175,BAO_0000219,,RBL-1,
4219,,,,B,H,Autocuration,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,,,1,12118,BAO_0000219,,RBL-1,
4220,,,,B,H,Autocuration,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,,,1,12118,BAO_0000219,,RBL-1,
4221,,,,B,H,Autocuration,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,,,1,12118,BAO_0000219,,RBL-1,
4222,,,,B,H,Autocuration,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,,,1,9225,BAO_0000219,,RBL-1,
4223,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,,,1,9401,BAO_0000019,,,
4224,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,1,137,BAO_0000357,,,
4225,,,,B,H,Autocuration,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,,,1,137,BAO_0000357,,,
4226,,,,B,H,Autocuration,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,1,4717,BAO_0000219,,RBL-1,
4227,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,1,3595,BAO_0000219,,RBL-1,
4228,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,,,1,10501,BAO_0000219,,RBL-1,
4229,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,,,1,10501,BAO_0000219,,RBL-1,
4230,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,,,1,10501,BAO_0000219,,RBL-1,
4231,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,1,12526,BAO_0000219,,RBL-1,
4232,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,,,1,14799,BAO_0000219,,RBL-1,
4233,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,,,1,14799,BAO_0000019,,,
4234,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,,,1,3595,BAO_0000219,,RBL-1,
4235,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,1,3595,BAO_0000219,,RBL-1,
4236,,,,B,H,Autocuration,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,1,12526,BAO_0000219,,RBL-1,
4237,,,,B,H,Autocuration,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,,,1,12526,BAO_0000219,,RBL-1,
4238,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,1,10193,BAO_0000019,,,
4239,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,1,10193,BAO_0000019,,,
4240,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,,,1,10193,BAO_0000019,,,
4241,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,,,1,10193,BAO_0000019,,,
4242,,,,B,H,Expert,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,,,1,9138,BAO_0000357,,,
4243,,,,B,H,Autocuration,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,,,1,9138,BAO_0000357,,,
4244,,,,B,H,Autocuration,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,,,1,11966,BAO_0000019,,,
4245,,,,B,H,Autocuration,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,,,1,165,BAO_0000219,,RBL-1,
4246,,,,B,H,Autocuration,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,,,1,165,BAO_0000219,,RBL-1,
4247,,,,B,H,Autocuration,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4248,,,,B,H,Autocuration,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4249,,,,F,H,Autocuration,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4250,,,,F,H,Autocuration,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,,,1,11311,BAO_0000019,,,
4251,,,,B,H,Autocuration,,,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,,,1,11311,BAO_0000357,,,
4252,,,,F,H,Autocuration,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,,,1,11311,BAO_0000219,,RBL-2H3,
4253,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,,,1,11087,BAO_0000019,,,
4254,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,,,1,11087,BAO_0000019,,,
4255,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,,,1,11087,BAO_0000019,,,
4256,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,1,11087,BAO_0000019,,,
4257,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,,,1,11087,BAO_0000019,,,
4258,,,,B,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,,,1,496,BAO_0000219,,RBL-1,
4259,,,,B,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,,,1,496,BAO_0000219,,RBL-1,
4260,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4261,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4262,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4263,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4264,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,,,1,13986,BAO_0000219,,RBL-1,
4265,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4266,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4267,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4268,,,,F,H,Autocuration,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,,,1,13986,BAO_0000219,,RBL-1,
4269,,Rattus norvegicus,,F,D,Expert,,10116.0,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,,,1,13986,BAO_0000019,,,
4270,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,,,1,10193,BAO_0000357,,,
4271,,,,B,H,Autocuration,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,,,1,9295,BAO_0000357,,,
4272,,,,B,H,Autocuration,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,,,1,4717,BAO_0000219,,RBL-1,
4273,,,,B,H,Autocuration,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,,,1,4717,BAO_0000219,,RBL-1,
4274,,,,B,H,Autocuration,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,,,1,11854,BAO_0000219,,RBL-1,
4275,,,,B,H,Autocuration,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,,,1,11854,BAO_0000219,,RBL-1,
4276,,,,B,H,Autocuration,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,,,1,11854,BAO_0000219,,RBL-1,
4277,,,,B,H,Autocuration,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,,,1,10193,BAO_0000019,,,
4278,,,,B,H,Autocuration,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,,,1,9295,BAO_0000219,,RBL-1,
4279,,,,B,H,Autocuration,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,,,1,9295,BAO_0000219,,RBL-1,
4280,,,,B,H,Autocuration,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,,,1,9295,BAO_0000219,,RBL-1,
4281,,,,B,H,Autocuration,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,,,1,9295,BAO_0000219,,RBL-1,
4282,,,,B,H,Autocuration,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,,,1,165,BAO_0000219,,RBL-1,
4283,,,,B,H,Autocuration,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,,,1,11311,BAO_0000219,,,
4284,,Homo sapiens,,B,H,Expert,,9606.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,,,1,10489,BAO_0000219,,RBL-1,
4285,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,,,1,10489,BAO_0000219,,RBL-1,
4286,,Rattus norvegicus,,B,D,Expert,,10116.0,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,,,1,10489,BAO_0000219,,RBL-1,
4287,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,,,1,14799,BAO_0000019,,,
4288,,Glycine max,,B,H,Autocuration,,3847.0,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,,,1,9295,BAO_0000357,,,
4289,,,,B,U,Autocuration,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,,,1,16811,BAO_0000019,,,
4290,,,,B,H,Expert,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,,,1,168,BAO_0000357,,,
4291,,,,B,H,Autocuration,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,,,1,6309,BAO_0000357,,,
4292,,,,B,H,Autocuration,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,,,1,6309,BAO_0000357,,,
4293,,,,B,H,Autocuration,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,,,1,3092,BAO_0000219,,RBL-1,
4294,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase.,55,,,1,168,BAO_0000357,,,
4295,,,,B,H,Autocuration,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,,,1,168,BAO_0000357,,,
4296,,,,B,H,Autocuration,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,,,1,168,BAO_0000357,,,
4297,,,,B,H,Autocuration,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,,,1,168,BAO_0000357,,,
4298,,,,F,H,Expert,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,,,1,12338,BAO_0000019,,,
4299,,,,B,H,Autocuration,,,Tested for the inhibitory activity against 5-lipoxygenase,55,,,1,4501,BAO_0000357,,,
4300,,,,B,H,Autocuration,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,,,1,1132,BAO_0000357,,,
4301,,,,B,H,Autocuration,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,,,1,2117,BAO_0000357,,,
4302,,,,B,H,Autocuration,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,,,1,168,BAO_0000357,,,
4303,,,,B,H,Autocuration,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,,,1,168,BAO_0000357,,,
4304,,,,B,H,Autocuration,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,,,1,13575,BAO_0000219,,RBL-1,
4305,,,,B,H,Autocuration,,,,12166,,,1,11089,BAO_0000357,,,
4306,,,,B,H,Autocuration,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,,,1,216,BAO_0000357,,,
4307,,,,B,H,Autocuration,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,,,1,13165,BAO_0000019,,,
4308,,,,B,H,Autocuration,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,,,1,3278,BAO_0000357,,,
4309,,,,B,H,Expert,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,,,1,3278,BAO_0000357,,,
4310,,,,B,H,Autocuration,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,,,1,11966,BAO_0000357,,,
4311,,,,B,H,Autocuration,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,,,1,175,BAO_0000357,,,
4312,,,,B,H,Autocuration,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,,,1,175,BAO_0000357,,,
4313,,,,B,H,Autocuration,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,,,1,13449,BAO_0000357,,,
4314,,,,B,H,Autocuration,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,,,1,12014,BAO_0000019,,,
4315,,,,B,H,Autocuration,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,,,1,12014,BAO_0000019,,,
4316,,,,B,H,Autocuration,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,,,1,12014,BAO_0000019,,,
4317,,,,B,S,Intermediate,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,,,1,99,BAO_0000220,,,
4318,,Homo sapiens,,F,U,Autocuration,,9606.0,The dark toxicity against 543 human galactophore carcinoma cells,22226,,,1,4349,BAO_0000019,,,
4319,,Homo sapiens,,F,N,Expert,,9606.0,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,,,1,4071,BAO_0000219,,Panel (56 tumour cell lines),
4320,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,,,1,17589,BAO_0000219,,5637,
4321,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,,,1,15002,BAO_0000219,,5637,
4322,,Homo sapiens,,F,N,Intermediate,,9606.0,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,,,1,13958,BAO_0000219,,5637,
4323,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition against human 5637 cell lines,80008,,,1,17589,BAO_0000219,,5637,
4324,,Homo sapiens,,F,N,Expert,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells.,80008,,,1,16748,BAO_0000219,,5637,
4325,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells,80008,,,1,16747,BAO_0000219,,5637,
4326,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against human bladder carcinoma 5637 cells,80008,,,1,16747,BAO_0000219,,5637,
4327,,Bos taurus,,B,D,Expert,,9913.0,In vitro inhibition of bovine trypsin(Trp).,10443,,,1,15285,BAO_0000357,,,
4328,,Cercopithecidae,,B,H,Expert,,9527.0,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,,,1,3726,BAO_0000219,,CV-1,
4329,,,,B,H,Autocuration,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,,,1,5033,BAO_0000357,,,
4330,,,,F,H,Autocuration,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,,,1,11756,BAO_0000019,,,
4331,In vivo,,,F,U,Autocuration,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,,,1,11953,BAO_0000218,,,
4332,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,,,1,5033,BAO_0000357,,,
4333,,Rattus norvegicus,,A,H,Expert,,10116.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,,,1,11347,BAO_0000251,,,Microsomes
4334,,Rattus norvegicus,,A,H,Expert,,10116.0,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,,,1,11347,BAO_0000251,,,Microsomes
4335,,,,F,U,Intermediate,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
4336,,,,F,U,Intermediate,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
4337,,Trypanosoma brucei,,B,H,Expert,,5691.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,,,1,17588,BAO_0000019,,,
4338,,Trypanosoma brucei,,B,H,Autocuration,,5691.0,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,,,1,17588,BAO_0000019,,,
4339,,Ovis aries,,B,H,Expert,,9940.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,,,1,17588,BAO_0000019,,,
4340,,Ovis aries,,B,H,Autocuration,,9940.0,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,,,1,17588,BAO_0000019,,,
4341,,,,B,H,Autocuration,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,,,1,16485,BAO_0000357,,,
4342,,Homo sapiens,,F,U,Intermediate,,9606.0,Average inhibitory concentration against 60 human cell lines was reported,22226,,,1,4337,BAO_0000019,,,
4343,,Homo sapiens,,F,U,Expert,,9606.0,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,,,1,4112,BAO_0000019,,,
4344,,Homo sapiens,,F,N,Intermediate,,9606.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,,,1,16160,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4345,,Homo sapiens,,F,N,Intermediate,,9606.0,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,,,1,16160,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4346,,,,F,N,Expert,,,In vitro mean growth inhibitory activity against 60-cell panel,80315,,,1,17376,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4347,,,,F,N,Expert,,,In vitro mean growth lethal concentration against 60-cell panel,80315,,,1,17376,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4348,,,,F,N,Expert,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,,,1,17376,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4349,,,,F,N,Expert,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,,,1,17376,BAO_0000219,,Panel NCI-60 (60 carcinoma cell lines),
4350,,,,F,H,Autocuration,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,1,3241,BAO_0000019,,,
4351,,,,F,H,Autocuration,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,,,1,3241,BAO_0000019,,,
4352,,,,B,H,Expert,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,,,1,3725,BAO_0000357,,,
4353,,Plasmodium falciparum,,F,N,Expert,,5833.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,,,1,10805,BAO_0000218,,,
4354,,Plasmodium falciparum,,F,N,Expert,,5833.0,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,,,1,10805,BAO_0000218,,,
4355,,Plasmodium falciparum,,F,N,Expert,,5833.0,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,,,1,10805,BAO_0000218,,,
4356,,Plasmodium falciparum,,F,N,Expert,,5833.0,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,,,1,10805,BAO_0000218,,,
4357,,Plasmodium falciparum,,F,N,Intermediate,,5833.0,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,,,1,10805,BAO_0000218,,,
4358,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4359,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4360,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4361,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4362,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4363,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,,,1,10144,BAO_0000218,,6C3HED,
4364,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,,,1,10685,BAO_0000218,,,
4365,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,,,1,10685,BAO_0000218,,,
4366,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,,,1,10685,BAO_0000218,,,
4367,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,,,1,10685,BAO_0000218,,,
4368,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,,,1,10685,BAO_0000218,,,
4369,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,,,1,10685,BAO_0000218,,,
4370,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,,,1,10685,BAO_0000218,,,
4371,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,,,1,10685,BAO_0000218,,,
4372,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,,,1,10685,BAO_0000218,,,
4373,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,,,1,10685,BAO_0000218,,,
4374,In vivo,Mus musculus,,F,U,Autocuration,,10090.0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,,,1,10685,BAO_0000218,,,
4375,,Mus musculus,,F,U,Autocuration,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,,,1,10144,BAO_0000218,,,
4376,,Mus musculus,,F,U,Autocuration,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,,,1,10144,BAO_0000218,,,
4377,,Mus musculus,,F,U,Autocuration,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,,,1,10144,BAO_0000218,,,
4378,,Mus musculus,,F,U,Autocuration,,10090.0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,,,1,10144,BAO_0000218,,,
4379,,Mus musculus,,F,U,Autocuration,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,,,1,10685,BAO_0000218,,,
4380,,Mus musculus,,F,U,Autocuration,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,,,1,10685,BAO_0000218,,,
4381,,Mus musculus,,F,U,Autocuration,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,,,1,10685,BAO_0000218,,,
4382,,Mus musculus,,F,U,Autocuration,,10090.0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,,,1,10685,BAO_0000218,,,
4383,,Mus musculus,,A,U,Autocuration,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,,,1,10685,BAO_0000218,,,
4384,,Mus musculus,,A,U,Autocuration,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,,,1,10685,BAO_0000218,,,
4385,,Mus musculus,,A,U,Autocuration,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,,,1,10685,BAO_0000218,,,
4386,,Mus musculus,,A,U,Autocuration,,10090.0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,,,1,10685,BAO_0000218,,,
4387,,Mus musculus,,F,N,Intermediate,,10090.0,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,,,1,8831,BAO_0000218,,6C3HED,
4388,In vivo,,,F,U,Autocuration,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,,,1,11704,BAO_0000218,,,
4389,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,,,1,11704,BAO_0000218,,,
4390,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,,,1,10685,BAO_0000218,,6C3HED,
4391,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,,,1,10685,BAO_0000218,,6C3HED,
4392,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,,,1,11368,BAO_0000218,,6C3HED,
4393,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,,,1,11368,BAO_0000218,,6C3HED,
4394,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,,,1,11368,BAO_0000218,,6C3HED,
4395,,Staphylococcus aureus,,B,U,Autocuration,,1280.0,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,,,1,17763,BAO_0000019,,,
4396,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4397,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4398,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4399,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4400,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4401,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4402,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4403,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4404,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4405,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4406,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4407,,Rattus norvegicus,,B,U,Autocuration,Liver,10116.0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,,,1,7411,BAO_0000251,,,Microsomes
4408,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,The apparent total plasma clearance in monkey,22224,,,1,347,BAO_0000218,,,
4409,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for Hepatic clearance in monkey,22224,,,1,3341,BAO_0000218,,,
4410,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,,,1,17853,BAO_0000218,,,
4411,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in rhesus monkey,22224,,,1,4514,BAO_0000218,,,
4412,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,,,1,6062,BAO_0000218,,,
4413,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance of compound was determined in monkey,22224,,,1,6821,BAO_0000218,,,
4414,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was calculated in rhesus monkey,22224,,,1,6057,BAO_0000218,,,
4415,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in rhesus monkey,22224,,,1,5145,BAO_0000218,,,
4416,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,,,1,6641,BAO_0000218,,,
4417,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was evaluated in rhesus,22224,,,1,5472,BAO_0000218,,,
4418,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,,,1,4257,BAO_0000218,,,
4419,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,,,1,5546,BAO_0000218,,,
4420,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4421,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4422,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,,,1,17509,BAO_0000218,,,
4423,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax in monkey after administration of 1 mg/kg iv,22224,,,1,6535,BAO_0000218,,,
4424,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,,,1,5668,BAO_0000218,,,
4425,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax in cynomolgus monkey by iv administration,22224,,,1,5922,BAO_0000218,,,
4426,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax in cynomolgus monkey by po administration,22224,,,1,5922,BAO_0000218,,,
4427,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Cmax value evaluated in monkey,22224,,,1,6078,BAO_0000218,,,
4428,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
4429,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,,,1,3249,BAO_0000218,,,
4430,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,,,1,3249,BAO_0000218,,,
4431,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Maximal plasma concentration in squirrel monkeys,22224,,,1,5553,BAO_0000218,,,
4432,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4433,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,,,1,6227,BAO_0000218,,,
4434,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4435,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,,,1,5355,BAO_0000218,,,
4436,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,,,1,5355,BAO_0000218,,,
4437,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,,,1,5355,BAO_0000218,,,
4438,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
4439,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,,,1,6221,BAO_0000218,,,
4440,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,,,1,167,BAO_0000218,,,
4441,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,,,1,167,BAO_0000218,,,
4442,In vivo,monkey,,A,U,Autocuration,,9443.0,Absolute bioavailability was evaluated in monkey,22224,,,1,4257,BAO_0000218,,,
4443,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,,,1,6221,BAO_0000218,,,
4444,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,,,1,17667,BAO_0000218,,,
4445,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Bioavailability of compound was determined in rhesus monkey,22224,,,1,17267,BAO_0000218,,,
4446,In vivo,marmosets,,A,U,Autocuration,,38020.0,Bioavailability determined after oral administration in marmoset,22224,,,1,4256,BAO_0000218,,,
4447,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Oral bioavailability in cynomolgus monkey,22224,,,1,4256,BAO_0000218,,,
4448,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,,,1,17853,BAO_0000218,,,
4449,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability was evaluated after oral administration in monkey,22224,,,1,16365,BAO_0000218,,,
4450,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4451,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4452,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4453,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability of the compound was determined in monkey,22224,,,1,17592,BAO_0000218,,,
4454,In vivo,Saimiri sciureus,,A,U,Autocuration,,9521.0,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,,,1,1399,BAO_0000218,,,
4455,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4456,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,3341,BAO_0000218,,,
4457,In vivo,Saimiri sciureus,,A,U,Autocuration,,9521.0,Compound was tested for bioavailability in squirrel monkey,22224,,,1,64,BAO_0000218,,,
4458,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey,22224,,,1,5005,BAO_0000218,,,
4459,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,,,1,5005,BAO_0000218,,,
4460,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,,,1,5237,BAO_0000218,,,
4461,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,,,1,5237,BAO_0000218,,,
4462,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey (dose 5 mg/kg),22224,,,1,5302,BAO_0000218,,,
4463,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability of compound at 5 mg/kg in monkey,22224,,,1,17667,BAO_0000218,,,
4464,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,,,1,6161,BAO_0000218,,,
4465,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,,,1,6161,BAO_0000218,,,
4466,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half life determined,50588,,,1,3854,BAO_0000218,,,
4467,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half life in dog,50588,,,1,993,BAO_0000218,,,
4468,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half-life in Beagle dogs,50588,,,1,4514,BAO_0000218,,,
4469,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
4470,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
4471,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
4472,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
4473,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for the half life period in dog,50588,,,1,5313,BAO_0000218,,,
4474,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for the half life period in dog at dosage of 10 mpk,50588,,,1,5313,BAO_0000218,,,
4475,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for half life in dog,50588,,,1,3880,BAO_0000218,,,
4476,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,,,1,3639,BAO_0000218,,,
4477,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The half life was determined,50588,,,1,3880,BAO_0000218,,,
4478,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The plasma half-life in dogs,50588,,,1,3918,BAO_0000218,,,
4479,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,,,1,16452,BAO_0000218,,,
4480,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog,50588,,,1,17796,BAO_0000218,,,
4481,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,,,1,5983,BAO_0000218,,,
4482,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
4483,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,,,1,16456,BAO_0000218,,,
4484,In vivo,Mustela putorius furo,,A,N,Expert,,9669.0,Cmax in ferrets after 30 mg/kg oral dose,50506,,,1,6113,BAO_0000218,,,
4485,In vivo,Mustela putorius furo,,F,N,Expert,,9669.0,Emesis in ferrets at 30 mg/kg oral dose,50506,,,1,6113,BAO_0000218,,,
4486,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Bioavailability in cynomolgus monkey,22224,,,1,17796,BAO_0000218,,,
4487,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Volume of distribution in cynomolgus,100710,,,1,17796,BAO_0000218,,,
4488,,Cavia porcellus,,A,U,Autocuration,Plasma,10141.0,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,,,1,5308,BAO_0000218,,,
4489,,Cavia porcellus,,A,U,Autocuration,,10141.0,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,,,1,4877,BAO_0000218,,,
4490,,Cavia porcellus,,A,U,Autocuration,,10141.0,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,,,1,4876,BAO_0000218,,,
4491,In vivo,Cavia porcellus,,A,U,Autocuration,Plasma,10141.0,AUC in guinea pig after 3mg/kg oral dose,22224,,,1,4878,BAO_0000218,,,
4492,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Bioavailability in guinea pig was tested,22224,,,1,5308,BAO_0000218,,,
4493,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,,,1,4877,BAO_0000218,,,
4494,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Tested for the oral bioavailability of the compound,22224,,,1,4876,BAO_0000218,,,
4495,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,,,1,4876,BAO_0000218,,,
4496,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,,,1,5308,BAO_0000218,,,
4497,In vivo,Cavia porcellus,,A,U,Autocuration,Lung,10141.0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,,,1,4877,BAO_0000218,,,
4498,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Cmax in guinea pig after 3mg/kg oral dose,22224,,,1,4878,BAO_0000218,,,
4499,,Cavia porcellus,,A,U,Autocuration,Blood,10141.0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4500,,Cavia porcellus,,A,U,Autocuration,Brain,10141.0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4501,,Cavia porcellus,,A,U,Autocuration,,10141.0,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4502,,Cavia porcellus,,A,U,Autocuration,Intestine,10141.0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4503,,Cavia porcellus,,A,U,Autocuration,Kidney,10141.0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4504,,Cavia porcellus,,A,U,Autocuration,Liver,10141.0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4505,,Cavia porcellus,,A,U,Autocuration,,10141.0,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4506,,Cavia porcellus,,A,U,Autocuration,Spleen,10141.0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,,,1,5689,BAO_0000019,,,
4507,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Elimination T1/2 in Guinea pig (PO dose),22224,,,1,14465,BAO_0000218,,,
4508,,Cavia porcellus,,A,U,Autocuration,,10141.0,Partition coefficient was measured as -log (counts per min ),22224,,,1,5689,BAO_0000019,,,
4509,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,,,1,611,BAO_0000218,,,
4510,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,,,1,611,BAO_0000218,,,
4511,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Elimination T1/2 in Guinea pig (PO dose),22224,,,1,14465,BAO_0000218,,,
4512,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,"Tested for the half life period of the compound, intravenously",22224,,,1,4876,BAO_0000218,,,
4513,,Cavia porcellus,,A,U,Autocuration,,10141.0,Half-life was measured,22224,,,1,5689,BAO_0000019,,,
4514,,Cavia porcellus,,A,U,Autocuration,,10141.0,The time required for onset of inotropy after addition of a single dose of delta F75,22224,,,1,7515,BAO_0000019,,,
4515,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,,,1,17667,BAO_0000218,,,
4516,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,,,1,17667,BAO_0000218,,,
4517,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,,,1,4727,BAO_0000218,,,
4518,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
4519,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
4520,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
4521,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
4522,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,,,1,10107,BAO_0000218,,,
4523,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
4524,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
4525,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4526,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4527,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4528,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4529,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4530,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4531,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4532,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4533,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4534,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4535,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4536,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4537,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4538,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4539,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4540,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4541,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4542,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4543,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4544,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4545,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4546,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4547,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4548,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4549,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4550,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4551,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4552,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4553,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4554,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4555,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,,,1,3655,BAO_0000218,,,
4556,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,,,1,3655,BAO_0000218,,,
4557,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,,,1,3655,BAO_0000218,,,
4558,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,,,1,16597,BAO_0000218,,,
4559,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,,,1,16597,BAO_0000218,,,
4560,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
4561,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
4562,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
4563,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,,,1,17764,BAO_0000218,,,
4564,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,,,1,3830,BAO_0000219,,A2780,
4565,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,,,1,3829,BAO_0000219,,A2780,
4566,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,,,1,2040,BAO_0000219,,A2780,
4567,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4568,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4569,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4570,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4571,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4572,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4573,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell line,81034,,,1,2859,BAO_0000219,,A2780,
4574,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against human tumor cell line A2780,81034,,,1,5618,BAO_0000219,,A2780,
4575,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4576,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4577,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4578,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4579,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,,,1,2113,BAO_0000219,,A2780,
4580,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,,,1,2113,BAO_0000219,,A2780,
4581,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,,,1,16745,BAO_0000219,,A2780,
4582,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,1,16597,BAO_0000218,,A2780,
4583,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,,,1,15684,BAO_0000219,,A2780,
4584,,Homo sapiens,,F,N,Intermediate,,9606.0,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,,,1,15684,BAO_0000219,,A2780,
4585,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,,,1,2040,BAO_0000219,,A2780,
4586,,Homo sapiens,,F,N,Intermediate,,9606.0,Relative resistance factor in A2780 cisplatin-resistant line,81034,,,1,2040,BAO_0000219,,A2780,
4587,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,,,1,16165,BAO_0000219,,A2780,
4588,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,,,1,16165,BAO_0000219,,A2780,
4589,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,1,16597,BAO_0000218,,A2780,
4590,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,,,1,16597,BAO_0000218,,A2780,
4591,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,,,1,3992,BAO_0000219,,A2780,
4592,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,,,1,10553,BAO_0000219,,A2780,
4593,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,,,1,15608,BAO_0000219,,A2780,
4594,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,,,1,15608,BAO_0000219,,A2780,
4595,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,,,1,15608,BAO_0000219,,A2780,
4596,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,,,1,15608,BAO_0000219,,A2780,
4597,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,,,1,15608,BAO_0000219,,A2780,
4598,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,,,1,15608,BAO_0000219,,A2780,
4599,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,,,1,15569,BAO_0000219,,A2780,
4600,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative effect of compound on A2780/DX cell line,81034,,,1,17420,BAO_0000219,,A2780,
4601,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,,,1,17420,BAO_0000219,,A2780,
4602,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,,,1,15099,BAO_0000219,,A2780,
4603,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,,,1,15099,BAO_0000219,,A2780,
4604,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,,,1,17672,BAO_0000219,,A2780,
4605,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,,,1,17672,BAO_0000219,,A2780,
4606,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A2780ADR cell line,81034,,,1,17270,BAO_0000219,,A2780,
4607,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A2780CIS cell line,81034,,,1,17270,BAO_0000219,,A2780,
4608,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,,,1,5574,BAO_0000219,,A2780,
4609,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,,,1,2113,BAO_0000219,,A2780,
4610,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4611,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4612,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability of compound in rhesus macaques,22224,,,1,17839,BAO_0000218,,,
4613,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,6821,BAO_0000218,,,
4614,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability evaluated in monkey,22224,,,1,6078,BAO_0000218,,,
4615,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,,,1,6535,BAO_0000218,,,
4616,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey,22224,,,1,4449,BAO_0000218,,,
4617,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability was calculated in rhesus monkey,22224,,,1,6057,BAO_0000218,,,
4618,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Oral bioavailability in cynomolgus monkey,22224,,,1,5922,BAO_0000218,,,
4619,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,5940,BAO_0000218,,,
4620,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,6265,BAO_0000218,,,
4621,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey (dose 1 mg/kg),22224,,,1,6265,BAO_0000218,,,
4622,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey (dose 5 mg/kg),22224,,,1,6265,BAO_0000218,,,
4623,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,5940,BAO_0000218,,,
4624,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey,22224,,,1,5940,BAO_0000218,,,
4625,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in rhesus monkey,22224,,,1,4514,BAO_0000218,,,
4626,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,,,1,5546,BAO_0000218,,,
4627,In vivo,Saimiri sciureus,,A,U,Autocuration,,9521.0,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,,,1,5553,BAO_0000218,,,
4628,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,,,1,6641,BAO_0000218,,,
4629,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey,22224,,,1,5472,BAO_0000218,,,
4630,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,,,1,5668,BAO_0000218,,,
4631,In vivo,monkey,,A,U,Autocuration,,9443.0,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,,,1,5711,BAO_0000218,,,
4632,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Bioavailability in Rhesus monkey,22224,,,1,5145,BAO_0000218,,,
4633,,Cercopithecidae,,A,U,Autocuration,,9527.0,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4634,,Cercopithecidae,,A,U,Autocuration,,9527.0,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4635,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,,,1,3249,BAO_0000218,,,
4636,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,,,1,3249,BAO_0000218,,,
4637,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
4638,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,,,1,5355,BAO_0000218,,,
4639,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,,,1,5355,BAO_0000218,,,
4640,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4641,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4642,,Cercopithecidae,,A,U,Autocuration,,9527.0,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4643,,Cercopithecidae,,A,U,Autocuration,,9527.0,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4644,,Cercopithecidae,,A,U,Autocuration,,9527.0,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4645,,Cercopithecidae,,A,U,Autocuration,,9527.0,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4646,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4647,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4648,,Cercopithecidae,,A,U,Autocuration,,9527.0,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,,,1,11271,BAO_0000019,,,
4649,,Cercopithecidae,,A,U,Autocuration,,9527.0,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4650,,Cercopithecidae,,A,U,Autocuration,,9527.0,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4651,,Cercopithecidae,,A,U,Autocuration,,9527.0,Elimination Half-life of compound was determined in monkey,22224,,,1,6821,BAO_0000019,,,
4652,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life of compound was determined in rhesus monkey,22224,,,1,17267,BAO_0000019,,,
4653,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Half life in monkey plasma,22224,,,1,5819,BAO_0000366,,,
4654,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Half life in monkey plasma; Not detected,22224,,,1,5819,BAO_0000366,,,
4655,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4656,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,,,1,17509,BAO_0000218,,,
4657,,Cercopithecidae,,A,U,Autocuration,,9527.0,Terminal half life of the compound.,22224,,,1,1399,BAO_0000019,,,
4658,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4659,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4660,,Cercopithecidae,,A,U,Autocuration,,9527.0,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,,,1,5546,BAO_0000218,,,
4661,,Cercopithecidae,,A,U,Autocuration,Urine,9527.0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4662,,Cercopithecidae,,A,U,Autocuration,Urine,9527.0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4663,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,,,1,4257,BAO_0000218,,,
4664,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,,,1,6221,BAO_0000218,,,
4665,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution was evaluated in rhesus,22224,,,1,5472,BAO_0000218,,,
4666,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,,,1,4727,BAO_0000218,,,
4667,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,,,1,4727,BAO_0000218,,,
4668,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Bioavailability in hamster was determined,22224,,,1,4727,BAO_0000218,,,
4669,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,,,1,4727,BAO_0000218,,,
4670,In vivo,Cricetulus griseus,,A,U,Autocuration,,10029.0,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,,,1,4727,BAO_0000218,,,
4671,,Cricetulus griseus,,A,U,Autocuration,Blood,10029.0,Half life of compound was determined in hamster blood,22224,,,1,4727,BAO_0000221,,,
4672,,Sus scrofa,,A,U,Autocuration,,9823.0,Michaelis-Menten constant of the compound.,22224,,,1,1452,BAO_0000019,,,
4673,,Sus scrofa,,A,U,Autocuration,,9823.0,Vmax value was measured at 0 uM concentration of silyl ether.,22224,,,1,1452,BAO_0000019,,,
4674,,Sus scrofa,,A,U,Autocuration,,9823.0,Vmax value was measured at 10 uM concentration of silyl ether.,22224,,,1,1452,BAO_0000019,,,
4675,,Sus scrofa,,A,U,Autocuration,,9823.0,Vmax value was measured at 5 uM concentration of silyl ether.,22224,,,1,1452,BAO_0000019,,,
4676,,Homo sapiens,,B,D,Expert,,9606.0,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,,,1,11706,BAO_0000357,,,
4677,,Homo sapiens,,A,U,Autocuration,,9606.0,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4678,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,,,1,17791,BAO_0000019,,,
4679,,Homo sapiens,,A,U,Autocuration,,9606.0,Active metabolite of ifosfamide determined in humans; A-Active,22224,,,1,7766,BAO_0000019,,,
4680,,Homo sapiens,,A,U,Autocuration,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,,,1,6567,BAO_0000019,,,
4681,,Homo sapiens,,A,U,Autocuration,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,,,1,6567,BAO_0000019,,,
4682,,Homo sapiens,,A,U,Autocuration,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,,,1,6567,BAO_0000019,,,
4683,,Homo sapiens,,A,U,Autocuration,,9606.0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,,,1,6567,BAO_0000019,,,
4684,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was evaluated for oral bioavailability in human,22224,,,1,17791,BAO_0000218,,,
4685,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Metabolite of ifosfamide determined in urine; NF-Not found,22224,,,1,7766,BAO_0000019,,,
4686,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,,,1,6852,BAO_0000019,,,
4687,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,,,1,6852,BAO_0000019,,,
4688,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,,,1,6852,BAO_0000019,,,
4689,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,,,1,6852,BAO_0000019,,,
4690,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,,,1,6852,BAO_0000019,,,
4691,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,,,1,6852,BAO_0000019,,,
4692,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent of compound in healthy individuals (Group D),22224,,,1,6852,BAO_0000019,,,
4693,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,,,1,4397,BAO_0000251,,,Microsomes
4694,,Homo sapiens,,A,U,Autocuration,,9606.0,Binding towards human plasma protein at 10 uM,22224,,,1,17409,BAO_0000019,,,
4695,,Homo sapiens,,A,U,Autocuration,,9606.0,Binding towards human plasma protein at 100 uM,22224,,,1,17409,BAO_0000019,,,
4696,,Homo sapiens,,A,U,Autocuration,,9606.0,Human plasma protein binding activity was determined,22224,,,1,17176,BAO_0000019,,,
4697,,Homo sapiens,,A,U,Autocuration,,9606.0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,,,1,15444,BAO_0000019,,,
4698,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent binding of compound towards human plasma protein was determined,22224,,,1,17267,BAO_0000019,,,
4699,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Plasma clearance in human liver microsomes,22224,,,1,5944,BAO_0000251,,,Microsomes
4700,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,In vitro intrinsic clearance in human liver microsome,22224,,,1,5668,BAO_0000251,,,Microsomes
4701,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,In vitro intrinsic clearance in human liver microsome,22224,,,1,5669,BAO_0000251,,,Microsomes
4702,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro microsome metabolism clearance in human was determined,22224,,,1,5041,BAO_0000251,,,Microsomes
4703,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro microsome metabolism clearance in human was determined; High,22224,,,1,5041,BAO_0000251,,,Microsomes
4704,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,,,1,5041,BAO_0000251,,,Microsomes
4705,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Pharmacokinetic property (clearance) in human liver microsome,22224,,,1,5676,BAO_0000251,,,Microsomes
4706,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Plasma clearance in human liver microsomes,22224,,,1,5944,BAO_0000251,,,Microsomes
4707,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,In vitro clearance in human liver microsomes,22224,,,1,17538,BAO_0000251,,,Microsomes
4708,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Intrinsic clearance in human liver microsomes was determined,22224,,,1,6331,BAO_0000251,,,Microsomes
4709,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Intrinsic clearance in human liver microsomes was determined,22224,,,1,5948,BAO_0000251,,,Microsomes
4710,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,,,1,5965,BAO_0000218,,,
4711,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
4712,,Homo sapiens,,A,U,Autocuration,,9606.0,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,,,1,5965,BAO_0000218,,,
4713,,Homo sapiens,,A,U,Autocuration,,9606.0,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,,,1,1299,BAO_0000019,,,
4714,,Homo sapiens,,A,U,Autocuration,,9606.0,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,,,1,1299,BAO_0000019,,,
4715,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4716,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4717,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4718,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4719,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
4720,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,,,1,17764,BAO_0000218,,,
4721,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,,,1,17764,BAO_0000218,,,
4722,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
4723,,Mus musculus,,A,N,Intermediate,,10090.0,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,,,1,14294,BAO_0000218,,,
4724,,Mus musculus,,A,N,Intermediate,,10090.0,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,,,1,14294,BAO_0000218,,,
4725,,Mus musculus,,A,N,Intermediate,,10090.0,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,,,1,14294,BAO_0000218,,,
4726,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vitro metabolic potential in mouse liver microsomes,50594,,,1,6251,BAO_0000218,,,
4727,,Mus musculus,,A,N,Intermediate,,10090.0,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,,,1,17582,BAO_0000218,,,
4728,,Mus musculus,,A,N,Intermediate,Adrenal gland,10090.0,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,,,1,17811,BAO_0000218,,,
4729,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,,,1,17811,BAO_0000218,,,
4730,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,,,1,17811,BAO_0000218,,,
4731,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,,,1,17811,BAO_0000218,,,
4732,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,,,1,17811,BAO_0000218,,,
4733,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,,,1,17811,BAO_0000218,,,
4734,,Mus musculus,,A,N,Intermediate,,10090.0,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,,,1,5288,BAO_0000218,,,
4735,,Mus musculus,,A,N,Intermediate,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,,,1,2717,BAO_0000218,,,
4736,,Mus musculus,,A,N,Intermediate,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,,,1,2717,BAO_0000218,,,
4737,,Mus musculus,,A,N,Intermediate,Serum,10090.0,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,,,1,2717,BAO_0000218,,,
4738,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4739,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4740,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4741,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,,,1,17764,BAO_0000218,,,
4742,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
4743,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,,,1,17764,BAO_0000218,,,
4744,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,,,1,17764,BAO_0000218,,,
4745,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Half life after intravenous administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
4746,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
4747,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,,,1,16597,BAO_0000218,,,
4748,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,,,1,2675,BAO_0000218,,,
4749,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
4750,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,,,1,16597,BAO_0000218,,,
4751,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,,,1,4890,BAO_0000218,,,
4752,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,,,1,429,BAO_0000218,,,
4753,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,,,1,17837,BAO_0000218,,,
4754,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
4755,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
4756,,Mus musculus,,A,N,Intermediate,,10090.0,Half life in ob/ob mice,50594,,,1,6619,BAO_0000218,,,
4757,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,,,1,4066,BAO_0000218,,,
4758,,Mus musculus,,A,N,Intermediate,,10090.0,Half-life was measured in mouse,50594,,,1,4239,BAO_0000218,,,
4759,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
4760,,Mus musculus,,A,N,Intermediate,,10090.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,,,1,8999,BAO_0000218,,,
4761,,Mus musculus,,A,N,Intermediate,,10090.0,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,,,1,8999,BAO_0000218,,,
4762,,Mus musculus,,A,N,Intermediate,Brain,10090.0,T2 in brain of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4763,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4764,,Mus musculus,,A,N,Intermediate,Liver,10090.0,T2 in liver of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4765,,Mus musculus,,A,N,Intermediate,Lung,10090.0,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4766,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4767,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,,,1,16597,BAO_0000218,,,
4768,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,,,1,4890,BAO_0000218,,,
4769,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,,,1,429,BAO_0000218,,,
4770,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,,,1,429,BAO_0000218,,,
4771,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,,,1,5969,BAO_0000218,,,
4772,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4773,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4774,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4775,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4776,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4777,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,,,1,16913,BAO_0000219,,A2780,
4778,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A2780TAX cell line,81034,,,1,17270,BAO_0000219,,A2780,
4779,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against human tumor cell line A2780cis,80017,,,1,5618,BAO_0000219,,A2780cisR,
4780,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,,,1,17777,BAO_0000219,,A2780,
4781,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,,,1,16112,BAO_0000219,,A2780cisR,
4782,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,,1,15748,BAO_0000219,,A2780cisR,
4783,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,,,1,6633,BAO_0000219,,A2780,
4784,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,,,1,16930,BAO_0000219,,A2780,
4785,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,,,1,17496,BAO_0000219,,A2780,
4786,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A2780cisR cell line.,81034,,,1,12989,BAO_0000219,,A2780,
4787,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,,,1,4840,BAO_0000219,,A2780,
4788,,Homo sapiens,,F,N,Expert,,9606.0,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,,,1,12989,BAO_0000219,,A2780,
4789,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,,,1,16745,BAO_0000219,,A2780cisR,
4790,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,,,1,16597,BAO_0000219,,A2780,
4791,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,,,1,16547,BAO_0000019,,,
4792,,,,F,H,Expert,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,,1,16547,BAO_0000019,,,
4793,,Rattus norvegicus,,F,D,Expert,,10116.0,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,,,1,16547,BAO_0000019,,,
4794,,Homo sapiens,,F,D,Expert,,9606.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,,,1,15856,BAO_0000219,,HEK293,
4795,,Homo sapiens,,F,D,Expert,,9606.0,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,,,1,15856,BAO_0000219,,HEK293,
4796,,Mus musculus,,B,D,Expert,,10090.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,,,1,16547,BAO_0000019,,,
4797,,,,F,H,Expert,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,,1,16547,BAO_0000019,,,
4798,,Mus musculus,,F,D,Expert,,10090.0,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,,,1,16547,BAO_0000019,,,
4799,,,,B,H,Expert,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,,,1,17402,BAO_0000357,,,
4800,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,,,1,11746,BAO_0000219,,T-cells,
4801,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,,,1,11746,BAO_0000219,,T-cells,
4802,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,,,1,5455,BAO_0000219,,A-375,
4803,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,,,1,2068,BAO_0000219,,A-375,
4804,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A375cell line extracted form melanoma,80018,,,1,2683,BAO_0000219,,A-375,
4805,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of cell growth in (A375) melan cell line,80018,,,1,15313,BAO_0000219,,A-375,
4806,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,,,1,13739,BAO_0000219,,A-375,
4807,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,,,1,13739,BAO_0000219,,A-375,
4808,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,,,1,14750,BAO_0000219,,A-375,
4809,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative activity measured against A427 human lung carcinoma,80019,,,1,14777,BAO_0000219,,A-427,
4810,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative activity measured against A427 human lung carcinoma,80019,,,1,14777,BAO_0000219,,A-427,
4811,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,,,1,17672,BAO_0000219,,A-427,
4812,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of large cell lung carcinoma (A427),80019,,,1,14368,BAO_0000219,,A-427,
4813,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,,,1,14368,BAO_0000219,,A-427,
4814,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,,,1,13866,BAO_0000219,,A-427,
4815,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration in human lung carcinoma A427 cell line,80019,,,1,2545,BAO_0000219,,A-427,
4816,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,,,1,2545,BAO_0000219,,A-427,
4817,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,,,1,6062,BAO_0000218,,,
4818,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Tested for volume of distribution upon iv administration to african green monkey,22224,,,1,4578,BAO_0000218,,,
4819,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution in monkey,22224,,,1,17592,BAO_0000218,,,
4820,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,,,1,5005,BAO_0000218,,,
4821,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,,,1,5005,BAO_0000218,,,
4822,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,,,1,5922,BAO_0000218,,,
4823,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The distribution volume after intravenous administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
4824,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,,,1,5355,BAO_0000218,,,
4825,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,,,1,5355,BAO_0000218,,,
4826,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume displacement was calculated in rhesus monkey,22224,,,1,6057,BAO_0000218,,,
4827,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution in steady state was determined in rhesus monkey,22224,,,1,5145,BAO_0000218,,,
4828,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution of compound was determined in monkey,22224,,,1,6821,BAO_0000218,,,
4829,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4830,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
4831,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,,,1,6641,BAO_0000218,,,
4832,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
4833,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume distribution in monkey after administration of 1 mg/kg iv,22224,,,1,6535,BAO_0000218,,,
4834,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4835,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,,,1,6062,BAO_0000218,,,
4836,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
4837,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Oral systemic bioavailability upon iv administration to african green monkey,22224,,,1,4578,BAO_0000218,,,
4838,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4839,,Cercopithecidae,,A,U,Autocuration,,9527.0,Baboon plasma free fraction. ,22224,,,1,11271,BAO_0000019,,,
4840,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under the curve was calculated in rhesus monkey after iv administration,22224,,,1,6057,BAO_0000218,,,
4841,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under the curve was calculated in rhesus monkey after peroral administration,22224,,,1,6057,BAO_0000019,,,
4842,,Cercopithecidae,,A,U,Autocuration,,9527.0,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,,,1,17853,BAO_0000019,,,
4843,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period in monkey after 5 mg/kg dose,22224,,,1,5302,BAO_0000218,,,
4844,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,,,1,4257,BAO_0000218,,,
4845,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,,,1,4257,BAO_0000218,,,
4846,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,,,1,13501,BAO_0000218,,,
4847,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,,,1,5394,BAO_0000218,,,
4848,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
4849,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for terminal half life in monkey,22224,,,1,3341,BAO_0000019,,,
4850,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,,,1,3045,BAO_0000218,,,
4851,In vivo,Macaca mulatta,,A,U,Autocuration,Plasma,9544.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,,,1,5005,BAO_0000218,,,
4852,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life of compound was determined in squirrel monkey,22224,,,1,4847,BAO_0000019,,,
4853,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Half life after iv administration in cynomolgus monkey,22224,,,1,4256,BAO_0000218,,,
4854,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Half life in monkey plasma after administration of 1 mg/kg iv,22224,,,1,6535,BAO_0000218,,,
4855,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life was calculated in rhesus monkey,22224,,,1,6057,BAO_0000019,,,
4856,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life in monkey,22224,,,1,17592,BAO_0000019,,,
4857,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,,,1,6641,BAO_0000218,,,
4858,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life was evaluated in rhesus,22224,,,1,5472,BAO_0000019,,,
4859,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,,,1,6221,BAO_0000218,,,
4860,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,,,1,5668,BAO_0000218,,,
4861,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,,,1,4809,BAO_0000218,,,
4862,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,,,1,5546,BAO_0000218,,,
4863,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,,,1,5553,BAO_0000218,,,
4864,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life was calculated in monkey,22224,,,1,6078,BAO_0000019,,,
4865,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life in Squirrel monkey,22224,,,1,5147,BAO_0000019,,,
4866,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life in rhesus monkey,22224,,,1,5145,BAO_0000019,,,
4867,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,,,1,6062,BAO_0000218,,,
4868,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life period after intravenous administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
4869,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life period after oral administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
4870,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,,,1,5355,BAO_0000218,,,
4871,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4872,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4873,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4874,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,,,1,7766,BAO_0000019,,,
4875,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,,,1,7766,BAO_0000019,,,
4876,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,,,1,7766,BAO_0000019,,,
4877,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,,,1,7766,BAO_0000019,,,
4878,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,,,1,7766,BAO_0000019,,,
4879,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,,,1,1916,BAO_0000218,,,
4880,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Oral bioavailability in human,22224,,,1,16643,BAO_0000218,,,
4881,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was tested for human plasma protein binding,22224,,,1,17248,BAO_0000019,,,
4882,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was tested for human plasma protein binding; Not determined,22224,,,1,17248,BAO_0000019,,,
4883,,Homo sapiens,,A,U,Autocuration,,9606.0,Protein binding activity of compound in human plasma; % Free,22224,,,1,6241,BAO_0000019,,,
4884,,Homo sapiens,,A,U,Autocuration,,9606.0,Unbound fraction (plasma),22224,,,1,17716,BAO_0000019,,,
4885,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life for the hydrolysis of compound in human blood serum,22224,,,1,17605,BAO_0000366,,,
4886,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life period in human plasma using phosphate buffer (0.08 M),22224,,,1,17625,BAO_0000366,,,
4887,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life period in human plasma using phosphate buffer (0.1 M),22224,,,1,17625,BAO_0000366,,,
4888,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life in human plasma was determined,22224,,,1,17747,BAO_0000366,,,
4889,,Homo sapiens,,A,U,Autocuration,,9606.0,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,,,1,15613,BAO_0000019,,,
4890,,Homo sapiens,,A,U,Autocuration,,9606.0,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,,,1,354,BAO_0000019,,,
4891,,Homo sapiens,,A,U,Autocuration,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,,,1,3741,BAO_0000019,,,
4892,,Homo sapiens,,A,U,Autocuration,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,,,1,3741,BAO_0000019,,,
4893,,Homo sapiens,,A,U,Autocuration,,9606.0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,,,1,3741,BAO_0000019,,,
4894,,Homo sapiens,,A,U,Autocuration,,9606.0,Partition coefficient (logP),22224,,,1,17599,BAO_0000019,,,
4895,,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,,,1,5486,BAO_0000019,,,
4896,,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,,,1,5600,BAO_0000251,,,Microsomes
4897,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,,,1,14294,BAO_0000019,,,
4898,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,,,1,14294,BAO_0000019,,,
4899,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,,,1,14294,BAO_0000019,,,
4900,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4901,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,,,1,14294,BAO_0000251,,,Microsomes
4902,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism of compound in human microsomes; Trace,22224,,,1,14294,BAO_0000251,,,Microsomes
4903,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,,,1,6260,BAO_0000251,,,Microsomes
4904,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,,,1,6187,BAO_0000251,,,Microsomes
4905,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,In vitro metabolic potential in human liver microsomes,22224,,,1,6251,BAO_0000251,,,Microsomes
4906,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,,,1,3246,BAO_0000019,,,
4907,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for human plasma protein binding of the compound; Not tested,22224,,,1,17313,BAO_0000019,,,
4908,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was tested for percent protein binding (PB) in human,22224,,,1,6227,BAO_0000019,,,
4909,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Protein binding in human plasma,22224,,,1,5530,BAO_0000019,,,
4910,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability coefficient (B to A) in Caco-2 cell,22224,,,1,6108,BAO_0000019,,,
4911,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,,,1,6108,BAO_0000019,,,
4912,,Homo sapiens,,A,U,Autocuration,,9606.0,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,,,1,2774,BAO_0000019,,,
4913,,Homo sapiens,,A,U,Autocuration,,9606.0,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,,,1,16643,BAO_0000019,,,
4914,,Homo sapiens,,A,U,Autocuration,,9606.0,Cellular permeability of compound was determined in Caco-2 cells; High,22224,,,1,17582,BAO_0000219,,Caco-2,
4915,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability in Caco-2 cells of compound,22224,,,1,6838,BAO_0000219,,Caco-2,
4916,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability coefficient (A to B) in Caco-2 cell,22224,,,1,6108,BAO_0000019,,,
4917,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability coefficient (B to A) in Caco-2 cell,22224,,,1,6108,BAO_0000019,,,
4918,,Homo sapiens,,A,U,Autocuration,,9606.0,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,,,1,6108,BAO_0000019,,,
4919,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,,,1,2146,BAO_0000019,,,
4920,,Homo sapiens,,A,U,Autocuration,,9606.0,Compound was tested for protein binding in human plasma,22224,,,1,4514,BAO_0000019,,,
4921,,Homo sapiens,,A,U,Autocuration,,9606.0,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,,,1,6108,BAO_0000019,,,
4922,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,,,1,7766,BAO_0000019,,,
4923,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
4924,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,,,1,3277,BAO_0000218,,,
4925,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,,,1,3802,BAO_0000218,,,
4926,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,,,1,2862,BAO_0000218,,,
4927,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,,,
4928,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
4929,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,,,1,5781,BAO_0000218,,,
4930,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax after peroral administration in mice at 2.4 uM/kg,50594,,,1,17764,BAO_0000218,,,
4931,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,,,1,4066,BAO_0000218,,,
4932,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4933,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4934,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4935,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4936,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Tmax in mice at 18 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
4937,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Tmax in mice at 23 uM/kg i.v. administration,50594,,,1,17764,BAO_0000218,,,
4938,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Tmax in mice at 25 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
4939,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Tmax in mice at 26 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
4940,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
4941,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
4942,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
4943,,Mus musculus,,A,N,Intermediate,,10090.0,Tmax value in IRC mice,50594,,,1,5951,BAO_0000218,,,
4944,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
4945,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
4946,,Mus musculus,,A,N,Intermediate,Urine,10090.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,,,1,429,BAO_0000218,,,
4947,,Mus musculus,,A,N,Intermediate,Urine,10090.0,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,,,1,429,BAO_0000218,,,
4948,,Mus musculus,,A,N,Intermediate,Urine,10090.0,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,,,1,4066,BAO_0000218,,,
4949,,Mus musculus,,A,N,Intermediate,,10090.0,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
4950,,Mus musculus,,A,N,Intermediate,,10090.0,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
4951,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,,,1,6062,BAO_0000218,,,
4952,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,,,1,5969,BAO_0000218,,,
4953,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
4954,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,,,1,5969,BAO_0000218,,,
4955,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Vd in mice,50594,,,1,5980,BAO_0000218,,,
4956,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution in mouse,50594,,,1,17592,BAO_0000218,,,
4957,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,,,
4958,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4959,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4960,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,,,1,17753,BAO_0000218,,,
4961,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (vdss) was measured in mouse,50594,,,1,4239,BAO_0000218,,,
4962,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Value distribution upon iv administration in mouse,50594,,,1,2862,BAO_0000218,,,
4963,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
4964,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution was evaluated in mice after intravenous administration,50594,,,1,2675,BAO_0000218,,,
4965,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
4966,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,,,1,17837,BAO_0000218,,,
4967,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Steady state volume of distribution was determined in mice,50594,,,1,5727,BAO_0000218,,,
4968,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume distribution (steady state) of compound was determined in mouse,50594,,,1,17852,BAO_0000218,,,
4969,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
4970,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
4971,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,,,1,6062,BAO_0000218,,,
4972,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of compound (oxidized form) in in kidney tissue,50594,,,1,16438,BAO_0000218,,,
4973,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,,,1,16438,BAO_0000218,,,
4974,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
4975,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
4976,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,,,1,10708,BAO_0000219,,A-427,
4977,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,,,1,16597,BAO_0000219,,A-431,
4978,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,,,1,16062,BAO_0000219,,A-431,
4979,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,,,1,16062,BAO_0000219,,A-431,
4980,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,,,1,16958,BAO_0000219,,A-431,
4981,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A431 human carcinoma cell proliferation,80852,,,1,6700,BAO_0000219,,A-431,
4982,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,,,1,17226,BAO_0000219,,A-431,
4983,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,,,1,6828,BAO_0000219,,A-431,
4984,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,,,1,12314,BAO_0000219,,A-431,
4985,,Homo sapiens,,F,D,Expert,,9606.0,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,,,1,13412,BAO_0000218,,A-431,
4986,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,,,1,13299,BAO_0000219,,A-431,
4987,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,,,1,17420,BAO_0000219,,A-431,
4988,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,,,1,13678,BAO_0000219,,A-431,
4989,,,,F,H,Expert,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,,,1,14171,BAO_0000219,,A-431,
4990,,Homo sapiens,,F,N,Expert,,9606.0,Tested for antiproliferative activity against human A431 cells,80852,,,1,6333,BAO_0000219,,A-431,
4991,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,,,1,2356,BAO_0000219,,A-431,
4992,,Homo sapiens,,F,N,Expert,,9606.0,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,,,1,15578,BAO_0000219,,A-431,
4993,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A431 cell proliferation,80852,,,1,5126,BAO_0000219,,A-431,
4994,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,,,1,6844,BAO_0000219,,A-431,
4995,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,,,1,6844,BAO_0000219,,A-431,
4996,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,,,1,4925,BAO_0000219,,A-431,
4997,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,,,1,4925,BAO_0000219,,A-431,
4998,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,,,1,13978,BAO_0000219,,A-431,
4999,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,,,1,16786,BAO_0000219,,A-431,
5000,,,,F,H,Expert,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,1,13412,BAO_0000219,,A-431,
5001,,Homo sapiens,,F,N,Intermediate,,9606.0,In vivo antiproliferative activity against A431 cell line,80852,,,1,17824,BAO_0000218,,A-431,
5002,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,,,1,12751,BAO_0000219,,A-431,
5003,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,,,1,12380,BAO_0000219,,A-431,
5004,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,,,1,4959,BAO_0000219,,A-431,
5005,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,,,1,6333,BAO_0000219,,A-431,
5006,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,,,1,6333,BAO_0000219,,A-431,
5007,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,,,1,6333,BAO_0000219,,A-431,
5008,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of EGFR overexpressing A431 cell proliferation,9,,,1,5296,BAO_0000019,,,
5009,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A431 cell proliferation,80852,,,1,12624,BAO_0000219,,A-431,
5010,,Homo sapiens,,F,D,Expert,,9606.0,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,,,1,14926,BAO_0000219,,A-431,
5011,,Homo sapiens,,F,D,Expert,,9606.0,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,,,1,14926,BAO_0000219,,A-431,
5012,,,,F,H,Expert,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,,,1,14926,BAO_0000219,,A-431,
5013,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,,,1,15144,BAO_0000219,,A-431,
5014,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,,,1,15144,BAO_0000219,,A-431,
5015,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,,,1,5245,BAO_0000219,,A-431,
5016,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,,,1,5245,BAO_0000219,,A-431,
5017,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,,,1,5245,BAO_0000219,,A-431,
5018,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,,,1,5245,BAO_0000219,,A-431,
5019,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,,,1,5245,BAO_0000219,,A-431,
5020,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life period in cynomolgus monkey,22224,,,1,5922,BAO_0000019,,,
5021,In vitro,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,,,1,1116,BAO_0000366,,,
5022,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,,,1,17853,BAO_0000218,,,
5023,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Plasma half life in monkey,22224,,,1,993,BAO_0000366,,,
5024,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Plasma half-life in rhesus monkey,22224,,,1,4514,BAO_0000366,,,
5025,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
5026,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,,,1,5334,BAO_0000218,,,
5027,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Tested for half life upon iv administration to african green monkey,22224,,,1,4578,BAO_0000218,,,
5028,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
5029,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,,,1,5355,BAO_0000218,,,
5030,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,,,1,5355,BAO_0000218,,,
5031,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
5032,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5033,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5034,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5035,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5036,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5037,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5038,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5039,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5040,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5041,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5042,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5043,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5044,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5045,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5046,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5047,,Cercopithecidae,,A,U,Autocuration,,9527.0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,,,1,11271,BAO_0000019,,,
5048,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,,,1,5809,BAO_0000218,,,
5049,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,,,
5050,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5051,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5052,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5053,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5054,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5055,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5056,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,,,1,3546,BAO_0000218,,,
5057,,Papio hamadryas,,A,U,Autocuration,,9557.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,,,1,10625,BAO_0000019,,,
5058,,Papio hamadryas,,A,U,Autocuration,,9557.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,,,1,10625,BAO_0000019,,,
5059,,Papio hamadryas,,A,U,Autocuration,,9557.0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,,,1,10625,BAO_0000019,,,
5060,,Papio hamadryas,,A,U,Autocuration,,9557.0,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,,,1,10625,BAO_0000019,,,
5061,,Papio hamadryas,,A,U,Autocuration,,9557.0,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,,,1,10625,BAO_0000019,,,
5062,,Papio hamadryas,,A,U,Autocuration,,9557.0,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,,,1,10625,BAO_0000019,,,
5063,,Papio hamadryas,,A,U,Autocuration,,9557.0,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,,,1,10625,BAO_0000019,,,
5064,,Papio hamadryas,,A,U,Autocuration,,9557.0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,,,1,10625,BAO_0000019,,,
5065,,beagle,,A,U,Autocuration,,9615.0,Area under curve after 1 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000019,,,
5066,,beagle,,A,U,Autocuration,,9615.0,Area under curve after 2 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000019,,,
5067,In vivo,beagle,,A,U,Autocuration,,9615.0,Cmax value after 1 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000218,,,
5068,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,,,1,7766,BAO_0000019,,,
5069,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,,,1,7766,BAO_0000019,,,
5070,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,,,1,7766,BAO_0000019,,,
5071,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,,,1,7766,BAO_0000019,,,
5072,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,,,1,7766,BAO_0000019,,,
5073,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,,,1,7766,BAO_0000019,,,
5074,,Homo sapiens,,A,U,Autocuration,Urine,9606.0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,,,1,7766,BAO_0000019,,,
5075,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,,,1,16643,BAO_0000251,,,Microsomes
5076,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,,,1,6852,BAO_0000019,,,
5077,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,,,1,6852,BAO_0000019,,,
5078,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,,,1,6852,BAO_0000019,,,
5079,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,,,1,6567,BAO_0000251,,,Microsomes
5080,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolic stability (% remaining at 30 mins) in human S9.,22224,,,1,6570,BAO_0000019,,,
5081,,Homo sapiens,,A,U,Autocuration,,9606.0,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,,,1,6570,BAO_0000019,,,
5082,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,,,1,5237,BAO_0000251,,,Microsomes
5083,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,,,1,5237,BAO_0000251,,,Microsomes
5084,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,,,1,5237,BAO_0000251,,,Microsomes
5085,,Homo sapiens,,A,U,Autocuration,,9606.0,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,,,1,5202,BAO_0000218,,,
5086,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,,,1,5481,BAO_0000019,,,
5087,,Homo sapiens,,A,U,Autocuration,,9606.0,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,,,1,5481,BAO_0000019,,,
5088,,Homo sapiens,,A,U,Autocuration,,9606.0,The percent remaining in human plasma after 30 min was determined,22224,,,1,3956,BAO_0000019,,,
5089,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Conversion rate of the prodrug in human plasma,22224,,,1,5074,BAO_0000366,,,
5090,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Conversion rate of the prodrug in human plasma; ND means no data,22224,,,1,5074,BAO_0000366,,,
5091,,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Half life of compound was determined in human blood,22224,,,1,4727,BAO_0000221,,,
5092,,Homo sapiens,,A,U,Autocuration,,9606.0,Half life of compound was determined in man with once daily dosing,22224,,,1,5965,BAO_0000019,,,
5093,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,Half life in human microsomes,22224,,,1,5732,BAO_0000251,,,Microsomes
5094,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life in human plasma,22224,,,1,5819,BAO_0000366,,,
5095,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life in human plasma; Not detected,22224,,,1,5819,BAO_0000366,,,
5096,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
5097,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,,,1,6597,BAO_0000251,,,Microsomes
5098,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life in human plasma,22224,,,1,5229,BAO_0000366,,,
5099,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life of the parent prodrug in plasma,22224,,,1,5229,BAO_0000366,,,
5100,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,In vitro half life in human plasma was determined,22224,,,1,2192,BAO_0000366,,,
5101,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,The compound was tested In Vitro for half life in human liver microsomes.,22224,,,1,3032,BAO_0000251,,,Microsomes
5102,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
5103,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Observed volume of distribution,22224,,,1,17716,BAO_0000218,,,
5104,In vivo,Homo sapiens,,A,U,Autocuration,,9606.0,Oral bioavailability in human,22224,,,1,15778,BAO_0000218,,,
5105,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for human plasma protein binding of the compound,22224,,,1,17313,BAO_0000019,,,
5106,,Homo sapiens,,A,U,Autocuration,,9606.0,"First order rate constant, k was determined in human plasma",22224,,,1,4231,BAO_0000019,,,
5107,,Homo sapiens,,A,U,Autocuration,,9606.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,,,1,4755,BAO_0000019,,,
5108,,Homo sapiens,,A,U,Autocuration,,9606.0,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,,,1,4755,BAO_0000019,,,
5109,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,,,1,16907,BAO_0000251,,,Microsomes
5110,,Homo sapiens,,A,U,Autocuration,,9606.0,The compound was tested for the plasma binding in human,22224,,,1,10839,BAO_0000019,,,
5111,,Homo sapiens,,A,U,Autocuration,,9606.0,Plasma protein binding (human),22224,,,1,10839,BAO_0000019,,,
5112,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Compound was evaluated for half-life in human liver microsomes,22224,,,1,3199,BAO_0000251,,,Microsomes
5113,In vitro,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Half life measured in vitro for its stability in human blood,22224,,,1,1345,BAO_0000221,,,
5114,,Homo sapiens,,A,U,Autocuration,Serum,9606.0,Half life in human serum,22224,,,1,4297,BAO_0000019,,,
5115,,Homo sapiens,,A,U,Autocuration,Serum,9606.0,Half life in human serum; ND=not determined,22224,,,1,4297,BAO_0000019,,,
5116,,Homo sapiens,,A,U,Autocuration,,9606.0,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,,,1,4297,BAO_0000019,,,
5117,,Homo sapiens,,A,U,Autocuration,,9606.0,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,,,1,4297,BAO_0000019,,,
5118,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life of the in human plasma,22224,,,1,4231,BAO_0000366,,,
5119,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,Half life period in human hepatic S9 fraction was determined,22224,,,1,5633,BAO_0000220,,,S9
5120,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Half life period in human liver microsome was determined,22224,,,1,5633,BAO_0000251,,,Microsomes
5121,,Homo sapiens,,A,U,Autocuration,,9606.0,Half life period was determined; 6-7,22224,,,1,17791,BAO_0000019,,,
5122,,Homo sapiens,,A,U,Autocuration,,9606.0,Half life period was evaluated in human,22224,,,1,17791,BAO_0000019,,,
5123,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life time in human plasma,22224,,,1,3160,BAO_0000366,,,
5124,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5125,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5126,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5127,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5128,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5129,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5130,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5131,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,,,1,16438,BAO_0000218,,,
5132,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5133,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,,,1,16438,BAO_0000218,,,
5134,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5135,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5136,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5137,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of compound (oxidized form) in blood tissue,50594,,,1,16438,BAO_0000218,,,
5138,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5139,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5140,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5141,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5142,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5143,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,,,1,16438,BAO_0000218,,,
5144,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5145,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5146,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5147,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5148,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5149,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,,,1,16438,BAO_0000218,,,
5150,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5151,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5152,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5153,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5154,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5155,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5156,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5157,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5158,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5159,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,,,
5160,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of compound (oxidized form) in liver tissue,50594,,,1,16438,BAO_0000218,,,
5161,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,,,
5162,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,,,
5163,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,,,1,5245,BAO_0000219,,A-431,
5164,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,,,1,5245,BAO_0000219,,A-431,
5165,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,,,1,16289,BAO_0000218,,A-431,
5166,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,,,1,16289,BAO_0000218,,A-431,
5167,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,1,16093,BAO_0000219,,A-431,
5168,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,,,1,16825,BAO_0000219,,A-431,
5169,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,,,1,4848,BAO_0000219,,A-431,
5170,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,,,1,14827,BAO_0000219,,A-431,
5171,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,,,1,14827,BAO_0000219,,A-431,
5172,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,,,1,16289,BAO_0000218,,A-431,
5173,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,1,16289,BAO_0000218,,A-431,
5174,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,,,1,16289,BAO_0000218,,A-431,
5175,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,,,1,16289,BAO_0000218,,A-431,
5176,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,,,1,16289,BAO_0000218,,A-431,
5177,,Homo sapiens,,F,D,Expert,,9606.0,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,,,1,16289,BAO_0000219,,A-431,
5178,,,,F,H,Expert,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,,,1,16289,BAO_0000219,,A-431,
5179,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,,,1,16289,BAO_0000218,,A-431,
5180,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,1,16289,BAO_0000218,,A-431,
5181,,,,F,N,Expert,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,,,1,16289,BAO_0000218,,A-431,
5182,,Mus musculus,,F,N,Expert,,10090.0,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,1,14555,BAO_0000218,,A-431,
5183,,Mus musculus,,F,N,Expert,,10090.0,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,1,14555,BAO_0000218,,A-431,
5184,,Mus musculus,,F,N,Expert,,10090.0,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,1,14555,BAO_0000218,,A-431,
5185,,Mus musculus,,F,N,Expert,,10090.0,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,,,1,14555,BAO_0000218,,A-431,
5186,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,,,1,1937,BAO_0000219,,A-431,
5187,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,,,1,13739,BAO_0000219,,A-431,
5188,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,,,1,3558,BAO_0000219,,A-431,
5189,,Homo sapiens,,F,N,Intermediate,,9606.0,Dose giving a 50% decrease in the living cell number (A437 cells),80852,,,1,3558,BAO_0000219,,A-431,
5190,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,,,1,17686,BAO_0000219,,A549,
5191,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,,,1,5305,BAO_0000219,,A549,
5192,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,,,1,3614,BAO_0000219,,A549,
5193,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against renal A498 tumor cell lines,80021,,,1,17229,BAO_0000219,,A498,
5194,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,,,1,15935,BAO_0000219,,A498,
5195,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,,,1,15935,BAO_0000219,,A498,
5196,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,,,1,15560,BAO_0000219,,A498,
5197,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,,,1,13891,BAO_0000219,,A498,
5198,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,,,1,13891,BAO_0000219,,A498,
5199,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,,,1,13788,BAO_0000219,,A498,
5200,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated against Human cell line renal A498,80021,,,1,15403,BAO_0000219,,A498,
5201,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for inhibition of A498 human renal cancer cell line,80021,,,1,1009,BAO_0000219,,A498,
5202,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity against A498 human cancer cell line,80021,,,1,1043,BAO_0000219,,A498,
5203,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against human renal A498 cell line,80021,,,1,5858,BAO_0000219,,A498,
5204,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against renal (A498) cell line,80021,,,1,5958,BAO_0000219,,A498,
5205,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,,,1,5506,BAO_0000219,,A498,
5206,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytostatic activity against renal A498 cell line,80021,,,1,12781,BAO_0000219,,A498,
5207,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,,,1,14399,BAO_0000219,,A498,
5208,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,,,1,5958,BAO_0000219,,A498,
5209,In vivo,beagle,,A,U,Autocuration,,9615.0,Cmax value after 2 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000218,,,
5210,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability,22224,,,1,3510,BAO_0000218,beagle,,
5211,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability after 1 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000218,beagle,,
5212,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability after 2 mpk peroral administration to beagles,22224,,,1,3510,BAO_0000218,beagle,,
5213,,Bos taurus,,A,U,Autocuration,,9913.0,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,,,1,3085,BAO_0000019,,,
5214,,Bos taurus,,A,U,Autocuration,,9913.0,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,,,1,3085,BAO_0000019,,,
5215,,Bos taurus,,A,U,Autocuration,,9913.0,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,,,1,3085,BAO_0000019,,,
5216,,Bos taurus,,A,U,Autocuration,,9913.0,Solubility against bovine alpha-chymotrypsin,22224,,,1,9372,BAO_0000019,,,
5217,,Bos taurus,,A,U,Autocuration,,9913.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,,,1,3085,BAO_0000019,,,
5218,,Bos taurus,,A,U,Autocuration,,9913.0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,,,1,3085,BAO_0000019,,,
5219,,Bos taurus,,A,U,Autocuration,Spleen,9913.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,,,1,1469,BAO_0000221,,,
5220,,Bos taurus,,A,U,Autocuration,,9913.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,,,1,4297,BAO_0000019,,,
5221,,Bos taurus,,A,U,Autocuration,,9913.0,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,,,1,4297,BAO_0000019,,,
5222,,Bos taurus,,A,U,Autocuration,,9913.0,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,,,1,17585,BAO_0000019,,,
5223,,Bos taurus,,A,U,Autocuration,Spleen,9913.0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,,,1,1336,BAO_0000221,,,
5224,,Bos taurus,,A,U,Autocuration,,9913.0,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,,,1,3085,BAO_0000019,,,
5225,,Bos taurus,,A,U,Autocuration,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,,,1,2857,BAO_0000019,,,
5226,,Bos taurus,,A,U,Autocuration,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,,,1,2857,BAO_0000019,,,
5227,,Bos taurus,,A,U,Autocuration,,9913.0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,,,1,2857,BAO_0000019,,,
5228,,Bos taurus,,A,U,Autocuration,,9913.0,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,,,1,1540,BAO_0000019,,,
5229,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,,,1,6316,BAO_0000218,,,
5230,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC after administration at 100 mg/kg/day in dogs,50588,,,1,17594,BAO_0000218,,,
5231,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,,,1,4953,BAO_0000218,,,
5232,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC value after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5233,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC value after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5234,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC value after administration of 4 mg/Kg oral dose in dog,50588,,,1,2959,BAO_0000218,,,
5235,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
5236,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,,,1,5356,BAO_0000218,,,
5237,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,,,1,16807,BAO_0000218,,,
5238,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
5239,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
5240,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,,,1,15660,BAO_0000218,,,
5241,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,,,1,15660,BAO_0000218,,,
5242,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,,,1,5802,BAO_0000218,,,
5243,,Canis lupus familiaris,,A,N,Expert,,9615.0,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
5244,,Canis lupus familiaris,,A,N,Expert,,9615.0,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
5245,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,1,5944,BAO_0000218,,,
5246,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,,,1,5944,BAO_0000218,,,
5247,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,1,5944,BAO_0000218,,,
5248,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,,,1,5944,BAO_0000218,,,
5249,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,,,1,4186,BAO_0000218,,,
5250,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,,,1,5007,BAO_0000218,,,
5251,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determine after peroral administration at 10 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5252,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determine after peroral administration at 5 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5253,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined,50588,,,1,5006,BAO_0000218,,,
5254,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dogs,50588,,,1,5006,BAO_0000218,,,
5255,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,,,1,3771,BAO_0000218,,,
5256,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,,,1,3771,BAO_0000218,,,
5257,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,,,1,3771,BAO_0000218,,,
5258,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,1,1916,BAO_0000218,,,
5259,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve value in dog at a dose of 5 mg/kg,50588,,,1,5302,BAO_0000218,,,
5260,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,,,1,5600,BAO_0000218,,,
5261,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,,,1,5600,BAO_0000218,,,
5262,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
5263,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,,,1,4368,BAO_0000218,,,
5264,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,,,1,5318,BAO_0000019,,,
5265,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,,,1,5318,BAO_0000019,,,
5266,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,,,1,5318,BAO_0000019,,,
5267,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,,,1,5318,BAO_0000019,,,
5268,,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,,,1,14518,BAO_0000221,,,
5269,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,,,1,2209,BAO_0000366,,,
5270,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life in human plasma,22224,,,1,6787,BAO_0000366,,,
5271,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life in human plasma was reported,22224,,,1,4898,BAO_0000366,,,
5272,,Homo sapiens,,A,U,Autocuration,Serum,9606.0,Half life in human serum,22224,,,1,6072,BAO_0000019,,,
5273,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life upon exposure to human plasma,22224,,,1,16907,BAO_0000366,,,
5274,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,t1/2 in human microsomes,22224,,,1,5656,BAO_0000251,,,Microsomes
5275,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half life period in 80% human plasma at 37 degree Centigrade,22224,,,1,4755,BAO_0000366,,,
5276,,Homo sapiens,,A,U,Autocuration,Zone of skin,9606.0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,,,1,17503,BAO_0000221,,,
5277,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,,,1,12357,BAO_0000366,,,
5278,,Homo sapiens,,A,U,Autocuration,,9606.0,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,,,1,3076,BAO_0000019,,,
5279,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,,,1,6410,BAO_0000251,,,Microsomes
5280,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,,,1,3741,BAO_0000366,,,
5281,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,,,1,3741,BAO_0000366,,,
5282,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,,,1,3741,BAO_0000366,,,
5283,,Homo sapiens,,A,U,Autocuration,,9606.0,Half-life in the CEM cell extracts,22224,,,1,1540,BAO_0000019,,,
5284,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,,,1,2905,BAO_0000366,,,
5285,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,,,1,2905,BAO_0000366,,,
5286,,Homo sapiens,,A,U,Autocuration,,9606.0,Half-life was determined,22224,,,1,5523,BAO_0000019,,,
5287,,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Half-life (human blood stability),22224,,,1,1499,BAO_0000221,,,
5288,,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Half-life (human blood stability); no data,22224,,,1,1499,BAO_0000221,,,
5289,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Half-life in human plasma,22224,,,1,17065,BAO_0000366,,,
5290,,Homo sapiens,,A,U,Autocuration,,9606.0,CYP3A4 metabolism half-life (t1/2),22224,,,1,6861,BAO_0000019,,,
5291,,Homo sapiens,,A,U,Autocuration,Blood,9606.0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,,,1,1499,BAO_0000221,,,
5292,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,In vitro half life in human plasma,22224,,,1,530,BAO_0000366,,,
5293,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,,,1,1116,BAO_0000366,,,
5294,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,In vitro hydrolysis in human plasma,22224,,,1,6695,BAO_0000366,,,
5295,In vitro,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,In vitro hydrolysis in human plasma; no data,22224,,,1,6695,BAO_0000366,,,
5296,In vitro,Homo sapiens,,A,U,Autocuration,Liver,9606.0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,,,1,10,BAO_0000251,,,Microsomes
5297,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Plasma half life in human,22224,,,1,993,BAO_0000366,,,
5298,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,Stability after incubation with human plasma (at 37 degree C),22224,,,1,15429,BAO_0000366,,,
5299,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,T1/2 was evaluated in human plasma,22224,,,1,1675,BAO_0000366,,,
5300,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,,,1,2209,BAO_0000366,,,
5301,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,,,1,2209,BAO_0000366,,,
5302,,Homo sapiens,,A,U,Autocuration,,9606.0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,,,1,5318,BAO_0000019,,,
5303,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,,,1,2412,BAO_0000019,,,
5304,In vitro,Homo sapiens,,A,U,Autocuration,,9606.0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,,,1,2412,BAO_0000019,,,
5305,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,,,1,2906,BAO_0000366,,,
5306,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,,,1,2906,BAO_0000366,,,
5307,,Homo sapiens,,A,U,Autocuration,,9606.0,Time taken for 50% to be consumed by serum PON1 was determined,22224,,,1,5495,BAO_0000019,,,
5308,,Homo sapiens,,A,U,Autocuration,,9606.0,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,,,1,5495,BAO_0000019,,,
5309,,Homo sapiens,,A,U,Autocuration,Liver,9606.0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,,,1,4397,BAO_0000251,,,Microsomes
5310,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5311,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5312,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5313,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5314,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5315,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,1,2413,BAO_0000218,,,
5316,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,,,1,6058,BAO_0000219,,786-0,
5317,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,,,1,17708,BAO_0000219,,786-0,
5318,,Homo sapiens,,F,N,Expert,,9606.0,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,,,1,14017,BAO_0000219,,786-0,
5319,,Homo sapiens,,F,N,Intermediate,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,,,1,16818,BAO_0000219,,786-0,
5320,,Homo sapiens,,F,N,Intermediate,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,,,1,16818,BAO_0000219,,786-0,
5321,,Homo sapiens,,F,N,Intermediate,,9606.0,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,,,1,16818,BAO_0000219,,786-0,
5322,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,,,1,11970,BAO_0000219,,786-0,
5323,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,,,1,12400,BAO_0000219,,786-0,
5324,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on renal cancer line 786-0,80640,,,1,12888,BAO_0000219,,786-0,
5325,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,,,1,15300,BAO_0000219,,786-0,
5326,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,,,1,14769,BAO_0000219,,786-0,
5327,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,,,1,15895,BAO_0000219,,786-0,
5328,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,,,1,17376,BAO_0000219,,786-0,
5329,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,,,1,14882,BAO_0000219,,786-0,
5330,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,,,1,14882,BAO_0000219,,786-0,
5331,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,,,1,15176,BAO_0000219,,786-0,
5332,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,,,1,12696,BAO_0000219,,786-0,
5333,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,,,1,2496,BAO_0000219,,786-0,
5334,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,,,1,11831,BAO_0000219,,791T cell line,
5335,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,,,1,11831,BAO_0000219,,791T cell line,
5336,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,,,1,11831,BAO_0000219,,791T cell line,
5337,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,,,1,11831,BAO_0000219,,791T cell line,
5338,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,,,1,11831,BAO_0000219,,791T cell line,
5339,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,,,1,11831,BAO_0000219,,791T cell line,
5340,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,,,1,11831,BAO_0000219,,791T cell line,
5341,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,,,1,11831,BAO_0000219,,791T cell line,
5342,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,,,1,11831,BAO_0000219,,791T cell line,
5343,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,,,1,11831,BAO_0000219,,791T cell line,
5344,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,,,1,12782,BAO_0000219,,786-0,
5345,,,,F,U,Intermediate,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
5346,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,,,1,15313,BAO_0000219,,RPMI-8226,
5347,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,,,1,15313,BAO_0000219,,RPMI-8226,
5348,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,,,1,11544,BAO_0000219,,RPMI-8226,
5349,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5350,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5351,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5352,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5353,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5354,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5355,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5356,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5357,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5358,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,,,1,14769,BAO_0000219,,A498,
5359,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,,,1,15354,BAO_0000219,,A498,
5360,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,,,1,17445,BAO_0000219,,A498,
5361,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory concentration against renal cancer cell line A498,80021,,,1,4337,BAO_0000219,,A498,
5362,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A 498 tumor cell line,80021,,,1,15277,BAO_0000219,,A498,
5363,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A498 human cancer cell line,80021,,,1,4812,BAO_0000219,,A498,
5364,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,,,1,4812,BAO_0000219,,A498,
5365,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory dose required against A498 human tumor cell lines,80021,,,1,4995,BAO_0000219,,A498,
5366,,Homo sapiens,,F,N,Intermediate,,9606.0,Anticancer activity against one renal cancer (A498 cell line),80021,,,1,5847,BAO_0000219,,A498,
5367,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against melanoma A498 cell line,80021,,,1,6557,BAO_0000219,,A498,
5368,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for growth inhibitory activity against A498 cell line,80021,,,1,2597,BAO_0000219,,A498,
5369,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for growth inhibition of renal cancer cell line A498,80021,,,1,6058,BAO_0000219,,A498,
5370,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,,,1,17708,BAO_0000219,,A498,
5371,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,,,1,15176,BAO_0000219,,A498,
5372,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,,,1,15300,BAO_0000219,,A498,
5373,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,,,1,11970,BAO_0000219,,A498,
5374,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,,,1,12400,BAO_0000219,,A498,
5375,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on renal cancer lines A498,80021,,,1,12888,BAO_0000219,,A498,
5376,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,,,1,3030,BAO_0000219,,A498,
5377,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,,,1,14769,BAO_0000219,,A498,
5378,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,,,1,17376,BAO_0000219,,A498,
5379,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,,,1,16558,BAO_0000219,,A498,
5380,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,,,1,5194,BAO_0000219,,A498,
5381,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,,,1,10708,BAO_0000219,,A498,
5382,,Homo sapiens,,F,N,Expert,,9606.0,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,,,1,16880,BAO_0000219,,A549,
5383,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against A549 human lung carcinoma cell line,80682,,,1,10196,BAO_0000219,,A549,
5384,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,,,1,10196,BAO_0000219,,A549,
5385,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,,,1,10196,BAO_0000219,,A549,
5386,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,,,1,12083,BAO_0000219,,A549,
5387,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,,,1,16464,BAO_0000219,,A549,
5388,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,,,1,16464,BAO_0000219,,A549,
5389,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity against human lung A549 cell line,80682,,,1,16470,BAO_0000219,,A549,
5390,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,,,1,16470,BAO_0000219,,A549,
5391,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human lung A549 cell line),80682,,,1,16470,BAO_0000219,,A549,
5392,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,,,1,16470,BAO_0000219,,A549,
5393,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,,,1,16582,BAO_0000219,,A549,
5394,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,,,1,15935,BAO_0000219,,A549,
5395,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,,,1,15935,BAO_0000219,,A549,
5396,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A549 human lung carcinoma cell proliferation,80682,,,1,16597,BAO_0000219,,A549,
5397,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,,,1,17376,BAO_0000219,,A549,
5398,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,,,1,16496,BAO_0000219,,A549,
5399,,Homo sapiens,,F,N,Intermediate,,9606.0,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,,,1,16152,BAO_0000219,,A549,
5400,,Homo sapiens,,F,N,Intermediate,,9606.0,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,,,1,16152,BAO_0000219,,A549,
5401,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,,,1,16464,BAO_0000219,,A549,
5402,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,,,1,2288,BAO_0000219,,A549,
5403,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,,,1,17350,BAO_0000219,,A549,
5404,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A549 cancer cell proliferation,80682,,,1,4090,BAO_0000219,,A549,
5405,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A549 cancer cell proliferation (Not tested),80682,,,1,4090,BAO_0000219,,A549,
5406,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,,,1,17350,BAO_0000219,,A549,
5407,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,,,1,4197,BAO_0000219,,A549,
5408,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,,,1,17072,BAO_0000219,,A549,
5409,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,,,1,17072,BAO_0000219,,A549,
5410,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against Renal cell lines A549 was determined,80682,,,1,5194,BAO_0000219,,A549,
5411,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,,,1,4257,BAO_0000218,,,
5412,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,,,1,6123,BAO_0000218,,,
5413,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
5414,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
5415,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,,,1,8833,BAO_0000218,,,
5416,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,,,1,8833,BAO_0000218,,,
5417,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,,,1,8833,BAO_0000218,,,
5418,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,,,1,8833,BAO_0000218,,,
5419,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Area under plasma concentration time curve in dog upon oral administration,50588,,,1,17657,BAO_0000218,,,
5420,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,,,1,17650,BAO_0000218,,,
5421,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,,,1,1977,BAO_0000218,,,
5422,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,,,1,1977,BAO_0000218,,,
5423,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve for the compound was obtained when tested in dog,50588,,,1,3132,BAO_0000218,,,
5424,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve at a dose of 1 mg/kg,50588,,,1,5473,BAO_0000218,,,
5425,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve at a dose of 1 mg/kg (oral),50588,,,1,5474,BAO_0000218,,,
5426,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve at i.v. dose of 0.2 mg/kg,50588,,,1,5474,BAO_0000218,,,
5427,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,,,1,6062,BAO_0000218,,,
5428,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
5429,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,,,1,2652,BAO_0000218,,,
5430,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,,,1,2652,BAO_0000218,,,
5431,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for area under the curve in dog blood.,50588,,,1,2877,BAO_0000218,,,
5432,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,,,1,5444,BAO_0000218,,,
5433,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC in dog after oral dose (1 mg/kg),50588,,,1,5130,BAO_0000218,,,
5434,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,,,1,6265,BAO_0000218,,,
5435,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,,,1,4657,BAO_0000218,,,
5436,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,,,1,16367,BAO_0000218,,,
5437,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC after oral administration to dogs,50588,,,1,16367,BAO_0000218,,,
5438,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,,,1,9579,BAO_0000218,,,
5439,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,,,1,9579,BAO_0000218,,,
5440,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,,,1,5983,BAO_0000218,,,
5441,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,,,1,6241,BAO_0000218,,,
5442,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,,,1,5313,BAO_0000218,,,
5443,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,,,1,5313,BAO_0000218,,,
5444,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,1,6642,BAO_0000218,,,
5445,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,1,6642,BAO_0000218,,,
5446,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,,,1,6641,BAO_0000218,,,
5447,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,,,1,6642,BAO_0000218,,,
5448,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for oral bioavailability in dog; 90-100,50588,,,1,17791,BAO_0000218,,,
5449,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,,,1,17655,BAO_0000218,,,
5450,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,,,1,17655,BAO_0000218,,,
5451,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,,,1,6596,BAO_0000218,,,
5452,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3880,BAO_0000218,,,
5453,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,,,1,16367,BAO_0000218,,,
5454,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma protein binding towards dog plasma at 10 uM,50588,,,1,17409,BAO_0000218,,,
5455,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma protein binding towards dog plasma at 100 uM,50588,,,1,17409,BAO_0000218,,,
5456,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 4 mg/kg p.o.),50588,,,1,2959,BAO_0000218,,,
5457,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,,,1,13501,BAO_0000218,,,
5458,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
5459,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dogs,50588,,,1,15145,BAO_0000218,,,
5460,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability,50588,,,1,4219,BAO_0000218,,,
5461,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,17538,BAO_0000218,,,
5462,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,,,1,17538,BAO_0000218,,,
5463,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,,,1,1466,BAO_0000218,,,
5464,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,,,1,17650,BAO_0000218,,,
5465,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,,,1,3132,BAO_0000218,,,
5466,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5467,,Mus sp.,,A,U,Autocuration,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5468,,Mus sp.,,A,U,Autocuration,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,1,2413,BAO_0000218,,,
5469,,Mus sp.,,A,U,Autocuration,Liver,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5470,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5471,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5472,,Mus sp.,,A,U,Autocuration,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5473,,Mus sp.,,A,U,Autocuration,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,1,2413,BAO_0000218,,,
5474,,Mus sp.,,A,U,Autocuration,Muscle tissue,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5475,,Mus sp.,,A,U,Autocuration,Spleen,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5476,,Mus sp.,,A,U,Autocuration,Spleen,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5477,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,,,1,2413,BAO_0000218,,,
5478,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,1,2413,BAO_0000218,,,
5479,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5480,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,,,1,2413,BAO_0000218,,,
5481,,Mus sp.,,A,U,Autocuration,,10095.0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,,,1,2413,BAO_0000218,,,
5482,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5483,,Cercopithecidae,,A,U,Autocuration,Cerebellum,9527.0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5484,,Cercopithecidae,,A,U,Autocuration,Frontal cortex,9527.0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5485,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5486,,Cercopithecidae,,A,U,Autocuration,Striatum,9527.0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5487,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5488,,Cercopithecidae,,A,U,Autocuration,Cerebellum,9527.0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5489,,Cercopithecidae,,A,U,Autocuration,Frontal cortex,9527.0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5490,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5491,,Cercopithecidae,,A,U,Autocuration,Striatum,9527.0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,,,1,17827,BAO_0000019,,,
5492,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for oral bioavailability in rats,22224,,,1,17791,BAO_0000218,,,
5493,In vivo,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,,,1,17667,BAO_0000218,,,
5494,,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life period was evaluated in monkey,22224,,,1,17791,BAO_0000019,,,
5495,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half-life in rhesus monkeys by intravenous administration of dose,22224,,,1,110,BAO_0000218,,,
5496,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,,,1,5781,BAO_0000218,,,
5497,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
5498,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC value was determined after oral administration,50594,,,1,17718,BAO_0000218,,,
5499,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,,,1,4573,BAO_0000218,,,
5500,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,,,1,3277,BAO_0000218,,,
5501,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve by ioral administration in mouse,50594,,,1,2862,BAO_0000218,,,
5502,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve by iv administration in mouse,50594,,,1,2862,BAO_0000218,,,
5503,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,,,1,5951,BAO_0000218,,,
5504,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,,,1,17729,BAO_0000218,,,
5505,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,,,1,17728,BAO_0000218,,,
5506,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,,,1,17728,BAO_0000218,,,
5507,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,,,1,17729,BAO_0000218,,,
5508,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5509,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5510,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5511,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5512,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5513,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5514,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5515,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5516,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5517,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5518,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5519,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5520,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5521,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5522,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5523,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,,,1,9424,BAO_0000219,,RPMI-8226,
5524,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,,,1,9424,BAO_0000219,,RPMI-8226,
5525,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,,,1,11544,BAO_0000219,,RPMI-8226,
5526,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound against 8226/DOX1V cells,80433,,,1,17378,BAO_0000219,,RPMI-8226,
5527,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound against 8226/S cells,80433,,,1,17378,BAO_0000219,,RPMI-8226,
5528,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against 8226 myeloma cancer cell line,80433,,,1,17079,BAO_0000219,,RPMI-8226,
5529,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,,,1,17079,BAO_0000219,,RPMI-8226,
5530,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,,,1,13466,BAO_0000219,,833K,
5531,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,,,1,13466,BAO_0000219,,833K,
5532,,Homo sapiens,,F,N,Expert,,9606.0,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,,,1,2392,BAO_0000219,,833K,
5533,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,,,1,2392,BAO_0000219,,833K,
5534,,,,B,U,Autocuration,,,Inhibitory activity against caspase-1,22226,,,1,6608,BAO_0000019,,,
5535,,Enterococcus faecalis,,B,H,Autocuration,,1351.0,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,,,1,10199,BAO_0000357,,,
5536,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,,,1,17749,BAO_0000219,,8701-BC,
5537,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,,,1,17749,BAO_0000219,,8701-BC,
5538,,,,F,U,Intermediate,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
5539,,,,F,U,Intermediate,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
5540,,,,F,U,Intermediate,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,,,1,1229,BAO_0000019,,,
5541,,,,B,U,Autocuration,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,,,1,6390,BAO_0000019,,,
5542,,Streptococcus pyogenes,,F,U,Autocuration,,1314.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,,,1,16219,BAO_0000019,,,
5543,,Streptococcus pyogenes,,F,U,Autocuration,,1314.0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,,,1,16219,BAO_0000019,,,
5544,,,,B,H,Autocuration,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,,,1,17043,BAO_0000357,,,
5545,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,,,1,6929,BAO_0000219,,KB ,
5546,,Homo sapiens,,A,N,Intermediate,,9606.0,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,,,1,6929,BAO_0000219,,KB ,
5547,,Homo sapiens,,F,U,Autocuration,,9606.0,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,,,1,7083,BAO_0000219,,,
5548,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Cytotoxic concentration against 9L cells was determined on day 3,80653,,,1,12446,BAO_0000219,,9L,
5549,,Rattus norvegicus,,F,N,Expert,,10116.0,Tested in vitro for anticancer activity against 9L cells,80653,,,1,15345,BAO_0000219,,9L,
5550,,Rattus norvegicus,,F,N,Expert,,10116.0,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,,,1,15345,BAO_0000219,,9L,
5551,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,,,1,6301,BAO_0000219,,A549,
5552,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,,,1,4833,BAO_0000219,,A549,
5553,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,,,1,4833,BAO_0000219,,A549,
5554,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,,,1,4833,BAO_0000219,,A549,
5555,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human lung carcinoma A549 cell line,80682,,,1,13330,BAO_0000219,,A549,
5556,,Homo sapiens,,F,D,Expert,,9606.0,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,,,1,17517,BAO_0000219,,A549,
5557,,Homo sapiens,,F,D,Expert,,9606.0,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,,,1,17517,BAO_0000219,,A549,
5558,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of A549, lung carcinoma",80682,,,1,14425,BAO_0000219,,A549,
5559,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro growth inhibition of A549, lung carcinoma.",80682,,,1,14425,BAO_0000219,,A549,
5560,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,1,5228,BAO_0000219,,A549,
5561,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,,,1,5351,BAO_0000219,,A549,
5562,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,,,1,12198,BAO_0000219,,A549,
5563,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,,,1,13891,BAO_0000219,,A549,
5564,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity in A549 (human carcinoma) cell line.,80682,,,1,5677,BAO_0000219,,A549,
5565,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on lung carcinoma (A-549) cell line,80682,,,1,13788,BAO_0000219,,A549,
5566,,Homo sapiens,,F,N,Expert,,9606.0,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,,,1,13384,BAO_0000219,,A549,
5567,,Homo sapiens,,F,N,Intermediate,,9606.0,Effective dose of compound against replication of A549 cell line was evaluated,80682,,,1,6726,BAO_0000219,,A549,
5568,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,,,1,3455,BAO_0000219,,A549,
5569,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,,,1,5726,BAO_0000219,,A549,
5570,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,,,1,5726,BAO_0000219,,A549,
5571,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was evaluated for antiproliferative activity against A549 cell line,80682,,,1,3936,BAO_0000219,,A549,
5572,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,,,1,14991,BAO_0000219,,A549,
5573,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,,,1,5243,BAO_0000219,,A549,
5574,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,,,1,12858,BAO_0000219,,A549,
5575,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition against A549 cell line was evaluated,80682,,,1,6776,BAO_0000219,,A549,
5576,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,,,1,16558,BAO_0000219,,A549,
5577,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,,,1,4583,BAO_0000219,,A549,
5578,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,,,1,13514,BAO_0000219,,A549,
5579,,Homo sapiens,,F,N,Expert,,9606.0,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,,,1,15166,BAO_0000219,,A549,
5580,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,,,1,13873,BAO_0000219,,A549,
5581,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,,,1,6447,BAO_0000219,,A549,
5582,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,,,1,2068,BAO_0000219,,A549,
5583,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,,,1,1863,BAO_0000219,,A549,
5584,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,,,1,13873,BAO_0000219,,A549,
5585,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,,,1,13873,BAO_0000219,,A549,
5586,,Homo sapiens,,F,N,Expert,,9606.0,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,,,1,13873,BAO_0000219,,A549,
5587,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,,,1,579,BAO_0000219,,A549,
5588,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,,,1,579,BAO_0000219,,A549,
5589,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,,,1,4584,BAO_0000219,,A549,
5590,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,,,1,5421,BAO_0000219,,A549,
5591,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,,,1,5421,BAO_0000219,,A549,
5592,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,,,1,5421,BAO_0000219,,A549,
5593,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,,,1,5421,BAO_0000219,,A549,
5594,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,,,1,14188,BAO_0000219,,A549,
5595,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,,,1,14188,BAO_0000219,,A549,
5596,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,,,1,15354,BAO_0000219,,A549,
5597,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,,,1,14253,BAO_0000219,,A549,
5598,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,,,1,13873,BAO_0000219,,A549,
5599,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (conscious),50588,,,1,3043,BAO_0000218,,,
5600,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,,,1,3045,BAO_0000218,,,
5601,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,,,1,3022,BAO_0000218,,,
5602,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,4453,BAO_0000218,,,
5603,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,1696,BAO_0000218,,,
5604,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5045,BAO_0000218,,,
5605,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (fasted),50588,,,1,5356,BAO_0000218,,,
5606,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
5607,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6448,BAO_0000218,,,
5608,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,1475,BAO_0000218,,,
5609,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Percent bioavailability in dog,50588,,,1,3788,BAO_0000218,,,
5610,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,,,1,3639,BAO_0000218,,,
5611,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,13397,BAO_0000218,,,
5612,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was evaluated for bioavailability in dogs; 34-44,50588,,,1,2137,BAO_0000218,,,
5613,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 4 mg/kg p.o.),50588,,,1,2959,BAO_0000218,,,
5614,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6448,BAO_0000218,,,
5615,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,8 hour trough Blood level in dog was measured after administration of compound,50588,,,1,6084,BAO_0000218,,,
5616,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,,,1,3639,BAO_0000218,,,
5617,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,C24 after oral administration at 5 mg/kg,50588,,,1,6316,BAO_0000218,,,
5618,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance after oral and iv dosing in dogs,50588,,,1,5238,BAO_0000218,,,
5619,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Clearance of the drug was measured in the plasma of dog,50588,,,1,17796,BAO_0000218,,,
5620,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,,,1,2652,BAO_0000218,,,
5621,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,,,1,5654,BAO_0000218,,,
5622,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance of compound was determined in dogs,50588,,,1,6621,BAO_0000218,,,
5623,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,,,1,6505,BAO_0000218,,,
5624,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,,,1,5802,BAO_0000218,,,
5625,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog was determined,50588,,,1,17267,BAO_0000218,,,
5626,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,,,1,4521,BAO_0000218,,,
5627,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
5628,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog after administration of 1 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
5629,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dogs,50588,,,1,6535,BAO_0000218,,,
5630,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,,,1,5542,BAO_0000218,,,
5631,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,,,1,5199,BAO_0000218,,,
5632,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5633,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5634,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma administration to dogs,50588,,,1,16367,BAO_0000218,,,
5635,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined,50588,,,1,5505,BAO_0000218,,,
5636,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,,,1,6215,BAO_0000218,,,
5637,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
5638,In vitro,Homo sapiens,,A,S,Intermediate,Liver,9606.0,Intrinsic clearance in human liver microsomes,102164,,,1,5007,BAO_0000251,,,Microsomes
5639,In vitro,Homo sapiens,,A,S,Intermediate,Liver,9606.0,Intrinsic clearance in human liver microsomes,102164,,,1,5007,BAO_0000251,,,Microsomes
5640,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,,,1,16452,BAO_0000218,,,
5641,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,,,1,16452,BAO_0000218,,,
5642,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance in dog (dose 1 mg/kg i.v.),50588,,,1,16452,BAO_0000218,,,
5643,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,,,1,6221,BAO_0000218,,,
5644,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,,,1,5007,BAO_0000218,,,
5645,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after peroral administration at 10 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5646,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after peroral administration at 5 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5647,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,,,1,5668,BAO_0000218,,,
5648,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was measured in dog,50588,,,1,15660,BAO_0000218,,,
5649,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was measured in dog,50588,,,1,15660,BAO_0000218,,,
5650,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,,,1,5983,BAO_0000218,,,
5651,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,,,1,5600,BAO_0000218,,,
5652,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
5653,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
5654,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
5655,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
5656,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,,,1,4368,BAO_0000218,,,
5657,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,,,1,4305,BAO_0000218,,,
5658,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Clearance value was evaluated in dog plasma,50588,,,1,1918,BAO_0000218,,,
5659,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,,,1,6005,BAO_0000218,,,
5660,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma clearance in dog,50588,,,1,4839,BAO_0000218,,,
5661,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,,,1,4239,BAO_0000218,,,
5662,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,,,1,17729,BAO_0000218,,,
5663,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,,,1,17728,BAO_0000218,,,
5664,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve value in mouse at a dose of 10 mg/kg,50594,,,1,5302,BAO_0000218,,,
5665,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
5666,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
5667,,Mus musculus,,F,N,Intermediate,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,,,1,17764,BAO_0000218,,,
5668,,Mus musculus,,F,N,Intermediate,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,,,1,17764,BAO_0000218,,,
5669,,Mus musculus,,F,N,Intermediate,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,,,1,17764,BAO_0000218,,,
5670,,Mus musculus,,F,N,Intermediate,,10090.0,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,,,1,17764,BAO_0000218,,,
5671,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
5672,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined for the compound at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
5673,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined for the compound at 40 mg/Kg,50594,,,1,17753,BAO_0000218,,,
5674,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined for the compound at 5 mg/Kg,50594,,,1,17753,BAO_0000218,,,
5675,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,,,
5676,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve for the compound was obtained when tested in mouse,50594,,,1,3132,BAO_0000218,,,
5677,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,,,1,17837,BAO_0000218,,,
5678,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,,,1,17837,BAO_0000218,,,
5679,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,,,1,6062,BAO_0000218,,,
5680,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,,,1,4066,BAO_0000218,,,
5681,,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,,,1,16597,BAO_0000218,,,
5682,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,,,
5683,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,,,
5684,,Mus musculus,,A,N,Intermediate,,10090.0,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,,,1,4890,BAO_0000218,,,
5685,,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,,,1,429,BAO_0000218,,,
5686,,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,,,1,429,BAO_0000218,,,
5687,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,,,1,5969,BAO_0000218,,,
5688,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
5689,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,,,1,5969,BAO_0000218,,,
5690,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,,,1,6091,BAO_0000218,,,
5691,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,,,1,6091,BAO_0000218,,,
5692,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,,,1,6091,BAO_0000218,,,
5693,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,,,1,6091,BAO_0000218,,,
5694,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,,,1,6178,BAO_0000218,,,
5695,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,,,1,6178,BAO_0000218,,,
5696,,Mus musculus,,A,N,Intermediate,,10090.0,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,,,1,6619,BAO_0000218,,,
5697,,Mus musculus,,A,N,Intermediate,,10090.0,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,,,1,6619,BAO_0000218,,,
5698,,Mus musculus,,A,N,Intermediate,,10090.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,,,1,3760,BAO_0000218,,,
5699,,Mus musculus,,A,N,Intermediate,,10090.0,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,,,1,3760,BAO_0000218,,,
5700,,Mus musculus,,A,N,Intermediate,,10090.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,,,1,3760,BAO_0000218,,,
5701,,Mus musculus,,A,N,Intermediate,,10090.0,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,,,1,3760,BAO_0000218,,,
5702,,Mus musculus,,A,N,Intermediate,,10090.0,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,,,1,3192,BAO_0000218,,,
5703,,Mus musculus,,A,N,Intermediate,,10090.0,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,,,1,3192,BAO_0000218,,,
5704,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve was evaluated in mice after intravenous administration,50594,,,1,2675,BAO_0000218,,,
5705,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the curve was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
5706,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
5707,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
5708,,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,,,1,16597,BAO_0000218,,,
5709,,Mus musculus,,A,N,Intermediate,,10090.0,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
5710,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5711,,,,F,N,Intermediate,,,The compound was tested in vitro for anticancer activity against 9L cells,80653,,,1,15345,BAO_0000219,,9L,
5712,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Anti proliferation activity determined; Weak effect,22226,,,1,2181,BAO_0000019,,,
5713,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,,,1,2181,BAO_0000219,,,
5714,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,,,1,2181,BAO_0000219,,,
5715,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,,,1,2181,BAO_0000219,,,
5716,,Mus musculus,,F,U,Autocuration,,10090.0,The cytotoxic activity was in vitro tested by 9PS assay method,22226,,,1,10486,BAO_0000019,,,
5717,,Mus musculus,,F,U,Autocuration,,10090.0,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,,,1,10486,BAO_0000019,,,
5718,,,,A,U,Autocuration,,,Partition coefficient (logD6.5),22224,,,1,15508,BAO_0000019,,,
5719,,Homo sapiens,,F,N,Expert,,9606.0,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,,,1,5242,BAO_0000219,,A2780,
5720,,Homo sapiens,,F,N,Intermediate,,9606.0,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,,,1,16167,BAO_0000219,,A-375,
5721,,Homo sapiens,,F,N,Expert,,9606.0,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,,,1,4782,BAO_0000219,,A-431,
5722,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,,,1,16093,BAO_0000219,,A-431,
5723,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,,,1,2596,BAO_0000219,,A498,
5724,,Homo sapiens,,F,N,Intermediate,,9606.0,in vitro cytotoxicity against A 498 cancer cell line,80021,,,1,2596,BAO_0000219,,A498,
5725,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,,,1,3239,BAO_0000219,,A498,
5726,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against A 498 renal cancer cell lines.,80021,,,1,1847,BAO_0000219,,A498,
5727,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,,,1,10553,BAO_0000219,,A498,
5728,,Staphylococcus aureus,,F,U,Autocuration,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,,,1,16219,BAO_0000019,,,
5729,,Staphylococcus aureus,,F,U,Autocuration,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,,,1,16219,BAO_0000019,,,
5730,,Staphylococcus aureus,,F,U,Autocuration,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,,,1,16219,BAO_0000019,,,
5731,,Staphylococcus aureus,,F,U,Autocuration,,1280.0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,,,1,16219,BAO_0000019,,,
5732,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration required against A 549 lung cancer cell line,80682,,,1,4782,BAO_0000219,,A549,
5733,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,,,1,11805,BAO_0000219,,A549,
5734,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,,,1,11805,BAO_0000219,,A549,
5735,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,,,1,2007,BAO_0000219,,A549,
5736,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its cytotoxicity against A 549 cell line,80682,,,1,4594,BAO_0000219,,A549,
5737,,Homo sapiens,,F,N,Expert,,9606.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,,,1,6018,BAO_0000219,,A549,
5738,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,,,1,6018,BAO_0000219,,A549,
5739,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,,,1,3599,BAO_0000219,,A549,
5740,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,,,1,2551,BAO_0000219,,A549,
5741,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,,,1,16132,BAO_0000219,,A549,
5742,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,,,1,16132,BAO_0000219,,A549,
5743,,Homo sapiens,,F,N,Expert,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,,,1,2551,BAO_0000219,,A549,
5744,,Homo sapiens,,F,N,Expert,,9606.0,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,,,1,2551,BAO_0000219,,A549,
5745,,,,F,U,Autocuration,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,,,1,11913,BAO_0000218,,,
5746,In vivo,,,F,H,Autocuration,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,,,1,12621,BAO_0000218,,,
5747,In vivo,,,F,H,Autocuration,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,,,1,12621,BAO_0000218,,,
5748,In vivo,,,F,H,Autocuration,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,,,1,12621,BAO_0000218,,,
5749,In vivo,,,F,H,Autocuration,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,,,1,12621,BAO_0000218,,,
5750,In vivo,,,F,H,Autocuration,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,,,1,12621,BAO_0000218,,,
5751,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A-498 human Renal cell proliferation,80021,,,1,3600,BAO_0000219,,A498,
5752,,Rattus norvegicus,,F,U,Autocuration,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,,,1,1796,BAO_0000019,,,
5753,,Rattus norvegicus,,F,U,Autocuration,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,,,1,1796,BAO_0000019,,,
5754,,Rattus norvegicus,,F,U,Autocuration,,10116.0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,,,1,1796,BAO_0000019,,,
5755,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,,,1,16464,BAO_0000219,,A 172,
5756,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,,,1,16464,BAO_0000219,,A 172,
5757,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,,,1,16464,BAO_0000219,,A 172,
5758,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,,,1,13617,BAO_0000219,,A549,
5759,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,,,1,4584,BAO_0000219,,A549,
5760,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic activity evaluated against A549 tumor cells,80682,,,1,13799,BAO_0000219,,A549,
5761,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,,,1,16726,BAO_0000219,,A549,
5762,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,,,1,16109,BAO_0000219,,A549,
5763,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,,,1,16109,BAO_0000219,,A549,
5764,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,,,1,15474,BAO_0000219,,A549,
5765,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound against A549 cell line,80682,,,1,6851,BAO_0000219,,A549,
5766,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,,,1,17534,BAO_0000219,,A549,
5767,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,,,1,2621,BAO_0000219,,A549,
5768,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,,,1,830,BAO_0000219,,A549,
5769,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,,,1,14255,BAO_0000219,,A549,
5770,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,,,1,14255,BAO_0000219,,A549,
5771,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,,,1,1590,BAO_0000219,,A549,
5772,,Homo sapiens,,F,N,Expert,,9606.0,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,,,1,6146,BAO_0000219,,A549,
5773,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,1,17427,BAO_0000219,,A549,
5774,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,,,1,5280,BAO_0000219,,A549,
5775,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,,,1,16786,BAO_0000219,,A549,
5776,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A549 (human lung cancer),80682,,,1,5895,BAO_0000219,,A549,
5777,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,,,1,14297,BAO_0000219,,A549,
5778,,Homo sapiens,,F,N,Intermediate,,9606.0,In vivo antiproliferative activity against A549 cell line,80682,,,1,17824,BAO_0000218,,A549,
5779,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,,,1,14368,BAO_0000219,,A549,
5780,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,,,1,14368,BAO_0000219,,A549,
5781,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,,,1,14254,BAO_0000219,,A549,
5782,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,,,1,15897,BAO_0000219,,A549,
5783,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,,,1,13866,BAO_0000219,,A549,
5784,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,,,1,13370,BAO_0000219,,A549,
5785,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 lung cancer cell line,80682,,,1,4862,BAO_0000219,,A549,
5786,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,,,1,4862,BAO_0000219,,A549,
5787,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,,,1,4862,BAO_0000219,,A549,
5788,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against A549 (lung cancer) cell line,80682,,,1,15970,BAO_0000219,,A549,
5789,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,,,1,17713,BAO_0000219,,A549,
5790,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,,,1,4833,BAO_0000219,,A549,
5791,,Homo sapiens,,F,N,Expert,,9606.0,Activity against A549 cancer cell line.,80682,,,1,13736,BAO_0000219,,A549,
5792,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was evaluated for cytotoxicity against A549 cell line,80682,,,1,4312,BAO_0000219,,A549,
5793,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,,,1,5421,BAO_0000219,,A549,
5794,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,,,1,5421,BAO_0000219,,A549,
5795,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,,,1,14717,BAO_0000219,,A549,
5796,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 lung cancer cell line,80682,,,1,4634,BAO_0000219,,A549,
5797,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 cell line; inactive,80682,,,1,1149,BAO_0000219,,A549,
5798,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,,,1,5421,BAO_0000219,,A549,
5799,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,,,1,5421,BAO_0000219,,A549,
5800,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,,,1,5421,BAO_0000219,,A549,
5801,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,,,1,3320,BAO_0000219,,A549,
5802,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,,,1,3320,BAO_0000219,,A549,
5803,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,,,1,3320,BAO_0000219,,A549,
5804,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,,,1,3320,BAO_0000219,,A549,
5805,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,,,1,3320,BAO_0000219,,A549,
5806,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,,,1,5726,BAO_0000219,,A549,
5807,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance (in vivo) in mongrel dogs was determined,50588,,,1,17800,BAO_0000218,,,
5808,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was measured in dog,50588,,,1,5985,BAO_0000218,,,
5809,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,,,1,5530,BAO_0000218,,,
5810,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,,,1,5530,BAO_0000218,,,
5811,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Tested for plasma clearance in dog,50588,,,1,4839,BAO_0000218,,,
5812,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for clearance in dog plasma.,50588,,,1,3639,BAO_0000218,,,
5813,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,,,1,4838,BAO_0000218,,,
5814,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,,,1,4137,BAO_0000218,,,
5815,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,,,1,5017,BAO_0000218,,,
5816,In vitro,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,In vitro clearance in dog liver microsomes,50588,,,1,17538,BAO_0000218,,,Microsomes
5817,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,,,1,6161,BAO_0000218,,,
5818,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,,,1,6161,BAO_0000218,,,
5819,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog,50588,,,1,1696,BAO_0000218,,,
5820,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance rate in dog,50588,,,1,6762,BAO_0000218,,,
5821,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,,,1,5932,BAO_0000218,,,
5822,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance in dogs,50588,,,1,6305,BAO_0000218,,,
5823,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dogs,50588,,,1,4942,BAO_0000218,,,
5824,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined,50588,,,1,4219,BAO_0000218,,,
5825,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Lower clearance in dog (i.v.) at 0.5 mpk,50588,,,1,17853,BAO_0000218,,,
5826,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in Beagle dogs,50588,,,1,4514,BAO_0000218,,,
5827,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance (Clp) in dog,50588,,,1,6448,BAO_0000218,,,
5828,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,,,1,6227,BAO_0000218,,,
5829,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,,,1,6227,BAO_0000218,,,
5830,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,,,1,6062,BAO_0000218,,,
5831,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance of compound was determined in dog,50588,,,1,6821,BAO_0000218,,,
5832,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
5833,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,,,1,4521,BAO_0000218,,,
5834,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog was determined,50588,,,1,5374,BAO_0000218,,,
5835,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was calculated in dog,50588,,,1,6057,BAO_0000218,,,
5836,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance at the dose of 2 mg/kg in dog,50588,,,1,4727,BAO_0000218,,,
5837,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog,50588,,,1,5145,BAO_0000218,,,
5838,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog,50588,,,1,17657,BAO_0000218,,,
5839,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog; Unable to calculate,50588,,,1,17657,BAO_0000218,,,
5840,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in rhesus monkey,50588,,,1,5145,BAO_0000218,,,
5841,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,1,6642,BAO_0000218,,,
5842,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6641,BAO_0000218,,,
5843,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6642,BAO_0000218,,,
5844,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was evaluated in dog,50588,,,1,5472,BAO_0000218,,,
5845,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was evaluated in dog; Not tested,50588,,,1,5472,BAO_0000218,,,
5846,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was evaluated in rhesus,50588,,,1,5472,BAO_0000218,,,
5847,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was evaluated in rhesus; Not tested,50588,,,1,5472,BAO_0000218,,,
5848,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,,,1,4257,BAO_0000218,,,
5849,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,,,1,6679,BAO_0000218,,,
5850,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,,,1,5546,BAO_0000218,,,
5851,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
5852,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance value at a dose of 0.2 mg/kg i.v.,50588,,,1,5474,BAO_0000218,,,
5853,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,,,1,6316,BAO_0000218,,,
5854,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
5855,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
5856,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,,,1,5802,BAO_0000218,,,
5857,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,,,1,6535,BAO_0000218,,,
5858,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax in dog after administration of 1 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
5859,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
5860,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,,,1,6505,BAO_0000218,,,
5861,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax was determine after peroral administration at 10 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5862,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax was determine after peroral administration at 5 mpk in dog,50588,,,1,5668,BAO_0000218,,,
5863,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,,,1,5668,BAO_0000218,,,
5864,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax after 0.3 mg/kg po administration in dog,50588,,,1,5600,BAO_0000218,,,
5865,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,,,1,17764,BAO_0000218,,,
5866,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax in dog after oral administration at 1 mg/kg,50588,,,1,6123,BAO_0000218,,,
5867,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,,,1,6123,BAO_0000218,,,
5868,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,,,1,6757,BAO_0000218,,,
5869,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5870,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5871,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5872,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5873,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5874,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5875,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5876,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5877,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5878,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5879,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5880,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5881,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5882,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5883,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5884,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5885,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5886,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5887,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5888,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5889,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5890,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5891,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5892,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5893,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5894,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5895,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5896,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5897,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5898,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5899,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5900,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5901,In vivo,Mus musculus,,A,N,Intermediate,Intestine,10090.0,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5902,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5903,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5904,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5905,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5906,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
5907,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A-172 human tumor cell lines,80012,,,1,2036,BAO_0000219,,A 172,
5908,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,,,1,2357,BAO_0000219,,A 172,
5909,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,,,1,1457,BAO_0000219,,A204,
5910,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,,,1,4379,BAO_0000219,,A2780,
5911,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,,,1,1093,BAO_0000219,,A-375,
5912,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro against A-375 cell line human melanoma,80018,,,1,12152,BAO_0000219,,A-375,
5913,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,,,1,16464,BAO_0000219,,A-427,
5914,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,,,1,16464,BAO_0000219,,A-427,
5915,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,,,1,16582,BAO_0000219,,A-427,
5916,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,,,1,16464,BAO_0000219,,A-427,
5917,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity on A-427 lung carcinoma cell lines,80019,,,1,10413,BAO_0000219,,A-427,
5918,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human A-427 lung tumor cell line,80019,,,1,6418,BAO_0000219,,A-427,
5919,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor effects against human A-427 cell lines.,80019,,,1,17134,BAO_0000219,,A-427,
5920,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,,,1,16132,BAO_0000219,,A-427,
5921,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,,,1,16132,BAO_0000219,,A-427,
5922,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,,,1,16780,BAO_0000219,,A-427,
5923,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,,,1,4085,BAO_0000219,,A-431,
5924,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,,,1,1276,BAO_0000219,,A498,
5925,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,,,1,3498,BAO_0000219,,A498,
5926,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,,,1,1169,BAO_0000219,,A498,
5927,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,,,1,4450,BAO_0000219,,A498,
5928,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,,,1,3311,BAO_0000219,,A498,
5929,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor cytotoxic activity against A-498 cell line was determined,80021,,,1,4461,BAO_0000219,,A498,
5930,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,,,1,3311,BAO_0000219,,A498,
5931,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,,,1,3311,BAO_0000219,,A498,
5932,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,,,1,1457,BAO_0000219,,A498,
5933,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,,,1,3664,BAO_0000219,,A498,
5934,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,,,1,15895,BAO_0000219,,A498,
5935,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,,,1,11843,BAO_0000219,,A549,
5936,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,,,1,11843,BAO_0000219,,A549,
5937,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,,,1,17705,BAO_0000219,,A549,
5938,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,,,1,17705,BAO_0000219,,A549,
5939,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,,,1,4369,BAO_0000219,,A549,
5940,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,,,1,4369,BAO_0000219,,A549,
5941,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,,,1,4369,BAO_0000219,,A549,
5942,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,,,1,4369,BAO_0000219,,A549,
5943,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,,,1,4369,BAO_0000219,,A549,
5944,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,,,1,4369,BAO_0000219,,A549,
5945,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,,,1,4369,BAO_0000219,,A549,
5946,,Homo sapiens,,F,N,Expert,,9606.0,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,,,1,4787,BAO_0000219,,A549,
5947,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,,,1,4787,BAO_0000219,,A549,
5948,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against A-549 cell line,80682,,,1,6513,BAO_0000219,,A549,
5949,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,,,1,6690,BAO_0000219,,A549,
5950,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,,,1,6690,BAO_0000219,,A549,
5951,,Homo sapiens,,F,N,Expert,,9606.0,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,,,1,12263,BAO_0000219,,A549,
5952,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,,,1,1054,BAO_0000219,,A549,
5953,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,,,1,1359,BAO_0000219,,A549,
5954,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,,,1,3547,BAO_0000219,,A549,
5955,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic activity towards A-549 cells,80682,,,1,5771,BAO_0000219,,A549,
5956,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.",80682,,,1,14425,BAO_0000219,,A549,
5957,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro percent inhibition of A549, lung carcinoma",80682,,,1,14425,BAO_0000219,,A549,
5958,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.",80682,,,1,14425,BAO_0000219,,A549,
5959,,Homo sapiens,,F,N,Intermediate,,9606.0,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,,,1,14425,BAO_0000219,,A549,
5960,,Homo sapiens,,F,N,Intermediate,,9606.0,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,,,1,5280,BAO_0000219,,A549,
5961,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,,,1,15176,BAO_0000219,,A549,
5962,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,,,1,15300,BAO_0000219,,A549,
5963,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,1,17824,BAO_0000218,,A549,
5964,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,1,17824,BAO_0000218,,A549,
5965,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,1,17824,BAO_0000218,,A549,
5966,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,1,17824,BAO_0000218,,A549,
5967,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,,,1,17824,BAO_0000218,,A549,
5968,,Homo sapiens,,F,N,Intermediate,,9606.0,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,,,1,17824,BAO_0000219,,A549,
5969,,Homo sapiens,,F,N,Intermediate,,9606.0,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,,,1,17528,BAO_0000218,,A549,
5970,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,,,1,6870,BAO_0000219,,A549,
5971,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,,,1,6870,BAO_0000219,,A549,
5972,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,,,1,6870,BAO_0000219,,A549,
5973,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,,,1,6870,BAO_0000219,,A549,
5974,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,,,1,16726,BAO_0000219,,A549,
5975,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,,,1,6170,BAO_0000219,,A549,
5976,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,,,1,6583,BAO_0000219,,A549,
5977,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,,,1,6583,BAO_0000219,,A549,
5978,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,,,1,6583,BAO_0000219,,A549,
5979,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,,,1,6583,BAO_0000219,,A549,
5980,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,,,1,6583,BAO_0000219,,A549,
5981,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,,,1,17321,BAO_0000219,,A549,
5982,,Homo sapiens,,F,N,Expert,,9606.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,,,1,17528,BAO_0000219,,A549,
5983,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,,,1,12888,BAO_0000219,,A549,
5984,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,,,1,4312,BAO_0000219,,A549,
5985,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,,,1,4312,BAO_0000219,,A549,
5986,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,,,1,4312,BAO_0000219,,A549,
5987,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro antiproliferative activity against A549 cell line,80682,,,1,17737,BAO_0000219,,A549,
5988,,,,F,N,Intermediate,,,Synergism with indomethacin in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5989,,,,F,N,Intermediate,,,Synergism with tolmetin in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5990,,,,F,N,Intermediate,,,Synergism with sulindac in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5991,,,,F,N,Intermediate,,,Antagonism of indomethacin in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5992,,,,F,N,Intermediate,,,Antagonism of sulindac in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5993,,,,F,N,Intermediate,,,Antagonism of tolmetin in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5994,,,,F,N,Intermediate,,,Synergism with indomethacin in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5995,,,,F,N,Intermediate,,,Synergism with sulindac in A549 cells,80682,,,1,6630,BAO_0000219,,A549,
5996,,,,F,N,Intermediate,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,,,1,6630,BAO_0000219,,A549,
5997,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
5998,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,1,5944,BAO_0000218,,,
5999,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,,,1,5944,BAO_0000218,,,
6000,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,,,1,5944,BAO_0000218,,,
6001,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,,,1,5944,BAO_0000218,,,
6002,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,,,1,2959,BAO_0000218,,,
6003,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value in dog,50588,,,1,6241,BAO_0000218,,,
6004,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value in dogs after oral administration at 1 mg/kg,50588,,,1,6241,BAO_0000218,,,
6005,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,,,1,2652,BAO_0000218,,,
6006,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,,,1,1806,BAO_0000218,,,
6007,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,,,1,1806,BAO_0000218,,,
6008,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Concentration maxima after oral dosing in dogs,50588,,,1,1021,BAO_0000218,,,
6009,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Concentration maxima after oral dosing in dogs; not available,50588,,,1,1021,BAO_0000218,,,
6010,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Concentration maxima after oral dosing in dogs; not available,50588,,,1,1021,BAO_0000218,,,
6011,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,,,1,5444,BAO_0000218,,,
6012,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,,,1,5444,BAO_0000218,,,
6013,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,,,1,5444,BAO_0000218,,,
6014,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,,,1,5444,BAO_0000218,,,
6015,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,,,1,5444,BAO_0000218,,,
6016,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax in dog plasma after oral dose (1 mg/kg),50588,,,1,5130,BAO_0000218,,,
6017,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,,,1,3249,BAO_0000218,,,
6018,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration at a dose of 1 mg/kg,50588,,,1,5473,BAO_0000218,,,
6019,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,,,1,5474,BAO_0000218,,,
6020,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,,,1,4657,BAO_0000218,,,
6021,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration of compound in dog was evaluated.,50588,,,1,3031,BAO_0000218,,,
6022,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
6023,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,,,1,4186,BAO_0000218,,,
6024,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,,,1,5007,BAO_0000218,,,
6025,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum concentration obtained in dog plasma was determined,50588,,,1,3132,BAO_0000218,,,
6026,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration was determined,50588,,,1,5006,BAO_0000218,,,
6027,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration at the dose of 2 mg/kg in dog,50588,,,1,4727,BAO_0000218,,,
6028,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,1,1916,BAO_0000218,,,
6029,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum concentration was evaluated in dog plasma,50588,,,1,1918,BAO_0000218,,,
6030,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration was evaluated after 75 min after administration in dog,50588,,,1,3045,BAO_0000218,,,
6031,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration determined in dog after oral administration of 17b,50588,,,1,9579,BAO_0000218,,,
6032,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration determined in dog after oral administration of 2b,50588,,,1,9579,BAO_0000218,,,
6033,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in dog,50588,,,1,933,BAO_0000218,,,
6034,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,,,1,17839,BAO_0000218,,,
6035,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,,,1,17839,BAO_0000218,,,
6036,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,,,1,17839,BAO_0000218,,,
6037,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,,,1,17839,BAO_0000218,,,
6038,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
6039,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,,,1,16367,BAO_0000218,,,
6040,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
6041,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
6042,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,,,1,5199,BAO_0000218,,,
6043,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,,,1,17650,BAO_0000218,,,
6044,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,,,1,6679,BAO_0000218,,,
6045,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,,,1,5356,BAO_0000218,,,
6046,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,,,1,5356,BAO_0000218,,,
6047,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,,,1,6227,BAO_0000218,,,
6048,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,,,1,6227,BAO_0000218,,,
6049,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,,,1,6227,BAO_0000218,,,
6050,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,,,1,6227,BAO_0000218,,,
6051,In vivo,Canis lupus familiaris,,A,N,Expert,Plasma,9615.0,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
6052,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,,,1,4368,BAO_0000218,,,
6053,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,,,1,6265,BAO_0000218,,,
6054,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
6055,In vivo,Mus musculus,,A,N,Intermediate,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,,,1,7767,BAO_0000218,,,
6056,In vivo,Mus musculus,,A,N,Intermediate,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,,,1,7767,BAO_0000218,,,
6057,In vivo,Mus musculus,,A,N,Intermediate,Urine,10090.0,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,,,1,7767,BAO_0000218,,,
6058,,Mus musculus,,A,N,Intermediate,,10090.0,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,,,1,17811,BAO_0000218,,,
6059,,Mus musculus,,A,N,Intermediate,,10090.0,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,,,1,17811,BAO_0000218,,,
6060,,Mus musculus,,A,N,Intermediate,,10090.0,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6061,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6062,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6063,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6064,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6065,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6066,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6067,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6068,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,,,1,17827,BAO_0000218,,,
6069,,Mus musculus,,A,N,Intermediate,,10090.0,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,1,17827,BAO_0000218,,,
6070,,Mus musculus,,A,N,Intermediate,,10090.0,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,1,17827,BAO_0000218,,,
6071,,Mus musculus,,A,N,Intermediate,,10090.0,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,,,1,17827,BAO_0000218,,,
6072,,Mus musculus,,A,N,Intermediate,,10090.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,,,1,17257,BAO_0000218,,,
6073,,Mus musculus,,A,N,Intermediate,,10090.0,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,,,1,17257,BAO_0000218,,,
6074,,Mus musculus,,A,N,Intermediate,,10090.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,,,1,17257,BAO_0000218,,,
6075,,Mus musculus,,A,N,Intermediate,,10090.0,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,,,1,17257,BAO_0000218,,,
6076,,Mus musculus,,A,N,Intermediate,,10090.0,Time at maximum activity in mice (Radiolabeled compound),50594,,,1,17827,BAO_0000218,,,
6077,,Mus musculus,,A,N,Intermediate,,10090.0,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,,,1,3760,BAO_0000218,,,
6078,,Mus musculus,,A,N,Intermediate,,10090.0,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,,,1,3760,BAO_0000218,,,
6079,,Mus musculus,,A,N,Intermediate,,10090.0,Binding towards mouse plasma protein at 10 uM,50594,,,1,17409,BAO_0000218,,,
6080,,Mus musculus,,A,N,Intermediate,,10090.0,Binding towards mouse plasma protein at 100 uM,50594,,,1,17409,BAO_0000218,,,
6081,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was evaluated in mice after intravenous administration,50594,,,1,2675,BAO_0000218,,,
6082,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
6083,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,,,1,3132,BAO_0000218,,,
6084,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,,,
6085,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
6086,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse,50594,,,1,2862,BAO_0000218,,,
6087,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
6088,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6089,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6090,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6091,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6092,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6093,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6094,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6095,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6096,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6097,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6098,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,,,1,1276,BAO_0000219,,A549,
6099,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,,,1,3498,BAO_0000219,,A549,
6100,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,,,1,1169,BAO_0000219,,A549,
6101,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,,,1,4450,BAO_0000219,,A549,
6102,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,,,1,358,BAO_0000219,,A549,
6103,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,,,1,358,BAO_0000219,,A549,
6104,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,,,1,358,BAO_0000219,,A549,
6105,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,,,1,358,BAO_0000219,,A549,
6106,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,,,1,358,BAO_0000219,,A549,
6107,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,,,1,358,BAO_0000219,,A549,
6108,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,,,1,358,BAO_0000219,,A549,
6109,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A-549 human lung cancer cells,80682,,,1,15167,BAO_0000219,,A549,
6110,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,,,1,4139,BAO_0000219,,A549,
6111,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,,,1,833,BAO_0000219,,A549,
6112,,Homo sapiens,,F,N,Expert,,9606.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,1,15718,BAO_0000219,,A549,
6113,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,,,1,12373,BAO_0000219,,A549,
6114,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,,,1,637,BAO_0000219,,A549,
6115,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,,,1,14867,BAO_0000219,,A549,
6116,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor cytotoxic activity against A-549 cell line was determined,80682,,,1,4461,BAO_0000219,,A549,
6117,,Homo sapiens,,F,N,Intermediate,,9606.0,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,,,1,5406,BAO_0000219,,A549,
6118,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,,,1,4457,BAO_0000219,,A549,
6119,,Homo sapiens,,F,N,Expert,,9606.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,,,1,1386,BAO_0000219,,A549,
6120,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumoral activity was assayed against A-549 cell line,80682,,,1,3265,BAO_0000219,,A549,
6121,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,,,1,2359,BAO_0000219,,A549,
6122,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,,,1,4457,BAO_0000219,,A549,
6123,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,,,1,12454,BAO_0000219,,A549,
6124,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for inhibition of cell growth of A-549 cells,80682,,,1,1481,BAO_0000219,,A549,
6125,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,,,1,1750,BAO_0000219,,A549,
6126,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,,,1,5065,BAO_0000219,,A549,
6127,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,,,1,808,BAO_0000219,,A549,
6128,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,,,1,16364,BAO_0000219,,A549,
6129,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against A-549 cell lines.,80682,,,1,1847,BAO_0000219,,A549,
6130,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,,,1,1747,BAO_0000219,,A549,
6131,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human A549 non small cell lung cell lines,80682,,,1,1003,BAO_0000219,,A549,
6132,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of cell growth in (A-549) lung cell line,80682,,,1,15313,BAO_0000219,,A549,
6133,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,,,1,3122,BAO_0000219,,A549,
6134,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against A-549 tumor cells.,80682,,,1,16049,BAO_0000219,,A549,
6135,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor effects against human A-549 cell lines.,80682,,,1,17134,BAO_0000219,,A549,
6136,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity of compound against A-549 cell line,80682,,,1,6406,BAO_0000219,,A549,
6137,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,,,1,627,BAO_0000219,,A549,
6138,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,,,1,12307,BAO_0000219,,A549,
6139,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,,,1,17861,BAO_0000219,,A549,
6140,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,,,1,6682,BAO_0000219,,A549,
6141,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration of compound against A-549 cell line,80682,,,1,6663,BAO_0000219,,A549,
6142,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,,,1,2454,BAO_0000219,,A549,
6143,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity against leukemia (A-549) cancer cell line,80682,,,1,14709,BAO_0000219,,A549,
6144,,Homo sapiens,,F,N,Expert,,9606.0,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,1,15718,BAO_0000219,,A549,
6145,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,,,1,15718,BAO_0000219,,A549,
6146,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,,,1,17130,BAO_0000219,,A549,
6147,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,,,1,17130,BAO_0000219,,A549,
6148,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,,,1,17130,BAO_0000219,,A549,
6149,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,,,1,17130,BAO_0000219,,A549,
6150,,,,F,N,Intermediate,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,,,1,6630,BAO_0000219,,A549,
6151,,Homo sapiens,,F,N,Intermediate,,9606.0,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,,,1,16726,BAO_0000219,,A549,
6152,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against A549 cells; No cytotoxicity,80682,,,1,17846,BAO_0000219,,A549,
6153,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,,,1,3415,BAO_0000219,,A549,
6154,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,,,1,3415,BAO_0000219,,A549,
6155,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anticancer activity against human lung (A549) cell line,80682,,,1,5609,BAO_0000219,,A549,
6156,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6157,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6158,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6159,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6160,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6161,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6162,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A549 human lung tumor cell proliferation,80682,,,1,16295,BAO_0000219,,A549,
6163,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,,,1,16825,BAO_0000219,,A549,
6164,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against human tumor cell line A549,80682,,,1,3439,BAO_0000219,,A549,
6165,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,,,1,10870,BAO_0000219,,A549,
6166,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,,,1,4845,BAO_0000219,,A549,
6167,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,,,1,5822,BAO_0000219,,A549,
6168,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,,,1,5822,BAO_0000219,,A549,
6169,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,,,1,5822,BAO_0000219,,A549,
6170,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6171,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6172,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6173,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anticancer activity against human lung (A549) cell line,80682,,,1,5609,BAO_0000219,,A549,
6174,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,,,1,4644,BAO_0000219,,A549,
6175,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,,,1,4644,BAO_0000219,,A549,
6176,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,,,1,4644,BAO_0000219,,A549,
6177,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,,,1,4644,BAO_0000219,,A549,
6178,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,,,1,5822,BAO_0000219,,A549,
6179,,Homo sapiens,,F,N,Expert,,9606.0,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,,,1,3415,BAO_0000219,,A549,
6180,,Homo sapiens,,F,N,Intermediate,,9606.0,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,,,1,16726,BAO_0000219,,A549,
6181,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,,,1,17206,BAO_0000219,,A549,
6182,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,,,1,17206,BAO_0000219,,A549,
6183,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,,,1,17206,BAO_0000219,,A549,
6184,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,,,1,17206,BAO_0000219,,A549,
6185,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,,,1,17206,BAO_0000219,,A549,
6186,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,,,1,17206,BAO_0000219,,A549,
6187,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,,,1,17206,BAO_0000219,,A549,
6188,,Homo sapiens,,F,N,Intermediate,,9606.0,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,,,1,17206,BAO_0000219,,A549,
6189,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6190,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6191,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,,,1,16726,BAO_0000219,,A549,
6192,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6193,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6194,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6195,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6196,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,,,1,6084,BAO_0000218,,,
6197,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic activity (Cmax) in dog,50588,,,1,6084,BAO_0000218,,,
6198,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,,,1,4809,BAO_0000218,,,
6199,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,,,1,5983,BAO_0000218,,,
6200,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,,,1,6251,BAO_0000218,,,
6201,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax in dog plasma after 30mg/kg oral dose,50588,,,1,5932,BAO_0000218,,,
6202,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Tested for the peak blood level in dog,50588,,,1,4273,BAO_0000218,,,
6203,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,,,1,5313,BAO_0000218,,,
6204,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,,,1,5313,BAO_0000218,,,
6205,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,,,1,6221,BAO_0000218,,,
6206,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
6207,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,,,1,167,BAO_0000218,,,
6208,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,,,1,6241,BAO_0000218,,,
6209,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,,,1,344,BAO_0000218,,,
6210,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,,,1,344,BAO_0000218,,,
6211,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,,,1,344,BAO_0000218,,,
6212,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,,,1,2189,BAO_0000218,,,
6213,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,,,1,2189,BAO_0000218,,,
6214,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,,,1,2189,BAO_0000218,,,
6215,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,,,1,2189,BAO_0000218,,,
6216,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Absolute bioavailability was evaluated in dog,50588,,,1,4257,BAO_0000218,,,
6217,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,,,1,6221,BAO_0000218,,,
6218,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,,,1,6215,BAO_0000218,,,
6219,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,17267,BAO_0000218,,,
6220,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,6621,BAO_0000218,,,
6221,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability after intravenous administration in dogs,50588,,,1,3854,BAO_0000218,,,
6222,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability after peroral administration in dogs,50588,,,1,3854,BAO_0000218,,,
6223,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,,,1,5007,BAO_0000218,,,
6224,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,,,1,4333,BAO_0000218,,,
6225,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,,,1,4333,BAO_0000218,,,
6226,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability,50588,,,1,5006,BAO_0000218,,,
6227,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability,50588,,,1,5199,BAO_0000218,,,
6228,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,,,1,4368,BAO_0000218,,,
6229,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,3771,BAO_0000218,,,
6230,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,4953,BAO_0000218,,,
6231,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,5064,BAO_0000218,,,
6232,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,17657,BAO_0000218,,,
6233,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,17796,BAO_0000218,,,
6234,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (p.o.) at 2.0 mpk,50588,,,1,17853,BAO_0000218,,,
6235,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,,,1,4521,BAO_0000218,,,
6236,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,,,1,4521,BAO_0000218,,,
6237,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,5006,BAO_0000218,,,
6238,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was evaluated after oral administration in dog,50588,,,1,16365,BAO_0000218,,,
6239,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,1,1916,BAO_0000218,,,
6240,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was evaluated in dog,50588,,,1,1918,BAO_0000218,,,
6241,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,4239,BAO_0000218,,,
6242,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,6505,BAO_0000218,,,
6243,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
6244,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
6245,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,,,1,4809,BAO_0000218,,,
6246,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
6247,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,,,1,6005,BAO_0000218,,,
6248,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability of compound in dog was determined after peroral administration,50588,,,1,17804,BAO_0000218,,,
6249,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3184,BAO_0000218,,,
6250,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,,,1,1806,BAO_0000218,,,
6251,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,,,1,1806,BAO_0000218,,,
6252,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,,,1,1806,BAO_0000218,,,
6253,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,4839,BAO_0000218,,,
6254,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,,,1,5017,BAO_0000218,,,
6255,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6256,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6257,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6258,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6259,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6260,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6261,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6262,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6263,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6264,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6265,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6266,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6267,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6268,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6269,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6270,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6271,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6272,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6273,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6274,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,,,1,846,BAO_0000218,,,
6275,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6276,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6277,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6278,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6279,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6280,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6281,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6282,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6283,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6284,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6285,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6286,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6287,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6288,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6289,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6290,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6291,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6292,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6293,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,,,1,17130,BAO_0000219,,A549,
6294,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,,,1,17130,BAO_0000219,,A549,
6295,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,,,1,17130,BAO_0000219,,A549,
6296,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,,,1,17130,BAO_0000219,,A549,
6297,,Homo sapiens,,F,N,Expert,,9606.0,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,,,1,3263,BAO_0000219,,A549,
6298,,Homo sapiens,,F,N,Expert,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,,,1,6663,BAO_0000219,,A549,
6299,,Homo sapiens,,F,N,Expert,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,,,1,6663,BAO_0000219,,A549,
6300,,Homo sapiens,,F,N,Expert,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,,,1,6663,BAO_0000219,,A549,
6301,,Homo sapiens,,F,N,Expert,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,,,1,6663,BAO_0000219,,A549,
6302,,Homo sapiens,,F,N,Expert,,9606.0,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,,,1,6663,BAO_0000219,,A549,
6303,,Homo sapiens,,F,N,Intermediate,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,,,1,6663,BAO_0000219,,A549,
6304,,Homo sapiens,,F,N,Intermediate,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,,,1,6663,BAO_0000219,,A549,
6305,,Homo sapiens,,F,N,Intermediate,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,,,1,6663,BAO_0000219,,A549,
6306,,Homo sapiens,,F,N,Intermediate,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,,,1,6663,BAO_0000219,,A549,
6307,,Homo sapiens,,F,N,Intermediate,,9606.0,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,,,1,6663,BAO_0000219,,A549,
6308,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,,,1,3983,BAO_0000219,,A549,
6309,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,,,1,11141,BAO_0000219,,A549,
6310,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 tumor cell line.,80682,,,1,5076,BAO_0000219,,A549,
6311,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,,,1,3311,BAO_0000219,,A549,
6312,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,,,1,3311,BAO_0000219,,A549,
6313,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,,,1,3311,BAO_0000219,,A549,
6314,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,,,1,5076,BAO_0000219,,A549,
6315,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,,,1,4150,BAO_0000219,,A549,
6316,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,,,1,2150,BAO_0000219,,A549,
6317,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,,,1,4644,BAO_0000219,,A549,
6318,,Homo sapiens,,F,N,Intermediate,,9606.0,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,,,1,263,BAO_0000219,,A549,
6319,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic concentration against A-549 tumor cells.,80682,,,1,11333,BAO_0000219,,A549,
6320,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,,,1,11333,BAO_0000219,,A549,
6321,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,,,1,15895,BAO_0000219,,A549,
6322,,Acinetobacter baumannii,,F,N,Expert,,470.0,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,,,1,16677,BAO_0000218,,,
6323,,Acinetobacter calcoaceticus,,F,N,Intermediate,,471.0,Activity against Acinetobacter calcoaceticus (AC54),50192,,,1,10624,BAO_0000218,,,
6324,,Aspergillus flavus,,F,N,Expert,,5059.0,In vitro antifungal activity against Aspergillus flavus CM74,50274,,,1,16717,BAO_0000218,,,
6325,,Aspergillus flavus,,F,N,Expert,,5059.0,In vitro antifungal activity against Aspergillus flavus CM74,50274,,,1,16717,BAO_0000218,,,
6326,,Aspergillus fumigatus,,F,N,Intermediate,,746128.0,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,,,1,5513,BAO_0000218,,,
6327,,Aspergillus fumigatus,,F,N,Intermediate,,746128.0,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,,,1,15962,BAO_0000218,,,
6328,,Aspergillus fumigatus,,F,N,Intermediate,,746128.0,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,1,15962,BAO_0000218,,,
6329,,Aspergillus fumigatus,,F,N,Intermediate,,746128.0,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,1,15962,BAO_0000218,,,
6330,,Aspergillus fumigatus,,F,N,Intermediate,,746128.0,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,,,1,15962,BAO_0000218,,,
6331,,Aspergillus fumigatus,,F,N,Expert,,746128.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,,,1,16717,BAO_0000218,,,
6332,,Aspergillus fumigatus,,F,N,Expert,,746128.0,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,,,1,16717,BAO_0000218,,,
6333,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,,,1,8117,BAO_0000218,,,
6334,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,,,1,8117,BAO_0000218,,,
6335,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,,,1,15472,BAO_0000218,,,
6336,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,,,1,15472,BAO_0000218,,,
6337,,Aggregatibacter actinomycetemcomitans,,F,N,Intermediate,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,,,1,16443,BAO_0000218,,,
6338,,Aggregatibacter actinomycetemcomitans,,F,N,Intermediate,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,,,1,16443,BAO_0000218,,,
6339,,Aggregatibacter actinomycetemcomitans,,F,N,Intermediate,,714.0,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,,,1,16443,BAO_0000218,,,
6340,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6341,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6342,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6343,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6344,,Homo sapiens,,F,N,Intermediate,,9606.0,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,,,1,16381,BAO_0000219,,A549,
6345,,Homo sapiens,,F,N,Intermediate,,9606.0,GI values against A549 cells (lung cancer),80682,,,1,16381,BAO_0000219,,A549,
6346,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,,,1,17206,BAO_0000219,,A549,
6347,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 human adenocarcinoma,80682,,,1,16325,BAO_0000219,,A549,
6348,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,,,1,10708,BAO_0000218,,A549,
6349,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,,,1,10708,BAO_0000218,,A549,
6350,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,,,1,17376,BAO_0000219,,A549,
6351,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,,,1,17376,BAO_0000219,,A549,
6352,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human A549 lung cells,80682,,,1,17488,BAO_0000219,,A549,
6353,,Homo sapiens,,F,N,Intermediate,,9606.0,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,,,1,17404,BAO_0000218,,A549,
6354,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,,,1,10958,BAO_0000219,,A549,
6355,,Homo sapiens,,F,N,Expert,,9606.0,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,,,1,17099,BAO_0000219,,A549,
6356,,Homo sapiens,,F,N,Intermediate,,9606.0,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,,,1,17099,BAO_0000219,,A549,
6357,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,,,1,4096,BAO_0000219,,A549,
6358,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,,,1,4096,BAO_0000219,,A549,
6359,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,,,1,4096,BAO_0000219,,A549,
6360,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against A549 tumor cell culture,80682,,,1,2525,BAO_0000219,,A549,
6361,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,,,1,2525,BAO_0000219,,A549,
6362,,Homo sapiens,,F,N,Intermediate,,9606.0,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,,,1,5302,BAO_0000219,,A549,
6363,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,,,1,16325,BAO_0000219,,A549,
6364,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,,,1,16939,BAO_0000219,,A549,
6365,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,,,1,17229,BAO_0000219,,A549,
6366,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,,,1,17380,BAO_0000219,,A549,
6367,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,,,1,17380,BAO_0000219,,A549,
6368,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,,,1,1903,BAO_0000219,,A549,
6369,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,,,1,3838,BAO_0000219,,A549,
6370,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,,,1,14696,BAO_0000219,,A549,
6371,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,,,1,3838,BAO_0000219,,A549,
6372,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,,,1,1522,BAO_0000219,,A549,
6373,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,,,1,12400,BAO_0000219,,A549,
6374,,Homo sapiens,,F,N,Intermediate,,9606.0,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,,,1,14696,BAO_0000219,,A549,
6375,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,,,1,14769,BAO_0000219,,A549,
6376,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,,,1,14696,BAO_0000219,,A549,
6377,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,,,1,1888,BAO_0000219,,A549,
6378,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,,,1,12016,BAO_0000219,,A549,
6379,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,,,1,6058,BAO_0000219,,A549,
6380,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,,,1,17708,BAO_0000219,,A549,
6381,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against A549/ATCC cell line,80682,,,1,12301,BAO_0000219,,A549,
6382,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,,,1,11970,BAO_0000219,,A549,
6383,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A549/ATCC cell line.,80682,,,1,11818,BAO_0000219,,A549,
6384,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,,,1,12400,BAO_0000219,,A549,
6385,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,,,1,3381,BAO_0000219,,A549,
6386,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,,,1,17376,BAO_0000219,,A549,
6387,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,,,1,10708,BAO_0000219,,A549,
6388,,Homo sapiens,,F,U,Autocuration,,9606.0,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,,,1,2964,BAO_0000219,,,
6389,In vivo,Canis lupus familiaris,,A,U,Intermediate,,9615.0,Compound was tested for oral bioavailability in dogs,22224,,,1,5005,BAO_0000218,,,
6390,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,,,1,6229,BAO_0000218,,,
6391,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,,,1,6229,BAO_0000218,,,
6392,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5374,BAO_0000218,,,
6393,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for the oral bioavailability in dog; No availability,50588,,,1,5374,BAO_0000218,,,
6394,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),50588,,,1,6265,BAO_0000218,,,
6395,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,,,1,5654,BAO_0000218,,,
6396,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,,,1,5654,BAO_0000218,,,
6397,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,,,1,16456,BAO_0000218,,,
6398,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),50588,,,1,5302,BAO_0000218,,,
6399,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,,,1,3624,BAO_0000218,,,
6400,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability of active FTIs in dogs,50588,,,1,16452,BAO_0000218,,,
6401,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,,,1,5802,BAO_0000218,,,
6402,In vivo,Canis lupus familiaris,,A,N,Expert,,9615.0,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
6403,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,17839,BAO_0000218,,,
6404,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6762,BAO_0000218,,,
6405,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6821,BAO_0000218,,,
6406,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability of compound was determined in dog; Not tested,50588,,,1,6821,BAO_0000218,,,
6407,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5210,BAO_0000218,,,
6408,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability (10 mg/kg) was determined in dog,50588,,,1,6227,BAO_0000218,,,
6409,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability,50588,,,1,761,BAO_0000218,,,
6410,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,,,1,761,BAO_0000218,,,
6411,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability administered in solution in rats,50588,,,1,761,BAO_0000218,,,
6412,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6413,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,,,1,5474,BAO_0000218,,,
6414,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,,,1,6535,BAO_0000218,,,
6415,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in Dog; ND = not determined,50588,,,1,6535,BAO_0000218,,,
6416,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3352,BAO_0000218,,,
6417,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6168,BAO_0000218,,,
6418,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5988,BAO_0000218,,,
6419,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,4942,BAO_0000218,,,
6420,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dogs; No data,50588,,,1,4942,BAO_0000218,,,
6421,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability measured in dogs,50588,,,1,14541,BAO_0000218,,,
6422,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,4449,BAO_0000218,,,
6423,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability was calculated in dog,50588,,,1,6057,BAO_0000218,,,
6424,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,,,1,5600,BAO_0000218,,,
6425,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (i.v. dosing),50588,,,1,5542,BAO_0000218,,,
6426,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5542,BAO_0000218,,,
6427,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,,,1,5546,BAO_0000218,,,
6428,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in Beagle dogs,50588,,,1,4514,BAO_0000218,,,
6429,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3624,BAO_0000218,,,
6430,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3854,BAO_0000218,,,
6431,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5836,BAO_0000218,,,
6432,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5940,BAO_0000218,,,
6433,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6168,BAO_0000218,,,
6434,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6227,BAO_0000218,,,
6435,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6251,BAO_0000218,,,
6436,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6448,BAO_0000218,,,
6437,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6647,BAO_0000218,,,
6438,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5940,BAO_0000218,,,
6439,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,933,BAO_0000218,,,
6440,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5210,BAO_0000218,,,
6441,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,,,1,6642,BAO_0000218,,,
6442,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,,,1,6641,BAO_0000218,,,
6443,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,,,1,6642,BAO_0000218,,,
6444,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5472,BAO_0000218,,,
6445,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5985,BAO_0000218,,,
6446,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,15660,BAO_0000218,,,
6447,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,,,1,5530,BAO_0000218,,,
6448,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,,,1,5530,BAO_0000218,,,
6449,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability (F) in dogs,50588,,,1,6305,BAO_0000218,,,
6450,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,5210,BAO_0000218,,,
6451,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,5238,BAO_0000218,,,
6452,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,5668,BAO_0000218,,,
6453,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,,,1,5668,BAO_0000218,,,
6454,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 mg/kg),50588,,,1,5668,BAO_0000218,,,
6455,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,6084,BAO_0000218,,,
6456,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6457,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6458,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6459,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6460,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6461,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6462,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6463,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6464,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6465,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6466,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6467,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6468,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6469,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6470,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6471,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6472,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6473,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6474,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6475,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6476,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6477,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6478,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6479,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6480,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6481,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6482,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6483,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6484,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6485,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6486,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6487,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6488,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6489,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6490,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6491,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6492,,Mus musculus,,A,N,Intermediate,Heart,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6493,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6494,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6495,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6496,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6497,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6498,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6499,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6500,,aeinetobacter anitrotap,,F,N,Intermediate,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,1,12269,BAO_0000218,,,
6501,,Acinetobacter calcoaceticus subsp. anitratus,,F,N,Intermediate,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,1,12269,BAO_0000218,,,
6502,,Acinetobacter calcoaceticus subsp. anitratus,,F,N,Intermediate,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,1,12269,BAO_0000218,,,
6503,,aeinetobacter anitrotap,,F,N,Intermediate,,107673.0,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,,,1,12269,BAO_0000218,,,
6504,,Acinetobacter calcoaceticus,,F,N,Intermediate,,471.0,Activity against Acinetobacter calcoaceticus (AC54),50192,,,1,10624,BAO_0000218,,,
6505,,Anolis carolinensis,,F,N,Intermediate,,28377.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,,,1,17216,BAO_0000218,,,
6506,,Anolis carolinensis,,F,N,Intermediate,,28377.0,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,,,1,17216,BAO_0000218,,,
6507,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,,,1,9560,BAO_0000218,,,
6508,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,,,1,9560,BAO_0000218,,,
6509,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,,,1,9560,BAO_0000218,,,
6510,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,,,1,9560,BAO_0000218,,,
6511,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Plaque bactericidal index against Actinomyces naeslundii 631,50296,,,1,9560,BAO_0000218,,,
6512,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,,,1,9560,BAO_0000218,,,
6513,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Plaque bactericidal index against Actinomyces naeslundii B74,50296,,,1,9560,BAO_0000218,,,
6514,,Actinomyces naeslundii,,F,N,Intermediate,,1655.0,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,,,1,9560,BAO_0000218,,,
6515,,Artemia salina,,F,N,Intermediate,,85549.0,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,,,1,114,BAO_0000218,,,
6516,,Artemia salina,,F,N,Intermediate,,85549.0,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,,,1,114,BAO_0000218,,,
6517,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,,,1,10841,BAO_0000218,,,
6518,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,,,1,10841,BAO_0000218,,,
6519,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,,,1,10841,BAO_0000218,,,
6520,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,,,1,10841,BAO_0000218,,,
6521,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,,,1,10841,BAO_0000218,,,
6522,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,,,1,10841,BAO_0000218,,,
6523,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,,,1,10841,BAO_0000218,,,
6524,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,,,1,10841,BAO_0000218,,,
6525,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,,,1,10841,BAO_0000218,,,
6526,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,,,1,10841,BAO_0000218,,,
6527,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,,,1,10841,BAO_0000218,,,
6528,,Ascaris suum,,F,N,Intermediate,,6253.0,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,,,1,10841,BAO_0000218,,,
6529,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,,,1,8117,BAO_0000218,,,
6530,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,,,1,8117,BAO_0000218,,,
6531,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,,,1,9560,BAO_0000218,,,
6532,,Actinomyces viscosus,,F,N,Expert,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,,,1,9560,BAO_0000218,,,
6533,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,,,1,9560,BAO_0000218,,,
6534,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,,,1,9560,BAO_0000218,,,
6535,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,,,1,9560,BAO_0000218,,,
6536,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Plaque bactericidal index against Actinomyces viscosus M-100,50366,,,1,9560,BAO_0000218,,,
6537,,Actinomyces viscosus,,F,N,Expert,,1656.0,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,,,1,9560,BAO_0000218,,,
6538,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,,,1,9560,BAO_0000218,,,
6539,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,,,1,9560,BAO_0000218,,,
6540,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Plaque bactericidal index against Actinomyces viscosus 626,50366,,,1,9560,BAO_0000218,,,
6541,,Actinomyces viscosus,,F,N,Intermediate,,1656.0,Plaque bactericidal index against Actinomyces viscosus T14V,50366,,,1,9560,BAO_0000218,,,
6542,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6543,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6544,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6545,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6546,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6547,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,,,1,10708,BAO_0000219,,A673,
6548,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,,,1,10708,BAO_0000219,,A704,
6549,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,,,1,416,BAO_0000219,,,
6550,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,,,1,14354,BAO_0000219,,A9,
6551,,Mus musculus,,F,N,Intermediate,,10090.0,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,,,1,14354,BAO_0000219,,A9,
6552,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,,,1,5116,BAO_0000219,,A9,
6553,,Homo sapiens,,F,N,Intermediate,,9606.0,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,,,1,5116,BAO_0000219,,A9,
6554,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,,,1,15694,BAO_0000219,,Human ovarian carcinoma cell line,
6555,,Mus musculus,,F,N,Expert,,10090.0,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,,,1,13038,BAO_0000219,,A9,
6556,,Mus musculus,,F,N,Expert,,10090.0,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,,,1,13038,BAO_0000219,,A9,
6557,,Mus musculus,,F,N,Expert,,10090.0,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,,,1,10923,BAO_0000219,,A9,
6558,,Mus musculus,,F,N,Intermediate,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,,,1,10923,BAO_0000219,,A9,
6559,,Mus musculus,,F,N,Intermediate,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,,,1,10923,BAO_0000219,,A9,
6560,,,,F,H,Expert,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,,,1,10923,BAO_0000019,,,
6561,,Mus musculus,,F,N,Intermediate,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,,,1,10923,BAO_0000219,,A9,
6562,,Mus musculus,,F,N,Intermediate,,10090.0,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,,,1,10923,BAO_0000219,,A9,
6563,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,,,1,8158,BAO_0000219,,AA6,
6564,,Homo sapiens,,F,U,Autocuration,,9606.0,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,,,1,15494,BAO_0000219,,,
6565,,Homo sapiens,,F,U,Autocuration,,9606.0,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,,,1,15494,BAO_0000219,,,
6566,,Homo sapiens,,F,N,Intermediate,,9606.0,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,,,1,12348,BAO_0000219,,AA5,
6567,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,,,1,12348,BAO_0000219,,AA5,
6568,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,,,1,2726,BAO_0000219,,AA5,
6569,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,,,1,2726,BAO_0000219,,U-937,
6570,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,,,1,10747,BAO_0000219,,UV4,
6571,,Cricetulus griseus,,F,N,Expert,,10029.0,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,,,1,11005,BAO_0000219,,CHO-AA8,
6572,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Average intracellular compound concentration when the hypoxic SER=1.6,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6573,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6574,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6575,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6576,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6577,,Cricetulus griseus,,F,N,Intermediate,,10029.0,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,,,1,13436,BAO_0000219,,CHO-AA8,
6578,,Cricetulus griseus,,F,N,Intermediate,,10029.0,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,,,1,13435,BAO_0000219,,CHO-AA8,
6579,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,,,1,13302,BAO_0000219,,CHO-AA8,
6580,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6581,,Cricetulus griseus,,A,N,Intermediate,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6582,,Cricetulus griseus,,A,N,Intermediate,,10029.0,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6583,,Cricetulus griseus,,A,N,Expert,,10029.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,,,1,12878,BAO_0000219,,CHO-AA8,
6584,,Cricetulus griseus,,A,N,Intermediate,,10029.0,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,,,1,12878,BAO_0000219,,CHO-AA8,
6585,,Cricetulus griseus,,F,N,Expert,,10029.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,,,1,14367,BAO_0000219,,CHO-AA8,
6586,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,,,1,14367,BAO_0000219,,CHO-AA8,
6587,,hampster,,F,N,Expert,,36483.0,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,,,1,12398,BAO_0000219,,CHO-AA8,
6588,,Cricetulus griseus,,F,N,Expert,,10029.0,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,,,1,12878,BAO_0000219,,CHO-AA8,
6589,,Cricetulus griseus,,F,N,Expert,,10029.0,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,,,1,13820,BAO_0000219,,CHO-AA8,
6590,,Cricetulus griseus,,F,N,Expert,,10029.0,Inhibition of growth under aerobic conditions in AA8 cells,80089,,,1,13436,BAO_0000219,,CHO-AA8,
6591,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,6084,BAO_0000218,,,
6592,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog at 10 mg/kg of the compound,50588,,,1,5711,BAO_0000218,,,
6593,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),50588,,,1,4353,BAO_0000218,,,
6594,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),50588,,,1,4353,BAO_0000218,,,
6595,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (mongrel),50588,,,1,17800,BAO_0000218,,,
6596,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,3994,BAO_0000218,,,
6597,In vivo,Canis lupus familiaris,,F,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 10 mg/kg),50588,,,1,3994,BAO_0000218,,,
6598,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,5145,BAO_0000218,,,
6599,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),50588,,,1,16452,BAO_0000218,,,
6600,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,,,1,16452,BAO_0000218,,,
6601,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,,,1,5983,BAO_0000218,,,
6602,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,4273,BAO_0000218,,,
6603,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 3-10 mg/kg),50588,,,1,12500,BAO_0000218,,,
6604,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,,,1,12500,BAO_0000218,,,
6605,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3639,BAO_0000218,,,
6606,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,3880,BAO_0000218,,,
6607,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog,50588,,,1,4838,BAO_0000218,,,
6608,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,oral bioavailability was measured in dogs,50588,,,1,15600,BAO_0000218,,,
6609,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for plasma protein binding in dog; Not determined,50588,,,1,17248,BAO_0000218,,,
6610,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for plasma protein binding of dog,50588,,,1,17248,BAO_0000218,,,
6611,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for plasma protein binding of dog; Not determined,50588,,,1,17248,BAO_0000218,,,
6612,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,,,1,17443,BAO_0000218,,,
6613,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,,,1,4186,BAO_0000218,,,
6614,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was determined,50588,,,1,3749,BAO_0000218,,,
6615,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,,,1,3249,BAO_0000218,,,
6616,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was evaluated in dog,50588,,,1,3022,BAO_0000218,,,
6617,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was determined,50588,,,1,3749,BAO_0000218,,,
6618,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6619,In vivo,Canis lupus familiaris,,A,N,Intermediate,Heart,9615.0,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6620,In vivo,Canis lupus familiaris,,A,N,Intermediate,Kidney,9615.0,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6621,In vivo,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6622,In vivo,Canis lupus familiaris,,A,N,Intermediate,Lung,9615.0,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6623,In vivo,Canis lupus familiaris,,A,N,Intermediate,Spleen,9615.0,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,,,1,2517,BAO_0000218,,,
6624,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,LogP in dog,50588,,,1,3639,BAO_0000218,,,
6625,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Partition coefficient (logP),50588,,,1,6227,BAO_0000218,,,
6626,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Partition coefficient in dog,50588,,,1,6227,BAO_0000218,,,
6627,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
6628,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,,,1,4809,BAO_0000218,,,
6629,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,,,1,5600,BAO_0000218,,,
6630,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,,,1,14294,BAO_0000218,,,
6631,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,,,1,14294,BAO_0000218,,,
6632,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Metabolism of compound in dog S9 microsomes; Trace,50588,,,1,14294,BAO_0000218,,,
6633,,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,In vitro metabolic potential in dog liver microsomes,50588,,,1,6251,BAO_0000218,,,
6634,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,,,1,3748,BAO_0000218,,,
6635,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,2713,BAO_0000218,,,
6636,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6512,BAO_0000218,,,
6637,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,,,1,6679,BAO_0000218,,,
6638,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for bioavailability in dogs,50588,,,1,3749,BAO_0000218,,,
6639,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for oral bioavailability in dogs,50588,,,1,3749,BAO_0000218,,,
6640,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog,50588,,,1,6742,BAO_0000218,,,
6641,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for percent protein binding (PB) in dog,50588,,,1,6227,BAO_0000218,,,
6642,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,,,1,6874,BAO_0000218,,,
6643,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was evaluated for plasma clearance.,50588,,,1,2877,BAO_0000218,,,
6644,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The compound was tested for plasma clearance in dog,50588,,,1,12500,BAO_0000218,,,
6645,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,,,1,12500,BAO_0000218,,,
6646,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
6647,,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,,,1,5542,BAO_0000218,,,
6648,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
6649,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,,,1,2652,BAO_0000218,,,
6650,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
6651,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6652,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6653,,Mus musculus,,A,N,Intermediate,Lung,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6654,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6655,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6656,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6657,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6658,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,,,1,6599,BAO_0000218,,CCRF S-180,
6659,,Mus musculus,,A,N,Intermediate,Brain,10090.0,C2 in brain of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6660,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6661,,Mus musculus,,A,N,Intermediate,Liver,10090.0,C2 in liver of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6662,,Mus musculus,,A,N,Intermediate,Lung,10090.0,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6663,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6664,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance in mouse,50594,,,1,17852,BAO_0000218,,,
6665,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,,,1,17764,BAO_0000218,,,
6666,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,,,1,17837,BAO_0000218,,,
6667,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance was evaluated in mice after intravenous administration,50594,,,1,2675,BAO_0000218,,,
6668,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
6669,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,,,1,4239,BAO_0000218,,,
6670,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance of compound was determined at 40 mg/Kg,50594,,,1,17753,BAO_0000218,,,
6671,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance of at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
6672,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
6673,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance at 5 mg/Kg,50594,,,1,17753,BAO_0000218,,,
6674,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance in mice,50594,,,1,5727,BAO_0000218,,,
6675,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance value upon iv administration in mouse,50594,,,1,2862,BAO_0000218,,,
6676,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Total plasma clearance in mice,50594,,,1,5980,BAO_0000218,,,
6677,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance in mouse,50594,,,1,17592,BAO_0000218,,,
6678,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance value was determined,50594,,,1,17718,BAO_0000218,,,
6679,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
6680,,,,P,U,Intermediate,,,Calculated partition coefficient (clogP),22229,,,1,17384,BAO_0000100,,,
6681,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,,,1,6062,BAO_0000218,,,
6682,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
6683,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,,,
6684,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,,,1,5969,BAO_0000218,,,
6685,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
6686,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,,,1,5969,BAO_0000218,,,
6687,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,,,1,16597,BAO_0000218,,,
6688,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,,,1,5781,BAO_0000218,,,
6689,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax after peroral administration in mice at 2.4 uM/kg,50594,,,1,17764,BAO_0000218,,,
6690,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6691,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6692,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6693,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6694,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Cmax in mice at 18 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
6695,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Cmax in mice at 23 uM/kg i.v. administration,50594,,,1,17764,BAO_0000218,,,
6696,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Cmax in mice at 24 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
6697,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Cmax in mice at 25 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
6698,In vivo,Mus musculus,,F,N,Intermediate,,10090.0,Cmax in mice at 26 uM/kg i.p. administration,50594,,,1,17764,BAO_0000218,,,
6699,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,,,1,17641,BAO_0000218,,,
6700,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,,,1,16597,BAO_0000218,,,
6701,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,,,1,16597,BAO_0000218,,,
6702,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value was determined,50594,,,1,5727,BAO_0000218,,,
6703,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value in IRC mice,50594,,,1,5951,BAO_0000218,,,
6704,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
6705,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,,,1,5506,BAO_0000218,,,
6706,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,,,
6707,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,,,1,4890,BAO_0000218,,,
6708,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,,,1,429,BAO_0000218,,,
6709,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6710,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6711,,Acanthocheilonema viteae,,F,N,Intermediate,,6277.0,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,,,1,10986,BAO_0000218,,,
6712,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,,,1,13227,BAO_0000219,,A-375,
6713,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,,,1,4481,BAO_0000249,,,Brain membranes
6714,,Homo sapiens,,F,D,Expert,,9606.0,Forskolin-induced cAMP production at human A1 adenosine receptor,114,,,1,16931,BAO_0000019,,,
6715,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6716,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6717,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,,,1,3850,BAO_0000219,,CHO,
6718,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,,,1,3850,BAO_0000219,,CHO,
6719,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6720,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,,,1,3850,BAO_0000219,,CHO,
6721,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6722,,Homo sapiens,,F,D,Expert,,9606.0,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6723,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,,,1,3850,BAO_0000219,,CHO,
6724,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6725,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,,,1,3850,BAO_0000219,,CHO,
6726,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6727,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6728,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,,,1,3850,BAO_0000219,,CHO,
6729,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6730,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6731,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,,,1,3850,BAO_0000219,,CHO,
6732,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6733,,,,F,H,Autocuration,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,,,1,3850,BAO_0000219,,CHO,
6734,,,,F,H,Expert,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,,,1,3850,BAO_0000219,,CHO,
6735,,Oryctolagus cuniculus,,F,N,Intermediate,,9986.0,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,,,1,12680,BAO_0000219,,A10,
6736,,Rattus norvegicus,,F,U,Autocuration,,10116.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,,,1,1313,BAO_0000219,,A10,
6737,,Rattus norvegicus,,F,U,Autocuration,,10116.0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,,,1,1313,BAO_0000219,,A10,
6738,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,,,1,17567,BAO_0000219,,A10,
6739,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,,,1,17567,BAO_0000219,,A10,
6740,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,,,1,11819,BAO_0000219,,A10,
6741,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,,,1,13436,BAO_0000219,,CHO-AA8,
6742,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,,,1,12687,BAO_0000219,,CHO-AA8,
6743,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,,,1,12651,BAO_0000219,,CHO-AA8,
6744,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,,,1,13300,BAO_0000219,,CHO-AA8,
6745,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,,,1,15296,BAO_0000219,,CHO-AA8,
6746,,Cricetulus griseus,,F,N,Intermediate,,10029.0,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,,,1,15328,BAO_0000219,,CHO-AA8,
6747,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,,,1,13302,BAO_0000219,,CHO-AA8,
6748,,Cricetulus griseus,,F,N,Expert,,10029.0,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,,,1,14367,BAO_0000219,,CHO-AA8,
6749,,Cricetulus griseus,,F,N,Expert,,10029.0,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,,,1,17002,BAO_0000219,,CHO-AA8,
6750,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,,,1,13436,BAO_0000219,,CHO-AA8,
6751,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Inhibitory activity against aerobic growth of AA8 cells.,80089,,,1,13435,BAO_0000219,,CHO-AA8,
6752,,Cricetulus griseus,,A,N,Intermediate,,10029.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,1,10503,BAO_0000219,,CHO-AA8,
6753,,Cricetulus griseus,,F,N,Expert,,10029.0,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,1,10503,BAO_0000219,,CHO-AA8,
6754,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,,,1,10503,BAO_0000219,,CHO-AA8,
6755,,Cricetulus griseus,,F,N,Expert,,10029.0,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,,,1,15090,BAO_0000219,,CHO-AA8,
6756,,Cricetulus griseus,,F,N,Expert,,10029.0,Cytotoxicity against AA8 cell line,80089,,,1,10368,BAO_0000219,,CHO-AA8,
6757,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,,,1,12651,BAO_0000219,,CHO-AA8,
6758,,Cricetulus griseus,,A,N,Intermediate,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,1,12687,BAO_0000219,,CHO-AA8,
6759,,Cricetulus griseus,,F,N,Intermediate,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,1,12687,BAO_0000219,,CHO-AA8,
6760,,Cricetulus griseus,,A,N,Intermediate,,10029.0,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,,,1,12687,BAO_0000219,,CHO-AA8,
6761,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,,,1,1890,BAO_0000219,,CHO-AA8,
6762,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,,,1,10747,BAO_0000219,,CHO-AA8,
6763,,Cricetulus griseus,,F,N,Intermediate,,10029.0,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,,,1,10747,BAO_0000219,,CHO-AA8,
6764,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,,,1,11616,BAO_0000218,,,
6765,,Cricetulus griseus,,F,N,Expert,,10029.0,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,,,1,11616,BAO_0000219,,CHO-AA8,
6766,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6767,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6768,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6769,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6770,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6771,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6772,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,,,1,3471,BAO_0000219,,CHO-AA8,
6773,,Cricetulus griseus,,F,N,Expert,,10029.0,Concentration required to reduce AA8 cell survival by 10%,80089,,,1,11616,BAO_0000219,,CHO-AA8,
6774,,Cricetulus griseus,,F,U,Autocuration,,10029.0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,,,1,2656,BAO_0000219,,CHO-AA8,
6775,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6776,,Cricetulus griseus,,F,U,Autocuration,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6777,,Cricetulus griseus,,F,U,Autocuration,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6778,,Cricetulus griseus,,F,U,Autocuration,,10029.0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6779,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,,,1,16156,BAO_0000219,,CHO-AA8,
6780,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,,,1,2656,BAO_0000219,,CHO-AA8,
6781,,Cricetulus griseus,,F,U,Autocuration,,10029.0,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,,,1,11005,BAO_0000019,,,
6782,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,,,1,11942,BAO_0000219,,CHO-AA8,
6783,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,,,1,2128,BAO_0000219,,CHO-AA8,
6784,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6785,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6786,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was measured after oral 2b administration (tested in 6 dogs),50588,,,1,9579,BAO_0000218,,,
6787,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was measured in dog after oral 17b administration,50588,,,1,9579,BAO_0000218,,,
6788,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,,,1,9579,BAO_0000218,,,
6789,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,,,1,9579,BAO_0000218,,,
6790,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax value after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6791,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax value after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6792,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for its half life when administered intravenously in dog,50588,,,1,3184,BAO_0000218,,,
6793,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,,,1,5017,BAO_0000218,,,
6794,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Elimination Half-life of compound was determined in dog,50588,,,1,6821,BAO_0000218,,,
6795,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life of compound in dog following oral administration,50588,,,1,17839,BAO_0000218,,,
6796,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life of compound was determined in dog,50588,,,1,17267,BAO_0000218,,,
6797,,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Half life of compound was determined in dog blood,50588,,,1,4727,BAO_0000218,,,
6798,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life after oral and iv dosing in dogs,50588,,,1,5238,BAO_0000218,,,
6799,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dogs in hours,50588,,,1,4942,BAO_0000218,,,
6800,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,,,1,6505,BAO_0000218,,,
6801,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,t1/2 in dog after oral dose (1 mg/kg),50588,,,1,5130,BAO_0000218,,,
6802,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was evaluated in dog,50588,,,1,1475,BAO_0000218,,,
6803,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,,,1,17804,BAO_0000218,,,
6804,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,,,1,17804,BAO_0000218,,,
6805,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period (10 mg/kg) was determined in dog,50588,,,1,6084,BAO_0000218,,,
6806,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period (10 mg/kg) was determined in dog,50588,,,1,6084,BAO_0000218,,,
6807,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,,,1,5542,BAO_0000218,,,
6808,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,,,1,5542,BAO_0000218,,,
6809,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period in dog,50588,,,1,6084,BAO_0000218,,,
6810,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period in dogs after oral administration at 1 mg/kg,50588,,,1,6241,BAO_0000218,,,
6811,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,1,1916,BAO_0000218,,,
6812,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound was determined in dogs,50588,,,1,6621,BAO_0000218,,,
6813,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half-life in dog plasma,50588,,,1,1696,BAO_0000218,,,
6814,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in mongrel dogs was determined,50588,,,1,17800,BAO_0000218,,,
6815,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dog upon oral administration,50588,,,1,17657,BAO_0000218,,,
6816,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dog upon oral administration; Unable to calculate,50588,,,1,17657,BAO_0000218,,,
6817,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was measured in dog,50588,,,1,4239,BAO_0000218,,,
6818,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was measured in dog,50588,,,1,5985,BAO_0000218,,,
6819,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,,,1,9932,BAO_0000218,,,
6820,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral half life was determined,50588,,,1,5199,BAO_0000218,,,
6821,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,,,1,5199,BAO_0000218,,,
6822,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half life was evaluated,50588,,,1,1475,BAO_0000218,,,
6823,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half life was evaluated in Dog,50588,,,1,1475,BAO_0000218,,,
6824,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma half life was evaluated in dog,50588,,,1,1475,BAO_0000218,,,
6825,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,,,1,6316,BAO_0000218,,,
6826,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for the half life value in dog,50588,,,1,4883,BAO_0000218,,,
6827,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum time at the dose of 2 mg/kg in dog,50588,,,1,4727,BAO_0000218,,,
6828,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,,,1,1916,BAO_0000218,,,
6829,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
6830,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
6831,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,,,1,6265,BAO_0000218,,,
6832,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,,,1,4809,BAO_0000218,,,
6833,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,,,1,5983,BAO_0000218,,,
6834,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,,,1,5313,BAO_0000218,,,
6835,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,,,1,5313,BAO_0000218,,,
6836,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,,,1,17650,BAO_0000218,,,
6837,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,,,1,5199,BAO_0000218,,,
6838,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Time taken for maximum plasma concentration in dog,50588,,,1,933,BAO_0000218,,,
6839,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Time to reach Cmax after oral administration to dogs,50588,,,1,16367,BAO_0000218,,,
6840,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
6841,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,,,1,6316,BAO_0000218,,,
6842,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,,,1,6215,BAO_0000218,,,
6843,In vivo,Canis lupus familiaris,,A,N,Expert,,9615.0,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
6844,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
6845,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,,,1,17764,BAO_0000218,,,
6846,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo Cmax in mice at dose of 100 mg/kg,50594,,,1,5969,BAO_0000218,,,
6847,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,In vivo Cmax in mice at dose of 50 mg/kg,50594,,,1,5969,BAO_0000218,,,
6848,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,,,1,4573,BAO_0000218,,,
6849,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,,,1,3277,BAO_0000218,,,
6850,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,,,
6851,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum concentration obtained in mouse plasma was determined,50594,,,1,3132,BAO_0000218,,,
6852,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,,,
6853,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,,,
6854,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,,,1,17729,BAO_0000218,,,
6855,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,,,1,17729,BAO_0000218,,,
6856,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,,,1,17729,BAO_0000218,,,
6857,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,,,1,17728,BAO_0000218,,,
6858,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,,,1,17728,BAO_0000218,,,
6859,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,,,1,17728,BAO_0000218,,,
6860,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,,,1,4066,BAO_0000218,,,
6861,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,,,1,6178,BAO_0000218,,,
6862,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,,,1,6178,BAO_0000218,,,
6863,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,,,1,3760,BAO_0000218,,,
6864,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,,,1,3760,BAO_0000218,,,
6865,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,,,1,3760,BAO_0000218,,,
6866,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,,,1,3760,BAO_0000218,,,
6868,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax in male mice after 2 mg/kg oral dose,50594,,,1,5961,BAO_0000218,,,
6869,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,,,1,6137,BAO_0000218,,,
6870,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,,,1,3802,BAO_0000218,,,
6871,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,,,1,3535,BAO_0000218,,,
6872,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,,,1,3535,BAO_0000218,,,
6873,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,,,1,3535,BAO_0000218,,,
6874,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,,,1,3535,BAO_0000218,,,
6875,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,,,1,3535,BAO_0000218,,,
6876,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,,,1,3535,BAO_0000218,,,
6877,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum concentration in plasma upon oral administration in mouse,50594,,,1,2862,BAO_0000218,,,
6878,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,,,
6879,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,,,1,2675,BAO_0000218,,,
6880,,Mus musculus,,A,N,Intermediate,,10090.0,Dose at which the compound induced fecal excretion in mice,50594,,,1,5399,BAO_0000218,,,
6893,,Rattus norvegicus,,F,N,Expert,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,,,1,11819,BAO_0000219,,A10,
6894,,Rattus norvegicus,,F,N,Expert,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,,,1,11819,BAO_0000219,,A10,
6895,,Rattus norvegicus,,F,N,Expert,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,,,1,11819,BAO_0000219,,A10,
6896,,Rattus norvegicus,,F,N,Expert,,10116.0,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,,,1,11819,BAO_0000219,,A10,
6897,,Rattus norvegicus,,F,N,Intermediate,,10116.0,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,,,1,16361,BAO_0000219,,A10,
6898,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,,,1,2288,BAO_0000219,,A121,
6899,,Homo sapiens,,F,N,Intermediate,,9606.0,Anticancer activity against human ovarian carcinoma A121 cells,80655,,,1,10404,BAO_0000219,,A121,
6900,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,,,1,14790,BAO_0000219,,A121,
6901,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,,,1,14790,BAO_0000219,,A121,
6902,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,,,1,14253,BAO_0000219,,A121,
6903,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,,,1,13617,BAO_0000219,,A121,
6904,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human A121 ovarian cells,80655,,,1,1003,BAO_0000219,,A121,
6905,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,,,1,830,BAO_0000219,,A121,
6906,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human ovarian carcinoma A21,80655,,,1,12307,BAO_0000219,,A121,
6907,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,,,1,14254,BAO_0000219,,A121,
6908,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity of compound against human A121 ovarian cell line.,80655,,,1,13370,BAO_0000219,,A121,
6909,,Homo sapiens,,F,N,Intermediate,,9606.0,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,,,1,14790,BAO_0000219,,A121,
6910,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,,,1,3614,BAO_0000219,,A121,
6911,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,,,1,2664,BAO_0000219,,A 172,
6912,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A172 human tumor cell lines.,80012,,,1,2037,BAO_0000219,,A 172,
6913,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,,,1,14539,BAO_0000219,,A 172,
6914,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,,,1,2836,BAO_0000219,,A 172,
6915,,Homo sapiens,,F,N,Intermediate,,9606.0,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,,,1,10708,BAO_0000219,,A 172,
6916,,Canis lupus familiaris,,B,H,Autocuration,,9615.0,Association constant against A2 adenosine receptor,104729,,,1,8975,BAO_0000224,,,
6917,,fish,,F,N,Intermediate,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,,,1,7645,BAO_0000219,,A2,
6918,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,,,1,11377,BAO_0000224,,,
6919,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,,,1,13528,BAO_0000219,,A204,
6920,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,,,1,10160,BAO_0000219,,A204,
6921,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,,,1,15144,BAO_0000219,,A2058,
6922,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition against Human squamous cell line(A 253),80657,,,1,13160,BAO_0000219,,A253 cell line,
6923,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,,,1,12898,BAO_0000219,,A253 cell line,
6924,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,,,1,13069,BAO_0000219,,A253 cell line,
6925,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of A253 cell lines.,80657,,,1,15984,BAO_0000219,,A253 cell line,
6926,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,,,1,15564,BAO_0000219,,A253 cell line,
6927,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,,,1,15564,BAO_0000219,,A253 cell line,
6928,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,,,1,15564,BAO_0000219,,A253 cell line,
6929,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,,,1,4720,BAO_0000219,,A2780,
6930,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,,,1,16112,BAO_0000219,,A2780,
6931,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,,,1,16597,BAO_0000219,,A2780,
6932,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,,,1,16378,BAO_0000219,,A2780,
6933,,Homo sapiens,,F,N,Expert,,9606.0,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,,,1,16085,BAO_0000219,,A2780,
6934,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,,,1,16317,BAO_0000219,,A2780,
6935,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,,,1,15748,BAO_0000219,,A2780,
6936,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,,,1,16597,BAO_0000219,,A2780,
6937,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,,,1,16597,BAO_0000219,,A2780,
6938,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,,,1,16597,BAO_0000219,,A2780,
6939,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,,,1,15608,BAO_0000219,,A2780,
6940,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,,,1,15608,BAO_0000219,,A2780,
6941,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,,,1,15608,BAO_0000219,,A2780,
6942,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,,,1,15296,BAO_0000019,,,
6943,,Cricetulus griseus,,A,U,Autocuration,,10029.0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,,,1,10251,BAO_0000219,,CHO-AA8,
6944,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,,,1,10251,BAO_0000219,,CHO-AA8,
6945,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,,,1,10251,BAO_0000219,,CHO-AA8,
6946,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,,,1,10251,BAO_0000219,,CHO-AA8,
6947,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Growth inhibition against CHO-derived cell line AA8,22224,,,1,11858,BAO_0000019,,,
6948,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,,,1,11858,BAO_0000219,,CHO-AA8,
6949,,hampster,,F,N,Expert,,36483.0,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,,,1,11616,BAO_0000219,,CHO-AA8,
6950,,Cricetulus griseus,,F,N,Expert,,10029.0,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,,,1,11616,BAO_0000219,,CHO-AA8,
6951,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6952,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,,,1,11396,BAO_0000219,,CHO-AA8,
6953,,Cricetulus griseus,,F,U,Autocuration,,10029.0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,,,1,10518,BAO_0000219,,CHO-AA8,
6954,,Cricetulus griseus,,F,N,Expert,,10029.0,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,,,1,11616,BAO_0000219,,CHO-AA8,
6955,,,,F,H,Autocuration,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,,,1,14837,BAO_0000019,,,
6956,,,,F,H,Autocuration,,,Number of binding sites (n) of isolated serum protein AAG,12675,,,1,14837,BAO_0000019,,,
6957,,,,B,M,Intermediate,,,Association constant for binding to AATT duplex,22222,,,1,16037,BAO_0000225,,,
6958,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of ABAE human fibroblast cell proliferation,100090,,,1,16597,BAO_0000219,,ABAE,
6959,,Mus musculus,,F,N,Intermediate,,10090.0,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,,,1,8831,BAO_0000218,,AC755,
6960,,Oryctolagus cuniculus,,F,D,Expert,,9986.0,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,,,1,13419,BAO_0000218,,,
6961,In vivo,Oryctolagus cuniculus,,F,D,Expert,,9986.0,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,,,1,13419,BAO_0000218,,,
6962,,,,B,H,Autocuration,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,,,1,15778,BAO_0000357,,,
6963,,,,B,H,Autocuration,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,,,1,15778,BAO_0000357,,,
6964,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,,,1,12988,BAO_0000219,,ACH-2 cell line,
6965,,Homo sapiens,,F,N,Intermediate,,9606.0,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,,,1,12988,BAO_0000219,,ACH-2 cell line,
6966,,Human immunodeficiency virus 1,,F,U,Autocuration,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,,,1,12988,BAO_0000219,,T cell line,
6967,,Human immunodeficiency virus 1,,F,U,Autocuration,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,,,1,12988,BAO_0000219,,T cell line,
6968,,Human immunodeficiency virus 1,,F,U,Autocuration,,11676.0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,,,1,12988,BAO_0000219,,T cell line,
6969,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of renal cancer ACHN cell line,80025,,,1,11843,BAO_0000219,,ACHN,
6970,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of ACHN renal cancer cell line,80025,,,1,16939,BAO_0000219,,ACHN,
6971,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration required against ACHN renal cancer cell line,80025,,,1,4782,BAO_0000219,,ACHN,
6972,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,,,1,6310,BAO_0000219,,ACHN,
6973,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,,,1,6310,BAO_0000219,,ACHN,
6974,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against ACHN Renal cancer cell line,80025,,,1,12858,BAO_0000219,,ACHN,
6975,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity evaluation against ACHN renal cancer cells,80025,,,1,17380,BAO_0000219,,ACHN,
6976,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against human renal ACHN cell line,80025,,,1,5858,BAO_0000219,,ACHN,
6977,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,,,1,3838,BAO_0000219,,ACHN,
6978,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,,,1,3838,BAO_0000219,,ACHN,
6979,,Homo sapiens,,F,N,Intermediate,,9606.0,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,,,1,5406,BAO_0000219,,ACHN,
6980,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,,,1,4071,BAO_0000219,,ACHN,
6981,,Homo sapiens,,F,N,Expert,,9606.0,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,,,1,4071,BAO_0000219,,ACHN,
6982,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,,,1,4071,BAO_0000219,,ACHN,
6983,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,,,1,15002,BAO_0000219,,ACHN,
6984,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,,,1,14769,BAO_0000219,,ACHN,
6985,,Homo sapiens,,F,N,Intermediate,,9606.0,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,,,1,13958,BAO_0000219,,ACHN,
6986,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,,,1,1665,BAO_0000219,,ACHN,
6987,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,,,1,15354,BAO_0000219,,ACHN,
6988,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,,,1,15354,BAO_0000219,,ACHN,
6989,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,,,1,13978,BAO_0000219,,ACHN,
6990,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,,,1,6798,BAO_0000219,,ACHN,
6991,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,,,1,2959,BAO_0000218,,,
6992,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,,,1,9932,BAO_0000218,,,
6993,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,,,1,5546,BAO_0000218,,,
6994,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution after 15 mg/kg iv dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6995,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution after 30 mg/kg po dose in Dogs,50588,,,1,16907,BAO_0000218,,,
6996,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,,,1,4257,BAO_0000218,,,
6997,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,,,1,4305,BAO_0000218,,,
6998,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was evaluated in dog,50588,,,1,5472,BAO_0000218,,,
6999,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,,,1,6062,BAO_0000218,,,
7000,,Canis lupus familiaris,,A,N,Expert,,9615.0,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,,,1,3598,BAO_0000218,,,
7001,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for volume of distribution in dog,50588,,,1,12500,BAO_0000218,,,
7002,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,,,1,12500,BAO_0000218,,,
7003,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vd (1 mg/kg) was determined in dog (in vivo),50588,,,1,6227,BAO_0000218,,,
7004,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vd in dog,50588,,,1,6227,BAO_0000218,,,
7005,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution was determined,50588,,,1,4219,BAO_0000218,,,
7006,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution in dog,50588,,,1,1696,BAO_0000218,,,
7007,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,,,1,5542,BAO_0000218,,,
7008,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,,,1,5199,BAO_0000218,,,
7009,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
7010,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution at the dose of 2 mg/kg in dog,50588,,,1,4727,BAO_0000218,,,
7011,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Steady state volume of distribution was determined,50588,,,1,16367,BAO_0000218,,,
7012,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,,,1,2652,BAO_0000218,,,
7013,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,,,1,16452,BAO_0000218,,,
7014,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,,,1,16452,BAO_0000218,,,
7015,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),50588,,,1,16452,BAO_0000218,,,
7016,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
7017,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property (vdss) was measured in dog,50588,,,1,4239,BAO_0000218,,,
7018,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
7019,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,,,1,5600,BAO_0000218,,,
7020,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume displacement was calculated in dog,50588,,,1,6057,BAO_0000218,,,
7021,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,,,1,5654,BAO_0000218,,,
7022,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution constant was determined,50588,,,1,5505,BAO_0000218,,,
7023,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
7024,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,,,1,4521,BAO_0000218,,,
7025,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,,,1,4521,BAO_0000218,,,
7026,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution (Vdss) was measured in dog,50588,,,1,15660,BAO_0000218,,,
7027,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution (Vdss) was measured in dog,50588,,,1,15660,BAO_0000218,,,
7028,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,,,1,6679,BAO_0000218,,,
7029,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution in steady state was determined in dog,50588,,,1,5145,BAO_0000218,,,
7030,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution of compound was determined in dog,50588,,,1,6821,BAO_0000218,,,
7031,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,,,1,4137,BAO_0000218,,,
7032,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,,,1,5334,BAO_0000218,,,
7033,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution (Vdss) was measured in dog,50588,,,1,15660,BAO_0000218,,,
7034,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,1,6642,BAO_0000218,,,
7035,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6641,BAO_0000218,,,
7036,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6642,BAO_0000218,,,
7037,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum rate of depolarization of the upstroke of the action potential,50588,,,1,11659,BAO_0000218,,,
7038,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Steady state volume distribution in dog,50588,,,1,6448,BAO_0000218,,,
7039,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,,,1,5474,BAO_0000218,,,
7040,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,,,1,1466,BAO_0000218,,,
7041,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,,,1,6535,BAO_0000218,,,
7042,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution in dog after administration of 1 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
7043,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,,,1,17764,BAO_0000218,,,
7044,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,,,1,6215,BAO_0000218,,,
7045,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,,,1,6505,BAO_0000218,,,
7046,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vss was determined,50588,,,1,3639,BAO_0000218,,,
7047,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vss in dog,50588,,,1,3639,BAO_0000218,,,
7048,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,,,1,6062,BAO_0000218,,,
7049,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume distribution in dogs,50588,,,1,4942,BAO_0000218,,,
7050,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution in dog,50588,,,1,17796,BAO_0000218,,,
7051,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for the oral bioavailability in dog,50588,,,1,4883,BAO_0000218,,,
7060,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,,,1,17837,BAO_0000218,,,
7061,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,,,1,17729,BAO_0000218,,,
7062,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,,,1,17729,BAO_0000218,,,
7063,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was measured in mouse,50594,,,1,4239,BAO_0000218,,,
7064,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse,50594,,,1,17592,BAO_0000218,,,
7065,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,,,
7066,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse,50594,,,1,2801,BAO_0000218,,,
7067,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,,,1,2801,BAO_0000218,,,
7068,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse,50594,,,1,17718,BAO_0000218,,,
7069,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral availability at 50 mg/kg po in male mice,50594,,,1,5727,BAO_0000218,,,
7070,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse (dose 10 mg/kg),50594,,,1,5302,BAO_0000218,,,
7071,In vivo,Mus musculus,,A,N,Expert,,10090.0,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,,,1,3598,BAO_0000218,,,
7072,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,,,1,5961,BAO_0000218,,,
7074,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse,50594,,,1,6091,BAO_0000218,,,
7075,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in vivo in mice;ND=Not determined,50594,,,1,6091,BAO_0000218,,,
7076,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,,,1,5711,BAO_0000218,,,
7077,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,,,1,17728,BAO_0000218,,,
7078,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,,,1,17728,BAO_0000218,,,
7079,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tested for bioavailability of the compound,50594,,,1,3802,BAO_0000218,,,
7080,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,,,1,3802,BAO_0000218,,,
7081,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,,,1,14029,BAO_0000218,,,
7082,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,,,1,14029,BAO_0000218,,,
7083,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,,,1,14029,BAO_0000218,,,
7084,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,,,1,14029,BAO_0000218,,,
7085,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,,,1,14029,BAO_0000218,,,
7086,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,,,1,17753,BAO_0000218,,,
7087,,Mus musculus,,A,N,Intermediate,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,,,1,17753,BAO_0000218,,,
7088,,Mus musculus,,A,N,Intermediate,,10090.0,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,,,1,17753,BAO_0000218,,,
7089,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7090,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7091,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7092,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7093,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7094,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7095,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7096,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7097,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,,,1,10107,BAO_0000218,,,
7098,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,,,1,15608,BAO_0000219,,A2780,
7099,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,,,1,3290,BAO_0000219,,A2780,
7100,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for cytotoxicity against A2780 cell line,81034,,,1,2859,BAO_0000219,,A2780,
7101,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of A2780 cell clonogenic assay,81034,,,1,15688,BAO_0000219,,A2780,
7102,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on ovarian cancer cell line (A2780),81034,,,1,5642,BAO_0000219,,A2780,
7103,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,,,1,6633,BAO_0000219,,A2780,
7104,,Homo sapiens,,F,N,Intermediate,,9606.0,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,,,1,3906,BAO_0000219,,A2780,
7105,,Homo sapiens,,F,N,Expert,,9606.0,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,,,1,6788,BAO_0000219,,A2780,
7106,,Homo sapiens,,F,N,Expert,,9606.0,Antiproliferative activity against human A2780 cells,81034,,,1,17582,BAO_0000219,,A2780,
7107,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of human A2780 cell proliferation,81034,,,1,17764,BAO_0000219,,A2780,
7108,,Homo sapiens,,F,N,Expert,,9606.0,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,,,1,17764,BAO_0000219,,A2780,
7109,,Homo sapiens,,F,N,Expert,,9606.0,Inhibition of human A2780 cell proliferation (No data),81034,,,1,17764,BAO_0000219,,A2780,
7110,,Homo sapiens,,F,N,Intermediate,,9606.0,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,,,1,2815,BAO_0000219,,A2780,
7111,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,,,1,16930,BAO_0000219,,A2780,
7112,,Homo sapiens,,F,N,Expert,,9606.0,Growth inhibition against A2780 wild-type ovarian cell lines,81034,,,1,17777,BAO_0000219,,A2780,
7113,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,,,1,17777,BAO_0000219,,A2780,
7114,,Homo sapiens,,F,D,Autocuration,,9606.0,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,,,1,16936,BAO_0000019,,,
7115,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,,,1,13759,BAO_0000219,,A2780,
7116,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,,,1,13759,BAO_0000219,,A2780,
7117,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,,,1,13759,BAO_0000219,,A2780,
7118,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,,,1,13759,BAO_0000219,,A2780,
7119,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,,,1,15292,BAO_0000219,,A2780,
7120,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,,,1,15292,BAO_0000219,,A2780,
7121,,Homo sapiens,,F,N,Expert,,9606.0,In vitro inhibition of human ovarian cell line A2780,81034,,,1,15069,BAO_0000219,,A2780,
7122,,Homo sapiens,,F,N,Expert,,9606.0,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,,,1,15069,BAO_0000219,,A2780,
7123,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,,,1,14073,BAO_0000219,,A2780,
7124,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit A2780-cell growth by 50%,81034,,,1,14553,BAO_0000219,,A2780,
7125,,Homo sapiens,,F,N,Expert,,9606.0,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,,,1,13040,BAO_0000219,,A2780,
7126,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,,,1,6891,BAO_0000219,,A2780,
7127,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,,,1,15569,BAO_0000219,,A2780,
7128,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,,,1,14190,BAO_0000219,,A2780,
7129,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,,,1,15014,BAO_0000219,,A2780,
7130,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,,,1,15014,BAO_0000219,,A2780,
7131,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,,,1,17496,BAO_0000219,,A2780,
7132,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,,,1,13617,BAO_0000219,,A2780,
7133,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,,,1,13617,BAO_0000219,,A2780,
7134,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,,,1,13617,BAO_0000219,,A2780,
7135,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,,,1,13617,BAO_0000219,,A2780,
7136,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,,,1,17672,BAO_0000219,,A2780,
7137,,Homo sapiens,,F,N,Intermediate,,9606.0,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,,,1,4544,BAO_0000219,,A2780,
7138,,Homo sapiens,,F,N,Intermediate,,9606.0,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,,,1,4544,BAO_0000219,,A2780,
7139,,Homo sapiens,,F,N,Intermediate,,9606.0,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,,,1,16317,BAO_0000219,,A2780,
7140,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,,,1,15099,BAO_0000219,,A2780,
7141,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,,,1,13978,BAO_0000219,,A2780,
7142,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against A2780 cell line.,81034,,,1,12989,BAO_0000219,,A2780,
7143,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,,,1,5574,BAO_0000219,,A2780,
7144,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,,,1,13528,BAO_0000219,,A2780,
7145,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,,,1,12782,BAO_0000219,,ACHN,
7146,,Homo sapiens,,F,N,Intermediate,,9606.0,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,,,1,14255,BAO_0000219,,ACHN,
7147,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,,,1,16364,BAO_0000219,,ACHN,
7148,,Homo sapiens,,F,N,Expert,,9606.0,In vitro lethal concentration against most sensitive ACHN cell line,80025,,,1,17376,BAO_0000219,,ACHN,
7149,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,,,1,12016,BAO_0000219,,ACHN,
7150,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,,,1,6058,BAO_0000219,,ACHN,
7151,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,,,1,17708,BAO_0000219,,ACHN,
7152,,Homo sapiens,,F,N,Intermediate,,9606.0,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,,,1,15176,BAO_0000219,,ACHN,
7153,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anticancer activity against ACHN renal cancer cell line,80025,,,1,2806,BAO_0000219,,ACHN,
7154,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,,,1,15300,BAO_0000219,,ACHN,
7155,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent selectivity was evaluated in renal ACHN cell lines,80025,,,1,16364,BAO_0000219,,ACHN,
7156,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against renal ACHN cancer cell line,80025,,,1,13859,BAO_0000219,,ACHN,
7157,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,,,1,11970,BAO_0000219,,ACHN,
7158,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,,,1,2450,BAO_0000219,,ACHN,
7159,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,,,1,12696,BAO_0000219,,ACHN,
7160,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,,,1,12400,BAO_0000219,,ACHN,
7161,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect on renal cancer line ACHN,80025,,,1,12888,BAO_0000219,,ACHN,
7162,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,,,1,3156,BAO_0000219,,ACHN,
7163,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of Renal Cancer ACHN cell lines,80025,,,1,3381,BAO_0000219,,ACHN,
7164,,Homo sapiens,,F,N,Intermediate,,9606.0,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,,,1,16747,BAO_0000219,,ACHN,
7165,,Homo sapiens,,F,N,Expert,,9606.0,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,,,1,16748,BAO_0000219,,ACHN,
7166,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,,,1,12062,BAO_0000219,,ACHN,
7167,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,,,1,14769,BAO_0000219,,ACHN,
7168,,Homo sapiens,,F,N,Intermediate,,9606.0,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,,,1,15895,BAO_0000219,,ACHN,
7169,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,,,1,17376,BAO_0000219,,ACHN,
7170,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,,,1,14882,BAO_0000219,,ACHN,
7171,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,,,1,14882,BAO_0000219,,ACHN,
7172,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,,,1,15661,BAO_0000219,,ACHN,
7173,,,,A,U,Autocuration,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,1,9680,BAO_0000019,,,
7174,,,,F,H,Autocuration,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,,,1,14579,BAO_0000019,,,
7175,,Cytomegalovirus,,F,N,Expert,,10358.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,,,1,17290,BAO_0000218,,HEL,
7176,,Cytomegalovirus,,F,N,Intermediate,,10358.0,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,,,1,17290,BAO_0000218,,,
7177,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,,,1,15891,BAO_0000357,,,
7178,,,,B,H,Autocuration,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,,,1,15890,BAO_0000357,,,
7179,,Bos taurus,,F,N,Intermediate,,9913.0,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,,,1,3801,BAO_0000219,,ADDP cell line,
7180,,Mus musculus,,F,N,Intermediate,,10090.0,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,,,1,9222,BAO_0000219,,ADJ/PC6,
7181,,Mus musculus,,F,N,Intermediate,,10090.0,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,,,1,9222,BAO_0000219,,ADJ/PC6,
7182,,Mus musculus,,F,N,Intermediate,,10090.0,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,,,1,7257,BAO_0000219,,ADJ/PC6,
7183,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,,,1,7257,BAO_0000219,,ADJ/PC6,
7184,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,,,1,7257,BAO_0000219,,ADJ/PC6,
7185,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,,,1,8084,BAO_0000219,,ADJ/PC6,
7186,,Mus musculus,,F,U,Autocuration,,10090.0,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,,,1,14943,BAO_0000019,,,
7187,,Mus musculus,,F,U,Autocuration,,10090.0,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,,,1,14943,BAO_0000019,,,
7188,,Mus musculus,,F,U,Autocuration,,10090.0,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,,,1,14943,BAO_0000019,,,
7189,In vivo,Bacillus subtilis,,A,U,Autocuration,,1423.0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,,,1,10524,BAO_0000218,,,
7190,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7191,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7192,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7193,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7194,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7195,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for its clearance when administered intravenously in dog,50588,,,1,3184,BAO_0000218,,,
7196,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,,,1,16456,BAO_0000218,,,
7197,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,,,1,4809,BAO_0000218,,,
7198,,,,P,U,Intermediate,,,Calculated partition coefficient (clogP),22229,,,1,4219,BAO_0000100,,,
7199,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog,50588,,,1,3748,BAO_0000218,,,
7200,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Time taken for EC90 was determined when tested in dog,50588,,,1,3132,BAO_0000218,,,
7201,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life (iv) was determined,50588,,,1,4219,BAO_0000218,,,
7202,,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,,,1,16907,BAO_0000218,,,
7203,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was calculated in dog after iv administration,50588,,,1,6057,BAO_0000218,,,
7204,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was calculated in dog after peroral administration,50588,,,1,6057,BAO_0000218,,,
7205,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,,,1,17853,BAO_0000218,,,
7206,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,pKa was evaluated in dog,50588,,,1,3639,BAO_0000218,,,
7207,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,,,1,14541,BAO_0000218,,,
7208,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,,,1,16456,BAO_0000218,,,
7209,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,,,1,16456,BAO_0000218,,,
7210,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,,,1,2652,BAO_0000218,,,
7211,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the half-life (t 1/2) in hours,50588,,,1,3624,BAO_0000218,,,
7212,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
7213,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,,,1,1337,BAO_0000218,,,
7214,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life after intravenous administration of 1 mg/kg in dog,50588,,,1,4709,BAO_0000218,,,
7215,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was measured in dog,50588,,,1,15660,BAO_0000218,,,
7216,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period in dog after 5 mg/kg dose,50588,,,1,5302,BAO_0000218,,,
7217,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was evaluated in dog; 4-4.8,50588,,,1,17791,BAO_0000218,,,
7218,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,,,1,6348,BAO_0000218,,,
7219,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was determined in dog after a3 mg/kg of iv dose,50588,,,1,4257,BAO_0000218,,,
7220,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was determined,50588,,,1,3771,BAO_0000218,,,
7221,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dogs,50588,,,1,6305,BAO_0000218,,,
7222,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,,,1,13501,BAO_0000218,,,
7223,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
7224,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,,,1,3045,BAO_0000218,,,
7225,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,,,1,3043,BAO_0000218,,,
7226,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for half life in dog,50588,,,1,4839,BAO_0000218,,,
7227,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for its half life in dog,50588,,,1,4839,BAO_0000218,,,
7228,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,,,1,5802,BAO_0000218,,,
7229,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life of compound in dog was determined,50588,,,1,17839,BAO_0000218,,,
7230,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life (iv) was determined,50588,,,1,4219,BAO_0000218,,,
7231,,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,,,1,13966,BAO_0000218,,,
7232,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,,,1,3994,BAO_0000218,,,
7233,In vivo,Canis lupus familiaris,,F,N,Intermediate,Plasma,9615.0,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,,,1,3994,BAO_0000218,,,
7234,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog,50588,,,1,4453,BAO_0000218,,,
7235,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life in dog plasma,50588,,,1,6535,BAO_0000218,,,
7236,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
7237,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life in dog plasma after administration of 1 mg/kg iv,50588,,,1,6535,BAO_0000218,,,
7238,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life in dog plasma was determined at dose 10 mg/kg,50588,,,1,3132,BAO_0000218,,,
7239,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog was determined,50588,,,1,5374,BAO_0000218,,,
7240,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,,,1,5007,BAO_0000218,,,
7241,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half life upon exposure to human plasma,50588,,,1,16907,BAO_0000218,,,
7242,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was calculated in dog,50588,,,1,6057,BAO_0000218,,,
7243,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was determined,50588,,,1,5006,BAO_0000218,,,
7244,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was determined,50588,,,1,5473,BAO_0000218,,,
7245,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life by intravenous administration of 1.2 mg/kg in dog,50588,,,1,4368,BAO_0000218,,,
7246,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog,50588,,,1,6448,BAO_0000218,,,
7247,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog after intra venous administration of the compound,50588,,,1,4353,BAO_0000218,,,
7248,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,,,1,4353,BAO_0000218,,,
7249,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog after po administration of the compound,50588,,,1,4353,BAO_0000218,,,
7250,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog after po administration of the compound; ND means Not determined,50588,,,1,4353,BAO_0000218,,,
7251,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog at the single oral dose of 1 mg/kg,50588,,,1,6265,BAO_0000218,,,
7252,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dogs,50588,,,1,5006,BAO_0000218,,,
7253,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,,,1,5356,BAO_0000218,,,
7254,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in rat,50588,,,1,405,BAO_0000218,,,
7255,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,,,1,6642,BAO_0000218,,,
7256,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7257,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7258,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7259,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7260,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7261,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7262,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7263,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7264,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7265,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7266,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7267,In vivo,Mus musculus,,A,N,Intermediate,Gut,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7268,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7269,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7270,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7271,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7272,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7273,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7274,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7275,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7276,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,,,1,10107,BAO_0000218,,,
7277,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7278,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7279,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7280,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7281,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7282,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7283,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7284,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7285,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7286,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7287,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7288,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7289,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7290,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,,,1,5895,BAO_0000219,,A2780,
7291,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,,,1,6338,BAO_0000219,,A2780,
7292,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,,,1,15163,BAO_0000219,,A2780,
7293,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,,,1,15163,BAO_0000219,,A2780,
7294,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,,,1,15000,BAO_0000219,,A2780,
7295,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,,,1,15000,BAO_0000219,,A2780,
7296,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,,,1,14729,BAO_0000219,,A2780,
7297,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity against A2780 cell line,81034,,,1,17270,BAO_0000219,,A2780,
7298,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,,,1,5685,BAO_0000219,,A2780,
7299,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,,,1,3563,BAO_0000219,,A2780,
7300,,Homo sapiens,,F,N,Intermediate,,9606.0,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,,,1,17753,BAO_0000218,,A2780,
7301,,Homo sapiens,,F,N,Intermediate,,9606.0,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,,,1,16317,BAO_0000219,,A2780,
7302,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of tubulin polymerization in analogy of ca.,81034,,,1,16936,BAO_0000219,,A2780,
7303,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,,,1,3801,BAO_0000219,,A2780,
7304,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxic effect in ovarian cancer cell line (A2780),81034,,,1,6181,BAO_0000219,,A2780,
7305,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,,,1,5318,BAO_0000219,,A2780,
7306,,Homo sapiens,,F,N,Intermediate,,9606.0,Tested for the cytotoxicity in A2780 ovarian cell line,81034,,,1,4840,BAO_0000219,,A2780,
7307,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,,,1,15748,BAO_0000219,,A2780,
7308,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,,,1,15748,BAO_0000219,,A2780,
7309,,,,F,N,Intermediate,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,,,1,15748,BAO_0000219,,A2780cisR,
7310,,,,F,N,Intermediate,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,,,1,15748,BAO_0000219,,A2780cisR,
7311,,,,F,N,Intermediate,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,,,1,15748,BAO_0000219,,A2780cisR,
7312,,,,F,N,Intermediate,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,,,1,15748,BAO_0000219,,A2780cisR,
7313,,Homo sapiens,,F,N,Intermediate,,9606.0,In vivo log of cells killed after administration of compound in A2780 cell line,81034,,,1,17753,BAO_0000218,,A2780,
7314,In vivo,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,,,1,17753,BAO_0000218,,A2780,
7315,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,,,1,16936,BAO_0000219,,A2780,
7316,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,,,1,16936,BAO_0000219,,A2780,
7317,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,,,1,16936,BAO_0000219,,A2780,
7318,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,,,1,16936,BAO_0000219,,A2780,
7319,,Homo sapiens,,F,N,Intermediate,,9606.0,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,,,1,17528,BAO_0000218,,A2780,
7320,,Homo sapiens,,F,N,Intermediate,,9606.0,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,,,1,6633,BAO_0000219,,A2780,
7321,,Homo sapiens,,F,N,Expert,,9606.0,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,,,1,15000,BAO_0000219,,A2780,
7322,,Homo sapiens,,F,N,Expert,,9606.0,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,,,1,17528,BAO_0000219,,A2780,
7323,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,,,1,16936,BAO_0000219,,A2780,
7324,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,,,1,16936,BAO_0000219,,A2780,
7325,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,,,1,16936,BAO_0000219,,A2780,
7326,,Homo sapiens,,F,N,Intermediate,,9606.0,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,,,1,16936,BAO_0000219,,A2780,
7327,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,,,1,16936,BAO_0000219,,A2780,
7328,,Homo sapiens,,F,N,Expert,,9606.0,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,,,1,16936,BAO_0000219,,A2780,
7329,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,1,16936,BAO_0000219,,A2780,
7330,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,1,16936,BAO_0000219,,A2780,
7331,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,,,1,16936,BAO_0000219,,A2780,
7332,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro antiproliferative activity against A2780 cell line,81034,,,1,17737,BAO_0000219,,A2780,
7333,,Mus musculus,,F,N,Expert,,10090.0,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,,,1,17764,BAO_0000219,,A2780,
7334,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,,,1,3830,BAO_0000219,,A2780,
7335,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,,,1,3829,BAO_0000219,,A2780,
7336,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7337,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,,,1,3546,BAO_0000218,,,
7338,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,,,1,5668,BAO_0000019,,,
7339,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
7340,,Cercopithecidae,,A,U,Autocuration,Plasma,9527.0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
7341,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,,,1,4256,BAO_0000218,,,
7342,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,,,1,4256,BAO_0000218,,,
7343,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,,,1,4256,BAO_0000218,,,
7344,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral Bioavailability in rat,22224,,,1,4256,BAO_0000218,,,
7345,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,,,1,1916,BAO_0000218,,,
7346,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve value in monkey at a dose of 5 mg/kg,22224,,,1,5302,BAO_0000218,,,
7347,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,,,1,4257,BAO_0000218,,,
7348,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000019,,,
7349,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000019,,,
7350,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,,,1,5355,BAO_0000019,,,
7351,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,,,1,6078,BAO_0000218,,,
7352,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,,,1,6078,BAO_0000218,,,
7353,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,,,1,6062,BAO_0000218,,,
7354,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
7355,,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000019,,,
7356,,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,,,1,5394,BAO_0000218,,,
7357,,Cercopithecidae,,A,U,Autocuration,,9527.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,,,1,4397,BAO_0000218,,,
7358,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,,,1,17509,BAO_0000218,,,
7359,,Cercopithecidae,,A,U,Autocuration,,9527.0,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,,,1,17509,BAO_0000218,,,
7360,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,,,1,6641,BAO_0000218,,,
7361,,Cercopithecidae,,A,U,Autocuration,,9527.0,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,,,1,5355,BAO_0000218,,,
7362,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
7363,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,,,1,3443,BAO_0000218,,,
7364,,Cercopithecidae,,A,U,Autocuration,,9527.0,Binding towards monkey plasma protein at 10 uM,22224,,,1,17409,BAO_0000019,,,
7365,,Cercopithecidae,,A,U,Autocuration,,9527.0,Binding towards monkey plasma protein at 100 uM,22224,,,1,17409,BAO_0000019,,,
7366,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Apparent bioavailability in squirrel monkey was determined,22224,,,1,1052,BAO_0000218,,,
7367,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,,,1,13501,BAO_0000218,,,
7368,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability in monkey (dose 2 mg/kg),22224,,,1,17509,BAO_0000218,,,
7369,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,,,1,5394,BAO_0000218,,,
7370,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
7371,In vivo,monkey,,A,U,Autocuration,,9443.0,Bioavailability in monkey (i.d. dosing),22224,,,1,11219,BAO_0000218,,,
7372,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,,,1,3045,BAO_0000218,,,
7373,,Cercopithecidae,,A,U,Autocuration,,9527.0,Clearance of the drug was measured in cynomolgus,22224,,,1,17796,BAO_0000019,,,
7374,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,,,1,1399,BAO_0000218,,,
7375,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,,,1,2661,BAO_0000218,,,
7376,In vivo,Macaca mulatta,,A,U,Autocuration,Plasma,9544.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,,,1,5005,BAO_0000218,,,
7377,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in rhesus monkey was determined,22224,,,1,17267,BAO_0000218,,,
7378,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,,,1,6535,BAO_0000218,,,
7379,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance in cynomolgus monkey,22224,,,1,5922,BAO_0000218,,,
7380,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,,,1,6221,BAO_0000218,,,
7381,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,,,1,5668,BAO_0000218,,,
7382,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,,,1,5355,BAO_0000218,,,
7383,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,,,1,5355,BAO_0000218,,,
7384,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,,,1,5355,BAO_0000218,,,
7385,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Tested for Clearance upon iv administration to african green monkey,22224,,,1,4578,BAO_0000218,,,
7386,In vivo,Cercopithecidae,,A,U,Autocuration,,9527.0,Clearance in monkey,22224,,,1,17592,BAO_0000218,,,
7387,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6641,BAO_0000218,,,
7388,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,,,1,6642,BAO_0000218,,,
7389,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was evaluated after intravenous administration to dogs,50588,,,1,16367,BAO_0000218,,,
7390,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was evaluated in dog,50588,,,1,5472,BAO_0000218,,,
7391,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life was evaluated in dog,50588,,,1,5474,BAO_0000218,,,
7392,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,,,1,5654,BAO_0000218,,,
7393,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,,,1,6227,BAO_0000218,,,
7394,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period after intravenous administration in dog,50588,,,1,6227,BAO_0000218,,,
7395,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,,,1,6221,BAO_0000218,,,
7396,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period at a dose of 1 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
7397,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determine after peroral administration at 10 mpk in dog,50588,,,1,5668,BAO_0000218,,,
7398,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determine after peroral administration at 5 mpk in dog,50588,,,1,5668,BAO_0000218,,,
7399,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determined,50588,,,1,3854,BAO_0000218,,,
7400,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determined,50588,,,1,5505,BAO_0000218,,,
7401,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,,,1,6251,BAO_0000218,,,
7402,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was evaluated in dog,50588,,,1,1918,BAO_0000218,,,
7403,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,,,1,5546,BAO_0000218,,,
7404,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,,,1,4809,BAO_0000218,,,
7405,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,,,1,6215,BAO_0000218,,,
7406,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,,,1,4527,BAO_0000218,,,
7407,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,,,1,17594,BAO_0000218,,,
7408,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,,,1,17839,BAO_0000218,,,
7409,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,,,1,17839,BAO_0000218,,,
7410,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,,,1,17839,BAO_0000218,,,
7411,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,,,1,17839,BAO_0000218,,,
7412,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half-life of compound in plasma of dog was determined,50588,,,1,5210,BAO_0000218,,,
7413,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of compound was determined in dogs,50588,,,1,5210,BAO_0000218,,,
7414,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life after administration of 4 mg/Kg oral dose in dog,50588,,,1,2959,BAO_0000218,,,
7415,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,,,1,4137,BAO_0000218,,,
7416,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in Dog,50588,,,1,5064,BAO_0000218,,,
7417,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in Dog,50588,,,1,5147,BAO_0000218,,,
7418,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dog,50588,,,1,5145,BAO_0000218,,,
7419,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dog after oral administration at 1 mg/kg,50588,,,1,6123,BAO_0000218,,,
7420,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,,,1,6123,BAO_0000218,,,
7421,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dogs,50588,,,1,4333,BAO_0000218,,,
7422,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in dogs; ND indicates not determined,50588,,,1,4333,BAO_0000218,,,
7423,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half-life in plasma of dog,50588,,,1,12500,BAO_0000218,,,
7424,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Half-life in plasma of dog at dose of 3-10 mgkg,50588,,,1,12500,BAO_0000218,,,
7425,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,,,1,6005,BAO_0000218,,,
7426,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,,,1,6062,BAO_0000218,,,
7427,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,,,1,17650,BAO_0000218,,,
7428,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,,,1,5530,BAO_0000218,,,
7429,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,,,1,5530,BAO_0000218,,,
7430,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,,,1,5600,BAO_0000218,,,
7431,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
7432,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
7433,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,,,1,6039,BAO_0000218,,,
7434,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,t1/2 in dog,50588,,,1,6227,BAO_0000218,,,
7435,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period measured in dogs,50588,,,1,14541,BAO_0000218,,,
7436,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,,,1,4521,BAO_0000218,,,
7437,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,,,1,4521,BAO_0000218,,,
7438,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,,,1,6679,BAO_0000218,,,
7439,In vitro,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,,,1,1116,BAO_0000218,,,
7440,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo half life period was calculated at 1 mg/kg in dog,50588,,,1,5444,BAO_0000218,,,
7441,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,,,1,5444,BAO_0000218,,,
7442,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Longer half-life in dog (i.v.) at 0.5 mpk,50588,,,1,17853,BAO_0000218,,,
7443,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog (dose 5 uM/kg),50588,,,1,4353,BAO_0000218,,,
7444,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,,,1,16452,BAO_0000218,,,
7445,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,,,1,16452,BAO_0000218,,,
7446,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability in dog (dose 1 mg/kg i.v.),50588,,,1,16452,BAO_0000218,,,
7447,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,,,1,10107,BAO_0000218,,,
7448,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7449,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7450,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7451,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7452,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7453,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7454,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,,,1,10107,BAO_0000218,,,
7455,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7456,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7457,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7458,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7459,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7460,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7461,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7462,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7463,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7464,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7465,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7466,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7467,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7468,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7469,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7470,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7471,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7472,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7473,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7474,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,,,1,10107,BAO_0000218,,,
7475,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,,,1,10107,BAO_0000218,,,
7476,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,,,1,10107,BAO_0000218,,,
7477,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,,,1,10107,BAO_0000218,,,
7478,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,,,1,10107,BAO_0000218,,,
7479,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,,,1,10107,BAO_0000218,,,
7480,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,,,1,10107,BAO_0000218,,,
7481,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4689,BAO_0000218,,,
7482,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for the bioavailability in rat,50597,,,1,4950,BAO_0000218,,,
7483,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,,,1,5328,BAO_0000218,,,
7484,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,406,BAO_0000218,,,
7485,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,12500,BAO_0000218,,,
7486,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 3-10 mg/kg),50597,,,1,12500,BAO_0000218,,,
7487,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5247,BAO_0000218,,,
7488,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,,,
7489,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,,,
7490,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after oral administration was determined in rats at 6 mg/kg,50597,,,1,6647,BAO_0000218,,,
7491,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was determined,50597,,,1,6484,BAO_0000218,,,
7492,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,,,1,3249,BAO_0000218,,,
7493,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,,,1,6281,BAO_0000218,,,
7494,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,3307,BAO_0000218,,,
7495,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,,,1,12058,BAO_0000218,,,
7496,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hill coefficient of the compound,50597,,,1,8833,BAO_0000218,,,
7497,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,,,1,3193,BAO_0000218,,,
7498,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,,,1,3193,BAO_0000218,,,
7499,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,,,1,3193,BAO_0000218,,,
7500,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,,,1,3193,BAO_0000218,,,
7501,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,,,1,3193,BAO_0000218,,,
7502,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,,,1,3193,BAO_0000218,,,
7503,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,,,1,3193,BAO_0000218,,,
7504,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,,,1,5960,BAO_0000218,,,
7505,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7506,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7507,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7508,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7509,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7510,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7511,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7512,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7513,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7514,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,,,1,13950,BAO_0000218,,,
7515,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
7516,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,,,
7517,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
7518,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
7519,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,,,
7520,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
7521,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
7522,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,,,
7523,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,,,
